frontiers | Research Topics

Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma

Edited by
Luana Mota Ferreira and Marcel Henrique Marcondes Sari

Coordinated by
Juliana Hofstatter Azambuja

Published in
Frontiers in Oncology
Frontiers in Pharmacology
Frontiers in Cell and Developmental Biology



ISSN 1664-8714
ISBN 978-2-8325-4779-3
DOI 10.3389/978-2-8325-4779-3

About Frontiers

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals.

Frontiers journal series

The Frontiers journal series is a multi-tier and interdisciplinary set of open-access, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the *Frontiers journal series* operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too.

Dedication to quality

Each Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public - and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation.

What are Frontiers Research Topics?

Frontiers Research Topics are very popular trademarks of the *Frontiers journals series*: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers editorial office: frontiersin.org/about/contact

Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma

Topic editors
Luana Mota Ferreira — Federal University of Paraná, Brazil
Marcel Henrique Marcondes Sari — Federal University of Paraná, Brazil

Topic Coordinator
Juliana Hofstatter Azambuja — University of Pittsburgh, United States

Citation
Ferreira, L. M., Sari, M. H. M., Azambuja, J. H., eds. (2024). *Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma*. Lausanne: Frontiers Media SA. doi: 10.3389/978-2-8325-4779-3

Table of contents

05 Editorial: Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma
Marcel Henrique Marcondes Sari and Luana Mota Ferreira

08 Operative management of immune checkpoint colitis following in-transit melanoma: Case report
Betzaira G. Childers, Eileen Donovan, Winifred M. Lo, Lauren M. Janowak, Jeffrey Sussman and Christopher F. Janowak

13 Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
Selina Reiter, Christopher Schroeder, Julian Broche, Tobias Sinnberg, Irina Bonzheim, Daniela Süsskind, Lukas Flatz and Andrea Forschner

19 ITGAL as a prognostic biomarker correlated with immune infiltrates in melanoma
TengFei Deng, Chaoyong Wang, Cong Gao, Qiang Zhang and Jun Guo

33 Mapping knowledge landscapes and emerging trends of the biomarkers in melanoma: a bibliometric analysis from 2004 to 2022
Yantong Wan, Junyi Shen, Yinghao Hong, Jinghua Liu, Tieliu Shi and Junwei Cai

52 Causal association between serum 25-Hydroxyvitamin D levels and cutaneous melanoma: a two-sample Mendelian randomization study
Beichen Cai, Qian Lin, Ruonan Ke, Xiuying Shan, Jiaqi Yu, Xuejun Ni, Xinjian Lin and Biao Wang

65 Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma
Lei Tao, Yingyue Cui, Jiarui Sun, Yu Cao, Zhen Dai, Xiaoming Ge, Ling Zhang, Run Ma and Yunyao Liu

78 Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
Carlotta Guzzetti, Cristina Corno, Elisabetta Vergani, Luca Mirra, Emilio Ciusani, Monica Rodolfo, Paola Perego and Giovanni L. Beretta

87 Ferroptosis as a promising therapeutic strategy for melanoma
Na Ta, Xiaodong Jiang, Yongchun Zhang and Hongquan Wang

98 Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma
Karam Khaddour, Alice Zhou, Omar Butt, Jiayi Huang and George Ansstas

103 Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
Yahong Liu, Ying Cheng, Gongchao Huang, Xiangying Xia, Xingkai Wang and Hongqi Tian

115 Mechanisms underlying the therapeutic effects of cinobufagin in treating melanoma based on network pharmacology, single-cell RNA sequencing data, molecular docking, and molecular dynamics simulation
Jiansheng Yang, Chunchao Cheng and Zhuolin Wu

frontiers | Frontiers in Oncology

TYPE Editorial
PUBLISHED 04 April 2024
DOI 10.3389/fonc.2024.1403778

OPEN ACCESS

EDITED AND REVIEWED BY
Olivier Feron,
Université catholique de Louvain, Belgium

*CORRESPONDENCE
Marcel Henrique Marcondes Sari
marcelsarih@hotmail.com
Luana Mota Ferreira
luanamota@ufpr.br

†These authors have contributed equally to this work

RECEIVED 19 March 2024
ACCEPTED 27 March 2024
PUBLISHED 04 April 2024

CITATION
Sari MHM and Ferreira LM (2024) Editorial: Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma.
Front. Oncol. 14:1403778.
doi: 10.3389/fonc.2024.1403778

Editorial: Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma

Marcel Henrique Marcondes Sari [1*†] and Luana Mota Ferreira [2*†]

[1]Departamento de Análises Clínicas, Universidade Federal do Paraná, Curitiba, Paraná, Brazil, [2]Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Paraná, Curitiba, Paraná, Brazil

KEYWORDS

skin cancer, melanoma, immunology, nanotechnology, cancer biomarkers, drug repositioning, immunotherapy

Editorial on the Research Topic
Advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma

Over the years, extensive research efforts have been made to identify specific biomarkers that can predict the growth and behavior of melanoma cells, with the ultimate goal of developing targeted therapies that can effectively treat this disease. To address this challenge, researchers are actively working to develop new and improved targeted therapies. Collectively, eleven studies were published by authors from China (7/11), United States (2/11), Germany (1/11), and Italy (1/11), approaching novel targets for melanoma diagnosis and prognosis, and promising therapeutic interventions to counteract the disease.

Ferroptosis could be an effective way to prevent malignant melanoma (MM) development. In the review of Ta et al., a comprehensive overview of the fundamental mechanisms underlying the ferroptosis development in MM cells and its potential as a therapeutic target were proposed. Inducing ferroptosis is generally considered an effective approach to induce cell death in therapy-resistant MM cells. Additionally, nano-based medicines have shown promise in inducing the ferroptosis pathway in MM. Aiming to comprehend the mechanisms underlying cinobufagin action in melanoma, Yang et al. combined network pharmacology with other sequencing data to identify key targets. Results showed that cinobufagin may exert its effects by halting the cell cycle through three protein tyrosine/serine kinases (EGFR, ERBB2, and CDK2) inhibition. Liu et al. developed a new Mitogen-activated protein kinase (MEK) inhibitor, the tunlametinib, which exhibits high *in vitro* selectivity and shows significant potency against RAS/RAF mutant cells. *In vivo* studies demonstrate that tunlametinib has a favorable pharmacokinetic profile and leads to significant tumor suppression. When combined with BRAF/KRASG12C/SHP2 inhibitors or docetaxel, tunlametinib exhibits a synergistic response and substantial tumor inhibition.

Wan et al. employ bibliometrics to analyze research on biomarkers in melanoma, offering insights into the field's historical development, current status, and future research directions. Findings reveal a steady increase in both the number of publications and citation frequency in this area, with a notable surge in citation frequency observed post-2018. Biomarkers associated with melanoma diagnosis, treatment, and prognosis are identified as key topics and cutting-edge areas of interest within the field. Another study conducted by Tao et al. explored public databases to prospect potential therapeutic targets for BRAF-mutated melanoma. A total of 24 overlapping genes were identified by analyzing differentially expressed genes common to melanoma and non-transformed tissue, BRAF-mutated and BRAF wild-type melanoma. Among them, (cytokine-like 1) CYTL1 was highly expressed in melanoma, especially in BRAFmutated melanoma, and the high expression of CYTL1 was associated with epithelial-mesenchymal transition, cell cycle, and cellular response to ultraviolet radiation. In melanoma patients, clinical studies showed a positive correlation between increased CYTL1 expression and shorter overall survival and disease-free survival. Lastly, the authors confirmed that the knockdown of CYTL1 significantly inhibited the migration and invasive ability of melanoma cells by conducting *in vitro* assessments.

Immune checkpoint inhibitors (ICI) are increasingly utilized in the treatment of melanoma. However, a recognized complication associated with these inhibitors is colitis, often managed with medical treatment. In this sense, Childers et al. presented a case involving a patient with stage IV melanoma undergoing ICI therapy. While ICIs-induced colitis can occur in patients with various types of cancer, the majority of existing evidence is predominantly associated with melanoma. This is because ICIs are commonly employed as the primary treatment for advanced-stage melanoma. While mild side effects can be monitored and treated symptomatically, severe immune-related adverse effects may progress rapidly, leading to complications requiring surgical intervention. The authors concluded that further research is warranted to comprehend the incidence of colitis progression in the context of single and multiple ICI combinations for malignancy. Similarly, Reiter et al. discussed a case report of a patient with metastatic Uveal melanoma (UM) who initially experienced extensive progression while receiving tebentafusp treatment but later exhibited a remarkable response to combined ICI therapy. Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager known as tebentafusp has gained approval for the treatment of unresectable UM. Despite its complex treatment regimen involving weekly administrations and close monitoring, the response rate remains limited. Moreover, there is limited data available on the use of combined ICIs in UM following prior progression on tebentafusp. In cases where progressive findings are observed during the initial follow-up, continuation with tebentafusp should be considered. However, in the event of further progression of metastases, treatment with combined ICI may be a viable option. Lastly, Deng et al. investigated the correlation between Integrin Subunit Alpha L (ITGAL) expression and immune infiltration, clinical prognosis, and specific T cell types in melanoma tissue. The results underscore the pivotal role of ITGAL in melanoma and its potential mechanism in regulating tumor-infiltrating immune cells, rendering it a promising diagnostic biomarker and therapeutic target for advanced melanoma. The findings reveal that heightened ITGAL expression correlates not only with PD1 and CTLA4 but also with other potential melanoma checkpoints, suggesting that ICIs have become melanoma treatment cornerstone, with PD1/PDL1 checkpoint blockade therapy being a standard approach.

Oligometastatic progression is a challenge in tumor immune evasion that occurs when tumors spread to a limited number of distant sites. This type of progression can be difficult to diagnose and manage using ICIs. A potential solution is to use circulating tumor DNA (ctDNA) alongside surveillance imaging for diagnosis and disease monitoring. Khaddour et al. discussed two cases of patients, one with metastatic melanoma and the other with metastatic Merkel cell carcinoma, who underwent ICI therapy and subsequently developed localized resistance due to oligometastatic progression. In response, stereotactic body radiation therapy (SBRT) was employed as a salvage approach to address the oligometastatic progression. Furthermore, the study elucidates the temporal and dynamic relationship of ctDNA before, during, and after SBRT, strongly suggesting the diagnosis without the need for obtaining a histological specimen.

The relationship between serum 25-Hydroxyvitamin D (25HVD) levels and the incidence of melanoma using Mendelian randomization (MR) was investigated by Cai et al. The MR analysis revealed a significant positive causal relationship between serum 25HVD levels and cutaneous melanoma incidence, suggesting that the risk of developing melanoma increases with each unit increase in serum 25HVD concentration. Remarkably, a potentially causal positive association between serum 25HVD levels and melanoma risk, challenging traditional beliefs about vitamin D's role in melanoma. Metastatic dissemination stands as a primary contributor to mortality in melanoma patients. In this sense, KiSS1 holds significant given its application as epigenetic agent, and it can exhibit a pro-apoptotic effect when combined with cisplatin. Guzzetti et al. demonstrated a significant augmentation of vemurafenib's pro-apoptotic activity by kisspeptin 54, a peptide derived from KiSS1 cleavage, even in cellular models resistant to the drug. The efficacy of this combination therapy appears to hinge on the intrinsic susceptibility of each cell line to drug-induced apoptosis.

Author contributions

MS: Writing – original draft, Writing – review & editing. LF: Writing – original draft, Writing – review & editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

frontiers | Frontiers in Oncology

TYPE Case Report
PUBLISHED 20 April 2023
DOI 10.3389/fonc.2023.1120808

OPEN ACCESS

EDITED BY
Nihal Ahmad,
University of Wisconsin-Madison,
United States

REVIEWED BY
Ichwaku Rastogi,
University of Wisconsin-Madison,
United States
Yue Chen,
Cedars Sinai Medical Center, United States

*CORRESPONDENCE
Christopher F. Janowak
christopher.janowak@uc.edu

SPECIALTY SECTION
This article was submitted to
Skin Cancer,
a section of the journal
Frontiers in Oncology

RECEIVED 10 December 2022
ACCEPTED 27 March 2023
PUBLISHED 20 April 2023

CITATION
Childers BG, Donovan E, Lo WM, Janowak LM, Sussman J and Janowak CF (2023) Operative management of immune checkpoint colitis following in-transit melanoma: Case report.
Front. Oncol. 13:1120808.
doi: 10.3389/fonc.2023.1120808

Operative management of immune checkpoint colitis following in-transit melanoma: Case report

Betzaira G. Childers[1], Eileen Donovan[1], Winifred M. Lo[2], Lauren M. Janowak[3], Jeffrey Sussman[1] and Christopher F. Janowak[1]*

[1]College of Medicine, University of Cincinnati, Cincinnati, OH, United States, [2]Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States, [3]College of Nursing, University of Cincinnati, Cincinnati, OH, United States

Immune checkpoint inhibitors are increasingly used as powerful anti-neoplastic therapies in the setting of melanoma. Colitis is a known complication of immune checkpoint inhibitors that if often medically managed. We present a patient with stage IV melanoma with demonstrated in-transit disease undergoing immune checkpoint inhibitor therapy. The patient subsequently developed recalcitrant severe colitis that necessitated operative intervention and bowel resection. The association of immune check point inhibitors and immune related adverse effects are discussed as well as treatments of advanced colitis, including the possibility of surgical management in the setting of severe colitis with complications.

KEYWORDS

immune-checkpoint-inhibitor, colitis, melanoma, surgery, complications, hidradenitis

Introduction

Harnessing the immune system's ability to fight infection is a gateway to controlling and overcoming malignancy. Immune checkpoint inhibitors (ICI) are a powerful class of medications that have made use of this potential for melanoma since receiving Federal Drug Administration approval in 2015. Since then, several immune checkpoints have been approved for treatments including advanced and refractory disease. Given their systemic distribution, ICI can precipitate widespread immune related adverse events (iRAEs) including rashes, hypothyroidism, transaminitis, blindness, pancreatitis, diarrhea, & colitis. In a retrospective study of 70 patients receiving Nivolumab monotherapy for non-small cell lung cancer, 40% of patients developed iRAEs ranging from skin reactions to pneumonitis (1). Similarly, a retrospective review of 148 patients who received Nivolumab treatment for melanoma as a part of phase I clinical trials found that 68.2% of patients experienced an iRAE (2). While low-grade side effects can be monitored or treated medically, more severe iRAEs such as colitis have the potential for rapid progression

that may necessitate surgical intervention. In patients treated with anti PD-1/PD-L1 therapy, the reported incidence of colitis overall is 1.3-1.6%, while high-grade colitis is quite rare, occurring in approximately 0.9% of patients (3, 4). However, the relative risk of high-grade ICI colitis is higher in dual agent ICI therapy than single agent ICI (5). Overall, data is evolving regarding the optimal strategies for treating for these complex patients. Here, we present a rare case of severe colitis secondary to treatment with immunotherapy for melanoma that required surgical intervention.

Case

Our patient is a 37-year-old male with a history of hidradenitis and initially found to have stage III melanoma that was diagnosed *via* punch biopsy of a suspicious mid-upper back mole. The patient has a father who had a skin cancer of unknown type removed from his nose, but no other familial oncologic history. The patient's lesion was incidentally noticed in a tattooed area of skin. The biopsy revealed a 5.7 mm thick, non-ulcerated, BRAF positive, malignant melanoma with >20 mitoses per high powered field. Pathology following wide local excision with axillary lymph node biopsy revealed a melanoma with a final depth of 7 mm and 1 of 4 positive lymph nodes consistent with stage III disease. He was started on Nivolumab 100 mg and enrolled in the Elios Vaccine trial. During the first month of therapy the patient was noted to have multiple skin nodules in addition to hypermetabolic regions on positron emission tomography (PET) scan in a right supraclavicular node, bilateral axillae, and perineum. Changes seen in the axillae and perineum were found to be consistent with the patient's cystic acne and hidradenitis. Due to concern for metastases, a right mandibular lesion and supraclavicular node were excised. The mandibular lesion was found to be benign, but the supraclavicular node was positive for melanoma. He was then upstaged to stage IV disease and therapy was escalated to Ipilimumab plus Nivolumab per the NCCN guidelines (6). He completed 3 cycles of Nivolumab and two cycles of Ipilimumab plus Nivolumab with side effects including palpitations, rash, nausea, diarrhea, and recurrent grade 3 colitis over the course of 8 months. As treatment for the side effects, he received escalating doses of prednisone up to 100 mg daily. Repeat PET scan 6 months after diagnosis demonstrated hypermetabolic foci of uptake in the inguinal and pubic regions; however, this was correlated to areas of hidradenitis-related inflammation (Figure 1).

Soon thereafter, he presented to the emergency department with 24 hours of fatigue, weakness, peritoneal abdominal pain, and diarrhea that progressed to bright red blood per rectum. Cross-sectional imaging at the time demonstrated ileocecal intussusception and raised concerns for a cecal mass (Figure 2) suggesting neoplastic disease. Due to peritonitis, he was taken to the operating room and underwent an exploratory laparotomy. Intraoperative findings identified significant cecal induration, marked inflammation, patchy areas of ischemia, and the appearance of cecal intussusception. Specifically, the cecum appeared to invaginate from the coalescence of the tinea (where the appendiceal orifice would have been; however, the patient had a laparoscopic appendectomy years prior) and had intussuscepted antegrade along the ascending colon (Figure 3). There were signs of colonic ischemia, but no gangrene or perforation, and the affected area was resected with right hemicolectomy. Intestinal continuity was restored with an ileocolonic anastomosis. The postoperative course was complicated by a minor wound seroma and colitis with diarrhea that resolved with conservative management. The final surgical pathology was consistent with localized colonic ischemia and necrosis due to intussusception, with surrounding colitis. No evidence of malignancy was identified, and 30 reactive lymph nodes were recovered without evidence of metastasis. Notably, the lead point for the intussusception appeared to be at the site of the appendiceal stump from his prior appendectomy. At the time of manuscript preparation, the patient is doing well having completed encorafenib and binimetinib treatments and has had no further evidence of disease recurrence.

The patient has graciously given his permission for the use of his story to help enrich the understanding of disease. Informed consent obtained and CARE checklist completed. From the patient's perspective, the course of his melanoma disease was



FIGURE 1
Timeline of diagnostics and treatment of melanoma and subsequent severe colitis resulting in surgery. The asterisk reflects when the patient first noticed colitis symptoms. The PET, positron emission tomography; ED, Emergency department.

FIGURE 2
Cross-sectional imaging of a 37-year-old M with Stage IV in-transit melanoma receiving immune checkpoint inhibitor therapy who presents with severe abdominal pain. A characteristic target-sign for intussusception is appreciated in cecum (triangle) and can be seen on the axial, coronal, and sagittal views.

rapid, raising concerns from his treatment team early on as to whether his initial presentation represented Stage III vs. Stage IV disease. He also recalls that the timing of the colitis was "nearly instantaneous" with the initiation of combination Ipilimumab and Nivolumab therapy (indicated on Figure 1 with an asterisk). Symptom management with steroids was ineffective and the colitis continued to accelerate until it became a surgical emergency and ultimately one of the scariest chapters of his life. Coincidentally, the immunotherapy also exacerbated his hidradenitis disease, adding to the complexity of maintenance type therapies during this period. Through everything he has remained optimistic and recovered remarkably well.

Discussion

We present a case of melanoma treatment with ICIs that is complicated by a severe manifestation of colitis. While ICI colitis is not specific to melanoma, much of the growing body of evidence is based on melanoma due to the timing of ICIs as leading agents in the treatment of advanced stage melanoma. However, their use in other cancer types is growing and the incidence of cancer specific colitis remains to be seen. Overall, the incidence of colitis in patients undergoing treatment with immunotherapy is relatively uncommon, with a highest reported incidence of 13.6%, but the diagnosis requires prompt intervention and treatment due to the associated risk of significant morbidity and mortality (4, 7). Our understanding for the severity and incidence of iREAs is evolving and currently in-completely understood. The use of ICIs across various cancer types is expanding and emphasizes the importance of vigilant surveillance as criteria to predict what patients will fail conservative treatment is poorly understood. Tandon et al, identified five aCTLA4 colitis deaths though their specific clinical course and or candidacy for operative intervention is unclear (3). Additional work is needed to identify patient populations who will fail conservative management and will benefit from escalation of care to include operative intervention. Even after a period of cessation, iRAEs can reoccur in up to one third of patients after resumption of either an aCTLA4 or aPDL1. Less severe symptoms were associated with aPDL1 while aCTLA4 frequently required corticosteroids and anti-tumor necrosis factor alpha agents. The rate of diarrhea colitis recurrence appears to be higher in patients undergoing aPDL1 therapy (8). In addition, in randomized control trials the relative risk of high-grade ICI colitis is higher at 1.33 in dual therapy Ipilimumab + Nivolumab vs Ipilimumab alone (5). Continued work is necessary to better delineate the risks associated with single, combination, and repeated treatment regimens. Notably, iRAEs and



FIGURE 3
Photo of surgical resection specimen with terminal ileum, ileocecal valve, cecum, and ascending colon. The triangle denotes the location of the intussusception that appears to originate at the level of the coalescence of the tinea at the base of the cecum. Final pathology demonstrated advanced colitis and cecal ischemia.

specifically gastrointestinal related adverse events of any grade are associated with a statistically significant survival benefit ($p<0.01$). This is despite the use of immunosuppressive medication in severe cases (9). Unfortunately, even less is known about the immune modifying effects of surgery for those with severe, life-threatening colitis as is the case with our patient. For example, the typically immune suppressive effect of surgery on cancer during the perioperative period has been implicated in tumor escape and expansion (10, 11). Perioperative dosing of cytokines, toll-like receptor agonists, anti-catecholamines, anti-prostaglandins, and immune checkpoint medications have shown the potential to extend the progression free survival in animal models (9).

Beyond immunotherapy mediated colitis, operative intervention for any colitis events remains uncommon but is associated with significant morbidity. In one study, surgical resection was required in approximately 17% of all patients presenting with ischemic colitis (Yadav et al) (12). In a review of 4548 patients undergoing emergent colectomy for ischemic colitis of any etiology, 30-day post-operative mortality was found to be greater than 25% (Tseng et al) (13). In this cohort, disseminated cancer ($p < 0.001$) and chronic steroid use ($p < 0.001$) were both associated with increased mortality on univariate analysis. As the use of ICIs increases the development and use of escalating treatment guidelines for immune mediated colitis (14) may offer insights towards the prevention of severe colitis. However, at this point a patient undergoing immunotherapy for cancer who develops colitis necessitating operative intervention should be considered high-risk for poor post-operative outcomes. Colitis surveillance and mitigation may help avoid operative intervention and or guide timing of intervention to maximize patient outcomes.

Conclusion

Indications for ICI use in various malignancies are increasing. While low-grade side effects can be monitored and symptomatically treated, severe iRAEs can progress quickly and lead to complications that may require surgical intervention. Refractory colitis may portend surgical emergencies and should be evaluated with a high suspicion for operative intervention. More work is needed to understand the incidence of colitis progression in the setting of single and multiple ICI combinations for malignancy.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

Written informed consent was obtained from the participant/patient(s) for the publication of this case report.

Author contributions

WL, JS, and CJ contributed to the design of the study. BC, ED, LJ, and CJ contributed to the literature search and acquisition of data. BC, ED, LJ, and CJ drafted the manuscript. All authors contributed to the article and approved the submitted version.

Acknowledgments

The authors would like to thank the patient and his family for their support through the course of treatment, recovery and their invaluable insight into this manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

References

1. Toi Y, Sugawara S, Kawashima Y, Tomoiki A, Sachiko K, Ryohei S, et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-Small-Cell lung cancer treated with nivolumab. *Oncol* (2018) 23 (11):1358–65. doi: 10.1634/theoncologist.2017-0384

2. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. *Clin Cancer Res* (2016) 22(4):886–94. doi: 10.1158/1078-0432.CCR-15-1136

3. Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. *Journal of Immunotherapy* (2018) 41(3):101–08. doi: 10.1097/CJI.0000000000000213

4. Wang D, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. *OncoImmunology* (2017) 6(10). doi: 10.1080/2162402X.2017.1344805

5. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *New Engl J Med* (2015) 372(21):2006–17. doi: 10.1056/nejmoa1414428

6. *NCCN guidelines version 2.2023, melanoma: Cutaneous*. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.

7. Bellaguarda E, Hanauer S. Checkpoint inhibitor–induced colitis. *Am J Gastroenterol* (2020) 115(2):202–10. doi: 10.14309/ajg.0000000000000497

8. Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. *J Clin Oncol* (2019) 37(30):2738–45. doi: 10.1200/JCO.19.00320

9. Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. *Cancer Immunol Immunother* (2019) 68(4):553–61. doi: 10.1007/s00262-019-02303-1

10. Elias AW, Kasi PM, Stauffer JA, Thiel DD, Colibaseanu DT, Mody K, et al. The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a retrospective study. *Front Oncol* (2017) 7:121. doi: 10.3389/fonc.2017.00121

11. Bakos O, Lawson C, Rouleau S, Tai L-H. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. *J immunother Cancer* (2018) 6(1):86. doi: 10.1186/s40425-018-0398-7

12. Yadav S, Dave M, Edakkanambeth Varayil J, Harmsen WS, Tremaine WJ, Zinsmeister AR, et al. A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. *Clin Gastroenterol Hepatol* (2015) 13 (4):731–8.e1-6. doi: 10.1016/j.cgh.2014.07.061

13. Tseng J, Loper B, Jain M, Lewis AV, Margulies DR, Alban RF. Predictive factors of mortality after colectomy in ischemic colitis: an ACS-NSQIP database study. *Trauma Surg Acute Care Open* (2017) 2(1):1–6. doi: 10.1136/tsaco-2017-000126

14. Kennedy LC, Grivas P. Immunotherapy-related colitis: an emerging challenge and a quest for prospective data. *JCO Oncol Pract* (2020) 16(8):464–5. doi: 10.1200/OP.20.00620

frontiers | Frontiers in Oncology

TYPE Case Report
PUBLISHED 03 May 2023
DOI 10.3389/fonc.2023.1167791

OPEN ACCESS

EDITED BY
Marco Tucci,
University of Bari Aldo Moro, Italy

REVIEWED BY
Riccardo Marconcini,
Pisana University Hospital, Italy
Enrique Espinosa,
University Hospital La Paz, Spain

*CORRESPONDENCE
Andrea Forschner
andrea.forschner@med.uni-tuebingen.de

RECEIVED 16 February 2023
ACCEPTED 19 April 2023
PUBLISHED 03 May 2023

CITATION
Reiter S, Schroeder C, Broche J, Sinnberg T, Bonzheim I, Süsskind D, Flatz L and Forschner A (2023) Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Front. Oncol. 13:1167791.
doi: 10.3389/fonc.2023.1167791

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report

Selina Reiter[1], Christopher Schroeder[2], Julian Broche[2], Tobias Sinnberg[1], Irina Bonzheim[3], Daniela Süsskind[4], Lukas Flatz[1] and Andrea Forschner[1]*

[1]Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany, [2]Institute of Medical Genetics and Applied Genomics, University Hospital of Tübingen, Tübingen, Germany, [3]Institute of Pathology and Neuropathology, University Hospital of Tübingen, Tübingen, Germany, [4]Department of Ophthalmology, University Hospital of Tübingen, Tübingen, Germany

Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp, has been approved for the treatment of HLA-A*02:01 metastatic or unresectable UM. While the treatment regime is complex with weekly administrations and close monitoring, the response rate is limited. Only a few data exist on combined ICI in UM after previous progression on tebentafusp. In this case report, we present a patient with metastatic UM who first suffered extensive progression under treatment with tebentafusp but in the following had an excellent response to combined ICI. We discuss possible interactions that could explain responsiveness to ICI after pretreatment with tebentafusp in advanced UM.

KEYWORDS

tebentafusp, immune checkpoint inhibitors, uveal melanoma, bi-specific therapy, ctDNA

1 Introduction

Uveal melanoma (UM) is a rare tumor of the eye, most often arising from the melanocytes located in the choroid, with an incidence of about 5 cases per million per year. Studies showed that there is a geographic north-to-south decreasing gradient of incidence, probably due to the lack of protective effect of ocular pigmentation in northern, mostly Caucasian, populations. UM shows a rising incidence in positive correlation to age with a peak at 70 years. No significant difference between male and female is known (1).

Unlike cutaneous melanoma, which usually is associated with lymphatic metastasis but can also spread through blood, UM usually metastasizes only hematogenously. For this reason, the pattern of metastatic spread includes predominantly the liver (89%), but also the lung (29%) and bones (17%). The risk of metastases in uveal melanoma is high, as approximately 50% of patients develop metastases within 10 years after initial diagnosis. Median survival is 6 to 12 months once metastasis occurred (2).

Chromosomal aberrations and gene alterations are often found in metastatic UM and may be associated with distinct prognosis. For example, monosomy of chromosome 3 and chromosome 8 alterations are, especially when occurring simultaneously, associated with a worse prognosis. Furthermore, mutations in *BAP1* (BRCA1 Associated Protein 1) or *SF3B1* (Splicing Factor 3b Subunit 1 gene) are known risk factors for the development of metastases, while alterations in *GNAQ/GNA11* (G protein alpha subunits) are driver mutations with high diagnostic but lesser prognostic value (3, 4).

Treatment of primary UM usually consists of various non-surgical approaches for local tumor control preventing enucleation (e. g. external beam radiation or brachytherapy) and frequently preserving vision. In other cases, a surgical approach with enucleation of the affected eye can become necessary (5).

There are several treatment options for metastatic UM, depending on its pattern of metastatic spread, speed of progression and molecular profile. No guidelines are currently available. Liver-directed treatments are usually the first treatment of choice (if no other metastases are present or at least, liver metastases are prognosis-leading) and include hepatic resection, chemosaturation/isolated hepatic perfusion (IHP) or hepatic arterial chemoembolization. Recent data suggest that IHP has a high response rate and an overall survival benefit of about 14 months (6).

Immune checkpoint inhibitors (ICI) such as ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1) improved prognosis of cutaneous melanoma. In the 6.5-year outcome of the CheckMate 067 trial the median overall survival of previously untreated patients with stage III (unresectable) or stage IV melanoma was 72.1 months in the group that received the combined regimen with ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) once every three weeks for four doses (7).

There have been several prospective trials and retrospective analyses investigating ICI in patients with metastatic uveal melanoma. Ultimately, ICI have shown disappointing results compared to those achieved in patients with cutaneous melanoma. In contrast to cutaneous melanoma, combined ICI has limited impact in metastatic UM. Median progression-free survival (mPFS) ranges from 3-5.5 months and median overall survival (mOS) ranges from 12.7-19.1 months in phase 2 clinical trials (8, 9).

The underlying mechanisms of this ICI resistance are complex and not yet fully understood. Studies have shown a correlation between efficacy of ICI and a high tumor mutational burden which is common for cutaneous malignant tumors such as cutaneous melanoma or cutaneous squamous cell carcinoma. In contrast to this, uveal melanoma shows an exceptionally low tumor mutational burden (18 vs. 1.1 mutations per Mb) (10, 11). Accordingly, PD-L1 expression rates are substantially lower in metastatic uveal melanoma than metastatic cutaneous melanoma. This combined lack of neoantigens and PD-L1 expression suggests immune evasion of tumor cells (12). The eye itself is a so-called immune privileged site. It is shielded from the classical immune response (in particular the release of inflammatory mediators and macrophages) which could have dramatic consequences on tissue with limited regenerative capacity. The poor responsiveness to ICI of metastatic UM suggests that this shielded immunological environment is also recreated in metastatic tissue (13, 14).

In April 2022, tebentafusp (a bispecific gp100 peptide-HLA-directed CD3 T cell engager) has been approved in the European Union as systemic therapy for HLA-A*02:01 positive patients with metastatic uveal melanoma. The estimated median overall survival was 21.7 months (18.6-28.6), median progression-free survival was 3.3 months (3-5) (15). However, the median duration of response was rather short. Currently, there are several retrospective studies investigating therapy sequences in uveal melanoma. First results revealed a tendency towards a better overall survival in patients who progressed on tebentafusp and then received ICI compared to patients who progressed on ICI und were subsequently treated with tebentafusp. In the subsequent evaluation of a randomized phase III trial of metastatic uveal melanoma with first-line either tebentafusp or investigator's choice, patients with post-progression ICI appeared to have a better overall survival when they had been treated with tebentafusp before compared to ICI before tebentafusp (16).

In a small, single center retrospective cohort study comparing retrospectively 10 patients in each group treated by tebentafusp followed by ICI and vice versa, there was a significant survival benefit for the patients receiving ICI after progressive disease under tebentafusp (17).

2 Case presentation

A 78-year-old male patient was clinically diagnosed with uveal melanoma of the left eye in December 2019. The initial staging (cMRI, liver MRI, full body CT) remained tumor-free without any metastases. A skin examination was unsuspicious. In the following, an enucleation of the left eye was performed confirming the diagnosis pathologically as uveal melanoma with invasion of the sclera and an emissary vessel. The patient had no relevant concomitant diseases.

Within the follow-up the patient received eye ophthalmological controls every 3 months and a liver MRI every 6 months. First liver metastases were detected by liver MRI of July 2021, when new suspect hepatic lesions in segments VI and VIII were noted. As there was no sign of extrahepatic metastases, a liver-specific procedure was performed – first, a transarterial chemoembolization of the two metastases in segment VI and segment VIII and after notion of further hepatic progression in September 2021, a chemosaturation. A new hepatic lesion in segment VI was treated with a second transarterial chemoembolization in January 2022.

In March 2022 new lung metastases, soft tissue metastases, and size-progressive liver metastases were detected. At this time, an

HLA analysis had already been conducted and had confirmed HLA-A*02:01 positivity in the patient. As tebentafusp had recently been approved for HLA-A*02:01 positive patients with metastatic uveal melanoma, the patient received this treatment as one of the first patients outside of studies or early access program (EAP) at the University Hospital of Tübingen in April 2022. After the first cycle (20 µg) he experienced severe side effects with, fever, acute renal injury and elevation of CRP and liver enzymes. These side effects were treated symptomatically and also the uric acid was lowered with rasburicase as tumor lysis syndrome was suspected. The patient recovered quickly, but developed a cytokine release syndrome at the third cycle (30 µg) which was treated with tocilizumab. In the following, the symptoms decreased with each cycle; the full dose of tebentafusp was administered at the fifth cycle (68 µg). In total, the patient received 11 cycles of tebentafusp until June 2022.

The next full body staging was conducted in June 2022 which showed progressive pulmonary, hepatic and soft tissue metastases and also new osteolytic metastatic lesions. Consequently, the treatment with tebentafusp was discontinued and combined ICI was started 11 days after the last administration of tebentafusp. The patient received 4 cycles of ipilimumab (3 mg per kilogram body weight) and nivolumab (1 mg per kilogram body weight) which he tolerated without any side effects. The following staging of September 2022 showed a very good response with considerably reduced hepatic, pulmonary, lymphonodal and soft tissue metastases and increased demarcation of osseous metastases. In October 2022, the treatment was continued as recommended with nivolumab as monotherapy (480 mg, q28). Before the start of the combined immunotherapy, LDH levels had been elevated up to 680 U/l. After 4 cycles of immunotherapy, the LDH levels dropped down to 315 U/l and further decreased at the time of the second follow-up at the end of December 2022 with almost normal LDH levels (269 U/l). The staging revealed stable findings (Figure 1).

In addition to the HLA analysis which was performed in December 2021, Next-Generation Sequencing (NGS) was conducted after progression on tebentafusp and before starting combined ICI in June 2022. Two somatic changes were found in the *BAP1* gene, one being a frameshift mutation (c.908_918del, p.Ala303GlyfsTer91), another being a heterozygotic deletion in chromosome 3 (chr3; p21.1p21.31). Another somatic change was a missense mutation in the *GNA11* gene (c.626A>T, p.Gln209Leu). As a consequence, the molecular tumor board suggested an off-label use of the EZH2 inhibitior (Tazemetostat) as future therapy option in case of progression under ICI.

Based on the results from tumor normal sequencing, a tumor-specific enrichment panel was designed for hybridization capture NGS. Targeted ultra-deep sequencing was conducted with plasma cell-free DNA (cfDNA) obtained from peripheral blood. A total of five variants was analyzed at two different time points of therapy (Figure 2A, Supplementary Table 1). The first time point was baseline before the initiation of tebentafup, while the second time point fell into the period of response under combined ICI with regredient metastases. Unfortunately, no cfDNA sample was taken at the time point of progressive disease under tebentafusp. Four out of five tumor variants were detected at the first time point. In accordance with the clinical findings and imaging results, the allele frequencies were markedly reduced at time point 2 (Figure 2B). The only variant (*PRKDC*) not found in any of the cfDNA samples already displayed the lowest allele frequency (AF) in the tumor.

3 Discussion

There are high expectations regarding the new treatment option for advanced HLA-A*02:01 UM with tebentafusp. Nevertheless, the optimal sequence of tebentafusp and combined ICI is unknown (17, 18). We have seen an unexpectedly rapid and profound response in our patient to combined ICI after previous tebentafusp therapy and we would like to outline possible reasons that might argue for the use of combined ICI in case of progression to tebentafusp.



FIGURE 1
Course of the disease.

A

		cfDNA (03/2022)			cfDNA (12/2022)		
	Tumor AF	AF	REF	ALT	AF	REF	ALT
BAP1	0.8582	0.11912	9710	1313	0.01337	3763	51
GNA11	0.4393	0.13897	9201	1485	0.01573	2878	46
PRKDC	0.0743	0	1630	0	0	2798	0
BCR	0.4363	0.14086	9161	1502	0.02218	3218	73
EZH1	0.1196	0.00149	4682	7	0	3100	0

B



FIGURE 2
Summary of tumor variants monitored in plasma cfDNA. **(A)** Selected tumor variants detected by tumor normal sequencing with a comprehensive sequencing panel. Resulting variants were selected for a smaller tumor-specific hybridization-based enrichment panel and sequenced to an ultra-high depth. Allele frequencies (AF) were obtained from reference reads (REF, GRCh38) and alternative reads (ALT). Reads without duplicates were excluded during sequencing error correction. **(B)** ctDNA kinetics of selected tumor variants. Each line represents one variant. The allele frequencies are plotted over time and refer to reads with at least one duplicate. White circles indicate that the variant was found with a p-value < 0.05.

It is known that ICI is less effective with liver metastases (7, 19, 20). Median progression-free survival was markedly reduced for melanoma patients of the checkmate 067 study in case of baseline liver metastases (4.4 months; 2.8-11.5) compared to patients without baseline liver metastases (18.1 months; 10.7-42.7). Likewise, overall survival was found to be markedly worse (28.2 months; 15.2-71.9) when baseline liver metastases were present compared to patients without liver metastases at the beginning of ICI (NR; 50.7- NR) (7). Considering a 59% rate of grade 3-4 immune-mediated adverse events with a lower response rate than in cutaneous melanoma, the first-line use of combined ICI in metastatic uveal melanoma should be considered restrictive.

In an evaluation concerning the effect of post-progression treatment on the outcome of patients that had been included in the phase III trial of first-line tebentafusp or investigator's choice, patients with ICI after progression on tebentafusp tended to have improved survival (16).

Furthermore, a subgroup of patients from the first phase I trial, who were progressive on ICIs and then also progressive on tebentafusp, in some cases responded to a re-challenge of ICIs after all (21).

It is known that the application of tebentafusp results in an increase of T cells in the tumor microenvironment, as well as an increase of IFNγ, CXCL9, CXCL10 and CXCL1. Adverse effects such as skin rash or pruritus are probably due to the interaction of T cells with melanocytes expressing gp100 in the skin. Patients that experienced rash within the first week of tebentafusp treatment had a significant better 1-year overall survival rate (83%) compared to patients without rash (59%). High CXCL10 expression is known to be a predictive marker for treatment response to ICI. The predictive power of CXCL10 was even better than that of PD-1/PD-L1 (22, 23).

Considering the above-mentioned effect of tebentafusp on the tumor microenvironment, it might be reasonable to use ICI in metastatic UV primarily after previous treatment with tebentafusp, or at least to try it again after previous ICI progression after intermediate tebentafusp application.

We learned from Tumeh et al. that in cutaneous melanoma, the response to anti-PD-1 antibodies is based on the presence of tumor-infiltrating lymphocytes with a high proportion of CD8+ T cells (24). In terms of response, this could translate to UM, such that the aforementioned increase in T cells in the melanoma environment due to tebentafusp-induced recruitment and activation of T cells in the vicinity of gp100-peptide HLA-presenting melanoma cells becomes crucial. In addition, *in vitro* studies have shown that tebentafusp enhanced epitope spreading, whereby tumor-associated antigens released by apoptotic tumor cells are captured and displayed by dendritic cells, which then induce T cells to lyse additional melanoma cells (25). It is further known that chronic activation induces an exhausted phenotype in T cells characterized by the expression of exhaustion markers and inhibitory checkpoints such as PD-1 (26). This suggests a sequential therapeutic regimen with tebentafusp followed by immune checkpoint inhibition as a logical next step. With regard to the cycle of cancer immunity (27), this can be interpreted as enhanced recruitment and infiltration of T cells into the tumor (steps 4 and 5 of the cycle of cancer immunity) by tebentafusp, including T cells that recognize cancer cells (step 6 of the cycle), and enhanced T cell-mediated killing of melanoma cells by anti-PD-1-based ICI (step 7 of the cycle). In addition, the combination with anti-CTLA-4 could promote priming and activation of additional T cells (step 3 of the cycle).

Our case report underlines this regime with an excellent response to ICI after previous progression on tebentafusp. Furthermore, we were able to detect selected driver and passenger mutations in the personalized liquid biopsy, that could be performed baseline before initiation of tebentafusp and afterward under ICI. With this approach we were able to detect the lowly-abundant *EZH1* variant with an AF of 0.15%, and sensitivity was only limited by sequencing depth. In principle, circulating tumor DNA (ctDNA) monitoring can also be used for response evaluation. It was shown that in patients who were treated with tebentafusp, ctDNA reduction correlated with survival but not necessarily RECIST response. However, repeated ctDNA evaluations are not yet part of the daily routine of clinical care. In our case the ctDNA result at the time point of progression under tebentafusp would have been interesting. However, we have here only the two points in time before the start of therapy with tebentafusp and after 4 cycles of combined immunotherapy.

The main limitation of our case is that only one radiological diagnosis was made before switching to combined ICI due to the

multifocal and extensive progression. In the phase III study, treatment beyond progression was allowed under certain circumstances (15).

Based on this, our patient would have been allowed to receive another round of treatment with tebentafusp under study conditions for at least 4 weeks. However, since the progression was severe and there were many new metastases, there probably would not have been enough time to wait for another progress and only then to change the treatment regime. We suppose that the immediate switch to combined ICI and the tumor microenvironment being optimized by tebentafusp that probably enriched relevant chemokines such as CXCL10 in the tumor, has been essential for the excellent response to ICI.

Patients receiving tebentafusp under study conditions beyond progression were required to permanently discontinue study treatment if a further progression occurred, defined as any of the following events occurring at least 4 weeks after the initial PD assessment:

- An additional increase in tumor burden of ≥ 20%.
- Progressive disease of non-target lesions.
- New non-measurable lesions (15).

For the future, we suggest to start first-line tebentafusp in case of non-resectable metastases of UM. If there are progressive findings in the first follow-up, a continuation with tebentafusp should be considered. In case of further progression of metastases, treatment with combined ICI might be an option. Further studies are necessary to compare prospectively the optimal treatment sequence of tebentafusp and ICI, added by ctDNA monitoring by NGS.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article. The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice and applicable regulatory requirements.

Author contributions

Conception and design: SR, AF. Acquisition of data: SR, CS, AF. Analysis and interpretation of data: SR, CS, TS, LF, AF. Writing, review, revision of the manuscript: all authors. Study supervision: AF, LF. All authors contributed to the article and approved the submitted version.

Acknowledgments

We thank the whole team of the melanoma outpatient department for their care for our melanoma patients and the patient for his participation in this study.

Conflict of interest

AF served as consultant to Immunocore, Roche, Novartis, MSD, BMS, Pierre-Fabre; received travel support from Roche, Novartis, BMS, Pierre-Fabre, received speaker fees from Roche, Novartis, BMS, MSD and CeGaT. AF and CS report institutional research grants from BMS Stiftung Immunonkologie. IB received speaker fees from Novartis, Bayer, Pfizer, Takeda and AstraZeneca and honoraria for advisory board participation from BMS and Novartis.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1167791/full#supplementary-material

SUPPLEMENTARY TABLE 1
Coding information of tumor variants selected for monitoring in cfDNA. GRCh38 was used as reference genome.

References

1. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. *Eye (Lond)* (2017) 31(2):241–57. doi: 10.1038/eye.2016.275

2. Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. *Indian J Ophthalmol* (2015) 63(2):93–102. doi: 10.4103/0301-4738.154367

3. Gallenga CE, Franco E, Adamo GG, Violanti SS, Tassinari P, Tognon M, et al. Genetic basis and molecular mechanisms of uveal melanoma metastasis: a focus on prognosis. *Front Oncol* (2022) 12:828112. doi: 10.3389/fonc.2022.828112

4. Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. *Br J Ophthalmol* (2017) 101(1):38–44. doi: 10.1136/bjophthalmol-2016-309034

5. Weis E, Salopek TG, McKinnon JG, Larocque MP, Temple-Oberle C, Cheng T, et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline. *Curr Oncol* (2016) 23(1):e57–64. doi: 10.3747/co.23.2859

6. Olofsson R, Cahlin C, All-Ericsson C, Hashimi F, Mattsson J, Rizell M, et al. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. *Ann Surg Oncol* (2014) 21(2):466–72. doi: 10.1245/s10434-013-3304-z

7. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. *J Clin Oncol* (2022) 40(2):127–37. doi: 10.1200/JCO.21.02229

8. Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Carrion Alonso L, Martin-Algarra S, et al. Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402). *J Clin Oncol* (2021) 39(6):586–98. doi: 10.1200/JCO.20.00550

9. Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. *J Clin Oncol* (2021) 39(6):599–607. doi: 10.1200/JCO.20.00605

10. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. *N Engl J Med* (2017) 377(25):2500–1. doi: 10.1056/NEJMc1713444

11. Bakhoum MF, Esmaeli B. Molecular characteristics of uveal melanoma: insights from the cancer genome atlas (TCGA) project. *Cancers (Basel)* (2019) 11(8):1061. doi: 10.3390/cancers11081061

12. Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight R.M, Orloff M, et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. *Immunotherapy* (2017) 9(16):1323–30. doi: 10.2217/imt-2017-0066

13. Streilein JW. Immunoregulatory mechanisms of the eye. *Prog Retin Eye Res* (1999) 18(3):357–70. doi: 10.1016/s1350-9462(98)00022-6

14. Wessely A, Steeb T, Erdmann M, Heinzerling L, Vera J, Schlaak M, et al. The role of immune checkpoint blockade in uveal melanoma. *Int J Mol Sci* (2020) 21(3):879. doi: 10.3390/ijms21030879

15. Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. *N Engl J Med* (2021) 385(13):1196–206. doi: 10.1056/NEJMoa2103485

16. Orloff M, Carvajal RD, Shoushtari AN, Sacco JJ, Schlaak M, Watkins C, et al. Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma. *J Clin Oncol* (2021) 39(15_suppl):9526–6. doi: 10.1200/JCO.2021.39.15_suppl.9526

17. Koch EC, Arteaga Ceballos DP, Vilbert M, Lajkosz K, Muniz Pimentel T, Hirsch I, et al. 831P outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp. *Ann Oncol* (2022) 33:S928. doi: 10.1016/j.annonc.2022.07.957

18. Dimitriou F, Hassel JC, Orloff M, Hughes I, Kapiteijn E, Mehmi I, et al. 832P treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). *Ann Oncol* (2022) 33:S929. doi: 10.1016/j.annonc.2022.07.958

19. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. *Cancer Immunol Res* (2017) 5(5):417–24. doi: 10.1158/2326-6066.CIR-16-0325

20. Forschner A, Battke F., Hadaschik D., Schulze M., Weissgraeber S., Han CT, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. *J Immunother Cancer* (2019) 7(1):180. doi: 10.1186/s40425-019-0659-0

21. Yang J, Orloff MM., Sacco JJ., Hernandez-Aya LF., Lee K., Merrick S., et al. Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC). *J Clin Oncol* (2019) 37(15_suppl):9592–2.

22. Shi Z, Shen J., Qiu J., Zhao Q., Hua K., Wang H. CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors. *Theranostics* (2021) 11(15):7175–87. doi: 10.7150/thno.59056

23. Idorn M, Thor Straten P. Chemokine receptors and exercise to tackle the inadequacy of T cell homing to the tumor site. *Cells* (2018) 7(8):108. doi: 10.3390/cells7080108

24. Tumeh PC, Harview CL., Yearley JH., Shintaku IP., Taylor EJ., Robert L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* (2014) 515(7528):568–71. doi: 10.1038/nature13954

25. Bossi G, Buisson S., Oates J., Jakobsen BK., Hassan NJ. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. *Cancer Immunol Immunother* (2014) 63(5):437–48. doi: 10.1007/s00262-014-1525-z

26. Agata Y, Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and b lymphocytes. *Int Immunol* (1996) 8(5):765–72. doi: 10.1093/intimm/8.5.765

27. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity* (2013) 39(1):1–10. doi: 10.1016/j.immuni.2013.07.012

frontiers | Frontiers in Oncology

TYPE Original Research
PUBLISHED 14 June 2023
DOI 10.3389/fonc.2023.1181537

OPEN ACCESS

EDITED BY
Ravi Prakash Sahu,
Wright State University, United States

REVIEWED BY
Hui Lu,
Zhejiang University, China
Ming Wang,
First Affiliated Hospital of Zhengzhou University, China
Yan Yan,
First Affiliated Hospital of Zhengzhou University, in collaboration with reviewer MW

*CORRESPONDENCE
Jun Guo
junguo66@163.com

RECEIVED 07 March 2023
ACCEPTED 09 May 2023
PUBLISHED 14 June 2023

CITATION
Deng T, Wang C, Gao C, Zhang Q and Guo J (2023) ITGAL as a prognostic biomarker correlated with immune infiltrates in melanoma.
Front. Oncol. 13:1181537.
doi: 10.3389/fonc.2023.1181537

ITGAL as a prognostic biomarker correlated with immune infiltrates in melanoma

TengFei Deng[1], Chaoyong Wang[2], Cong Gao[1], Qiang Zhang[1] and Jun Guo[1]*

[1]Plastic Surgery Department, Yangzhou University Affiliated Hospital, Yangzhou, China, [2]Medical College of Yangzhou University, Yangzhou, China

This study investigates the relationship between ITGAL expression and immune infiltration, clinical prognosis, and specific types of T cells in melanoma tissue. The findings reveal the key role of ITGAL in melanoma and its potential mechanism of regulating tumor immune infiltrating cells, highlighting its potential as a diagnostic biomarker and therapeutic target for advanced melanoma.

KEYWORDS

ITGAL, melanoma, prognostic biomarker, immune infiltrates, MIHC

1 Background

Malignant melanoma is a common, highly malignant tumor of the skin and mucosa, and its incidence rate ranks third among skin tumors (1). At present, the number of patients increases by 3%–5% every year, making it the fastest-growing malignant tumor in the world (2, 3). The 5-year overall survival rate of patients with melanoma is 92%, and the 5-year survival rate of patients with advanced metastasis (stage IV) is 23% (4). With the emergence of new treatment methods and targeted drugs, it has brought new hope and a breakthrough to treatment (5, 6). However, because malignant melanoma is prone to recurrence and metastasis, any specific treatment cannot improve the overall survival rate (7). To solve the difficulties in the treatment of melanoma, it is necessary to explore potential biomarkers related to the prognosis of melanoma patients and serve as potential therapeutic targets for these patients.

ITGAL, also known as CD11a, encodes an integrin component of lymphocyte function-associated antigen-1 (LFA-1). ITGAL was highly expressed on the surface of activated CD4+T cells in peripheral blood, damaged skin, and gastric mucosa (8, 9), regulating intercellular adhesion and lymphocyte costimulatory signals (10, 11). Some studies have proved that ITGAL is related to the occurrence and progression of tumors (12, 13), including accelerating the cell cycle process (13), participating in immune reactions, and affecting the tumor microenvironment (14–16). It has the potential to become a new target for malignant tumors. However, the pathogenesis of ITGAL and melanoma is still unclear.

In this study, we combined various databases and biological experiments to study the relationship between the expression of ITGAL and immune infiltration in melanoma, and

performed functional analysis of ITGAL-mediated TCGA-SKCM data. In addition, the relationship between the expression of ITGAL and CD4+ CD8+T cells in melanoma tissue sections was studied by multiple immunofluorescence staining. This study revealed the key role of ITGAL in melanoma and the mechanism by which ITGAL may regulate tumor immune infiltrating cells.

2 Materials and methods

2.1 Data acquisition

GTEx gene expression data, TCGA-SKCM (FPKM) gene expression data, and related clinical characteristics data were downloaded from the UCSC Xena database (https://xenabrowser.net/datapages/). Patients with incomplete clinical data were not included. We obtained the data on log2 (x + 0.001) conversion. A total of 472 patients (all from TCGA) and 556 normal controls (all from GTEx data, including non-sun-exposed suprapubic skin and sun-exposed lower leg skin) were included in this study. The gene names of all expression matrix data were annotated through the "ClusterProfiler" and "org.Hs.eg.db" software packages (17).

2.2 Material preparation

Melanoma B16 cell line and mouse fibroblast NIH/3T3 cell line were obtained from Beyotime (https://www.beyotime.com) and stored in RPMI-1640 (Gibco) containing 10% fetal bovine serum and 1% penicillin–streptomycin.

The 98 cases of fresh tissue after surgery were collected from the Affiliated Hospital of Yangzhou University, including 90 cases of melanoma tissue and eight cases of normal tissue. No patient received radiotherapy or chemotherapy before tissue collection. Each tissue from six samples was divided into two parts, one for WB and the rest to produce the tissue microarray (TMA).

2.3 GEPIA online database

Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn) is a public database developed by Peking University to compare gene expression differences between normal and tumor tissues. The dataset includes RNA sequencing and expression data from more than 9,000 tumor samples and 8,000 normal samples from TCGA and GTEx, including 33 malignant tumors (18). This study used the GEPIA database to analyze the expression level of ITGAL in TCGA-SKCM and its relationship to the prognosis and survival of patients.

2.4 Tumor immune estimation resource database analysis

The Tumor Immune Estimation Resource (TIMER2.0) database can explore the molecular characterization of different immune cells in various cancer types and analyze the correlation between gene expression and the infiltration of various types of immune cells, including B cells, CD8+T cells, CD4+T cells, monocytes, neutrophils, and dendritic cells (19).

2.5 TNMplot online database

The TNMplot online database (https://www.tnmplot.com) is a web tool for the comparison of gene expression in normal, tumor, and metastatic tissues. It uses multiple RNA-seq and microarray datasets to establish the largest transcriptomic cancer database at present, including nearly 57,000 samples, and it can explore any gene database to evaluate the expression differences in normal, cancer, and metastatic samples (20).

2.6 GSEA analysis for KEGG and GO functional analysis

Gene Set Enrichment Analysis (GSEA) is a computational method that determines whether *a priori*-defined set of genes shows statistically significant and concordant differences between two biological states. Gene set enrichment analysis is a method to infer biological pathway activity from gene expression data (21). According to the expression of ITGAL in the sample data, we divide the TCGA-SKCM dataset into ITGAL-HIGH and ITGAL-LOW groups, then Limma R package (22) for differential gene (DEG) analysis, R package ClusterProfiler (17, 23) for GSEA enrichment analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) path analysis for DEGs. We specified an adjusted P-value of <0.05 and an FDR q-value of <0.25 to be statistically significant.

2.7 Protein–protein interaction network analysis

We use the STRING (https://stringdb.org/) (24) online tool to select multiple proteins in *Homo sapiens* to analyze the protein–protein interaction (PPI) network of differentially expressed mRNA target genes. Cytoscape 3.8 and the cytoHubba plug-in are used for PPI network topology analysis, and finally, the top 10 hub target genes with high connectivity are selected.

2.8 Western blotting

Protease inhibitors were used in three cases of melanoma tissue and three cases of normal tissue in the radioimmunoprecipitation assay buffer. Prepare a 10% SDS-PAGE gel containing equal amounts of protein (30 μg protein from cell lysate or 40 ng purified protein), transfer it to a PVDF membrane after electrophoresis, and add 5% BSA for blocking buffer. Then add rabbit anti-ITGAL (1∶1,000) and GAPDH (1∶2,000) and put them in a refrigerator at 4 °C overnight. The following antibodies were used: rabbit anti-ITGAL (EP1285Y, Abcam) and rabbit anti-GAPDH (ab245355, Abcam).

2.9 Real-time quantitative polymerase chain reaction

We used TRIzol reagent (Invitrogen, USA) to extract total RNA from mouse melanoma B16 cell lines and mouse fibroblast NIH/3T3 cell lines for quantitative PCR (qRT-PCR). The primers used for qRT-PCR had reaction conditions of 95 °C for 30 s, 95 °C for 5 s, and 60 °C for 30 s, for a total of 40 cycles. The ITGAL primer sequence is as follows:

forward 5′-CTGCTTTGCCAGCCTCTCTGT-3′
reverse 5′-GCTCACAGGTATCTGGCTATGG-3′

The β-actin primer sequence is as follows:

forward 5'-GGCTGTATTCCCCTCCATCG-3'-3′
reverse 5'-CCAGTTGGTAACAATGCCATGT-3

using $2^{-\Delta\Delta}$ Ct method.

2.10 Multiplexed immunohistochemistry

The melanoma tissue microarray (TMA) (90 cases of melanoma tissues, eight cases of normal tissues) is used for mIHC staining. Firstly, the tissue section is used for dewaxing and repairing antigen, and fixed with an appropriate fixing solution, and then added with an immune staining blocking solution and antibody for MIHC staining. After triple fluorescence staining with red fluorescence, green fluorescence, and blue fluorescence, the slide was scanned with the Vectra 3.0 automatic quantitative pathological imaging system to detect and measure the positive rate of biomarkers: rabbit anti-ITGAL (EP1285Y, Abcam),



FIGURE 1
(A) ITGAL mRNA expression in pan-cancer. **(B)** ITGAL mRNA expression in TCGA-SKCM. **(C)** The qPCR result for the TGAL gene showed high expression in melanoma B16 cells. **(D)** The WB result for the TGAL gene showed high expression in melanoma tissue.



FIGURE 2
(A) ITGAL mRNA expression in normal, tumor, and metastatic tissues. **(B)** ITGAL mRNA expression in different stages of melanoma. **(C)** The Kaplan–Meier curve shows that the high ITGAL group had a better prognosis. **(D)** The IHC result for the TGAL gene showed high expression in melanoma tissue.

TABLE 1 The correlation between ITGAL and clinicopathological features.

Characteristic	Total No.	Low or No Expression, No(%)	High Expression, No(%)	Pearson $\chi 2$	P-Value
Total No.	472	236(50.00)	236(50.00)		
Sex	472			2.158	0.14
Man	293	153	140		
Fenale	179	81	98		
Age(year)	471			4.671	***
≤60	249	112	137		
>60	222	122	100		
T	395			21.996	***
Ts+T1	72	21	51		
T2	79	39	40		
T3	91	42	49		
T4	153	95	58		

(Continued)

TABLE 1 Continued

Characteristic	Total No.	Low or No Expression, No(%)	High Expression, No(%)	Pearson $\chi 2$	P-Value
Total No.	472	236(50.00)	236(50.00)		
N	414			1.552	0.67
N0	235	122	113		
N1	74	38	36		
N2	49	22	27		
N3	56	25	31		
M	443			0.396	0.53
M0	418	207	211		
M1	25	14	11		
breslow_depth (mm)	360			21.61	***
< 1.0mm	50	12	38		
≥1mm and ≤4mm	167	79	88		
>4.0mm	143	88	55		
Clark's Level	322			17.239	***
Clark's Level I	6	3	3		
Clark's Level II:	18	3	15		
Clark's Level III	77	30	47		
Clark's Level IV	168	98	70		
Clark's Level V	53	30	23		

*** mean p<0.001.

rabbit anti-CD4 (EPR6855, Abcam), and rabbit anti-CD8 (CAL66, Abcam). The secondary antibody was Opal™ polymer HRP Ms+Rb (ARH1001EA, Perkin Elmer). Fluoroshield with DAPI (ab104139, Abcam) was used to stain the nuclei and seal the slices.

2.11 Statistical methods

In this study, the mean ± standard deviation (x ± s) was used to describe the expression of the ITGAL gene. The difference between the groups was analyzed by an independent t-test. The Kaplan–Meier method was used to determine the relationship between the expression of ITGAL and the prognosis of melanoma. A log-rank test was used for comparison between the groups. The difference between the two sides was statistically significant (P <0.05). Pearson correlation is used to evaluate the correlation between two gene expression data sets, and its value lies in the range of −1 to 1.

3 Results

3.1 Assessment of ITGAL expression in different cancer and normal tissues

We first assessed the expression of the ITGAL gene in different tumors using the GEPIA database and found that the gene was lowly expressed in kidney chromophobe (KICH), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma (READ), thyroid carcinoma (THCA), and thymoma (THYM) compared to normal tissues. We also found that ITGAL was highly expressed in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), and testicular germ cell tumor (TGCT) compared to normal tissue controls (e.g., Figure 1A). We used the GEPIA database to validate the expression of ITGAL in melanoma (e.g., Figure 1B). Then the results of qPCR verified that ITGAL was highly expressed in B16 cells of melanoma (e.g., Figure 1C). Further, the results of Western blotting showed that ITGAL was highly expressed in melanoma compared to normal tissue controls (e.g., Figure 1D). These results suggest that ITGAL is



FIGURE 3
(A) The correlation between ITGAL mRNA expression and different TILs. **(B–J)** The correlation between ITGAL mRNA expression and different biomarkers of TILs.

highly expressed in melanoma tissues and may be a potential diagnostic biomarker for melanoma.

3.2 High expression of ITGAL is associated with clinicopathological features

Although histological classification or clinical stage can help predict the prognosis of melanoma patients, there is still a need to explore the relationship between ITGAL expression and clinical features.

As shown in Figure 2A, TNMplotter database analysis showed that ITGAL gene expression increased sequentially in normal tissue, primary melanoma, and metastatic melanoma, which we further validated using immunohistochemical staining to obtain similar results (e.g., Figure 2D). Next, we analyzed the expression of ITGAL in different stages using the TCGA dataset of GEPIA. The results showed that ITGAL was significantly underexpressed in Stage II (e.g., Figure 2B). The results of Figure 2C indicate that high expression of ITGAL is associated with a good prognosis. This can be explained by the fact that high expression of ITGAL enhances the immune response.

We also analyzed the correlation between ITGAL expression and clinical–pathological features using clinical data from TCGA-SKCM after removing incomplete data. Detailed results are shown in Table 1.

These results suggest that ITGAL may be involved in the development of melanoma.

3.3 ITGAL expression correlated with immune cell infiltration in melanoma

The survival rate and lymph node metastasis rate are related to immune infiltration in melanoma (25–27). Therefore, we use the TIMER and TISIDB databases to explore the relationship between the expression of ITGAL and the immune infiltration in melanoma. In this study, the expression of ITGAL was negatively correlated with the purity of melanoma. The results showed that ITGAL was significantly correlated with most immune cells (see Figure 3A).

Among them, CD8+T cells (rho = 0.322), CD4+T cells (rho = 0.487), B cells (rho = 0.218), monocytes (rho = 0.791), neutrophils (rho = 0.666), T-cell regulation (rho = 0.38), NK cells (rho = 0.77), and myeloid dendritic cells (rho = 0.695) had a significant association with ITAGL. These results indicate that ITGAL plays an important role in the immune infiltration of melanoma. At the same time, we used the TIMER and GEPIA databases to explore the correlation between ITGAL and biomarkers of different tumor-infiltrating lymphocytes (TILs) in melanoma (e.g., Figures 3B-L). The results showed that ITGAL had a strong correlation with biomarkers of most immune cells. Further, we used GEPIA to verify and get similar results. We analyzed immune T cells (Th1/Th2/Th17/Tfh cells, Tregs, and exhausted T cells), as shown in Table 2.

3.4 Results of mIHC confirmed that the expression status of ITGAL is correlated with the levels of CD8+ T cells and CD4+T cells

Next, we use mIHC technology to explore the relationship between ITAGAL and CD4+ and CD8+T cells in immune infiltrates in melanoma. We used computer image techniques to perform spatial analysis of different T cells at the same location of the tissue sample, and the results are shown in Figure 4A.

The results confirmed that almost all samples had different grades of immune cell infiltration. We divided samples into ITGAL-high and ITGAL-low expression groups according to the level of median expression of ITGAL. Compared with the low expression group of ITGAL, the infiltration of CD4+T cells and CD8+T cells in the high expression group of ITGAL was significantly enhanced ($P < 0.05$).

In addition, we divided the sample into two groups: metastatic melanoma and primary melanoma. According to the expression of ITGAL in different groups, the results revealed that the level of immune cell infiltration increased with the progression of melanoma (e.g., Figure 4).

3.5 Relationships of ITGAL with immune checkpoint genes and cytokines

In addition to PD1/PD-L1, CTLA-4, LAG-3, TIM-3, and TIGIT are potential melanoma checkpoints in the future (28, 29). We used TIMER and GEPIA to explore the correlation between ITGAL and these immune checkpoints. As shown in Figures 5A–F, the expression level of ITGAL has a significant positive correlation with PD1/PD-L1, CTLA-4, LAG-3, TIM-3, and TIGIT. Then we used GEPIA to verify and get similar results (e.g., Figures 5G-N). These results suggest that tumor immune escape may participate in ITGAL-mediated melanoma.

TABLE 2 The correlation between ITGAL and biomarkers of immune cells.

Description	Gene marker	SKCM		SKIN(not sun exposed)	
		Cor	P	Cor	P
CD8+ T cell	CD8A	0.82	***	0.56	***
	CD8B	0.84	***	0.42	***
T cell (general)	CD3D	0.93	***	0.57	***
	CD3E	0.95	***	0.62	***
	CD2	0.93	***	0.73	***
B cell	CD19	0.6	***	0.11	0.087
	CD79A	0.64	***	0.35	***
Monocyte	CD86	0.79	***	0.47	***
	CD115(CSF1R)	0.6	***	0.63	***
TAM	CCL2	0.37	***	0.22	***
	CD68	0.39	***	0.32	***
	IL10	0.31	***	0.31	***
M1 Macrophage	CD80	0.72	***	0.43	***
	IRF5	0.65	***	0.23	***

(Continued)

TABLE 2 Continued

Description	Gene marker	SKCM		SKIN(not sun exposed)	
		Cor	P	Cor	P
	CD64	0.67	***	0.26	***
M2 Macrophage	CD163	0.45	***	0.25	***
	CD206	0.39	***	0.35	***
	VSIG4	0.49	***	0.29	***
	MS4A4A	0.57	***	0.42	***
Neutrophils	CD14	0.55	***	0.42	***
	CD11b(ITGAM)	0.57	***	0.48	***
	CCR7	0.66	***	0.15	***
Natural killer cell	IL2RB (CD122)	0.9	***	0.19	***
	CD244	0.57	***	0.44	***
	NCR1	0.41	***	0.43	***
	KLRD1	0.68	***	0.29	***
	ITGB2	0.84	***	0.47	***
Dendritic cell	CD209	0.53	***	0.49	***
	BTLA	0.6	***	0.53	***
	CLEC10A	0.71	***	0.71	***
	CD1C	0.57	***	0.62	***
	ID2	0.28	***	0.18	***
	CD11c(ITGAX)	0.58	***	0.44	***
Th1	T-bet(TBX21)	0.85	***	0.56	***
	STAT4	0.86	***	0.61	***
	STAT1	0.53	***	0.31	***
	IFN-r(IFNG)	0.72	***	0.28	***
	TNF-a(TNF)	0.54	***	0.06	***
Th2	GATA3	0.21	***	0.12	***
	STAT5A	0.27	***	0.27	***
	CCR3	0.67	***	0.11	***
	IL13	0.26	***	0.13	***
Tfh	BCL6	0.17	***	0.11	***
	IL21	0.7	***	0.04	***
Th17	BATF	0.6	***	0.28	***
	STAT3	0.16	***	0.15	***
Treg	FOXP3	0.77	***	0.29	***
	CCR8	0.66	***	0.34	***
	STAT5B	0.33	***	0.35	***
	TGFB(TGFB1)	0.36	***	0.2	***
T cell exhaustion	PD-1(PDCD1)	0.85	***	0.36	***
	PDL1(PDCD1LG2)	0.46	***	0.43	***

(Continued)

TABLE 2 Continued

Description	Gene marker	SKCM		SKIN(not sun exposed)	
		Cor	P	Cor	P
	CTLA4	0.2	***	0.39	***
	LAG3	0.72	***	0.22	***
	TIM-3(HAVCRP2)	0.78	***	0.48	***
	GZMB	0.57	***	0.5	***

*** mean p<0.001.

3.6 Functional enrichment analysis of DEGs from high-ITGAL and low-ITGAL groups

According to the expression level of TGAL, we divided the TCGA-SKCM dataset into high-ITGAL and low-ITGAL groups. R packages limma for differential expression (DE) analysis; there are 1,000 DEGs in total, including two upregulated genes and 998 downregulated genes (e.g., Figure 6A). Then we perform KEGG and GO functional analysis, and the results are shown in Figures 6B, C.

3.7 Protein–protein interaction analysis

Then we construct a PPI network using TOP 200 DEGs to explore the related functions of differential genes (e.g., Figure 7A).



FIGURE 4
(A) The infiltration of CD4+T cells and CD8+T cells was significantly enhanced in the high-ITGAL group. **(B)** The infiltration of CD4+T cells and CD8+T cells was significantly enhanced in the metastatic melanoma group.

Then, using the cytoHubba plug-in (30), we obtained 10 hub genes (e.g., Figure 7B). We used GEPIA to explore the relationship between ITGAL and these hub genes in melanoma. We found that CRTAM, IKZF3, GPR174, IL-21, and TNFRSF13B were significantly positively correlated with the expression of ITGAL (e.g., Figures 7C–N).

4 Discussion

In this study, we explored the expression levels and clinical features of ITGAL in melanoma by systematically analyzing data from public databases and clinically collected samples. Our study revealed that there was a relationship between high expression of ITGAL and a favorable prognosis. Furthermore, our results also showed that different immune cells and immune checkpoints were associated with higher expression of ITGAL. Thus, our study provides a novel perspective and evidence for understanding the critical function of ITGAL in melanoma, which may be an immune infiltration-related prognostic indicator.

We found that ITGAL was aberrantly expressed in different tumor tissues through databases, including GEPIA, Timer, TCGA, and TNMplotter. In particular, the results showed that ITGAL was highly expressed in melanoma. Subsequently, comparing the



FIGURE 5
(A–F) The correlation between ITGAL and PD1, PD-L1, CTLA-4, LAG-3, TIM-3, and TIGIT in the TIMER2.0 database. **(G–L)** The correlation between ITGAL and PD1, PD-L1, CTLA-4, LAG-3, TIM-3, and TIGIT in the GEPIA2 database.



FIGURE 6
(A) Volcano plot of DEGs. **(B, C)** KEGG and GO functional analysis for DEGs.

normal cells and tissue samples, we validated that ITGAL was highly expressed in melanoma samples using qPCR, WB, and mIHC. These results suggest that the expression of the ITGAL may serve as a potential diagnostic indicator for SKCM.

Next, we performed functional enrichment analysis of DEGs between high and low ITGAL, and the results showed that there were obvious correlations between DEGs and cytokine–cytokine receptor interaction, T-cell receptor signaling pathway, B-cell receptor signaling pathway, and hematopoietic cell lineage. It also implicates cytokine–cytokine activity, and the T-cell receptor signaling pathway plays an important role in the progression of ITGAL-mediated melanoma. We performed a correlation analysis on hub genes by using the GEPIA database and identified that the expression of ITGAL was positively correlated with cytokines, including CRTAM, IKZF3, GPR174TL6, IL-21, and TNFRSF13B.

Among these hub genes, class I-restricted T-cell-associated molecule (CRTAM) is a marker of CD4 CTL (31), as well as an early activation marker of NK and CD8+ T cells. CRTAM binds to its ligand, cell adhesion molecule-1 (32, 33). IKAROS Family Zinc Finger 3 (IKZF3) is a transcription factor that plays an important role in the regulation of B-lymphocyte activation, proliferation, and differentiation (34). G protein-coupled receptor 174 (GPR174), which regulate diverse aspects of T-cell activity and effector function, also plays an important role in the suppression of T-cell proliferation (35). IL-21 is a cytokine mainly produced by CD4+ T cells and natural killer T (NKT) cells. IL-21/IL-21 receptor (IL-21R)

10.3389/fonc.2023.1181537



FIGURE 7
(A) The PPI network of DEGs. **(B)** The hub genes of DEGs. **(C–I)** The correlation between ITGAL and the hub genes, including CRTAM, IKZF3, GPR174, IL-21, and TNFRSF13B.

signaling is important for the proliferation and differentiation of T cells, B cells, natural killer (NK) cells, macrophages, and dendritic cells (DCS) (36, 37). TNFRSF13B is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. This protein induces the activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a key role in humoral immunity by interacting with TNF ligands (38).

Cytokines are potent regulators of multiple cellular functions and activities, especially in the immune system (25). A review of the literature indicates that elevated expression of these cytokines, which are positively correlated with ITGAL expression, is all involved in promoting tumor cell survival, stemness, and proliferation (26, 27). For example, the tumor necrosis factor (TNF) superfamily can activate signaling pathways that regulate cell survival, death, and differentiation (39).

In the immune infiltration analysis, we found that the expression of ITGAL was significantly associated with multiple immune cells. Including CD4+ T cells, CD8+ T cells, Treg cells, B cells, neutrophils, Tam, DCS, NK cells, and monocytes. CD4+ T cells recognize peptides (about 13–17aa long) bound to the groove of MHC class II molecules (40) and participate in signal transduction by the T-cell antigen receptor (TCR) (41). In melanoma, CD4+ T cells can also activate CD8+ T cells to differentiate into cytotoxic T lymphocytes (CTLs), while maintaining and boosting the antitumor responses of CTLs (42, 43).

Our results showed that high expression of ITGAL was significantly positively correlated with CD4+ T cells and CD4+ T

cells in melanoma. The high expression of ITGAL was involved in the T-cell receptor signaling pathway. Further exploration revealed that ITGAL (CD11a) is a cell surface molecule that forms the LFA-1 complex by binding to the CD18 subunit. LFA-1 is an important adhesion molecule expressed on immune cells that can bind to its ligand, intercellular adhesion molecule-1 (ICAM-1). The LFA-1/ICAM-1 complex plays a role in immune T-cell adhesion, migration, and activation by increasing the production of IL-2 (44, 45), exhibiting anti-inflammatory and anti-tumor effects. ITGAL can promote an increase in the ratio of CD4 and CD8 T cells, improving the survival rate of patients with metastatic melanoma, which may explain why high expression of ITGAL is associated with a better prognosis.

Furthermore, the LFA-1/ICAM-1 complex has been found to be associated with the growth and metastasis of various cancers (46). In particular, the interaction between LFA-1/ICAM-1 and melanoma cells may activate signaling pathways, enhancing the invasive and metastatic abilities of melanoma cells. During the co-culture of melanoma and endothelial cells, Deshayes et al. (44) demonstrated that ICAM-1 and LFA-1 induction allowed melanoma cells to penetrate the endothelial layer *in vitro*, thus enhancing the migration ability of tumor cells. Our mIHC analysis of multiple clinical tissue samples further demonstrated the association between ITGAL and melanoma invasion, but the specific mechanisms still require further exploration through animal experiments.

Immune checkpoint inhibitors (ICIs) are now the mainstay of treatment for melanoma (47). PD1/PDL1 checkpoint blockade therapy is part of the standard therapy for melanoma (48), but because of immune tolerance, it has resulted in poor clinical outcomes in some patients treated with PD-1 pathway blockade (49). Our results show that increased expression of ITGAL is associated not only with PD1 and CTLA4, but also with other potential melanoma checkpoints (LAG-3, Tim-3, and TIGIT).

However, our study has some limitations. First, because most of the results are based on online platform databases, which would be discrepant, and second, further experiments are required to validate immune-related molecular mechanisms underlying the function of ITGAL in melanoma, which will be a future study.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Affiliated Hospital of Yangzhou University Ethics Committee, Affiliated Hospital of Yangzhou University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

TD conceived of the presented idea and finished the work. CW provided technical guidance in the biological experiment. CG helped with the clinical ethics application. QZ and JG provided writing and editing guidance. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

References

1. Mastoraki A, Schizas D, Ntella V, Roka A, Vailas M, Papanikolaou IS, et al. Clinical evidence, diagnostic approach and challenging therapeutic modalities for malignant melanoma of the anorectu [J]. *ANZ J Surg* (2021) 91:276–81.

2. Ortiz-Álvarez J, Durán-Romero AJ, Hernández-Rodríguez JC, Sendín-Martin M, Conejo-Mir J, Pereyra-Rodriguez J-J, et al. Cutaneous malignant melanoma mortality in Andalusia from 1979 to 2018. toward new perspectives? *Dermatol Ther* (2021) 34(1): e14715. doi: 10.1111/dth.14715

3. Neena A, Vineet K. Detection of malignant melanoma with supervised learning:A review. *Natl J System Inf Tech–nol* (2018) 11 (1):45–54.

4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA: Cancer J Clinic.* (2019) 69:7–34. doi: 10.3322/caac.21551

5. Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, et al. Systemic therapy for melanoma:AS– CO guideline. *J Clin Oncol* (2020) 38 (33):3947–70. doi: 10.1200/JCO.20.00198

6. Jin GQ, Cheah P, Qu J, Liu L, Zhao Y. Applications of nanomaterials for theranos – tics of melanoma. *J Nanotheranostics* (2020) 1 (1):39–55. doi: 10.3390/jnt1010004

7. Zhang X, Ding C, Tian H, Dong X, Meng X, Zhu W, et al. ZNF23 suppresses cutaneous melanoma cell malignancy *via* mitochondria-dependent pathway. *Cell Physiol Biochem* (2017) 43:147–57. doi: 10.1159/000480333

8. Stummvoll GH, Aringer M, Grisar J, Steiner CW, Smolen JS, Knobler R, et al. Increased transendothelial migration of scleroderma lymphocytes. *Ann Rheum Dis* (2004) 63:569–74. doi: 10.1136/ard.2002.004838

9. Manetti M, Neumann E, Müller A, Schmeiser T, Saar P, Milia AF, et al. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. *Arthritis Rheum* (2008) 58:2866–73. doi: 10.1002/art.23806

10. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol* (2007) 7 (9):678–89. doi: 10.1038/nri2156

11. Samatov TR, Tonevitsky AG, Schumacher U. Epithelialmesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. *Mol Cancer* (2013) 12(1):107. doi: 10.1186/1476-4598-12-107

12. Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. *Trends Cel Biol* (2015) 25(4):234–40. doi: 10.1016/j.tcb.2014.12.006

13. Xie J, Guo T, Zhong Z, Wang N, Liang Y, Zeng W, et al. ITGB1 drives hepatocellular carcinoma progression by modulating cell cycle process through PXN/YWHAZ/AKT pathways. *Front Cel Dev Biol* (2021) 9:711149. doi: 10.3389/fcell.2021.711149

14. Boguslawska J, Kedzierska H, Poplawski P, Rybicka B, Tanski Z, Piekielko-Witkowska A. Expression of genes involved in cellular adhesion and extracellular matrix remodeling correlates with poor survival of patients with renal cancer. *J Urol* (2016) 195(6):1892–902. doi: 10.1016/j.juro.2015.11.050

15. Song Y, Pan Y, Liu J. The relevance between the immune ResponseRelated gene module and clinical traits in head and neck squamous cell carcinoma. *Cmar* (2019) 11:7455–72. doi: 10.2147/cmar.S201177

16. Ji C, Li Y, Yang K, Gao Y, Sha Y, Xiao D, et al. Identification of four genes associated with cutaneous metastatic melanoma. *Open Med (Wars)* (2020) 15(1):531–9. doi: 10.1515/med-2020-0190

17. Yu G, Wang LG, Han Y, He QY. Clusterprofiler: an r package for comparing biological themes among gene clusters. *OMICS* (2012) 16:284–7. doi: 10.1089/omi.2011.0118

18. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* (2017) 45 (W1):W98–w102. doi: 10.1093/nar/gkx247

19. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Res* (2020) 48(W1):W509–14. doi: 10.1093/nar/gkaa407

20. Bartha Áron, Győrffy Balázs. TNMplot. com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. *Int J Mol Sci* (2021) 22.5 (2021):2622. doi: 10.3390/ijms22052622

21. Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, cytoscape and EnrichmentMap. *Nat Protoc* (2019) 14:482–517. doi: 10.1038/s41596-018-0103-9

22. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007

23. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. *Innovation* (2021) 2(3):100141. doi: 10.1016/j.xinn.2021.100141

24. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res* (2021) 49 (D1):D605–12. doi: 10.1093/nar/gkaa1074

25. Lin JX, Leonard WJ. Fine-tuning cytokine signals. *Annu Rev Immunol* (2019) 37:295–324. doi: 10.1146/annurev-immunol-042718-041447

26. Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. *Nat Rev Clin Oncol* (2022) 19(4):237–53. doi: 10.1038/s41571-021-00588-9

27. Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. *Cancers* (2020) 12(7):1765. doi: 10.3390/cancers12071765

28. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. *Mol Cancer* (2019) 18:1–14. doi: 10.1186/s12943-019-1091-2

29. Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. *Immunol Cell Biol* (2018) 96(1):21–33. doi: 10.1111/imcb.1003

30. Chin CH, Chen SH, Wu HH, Ho C-W, Ko M-T, Lin C-Y, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* (2014) 8(4):1–7. doi: 10.1186/1752-0509-8-S4-S11

31. Takeuchi A, Badr Mel S, Miyauchi K, Ishihara C, Onishi R, Guo Z, et al. CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. *J Exp Med* (2016) 213:123–38. doi: 10.1084/jem.20150519

32. Galibert L, GS D, Liu Z, RS J, JL S, Walzer T, et al. Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-i-restricted T-cell-associated molecule. *J Biol Chem* (2005) 280:21955–64. doi: 10.1074/jbc.M502095200

33. Arase N, Takeuchi A, Unno M, Hirano S, Yokosuka T, Arase H, et al. Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells. *Int Immunol* (2005) 17:1227–37. doi: 10.1093/intimm/dxh299

34. Sigvardsson M. Molecular regulation of differentiation in early b-lymphocyte development. *Int J Mol Sci* (2018) 19(7):1928. doi: 10.3390/ijms19071928

35. Barnes MJ, Cyster JG. Lysophosphatidylserine suppression of T-cell activation *via* GPR 174 requires gαs proteins. *Immunol Cell Biol* (2018) 96(4):439–45. doi: 10.1111/imcb.12025

36. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. *Nat Rev Immunol* (2005) 5(9):688–98. doi: 10.1038/nri1688

37. Gharibi T, Hosseini A, Marofi F, Oraei M, Jahandideh S, Abdollahpour-Alitappeh M, et al. IL-21 and IL-21-producing T cells are involved in multiple sclerosis severity and progression. *Immunol Lett* (2019) 216:12–20. doi: 10.1016/j.imlet.2019.09.003

38. Gardam S, Brink R. Non-canonical NF-κB signaling initiated by BAFF influences b cell biology at multiple junctures. *Front Immunol* (2014) 4:509. doi: 10.3389/fimmu.2013.00509

39. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* (2003) 3(9):745–56. doi: 10.1038/nri1184

40. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CAJr. Sequence analysis of peptides bound to MHC class II molecules. *Nature* (1991) 353:622–7. doi: 10.1038/353622a0

41. Weiss A, Irving BA, Tan LK, Koretzky GA. Signal transduction by the T cell antigen receptor[C]//Progress in immunology, in: *Proceedings of the 7 th International Congress Immunology Berlin 1989*, Vol. VII. pp. 687–92. Berlin; Heidelberg: Springer (1989). Available at: https://link.springer.com/chapter/10.1007/978-3-642-83755-5_93.

42. Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. *J Cell Physiol* (2019) 234(6):8509–21. doi: 10.1002/jcp.27782

43. Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. *Eur J Immunol* (2007) 37(6):1678–90. doi: 10.1002/eji.200636329

44. Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F, et al. LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines *in vitro*. *BMC Cancer* (2012) 12(1):1–11. doi: 10.1186/1471-2407-12-455

45. Chen T, Goldstein JS, O'Boyle K, Whitman MC, Brunswick M, Kozlowski S, et al. ICAM-1 co-stimulation has differential effects on the activation of CD4+ and CD8 + T cells. *Eur J Immunol* (1999) 29(3):809–14. doi: 10.1002/(SICI)1521-4141(199903)29:03<809::AID-IMMU809>3.0.CO;2-X

46. Reina M, Espel E. Role of LFA-1 and ICAM-1 in cancer. *Cancers* (2017) 9 (11):153. doi: 10.3390/cancers9110153

47. Jang SR, Nikita N, Banks J, Keith SW, Johnson JM, Wilson M, et al. Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma. *JAMA Network Open* (2021) 4(12):e2136823. doi: 10.1001/jamanetworkopen.2021.36823

48. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. *Clin Ther* (2015) 37(4):764–82. doi: 10.1016/j.clinthera.2015.02.018

49. Shergold AL, Millar R, Nibbs RJB. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. *Pharmacol Res* (2019) 145:104258. doi: 10.1016/j.phrs.2019.104258

frontiers | Frontiers in Oncology

TYPE Original Research
PUBLISHED 23 June 2023
DOI 10.3389/fonc.2023.1181164

OPEN ACCESS

EDITED BY
Ravi Prakash Sahu,
Wright State University, United States

REVIEWED BY
Hui Lu,
Zhejiang University, China
Tingsong Chen,
Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, China

*CORRESPONDENCE
Junwei Cai
cjw90107@smu.edu.cn
Tieliu Shi
tieliushi@yahoo.com
Jinghua Liu
liujhua@smu.edu.cn

†These authors have contributed equally to this work

RECEIVED 07 March 2023
ACCEPTED 07 June 2023
PUBLISHED 23 June 2023

CITATION
Wan Y, Shen J, Hong Y, Liu J, Shi T and Cai J (2023) Mapping knowledge landscapes and emerging trends of the biomarkers in melanoma: a bibliometric analysis from 2004 to 2022.
Front. Oncol. 13:1181164.
doi: 10.3389/fonc.2023.1181164

Mapping knowledge landscapes and emerging trends of the biomarkers in melanoma: a bibliometric analysis from 2004 to 2022

Yantong Wan[1†], Junyi Shen[2†], Yinghao Hong[1†], Jinghua Liu[1*], Tieliu Shi[3,4*] and Junwei Cai[1*]

[1]Guangdong Provincial Key Laboratory of Proteomics, Department of Pathophysiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China, [2]The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China, [3]The Center for Bioinformatics and Computational Biology, Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China, [4]Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing, China

Background: Melanoma is a skin tumor with a high mortality rate, and early diagnosis and effective treatment are the key to reduce its mortality rate. Therefore, more and more attention has been paid for biomarker identification for early diagnosis, prognosis prediction and prognosis evaluation of melanoma. However, there is still a lack of a report that comprehensively and objectively evaluates the research status of melanoma biomarkers. Therefore, this study aims to intuitively analyze the research status and trend of melanoma biomarkers through the methods of bibliometrics and knowledge graph.

Objective: This study uses bibliometrics to analyze research in biomarkers in melanoma, summarize the field's history and current status of research, and predict future research directions.

Method: Articles and Reviews related to melanoma biomarkers were retrieved by using Web of Science core collection subject search. Bibliometric analysis was performed in Excel 365, CiteSpace, VOSviewer and Bibliometrix (R-Tool of R-Studio).

Result: A total of 5584 documents from 2004 to 2022 were included in the bibliometric analysis. The results show that the number of publications and the frequency of citations in this field are increasing year by year, and the frequency of citations has increased rapidly after 2018. The United States is the most productive and influential country in this field, with the largest number of publications and institutions with high citation frequency. Caroline Robert, F. Stephen Hodi, Suzanne L. Topalian and others are authoritative authors in this field, and The New England Journal of Medicine, Journal of Clinical Oncology and Clinical Cancer Research are the most authoritative journals in this field. Biomarkers related to the diagnosis, treatment and prognosis of melanoma are hot topics and cutting-edge hotspots in this field.

Conclusion: For the first time, this study used the bibliometric method to visualize the research in the field of melanoma biomarkers, revealing the trends and frontiers of melanoma biomarkers research, which provides a useful reference for scholars to find key research issues and partners.

KEYWORDS

melanoma, VOSviewer, CiteSpace, biomarker, visual analysis

1 Introduction

Melanoma is a malignant tumor derived from melanocytes, which mainly occurs in human skin, mucous membranes, conjunctiva, extremities and other parts (1, 2). As a rare disease, melanoma accounts for only 4% of skin cancer cases, but it has a very high fatality rate, accounting for 75% of all skin cancer deaths (3). In the past 30 years, the incidence of melanoma worldwide has increased steadily (4). In the United States alone, an estimated 99,780 new cases of cutaneous melanoma will be diagnosed and 7,650 deaths will occur in 2022 (5). The pathogenesis of melanoma is closely related to external factors, and the most important risk factor is ultraviolet radiation (6). Evidences show that a large number of UV-characteristic mutations, such as C→T and G→T, can be observed in melanoma cells (2, 7). In addition, ultraviolet rays can also suppress the immune system locally or systemically, creating conditions for immune evasion of cancer cells (1). Other risk factors associated with melanoma include the number of moles, age, and family history of skin cancer (1, 8, 9). In terms of genetics, the onset of melanoma is closely related to chromosomal aberrations and gene mutations in melanocytes (10, 11). Studies have reported that the loss of the tumor suppressor gene p16 is closely related to the occurrence of sporadic and familial melanoma (10). In addition, mutations in genes such as cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase 4 (CDK4) have been shown to be the most common genetic variants in familial melanoma (10).

Mucosal melanoma distributed in the rectum, eyes, mouth, and nasopharynx is usually difficult to detect in the early stage, and it has a high degree of malignancy and a poor prognosis as the disease progresses (12). Therefore, it is important to find a method that can assist in the early detection and treatment of melanoma. Biomarkers are tumor or host-related factors that correlate with tumor biological behavior and patient prognosis (13). In recent years, with the in-depth researches on the genetic basis and molecular mechanism of melanoma, the application value of biomarker in the diagnosis and treatment of melanoma has received more and more attention (14). In terms of diagnosis, as antibodies to melanoma antigens, Melan-A and MATT-1 are the most widely used biomarkers for the diagnosis of melanoma, with extremely high sensitivity (3, 14, 15). In addition, Biomarkers such as S100 protein, micropthlamia transcription factor (MITF), tyrosinase and SOX10 are also widely used in the diagnosis of melanoma (16–18). In terms of treatment, melanocyte proliferation markers can be used to assess the cycle activity of diseased cells to clarify the degree of malignancy of the tumor (19). Ki-67, phosphohistone H3 (PHH3), etc. are common proliferation markers, which can be used clinically to evaluate the therapeutic effect of melanoma (20, 21). Notably, serological markers such as lactate dehydrogenase (LDH) can also be used for the assessment of melanoma prognosis (16). In addition, related Biomarkers have also been applied to the evaluation of melanoma treatment effects. For example, blocking PD-1/PD-L1 is an attractive cancer immunotherapy strategy, and PD-L1 immunohistochemistry is currently widely used to predict the efficacy of melanoma treatment response (22–24).

Bibliometric analysis is a method of qualitative and quantitative review and analysis of research in a specific research field within a specific time period using mathematical and statistical methods (25). This method can focus on countries, institutions, journals, authors and keywords related to research in a specific field, providing readers with objective field development trends and cutting-edge hotspots (26, 27). Bibliometric analysis has been applied in many fields closely related to melanoma biomarker, including immune checkpoint blockade, uveal melanoma, anti-PD-1/PD-L1 cancer therapy, etc (28–30). Although the research on melanoma-related biomarkers has developed rapidly in the past two decades, there is still a lack of bibliometric analysis of the latest melanoma-related biomarkers. Therefore, this study aims to analyze the overall situation of melanoma-related Biomarker research through two bibliometric software, VOSviewer and CiteSpace, and determine the research trends and frontier hotspots in the past two decades, so as to help researchers understand the corresponding fields and find cooperation partners for reference.

2 Method

2.1 Data collection

The data for the econometric analysis of this study came from the Web of Science Core Collection (WOSCC). WOSCC is a comprehensive, standardized set of databases widely used in academia (31). The search set used in this study is "TS= ("Melanoma" OR "Melanomas" OR "Malignant Melanoma" OR "Malignant Melanomas" OR "Melanoma, Malignant" OR

"Melanomas, Malignant")" AND TS=("Biomarkers" OR "Marker, Biological" OR "Biological Marker" OR "Marker, Biological" OR "Biological Markers" OR "Biological Markers" OR "Markers, Biological" OR "Biomarker" OR "Markers, Biological" OR "Markers, Biological" OR "Immune Markers" OR "Markers, Immune" OR "Marker, Immunologic" OR "Immunologic Markers" OR "Immune Marker" OR "Marker, Immune" OR "Immunologic Marker" OR "Serum Markers" OR "Markers, Serum" OR "Marker, Serum" OR "Serum Marker" OR "Surrogate Endpoints" OR "Endpoints, Surrogate" OR "Surrogate End Point" OR "End Point, Surrogate" OR "Surrogate End Points" OR "End Points, Surrogate" OR "Surrogate Endpoint" OR "Endpoint, Surrogate" OR "Markers, Clinical" OR "Clinical Markers" OR "Clinical Markers" OR "Marker, Clinical" OR "Viral Markers" OR "Markers, Viral" OR "Viral Markers" OR "Marker, Viral" OR "Biochemical Marker" OR "Markers, Biochemical" OR "Marker, Biochemical" OR "Biochemical Markers" OR "Markers, Laboratory" OR "Laboratory Markers" OR "Laboratory Marker" OR "Marker, Laboratory" OR "Marker, Laboratory" OR "Markers, Surrogate" OR "Marker, Surrogate" OR "Surrogate Marker"). The search period was limited from January 1, 2004 to September 17, 2022. Only "Article" and "Review" were selected for the article type, and the language was limited to English. Finally, 5584 documents were obtained. Search on WOSCC according to the above formula, and the results are exported as plain text documents in txt and csv formats. In order to prevent data bias caused by database updates, the literature search was completed on September 17, 2022.

2.2 Data analysis and visualization

CiteSpace, developed by Chaomei Chen, is currently the most widely used bibliometric analysis software (32). We used CiteSpace 6.1.R2 Advanced to visualize and analyze country distribution and collaboration, institution distribution, discipline regional distribution, keyword timeline map, literature explosion, etc. VOSviewer was developed by Nees Jan van Eck et al. It is mainly used for bibliometric network graph analysis (33). We used VOSviewer 1.6.18 to visually analyze country distribution, institution distribution, author distribution, keyword distribution, etc. In addition, we used Bibliometrix (R-Tool of R-Studio) (34) to visually analyze the distribution of countries, references and keywords, and used Microsoft Excel 365 to display the trend of publication and citation over the years. All primary data used in this study were obtained from public databases and therefore did not require ethical review.

3 Result

3.1 Annual publications and citation trends

Figure 1 shows the annual publication volume and annual citation frequency of relevant articles from 2004 to 2022. Overall, the number of annual publications related to Melanoma biomarkers showed an increasing trend. Among them, the number of publications decreased in 2013, and increased in the rest years. The annual citation frequency related to Melanoma biomarkers showed an increasing trend, and the uptrend of citation frequency increased significantly after 2018. In 2021, the annual publication volume and citation frequency are the highest in history, reaching 782 and 40,121 times.

3.2 Distribution of countries or regions

There are 99 countries/regions participating in the study of Melanoma biomarkers, mainly in the northern hemisphere. It is worth noting that the links between countries/regions are mainly enriched between North America and Europe, North America and East Asia, and there are also strong links between Europe and East Asia, and North America and Oceania (Figure 2A). Table 1 shows the top ten countries/regions in terms of publication volume and citation frequency. The country with the most publications is USA (2039), followed by China (1206) and Italy (521), and the publications of the rest of the countries are less than 500. In terms of citation frequency, the number of USA far surpasses other countries, reaching 120,666 times. In addition, countries such as Italy (25,464), Germany (24,490), China (24,077), France (22,693) and England (20,258) also have high citation frequency.



FIGURE 1
The annual publication volume and annual citation frequency of relevant articles from 2004 to 2022 (2022 data only until September 17).



FIGURE 2
Analysis of melanoma biomarker-related country/region. **(A)** Countries/regions engaged in melanoma-related biomarker research. The connections between countries demonstrate their collaboration and interconnection. **(B)** Visualization of collaboration networks among countries/regions using VOSviewer. The figure illustrates countries/regions with more than 1 document. Nodes of varying colors represent different clusters of countries/regions, and the node size corresponds to their respective prominence.

Other countries have less than 20,000 citations. In addition, countries such as South Korea (75.54), France (72.73), and the Netherlands (68.20) have high average citations per article. The United States has an average citation per article of 59.18, ranking 7th among all countries.

Figure 2B shows the collaboration between the countries involved in the Melanoma biomarker study. In VOSViewer, according to the closeness of cooperation, countries and regions are mainly divided into 3 blocks, which are represented by different colors. The green blocks mainly include countries such as USA,

TABLE 1 Top 10 countries/regions in terms of number of publications, the frequency of citations and the citations per article.

Rank	Countries/regions	Publications	Countries/regions	Citations	Countries/regions	Citations per article
1	USA	2039	USA	120666	South Korea	75.54
2	China	1206	Italy	25464	France	72.73
3	Italy	521	Germany	24490	Netherlands	68.20
4	Germany	487	China	24077	Sweden	64.24
5	England	401	France	22693	Spain	63.34
6	France	312	England	20258	Romania	59.48
7	Japan	277	Netherlands	14117	USA	59.18
8	Australia	275	Australia	14014	Brazil	53.16
9	Spain	213	Spain	13491	Canada	52.07
10	Netherlands	207	Sweden	9829	Greece	51.47

China, Japan, Australia, and Canada, the red blocks mainly include countries such as Italy, France, England, Spain, and the Netherlands, and the blue blocks mainly include countries such as Germany, Switzerland, and Brazil. The thickness of the line between country nodes is related to the strength of connection between countries. The results showed that the connections between USA and countries such as China, Italy, Germany and France were strong, indicating that those countries occupy the core position in the field of Melanoma biomarkers.

3.3 Distribution of institutions

Currently, a total of 303 institutions from more than 30 countries have high influence in the field of Melanoma biomarkers. Table 2 shows the top ten institutions in terms of publication volume and citation frequency. The institution with the most publications is The University of Texas MD Anderson Cancer Center (USA), with 205 publications. Followed by Memorial Sloan Kettering Cancer Center (USA) (116), University of Pittsburgh (USA) (109), Harvard Medical School (USA) (108) and The University of Sydney (Australia) (104), and others are less than 100 articles. The most frequently cited institution is Memorial Sloan Kettering Cancer Center, reaching 14,013 times; followed by The University of Texas MD Anderson Cancer Center (12,256) and Dana-Farber Cancer Institute (USA) (10,212). The remaining institutions have less than 10,000 citations.

The analysis of research institutions aims to understand the global distribution of Melanoma biomarker- related research and provide opportunities for cooperation. Figure 3A shows the collaboration of institutions involved in Melanoma biomarker research. In VOSViewer, according to the closeness of cooperation, the institution is mainly divided into 7 blocks, which are represented by different colors. The red block mainly includes institutions such as Memorial Sloan Kettering Cancer Center, University of Pittsburgh, and Harvard Medical School, the green block mainly includes institutions such as The University of Texas MD Anderson Cancer Center, University of Pennsylvania, and Sun Yat-Sen University, whereas the blue block mainly covers German Cancer Research Center and Netherlands Cancer Institute, the orange block mainly includes institutions such as The University of Sydney and Royal Prince Alfred Hospital, the yellow block mainly contains University of Naples Federico II, and the purple block mainly includes The Institute of Cancer Research and other institutions, the light blue block mainly includes institutions such as Lund University. Figure 3B displays publications for each reach institute in the past five years. By dividing the number of Melanoma-related publications of an institution in the past five years by the total number of related publications from 2004 to 2022, the ratio can reflect the contribution of the institution in each five years interval. Nodes with deeper yellow indicate that the institution has a high ratio; nodes with deeper purple indicate that the institution has a low ratio. The results show that the number of papers published by institutions such as Sun Yat-Sen University, Fudan University and Parker Institute for Cancer Immunotherapy has increased significantly in the past five years, indicating that they are emerging institutions in this field. In contrast, Harvard University, Heidelberg University and Melanoma Institute Australia have produced a relatively few related studies in the past five years.

Figure S1 shows the institutional collaboration network for Melanoma biomarker research. In CiteSpace, each node represents an institution, and the radius of the node increases as its contribution to Melanoma biomarker research increases. The connection between nodes indicates the cooperative relationship between various countries and regions, and the thickness of the link is positively correlated with the depth of cooperation. The betweennness centrality of a node indicates the degree of association between it and other nodes, which is proportional to the size of the purple ring around the surrounding nodes. The results showed that The University of Texas MD Anderson Cancer Center was the most productive institution. In addition, institutions such as Harvard Medical School, University of Sydney and University of Pittsburgh have high productivity. Notably, Karolinska Institute has a high central value, indicating extensive collaboration with other institutions around the world.

TABLE 2 Top 10 institutions in terms of number of articles issued and the frequency of citations.

Rank	Institution	Publications	Institution	Citations
1	The University of Texas MD Anderson Cancer Center (USA)	205	Memorial Sloan Kettering Cancer Center (USA)	14013
2	Memorial Sloan Kettering Cancer Center (USA)	116	The University of Texas MD Anderson Cancer Center (USA)	12256
3	University of Pittsburgh (USA)	109	Dana-Farber Cancer Institute (USA)	10212
4	Harvard Medical School (USA)	108	National Cancer Institute (USA)	8913
5	The University of Sydney (Australia)	104	Massachusetts General Hospital (USA)	8404
6	National Cancer Institute (USA)	85	University of Pennsylvania (USA)	7849
7	Massachusetts General Hospital (USA)	81	Harvard Medical School (USA)	7770
8	Sun Yat-Sen University (China)	78	Yale University (USA)	7324
9	University of Pennsylvania (USA)	76	Harvard University (USA)	7273
10	Dana-Farber Cancer Institute (USA)	71	Stanford University (USA)	5824



FIGURE 3
Analysis of melanoma biomarker-related institution. **(A)** Visualization of collaborative network among institutions using VOSviewer. The figure displays institutions with more than 5 documents. Nodes of varying colors represent different clusters of institutions, and the node size corresponds to the frequency of their occurrence. **(B)** Analysis of institution's recent article publication. The heat value of each institution in the past 5 years is calculated by dividing the number of publications in the past 5 years by the total number of publications.

3.4 Distribution of authors

Co-cited author analysis means that two authors' documents are cited by a third author at the same time. The higher the co-citation frequency, the closer the academic interest and the research density (35). Through the analysis of the authors with the largest number of publications and co-citation frequency in Melanoma biomarker- related research, it can intuitively reflect the author's research strength and Melanoma-related research hotspots. A total of 5584 articles published by 22,373 authors were included in this study. Table 3 shows the top ten authors in terms of publication volume and co-citation frequency. The author with the most publications is Paolo A. Ascierto (Istituto Nazionale Tumori Fondazione G Pascale, Italy) (64), followed by Richard A. Scolyer (Melanoma Institute Australia, Australia) (50) and Georgina V. Long (University of California, USA) (48). The author with the most co-citations is Caroline Robert (Paris-Saclay University, France) (1594), followed by F. Stephen Hodi (Dana-Farber Cancer Institute, USA) (1115) and Suzanne L. Topalian (Johns Hopkins University, USA) (923).

Figure 4A shows the collaboration of the authors involved in the Melanoma biomarker study. In VOSViewer, according to the closeness of cooperation, the author is mainly divided into 7 blocks, which are represented by different colors. The red blocks mainly include authors such as Caroline Robert, Keith T. Flaherty, the blue blocks mainly include Dirk Schadendorf, Claus Garbe, etc., and the green blocks mainly include, F. Stephen Hodi, Lisa H. Butterfield, etc., the yellow block mainly includes authors such as Richard A. Scolyer, Georgina V. Long, the orange block mainly includes authors such as Jedd D. Wolchok, Michael A. Postow, and the purple block mainly includes Qingyi Wei, Jeffery E. Lee and other authors, and the light blue block mainly includes Paolo A. Ascierto, Soldano Ferrone and other authors. The light blue block represented by Paolo A. Ascierto has extensive and close cooperation with other blocks. In contrast, the authors of purple and brown blocks have relatively limited cooperation with authors of other blocks. Figure 4B shows the co-citing author relationship network diagram. The results show that the research focus of the authors of Melanoma-related studies is highly homogeneous, mainly divided into 4 blocks. Red blocks include authors such as

10.3389/fonc.2023.1181164

TABLE 3 Top 10 authors in terms of number of publications and the frequency of co-citations.

Rank	Author	Publications	Author	Co-citations
1	Ascierto, Paolo A.	64	Robert, Caroline	1594
2	Scolyer, Richard A.	50	Hodi, F. Stephen	1115
3	Long, Georgina V.	48	Topalian, Suzanne L.	923
4	Schadendorf, Dirk	44	Larkin, James	849
5	Dummer, Reinhard	36	Wolchok, Jedd D.	838
6	Garbe, Claus	36	Ribas, Antoni	757
7	Kirkwood, John M.	33	Long, Georgina V.	706
8	Wolchok, Jedd D.	33	Balch, Charles M.	668
9	Flaherty, Keith T.	32	Weber, Jeffrey S.	574
10	Hoon, Dave S. B.	32	Eggermont, Alexander M. M.	550



FIGURE 4
Analysis of melanoma biomarker-related author. **(A)** Visualization of collaborative network among authors using VOSviewer. The figure displays authors with more than 8 documents. Nodes of varying colors represent authors in different clusters, and the node size corresponds to the frequency of their occurrence. **(B)** Visualization of authors' citation networks using VOSviewer. The size of the nodes reflects the frequency of their occurrence.

Charles M. Balch, Dirk Schadendorf, green blocks include authors such as Suzanne L. Topalian, Roy S. Herbst, yellow blocks include authors such as Caroline Robert, James Larkin, and blue Blocks include Jedd D. Wolchok, F. Stephen Hodi and other authors.

3.5 Distribution of journals

We used the bibliometric online analysis platform to identify journals with high publication volume and impact in the field of Melanoma biomarkers. The results showed that a total of 532 academic journals had published articles related to Melanoma biomarkers. Table 4 shows the top ten journals in terms of publication volume and co-citation frequency. The journal with the most publications is Cancers (6.575, Q1) (188), followed by Journal For Immunotherapy Of Cancer (12.487, Q1) (131) and Clinical Cancer Research (13.801, Q1) (126). The journal with the most co-citations is The New England Journal of Medicine (176.079, Q1) (11,688), followed by Journal of Clinical Oncology (50.769, Q1) (11,649) and Clinical Cancer Research (10,521). It is worth noting that the number of publications and co-citations of Clinical Cancer Research ranked third, indicating that it has a strong influence in Melanoma-related fields.

Figure 5A visualizes the journals that published articles related to Melanoma biomarkers and the relationship between them. In VOSviewer, journals are mainly divided into 5 blocks of different colors according to the similarity of the them. The red block mainly includes journals such as Frontiers In Oncology, Plos One, Malanoma Research, and Journal Of Investigative Dermatology, the green block mainly includes journals such as Clinical Cancer Research, Oncoimmunology, British Journal of Cancer, and the blue block mainly includes International Journal Of Molecular Sciences, Journal Of Translational Medicine, BMC Cancer and other journals, the yellow block mainly includes journals such as Journal For Immunotherapy Of Cancer, Frontiers In Immunology, Cancer Immunology Research, and the purple block mainly includes journals such as Cancers and European Journal Of Cancer. The research fields of the journals in the red block are mainly concentrated in the field of oncology (Frontiers In Oncology, Oncotarget, Melanoma Research, etc.); the research fields of the journals in the yellow block are mainly concentrated in the field of immunology (Frontiers In Immunology, Cancer Immunology Research, Journal For Immunotherapy Of Cancer, etc.); the research fields of green block journals are to a certain extent manifested in the intersection of oncology and immunology (Cancer Immunology Immunology Immunotherapy, Oncoimmunology, etc.), oncology and clinical Crossover (Clinical Cancer Research, Journal Of Clinical Oncology, etc.); similar to the red block, the journals in the purple block are also mainly focused on oncology (Cancers, European Journal Of Cancer, etc.); while the journals in the blue block covers relatively broad research fields with no obviously focused research field. According to the co-citation frequency, Melanoma biomarker- related journals are mainly divided into 4 blocks with similar research directions (Figure 5B). The red blocks mainly focus on BIOCHEMISTRY & MOLECULAR BIOLOGY (JOURNAL OF BIOLOGICAL CHEMISTRY, Cell, Oncogene, etc.), the green blocks mainly focus on the field of oncology (BRITISH JOURNAL OF CANCER, INTERNATIONAL JOURNAL OF CANCER, etc.), and the blue blocks Mainly focus on the field of clinical and oncology (NEW ENGLAND JOURNAL OF MEDICINE, LANCET ONCOLOGY, JOURNAL OF CLINICAL ONCOLOGY, etc.), and the yellow block mainly focuses on the direction of immunology (Frontiers In Immunology, Journal Of Immunology, etc.).

We used knowledge flow analysis to explore the evolution process of knowledge citation and co-citation between citing journals and cited journals (36). The dual-map overlay of journals shows the distribution of topics, citation trajectories, and movement

TABLE 4 Top 10 journals in terms of number of publications, the frequency of co-citations, and the corresponding IF (JCR 2021) and JCR quartile.

Rank	Journals	Publications	Journals	Co-citations
1	Cancers 6.575(Q1)	188	The New England Journal of Medicine 176.079(Q1)	11688
2	Journal For Immunotherapy Of Cancer 12.487(Q1)	131	Journal of Clinical Oncology 50.769(Q1)	11649
3	Clinical Cancer Research 13.801(Q1)	126	Clinical Cancer Research 13.801(Q1)	10521
4	Plos One 3.752(Q2)	113	Cancer Research 13.312(Q1)	9349
5	Frontiers In Oncology 5.738(Q2)	107	Nature 69.504(Q1)	7636
6	Melanoma Research 3.199(Q2)	97	Proceedings of the National Academy of Sciences of The United States Of America 12.779(Q1)	5335
7	Oncotarget -	90	Science 63.798(Q1)	5334
8	Frontiers In Immunology 8.786(Q1)	81	Cell 66.850(Q1)	4761
9	International Journal Of Molecular Sciences 6.208(Q1)	76	Plos One 3.752(Q2)	4535
10	Journal Of Translational Medicine 8.459 (Q1)	75	The LancetOncology 54.433(Q1)	3702



FIGURE 5
Analysis of melanoma biomarker-related journal. **(A)** Visualization of collaborative network among journals using VOSviewer. The figure displays journals with more than 10 documents. Nodes of varying colors represent journals in different clusters, and the node size corresponds to the frequency of their occurrence. **(B)** Visualization of journals' citation networks using VOSviewer. The size of the nodes reflects the frequency of their occurrence. **(C)** Dual-map overlay of journals, with citing journals on the left and cited journals on the right. Colored paths indicate citation relationships.

of research centers across academic journals (Figure 5C) (36, 37). The label on the left of the Dual-map represents citing journals, and the label on the right represents cited journals. The citation connection colored curve originating from the citing map and pointing to the cited map shows the complete context of the citation. In the citing map, the more papers a journal publishes, the longer the vertical axis of the ellipse; the larger the number of authors, the longer the horizontal axis of the ellipse. The topics of Citing Journals are mainly MOLECULAR, BIOLOGY, IMMUNOLOGY, MEDICINE, MEDICAL, CLINICAL, namely research frontier. The topics of Cited Journals are mainly MOLECULAR, BIOLOGY, GENETICS, HEALTH, NURSING, MEDICINE, DERMATOLOGY, DENTISTRY, SURGERY, namely the knowledge base.

3.6 Keyword analysis

As the core overview of the content of the article, keywords can be used to analyze the frontiers of Melanoma biomarker research. Table 5 shows the top 20 keywords with the frequency of occurrence. The most frequently occurring keyword was "melanoma" (1781), followed by

TABLE 5 Top 20 keywords in terms of frequency of occurrence and the corresponding total link strength.

Rank	Keyword	Occurrences	Total link strength
1	melanoma	1781	3421
2	biomarkers	1026	2465
3	immunotherapy	677	1848
4	prognostic	417	925
5	checkpoint inhibition	294	787
6	cancers	278	565
7	metastatic	198	470
8	pd-l1	180	585
9	pd-1	172	613
10	immunohistochemistry	130	217
11	tumor microenvironment	125	340
12	nivolumab	119	418
13	target therapy	112	344
14	ipilimumab	110	388
15	survival	107	246
16	breast cancer	94	212
17	exosomes	92	220
18	colorectal cancer	89	173
19	diagnostic	86	215
20	micrornas	85	218

"biomarkers" (1026) and "immunotherapy" (677). "prognostic" (417), "checkpoint inhibition" (294) and "cancers" (278) were also frequently occurring keywords, indicating that they are hot topics in the field of Melanoma biomarkers. The occurrence frequency of other keywords is less than 200 times. Figure 6A shows the keyword co-occurrence network diagram. Keywords with close co-occurrence relationship are clustered into one category, mainly with 4 larger blocks, which are represented by different colors. The keywords in the red block are mainly related to melanoma diagnostic biomarkers (diagnostic, metastatic, migration), and the keywords in the green block are mainly related to melanoma treatment-related biomarkers (immunotherapy, cancer therapy, pd-l1, c checkpoint inhibition), the keywords in the purple block are mainly related to melanoma prognosis-related biomarkers (prognostic, prognostic biomarkers), the keywords in the yellow block are mainly related to PD-L1 inhibitors (nivolumab, pembrolizumab, ipilimumab). It is worth noting that the red blocks have very extensive connections with other blocks, indicating their cross-fields in various related research fields. Figure 6B shows the popularity analysis of keywords in the past 3 years. By dividing the frequency of occurrence of keywords in the past 3 years by the total frequency of occurrence, we obtained the popularity value of the keyword in the past 3 years. The yellowish color of the node means that its popularity has been high in recent years, and the purple color of the node means that its popularity has been low in recent years. The results show that keywords such as c checkpoint inhibition, immune, bioinformatics have become more popular in the past three years. On the contrary, diagnostic, micrornas, epigenetics, apoptosis, s100, pd-1, etc. have become relatively less popular in the past three years.

Figure 7A shows the annual popularity of keywords from 2004 to 2022 (the number of citations of a keyword in a year/total citations of queried keywords in a year). In recent years, keywords such as tumor-infiltrating lymphocytes and breast cancer have had relatively low annual popularity. In contrast, skin cutaneous melanoma, TCGA (The Cancer Genome Atlas Program), immunotherapy, tumor microenvironment and immune-related adverse events have relatively high annual prevalence, proving that these keywords represent emerging frontier areas that may become the hotspot of future melanoma biomarker research. Figure 7B shows the correlation between popular keywords from 2004 to 2022, where keywords with high popularity in similar periods are clustered into different clusters marked with different colors. The results suggest that the pathogenesis of melanoma is closely related to the immune defense status of the body. For example, tumor and epigenetics, targeted therapy and drug resistance are closely correlated. Numerous studies have shown that abnormal epigenetic modifications lead to tumorigenesis, and epigenetic detection of tumor-related mutations allows for early and more accurate diagnosis and more precise treatment of tumors (38, 39). In addition, drug resistance has been a challenge for clinical



FIGURE 6
Analysis of melanoma biomarker-related keyword. **(A)** Visualization of keyword collaboration network using VOSviewer. The figure displays keywords that occur more than 15 times. Nodes of varying colors represent different clusters of keywords, and the node size corresponds to their frequency. **(B)** Analysis of keyword's recent article publication. The heat value of each keyword in the past 5 years is calculated by dividing the number of publications in the past 5 years by the total number of publications.

treatment, and targeted therapy can help overcome drug resistance (40, 41). Immune checkpoints usually appear together with keywords for tumor-related diseases such as melanoma, NSCLC (non-small cell lung cancer), and breast cancer, suggesting that immune checkpoints are closely related to the prognosis of tumor-related diseases and can improve effective strategies for clinical treatment (42, 43).

3.7 Highly cited reference analysis

Table 6 shows the top 15 articles with citation frequency and annual average citation frequency. The article with the highest citation frequency is "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients" (RS Herbst et al., 2014) (3399), in which Herbst et al. developed a high-affinity human monoclonal immunoglobulin G1 antibody (MPDL3280A) that specifically binds PD-L1 for clinical use to block PD-L1 and its ligands PD-1 or B7.1 (CD80), so as to achieve the purpose of enhancing the anti-cancer immunity of patients. Among them, the positive response rate to PD-L1 inhibition in melanoma patients reached 26% (11 of 43) (44). "Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies" (C Bettegowda et al., 2014) (2675) is the second most cited article. Bettegowda et al. evaluated the ability of circulating tumor DNA (ctDNA) to detect different types of tumors based on digital polymerase chain reaction technology, and the results showed that melanoma patients had sufficient levels of ctDNA to detect (45). In terms of average annual citation frequency, "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients" is still ranked first, reaching 377.67 times per year; followed by "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial" (Jonathan E. Rosenberg et al., 2016) (336.71 per year), which mainly evaluates the engineered human immune system that can selectively bind PD-L1 Efficacy of atezolizimab, a globulin G1 monoclonal antibody, in patients with metastatic urothelial carcinoma (46).

Article co-citation analysis analyzes the relationship between articles by analyzing the co-citation frequency of articles. Figure 8A shows the relationship between the studies. The authors and years of the documents whose co-citation frequency has exploded are marked



FIGURE 7
Heatmap analysis of melanoma biomarker-related keywords. **(A)** Annual heatmap from 2004 to 2022. The annual heat value of each keyword is obtained by dividing the number of citations in that year by the total number of citations in that year. **(B)** Keyword relevance heatmap. Keywords with high popularity in similar time periods are clustered into one category and marked with different colors.

in the figure, and the documents are clustered according to the closeness of the association. The results showed that, from 2002 to 2009, the research in the field of melanoma mainly had two independent development paths. In one of the paths, relevant early research mainly focused on 5 closely related clusters, including #27 (circulating endothelial cells), #25 (molecular epidemiology), #83 (aninal mode), #29 (survivin), #19 (functional genomics) and #18 (rt-pcr), these clusters subsequently developed into 2 clusters of #4 (mia) and #20 (oncogene). In another path, the earliest cluster was #15 (proteomics), which later developed into two clusters, #26 (IL-21) and #12 (clinical response). These two developmental paths eventually converged into a single cluster, #10 (molecular diagnostics). After 2010, cluster #10 developed into clusters #5 (braf), #2 (iphmmumab), #1 (breast cancer) and #0 (immunotherapy). It is noteworthy that

TABLE 6 Top 15 articles in terms of frequency of citation.

Rank	Article Title	Source Title	Authors	Year	Cited	DOI
1	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients	Nature	Herbst, Roy S. et al.	2014	3399	10.1038/nature14011
2	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies	Science Translational Medicine	Bettegowda, Chetan et al.	2014	2675	10.1126/scitranslmed.3007094
3	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial	Lancet	Rosenberg, Jonathan E. et al.	2016	2357	10.1016/S0140-6736(16)00561-4
4	Cancer immunotherapy: moving beyond current vaccines	Nature Medicine	Rosenberg, Steven A. et al.	2004	2247	10.1038/nm1100
5	Systematic identification of genomic markers of drug sensitivity in cancer cells	Nature	Garnett, Mathew J. et al.	2012	1574	10.1038/nature11005
6	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden	The New England Journal of Medicine	Hellmann, M. D. et al.	2018	1534	10.1056/NEJMoa1801946
7	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy	Nature Reviews Cancer	Topalian, Suzanne L. et al.	2016	1433	10.1038/nrc.2016.36
8	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations	Science Translational Medicine	Zou, Weiping et al.	2016	1341	10.1126/scitranslmed.aad7118
9	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy	Molecular Cancer Therapeutics	Patel, Sandip Pravin et al.	2015	1268	10.1158/1535-7163.MCT-14-0983
10	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response	Nature	Chen, Gang et al.	2018	1180	10.1038/s41586-018-0392-8
11	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers	Molecular Cancer Therapeutics	Goodman, Aaron M. et al.	2017	1159	10.1158/1535-7163.MCT-17-0386
12	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy	Nature Reviews Cancer	Havel, Jonathan J. et al.	2019	1017	10.1038/s41568-019-0116-x
13	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response	Nature Medicine	Jiang, Peng et al.	2018	1007	10.1038/s41591-018-0136-1
14	Comprehensive analyses of tumor immunity: implications for cancer immunotherapy	Genome Biology	Li, Bo et al.	2016	983	10.1186/s13059-016-1028-7
15	Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells	Nature Biotechnology	Ramskold, Daniel et al.	2012	941	10.1038/nbt.2282

within these clusters, the number of outbreak documents was significantly increased and their linkages between each other were significantly enhanced. Subsequently, Melanoma-related research developed into four relatively independent directions at different time points, namely #14 (lncrna) appeared around 2015, #13 (uveal melanoma) emerged around 2017, and #44 appeared around 2020 (immune infiltration) and #22 (skin cutaneous melanoma) appeared around 2022.

In CiteSpace, a timeline graph shows articles with high co-citations in each cluster over time (Figure 8B). #0 (immunotherapy) was the largest cluster, followed by #1 (ipilimumab), #2 (mia) and #3 (proteomics). In the field of immunotherapy, Eggermont AMM (2014), VAN ALLENEM (2015), etc. are earlier high-impact studies, while Mcgrail DJ (2021) is one of the latest high-impact studies. From the timeline, #11 (elispot assay) and #3 (proteomics) are the first two clusters, and #10 (uveal melanoma) is the latest one. Notably, the largest cluster #0 (immunotherapy) is also a late cluster, indicating that it is a hot topic that has emerged in recent years. Among the 13 clusters, research related to 6 clusters is still ongoing, indicating that these research directions are still hot spots in Melanoma-related research.

Figure 9 shows the top 25 references with the strongest citation bursts. The earliest burst of citations occurred in 2010, and the title of this article is "Final Version of 2009 AJCC Melanoma Staging and Classification", which was published in Journal of Clinical Oncology



FIGURE 8
Analysis of melanoma biomarker-related reference. **(A)** Analysis of reference network using CiteSpace. The size of each node represents the frequency of co-citation for the corresponding article. **(B)** Timeline view of reference. A horizontal line represents a cluster, with smaller numbers indicating larger clusters (#0 represents the largest cluster). Node size represents co-citation frequency, and the links between nodes indicate co-citation relationships. The occurrence year of each node indicates the initial co-citation time.

Top 25 References with the Strongest Citation Bursts

References	Year	Strength	Begin	End	2004 - 2022
Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799, DOI	2009	52.92	2010	2014	
Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466, DOI	2010	83.65	2011	2015	
Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011, DOI	2010	45.38	2011	2015	
Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107, DOI	2011	27.76	2011	2016	
Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782, DOI	2011	79.59	2012	2016	
Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621, DOI	2011	55.34	2012	2016	
Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013, DOI	2011	32.17	2012	2016	
Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690, DOI	2012	83.1	2013	2017	
Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694, DOI	2012	45.83	2013	2017	
Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421, DOI	2012	32.58	2013	2017	
Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X, DOI	2012	29.46	2013	2017	
Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369, DOI	2013	44.03	2014	2018	
Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133, DOI	2013	43.44	2014	2017	
Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498, DOI	2014	38.7	2015	2019	
Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239, DOI	2012	36	2015	2017	
Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011, DOI	2014	34.62	2015	2019	
Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105, DOI	2014	28.27	2015	2017	
Taube JM, 2012, SCI TRANSL MED, V4, P0, DOI 10.1126/scitranslmed.3003689, DOI	2012	28.06	2015	2017	
Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954, DOI	2014	48.44	2016	2019	
Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI 10.1056/NEJMoa1504030, DOI	2015	27.33	2016	2019	
Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824, DOI	2015	26.29	2016	2019	
Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836, DOI	2019	52.19	2020	2022	
Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8, DOI	2019	29.91	2020	2022	
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492, DOI	2018	29.8	2020	2022	
Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654, DOI	2021	27.96	2021	2022	

FIGURE 9
The top 25 references with the strongest citation bursts.

by Charles M. Balch et al. in 2009 (47). The article titled "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma" published in The New England Journal of Medicine by F. Stephen Hodi et al. in 2010 has the highest burst strength (Strength = 83.65) (48). 2015 was the year with the most citation outbreaks, with a total of 5 citation outbreaks, and the outbreak lasted until 2019; followed by 2013, with 4 citations. In addition, articles such as " Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma " by James Larkin, F.R.C.P. et al. and "Tumor mutational load predicts survival after immunotherapy across multiple cancer types" by Robert M. Samstein et al. are recent citing outbreak articles, and their outbreaks continue (49, 50).

4 Discussion

4.1 General information

The analysis of this study is based on 5584 articles related to melanoma biomarkers from 99 countries and 22,373 authors in the WoSSC database from January 1, 2004 to September 17, 2022. Overall, the number of articles and citations are increasing year by year, indicating that the field is attracting more and more attention. Compared with 2011, the frequency of citations and the number of publications in 2021 have increased by about 5 times and 13 times, respectively. It is worth noting that the number of studies in this field increased significantly in 2018, which may attribute to the fact that James Allison and Tasuku Honjo won the Nobel Prize in Physiology or Medicine for their outstanding contributions to the study of CTLA-4 and PD-1, increasing the popularity of the field.

The country/region analysis shows that the United States has far more publications and citation frequency than other countries, and is the most influential country in the field of melanoma biomarkers (Table 1). Most of the top institutions in this field are from the United States, and 8 of the top ten institutions in terms of publication volume are from the United States; all the top ten institutions in the citation frequency are also from the United States (Table 2). Among them, The University of Texas MD Anderson Cancer Center has the most publications and the second most citations, while Memorial Sloan Kettering Cancer Center has the most citations and the second most publications, indicating that these two institutions from the United States have the most important influence in this field. In terms of cooperation, the United States has the strongest and most links with other countries, indicating that it is a research center in this field (Figure 2). In addition to the United States, Italy, China, Germany, France and other countries with a high number of publications and citation frequency have strong influence in this field, and have extensive exchanges and cooperation with other countries.

The author analysis shows that Caroline Robert from Paris-Saclay University is the author with the most co-citations, indicating that he has outstanding influence in the field of melanoma markers. The second most cited author is F. Stephen Hodi from Dana- Farber Cancer Institute. It is worth noting that the article titled "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients" published by Hodi et al. on Nature in 2014 not only has the most citations in this field, but also has the most annual average citations. Suzanne L. Topalian has the third most co-citations. "Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy" published by Topalian et al. in 2016 ranks in the top ten in terms of citations and annual average citations, and has a high influence in this field (51). In addition, Georgina V. Long and Jedd D. Wolchok among the top ten authors in the number of publications are also the top ten authors in the number of co-citations, which shows that they are also authoritative figures in this field (Tables 3, 6).

Analysis of journals shows that Cancers, Journal For Immunotherapy Of Cancer, which ranks the top in the number of publications, and The New England Journal of Medicine, Journal of Clinical Oncology, and Clinical Cancer Research, which ranks the top in co-citation frequency, have strong competitiveness in this field. Influence. 5 of the top ten papers in terms of citation frequency and 6 of the top 10 papers in annual average citation frequency are from Nature and its sub-journals such as Nature Review Cancer, Nature Medicine, etc. top journals (Tables 4, 6). It is worth noting that among the top ten journals with co-citation frequency, The New England Journal of Medicine is a journal in the field of MEDICINE, Cell is a journal in the field of BIOCHEMISTRY & MOLECULAR BIOLOGY, Clinical Cancer Research, Journal of Clinical Oncology and Cancer Research belong to the field of ONCOLOGY, which is consistent with the dual-map analysis results in Figure 5C.

4.2 Hot topics and frontiers

Keyword analysis is helpful to understand the frontiers and hotspots of melanoma molecular markers. In existing studies, high-frequency keywords include "Melanoma", " Biomarkers", "Immunotherapy", "Prognostic", "Checkpoint Inhibition", "PD-L1", "Immunohistochemistry", etc. (Table 5), which is closely related to the diagnosis, treatment and prognosis of melanoma. The results of Figure 5A confirm this conclusion. In the keyword co-occurrence network, keywords are summarized into several main directions, including biomarkers in the diagnosis, treatment, and prognosis of melanoma. The high expression of some biomarkers in melanoma makes them suitable as a diagnostic marker for early screening of melanoma (52). In the red block in the keyword co-occurrence graph, "micrornas" and "angiogenesis" are commonly used biomarkers for the diagnosis and evaluation of melanoma, while "mass spectrometry" and "proteomics" are commonly used detection techniques. On the other hand, in the melanoma treatment keywords block, the more prominent keywords are "checkpoint inhibition", "immunotherapy", "PD-1" and "PD-L1". In recent years, immunotherapy against melanoma has shifted from cytokine-based therapy to antibody-mediated immune checkpoint inhibition, including programmed cell-death protein 1 (PD-1) (53). Previous studies have shown that tumor cells can escape immune surveillance by upregulating PD-1, and anti-PD-1 therapy can play a role in melanoma patients (1, 54). It is worth noting that in the keyword co-occurrence network diagram, PD-L1 inhibitors "ipilimumab", "nivolumab", and "pembrolizumab" also appear as a separate cluster (yellow). In

addition, among the top 10 most cited documents, 6 of them are related to PD-L1 inhibition. These results all indicate that studies related to PD-1/PD-L1 inhibition are highly popular in this field. In addition, the keyword "CTLA-4" is also a relatively popular checkpoint inhibition, which plays an important role in the immunotherapy of melanoma. In addition, some melanoma biomarkers can reflect the degree of tumor expansion and deterioration during treatment, and have good prognostic evaluation value (55). In the purple block, indicators such as "methylation" and "epigenetics" have been proven to be used as the evaluation of melanoma prognosis. Figure 7 shows that the heat of the field of melanoma treatment-related biomarkers continues to increase, mainly including keywords such as prognostic biomarker, immunotherapy and immune-related adverse events. In addition, the popularity of multi-omics continues to increase, including keywords such as TCGA, tumor mutation burden and next-generation sequencing. These findings underline the growing significance of these research domains and highlight their substantial impact on the field of biomarkers in melanoma.

4.2.1 Melanoma diagnostic biomarker

Melanoma diagnostic biomarkers can be divided into five categories, including visual features, histopathology, morphology, immunohistochemistry, and serological molecular biomarkers (56). In clinical practice, the visual distinction between benign nevus and malignant melanoma mainly follows the "ABCDE" principle, that is, asymmetry, border irregularity, color change, diameter (>6 mm), and degree of evolution (57). Histopathologically, ulceration, mitotic rate, lymphovascular invasion, and neural invasion are common features of melanoma (58). Optical Coherence Tomography (OCT), Reflectance Confocal Microscopy (RCT), High-frequency ultrasound (HFUS) and other techniques can be used to examine the morphological features of the lesion to assist in the diagnosis of melanoma (56). Common morphological features include disorganized lesion tissue architecture, the presence of atypical melanocytes, atypical keratinocytes in the superficial skin, and hypervascular lesions (59–61). With the gradual elucidation of the molecular mechanism of melanoma pathogenesis, relying on immunohistochemistry (IHC), more and more researchers and clinicians use molecular biomarkers to assist the diagnosis of melanoma (62). Melan-A is a melanocyte differentiation antigen expressed in melanocytes, melanoma and retinal pigment epithelial cells (16). There is evidence that Melan-A has high sensitivity and specificity in differentiating melanoma from non-melanocytic tumors (63). HMB-45 is a 100 kD glycoprotein, and studies have shown that it has higher specificity than Melan-A in the diagnosis of melanoma patients (64). Tyrosinase, an enzyme involved in melanogenesis in melanosomes, is also highly sensitive to primary melanoma (10). Chondroitin sulfate proteoglycan 4 (CSPG4) is another membrane-bound proteoglycan used in the diagnosis of melanoma, and its sensitivity to melanoma under immunostaining is greater than 85% (16, 65). In addition, S100 protein family, Microphthalmia-associated transcription factor (MITF), SOX10, etc. have been proven to be diagnostic molecular markers for melanoma (18, 66, 67). On the other hand, melanoma serological markers such as lactate dehydrogenase (LDH) have been proven to have diagnostic evaluation value in many studies (68). In addition, epigenetic factors such as abnormal DNA methylation and miRNA are closely related to the development of melanoma, which has potential significance in the diagnosis of melanoma (69, 70).

4.2.2 Predictive biomarkers for melanoma treatment response

Biomarkers can identify melanoma before it becomes overtly symptomatic and significantly improve melanoma treatment outcomes (52). Accompanying with our understanding of the mechanisms by which cancer cells evade the immune system, new cancer therapies such as cancer vaccines, adoptive cell therapy, and immunomodulatory approaches continue to emerge (71–74). For metastatic melanoma, the most effective treatment at present is the application of immune checkpoint inhibitors, mainly including PD-1/PD-L1 and CTLA4 antibodies (75, 76). Similar to the effect of PD-1, CDLA4 expressed in T-reg cells recognizes B7-1/2 receptors on APCs (Antigen-presenting cells) and competes with CD28 on T cells for binding to B7-1/2 receptors, thereby suppressing the immune response. By blocking its binding to the corresponding ligand, the suppressed immune response in cancer patients can be stimulated (3). Currently approved c checkpoint inhibitors for the treatment of melanoma include an anti-CTLA-4 antibody ipilimumab, an anti-PD-1 antibodies nivolumab and pembrolizumab, correspondingly, their related research has also proved to be one of the hot topics in our result (77–79). With the rapid development of melanoma therapy, the potential role of biomarkers in the prediction of response has received extensive attention. For example, PD-L1 immunohistochemistry has been used in the prediction of treatment response, considering that PD-L1 expression is significantly associated with response rate, progression-free survival, and overall survival in melanoma (7). In addition, monitoring of BRAF mutation status is critical in determining whether a patient may benefit from BRAF inhibitor therapy (80). In mucosal melanoma, there is evidence that activating mutations in c-kit may predict patient sensitivity to the kinase inhibitor imatinib (81).

4.2.3 Melanoma prognostic biomarker

Robust and reliable melanoma biomarkers help to assess patients' prognostic risk and select more beneficial treatment options. In current clinical practice, Breslow thickness, mitotic rate, and ulceration are the most important prognostic markers in the histopathological criteria of melanoma (13). In addition, the status of sentinel lymph node (SLN) is also an important prognostic indicator in melanoma (82). In recent years, the number of studies on immunohistochemical biomarkers predicting melanoma prognosis has grown rapidly (19, 83). Proliferation markers can reflect the number of cells in the cell cycle in the lesion, and are one of the indicators for evaluating the malignancy of melanoma (84). As a nuclear antigen highly expressed during the active phases of the cell cycle (G1, S, G2, and M), Ki-67 has been shown to be closely associated with melanoma prognosis (85). In thicker melanomas (>1mm), Ki-67 may be a better prognostic predictor than mitotic rate (20). Phosphohistone H3 (PHH3) is also a common mitotic marker, and studies have shown that it can be used

as a more precise prognostic marker than Ki-67, but more evidence is still needed to support this conclusion (3). Melanoma cell adhesion molecules (MCAMs) are commonly expressed on endothelial and smooth muscle cells in adult tissues (86). Although MCAM is less expressed in malignant tumors and benign nevi, it can be highly specifically expressed in melanoma cells and has been shown to be an independent predictor of melanoma prognosis (52, 87, 88). Metallothioneins are low-molecular-weight proteins that bind heavy metals, and their overexpression has been shown to be independently associated with tumor development and metastasis (89, 90). In addition to playing a role in diagnosis, serological markers such as LDH, S100, and C-reactive protein (CRP) also play an important role in the evaluation of melanoma prognosis (91–93).

5 Conclusion

In this study, we used bibliometric analysis to review the trends, hotspots, and frontiers of melanoma biomarker- related research in the past two decades. The number and citation frequency of melanoma biomarker- related studies are generally increasing year by year, and the importance of this field has been recognized globally. The United States is the core country for research on melanoma biomarkers and has important influence in this field accompanied by extensive cooperation with other countries. The New England Journal of Medicine, Clinical Cancer Research, etc. are highly influential journals in this field, and Robert, Caroline, Hodi, F. Stephen, etc. are authoritative authors in this field. Melanoma diagnosis, treatment and prognosis-related biomarkers are hot topics in this field. The application of melanoma biomarkers in the prediction of immunotherapy effect may be a key direction of future research. These findings provide researchers and policy makers with a comprehensive perspective to fully understand the field of melanoma molecular marker research.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: https://clarivate.com/products/scientific-and-academic-research/research-discovery-and-workflow-solutions/web-of-science/web-of-science-core-collection/.

Author contributions

JC, TS, and JL: study conception and design. YW, JS, and YH: study conduct. YW: data analysis. YW, JS, and YH: full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, data interpretation, and drafting of the manuscript. YW, JS, YH, LL, TS, and JL: critical revision of the manuscript for important intellectual content. All authors contributed to the article and approved the submitted version.

Funding

This work was funded by Guangdong Basic and Applied Basic Research Foundation, grant number 2020A1515011258, 2022A1515010529; Medical Scientific Research Foundation of Guangdong Province, grant number A2021465. The Open Research Fund of Key Laboratory of Advanced Theory and Application in Statistics and Data Science (East China Normal University), Ministry of Education.

Acknowledgments

We gratefully acknowledge the contributions of Peng Dong and Lixin Liang for their insightful suggestions on the manuscript, which greatly enhanced the quality of our research.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1181164/full#supplementary-material

References

1. Eddy K, Chen S. Overcoming immune evasion in melanoma. *Int J Mol Sci* (2020) 21(23):8984. doi: 10.3390/ijms21238984

2. Shain AH, Bastian BC. From melanocytes to melanomas. *Nat Rev Cancer* (2016) 16(6):345–58. doi: 10.1038/nrc.2016.37

3. Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. *Cancer Biol Ther* (2019) 20(11):1366–79. doi: 10.1080/15384047.2019.1640032

4. Guy GPJr., Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC, et al. Vital signs: melanoma incidence and mortality trends and projections - united states, 1982-2030. *MMWR Morb Mortal Wkly Rep* (2015) 64(21):591–6.

5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin* (2022) 72(1):7–33. doi: 10.3322/caac.21708

6. Sample A, He YY. Mechanisms and prevention of UV-induced melanoma. *Photodermatol Photoimmunol Photomed* (2018) 34(1):13–24. doi: 10.1111/phpp.12329

7. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. *Lancet* (2018) 392(10151):971–84. doi: 10.1016/S0140-6736(18)31559-9

8. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. *Vivo* (2014) 28(6):1005–11.

9. Natale CA, Duperret EK, Zhang J, Sadeghi R, Dahal A, O'Brien KT, et al. Sex steroids regulate skin pigmentation through nonclassical membrane-bound receptors. *Elife* (2016) 5:e15104. doi: 10.7554/eLife.15104

10. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. *Arch Pathol Lab Med* (2001) 125(10):1295–306. doi: 10.5858/2001-125-1295-MM

11. Patrone S, Maric I, Rutigliani M, Lanza F, Puntoni M, Banelli B, et al. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma. *Genes Chromosomes Cancer* (2018) 57(8):387–400. doi: 10.1002/gcc.22541

12. Ballester Sanchez R, de Unamuno Bustos B, Navarro Mira M, Botella Estrada R. Mucosal melanoma: an update. *Actas Dermosifiliogr* (2015) 106(2):96–103. doi: 10.1016/j.ad.2014.04.012

13. Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, et al. Biomarkers in melanoma. *Ann Oncol* (2009) 20(Suppl 6):vi8–13. doi: 10.1093/annonc/mdp251

14. Willis BC, Johnson G, Wang J, Cohen C. SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes. *Appl Immunohistochem Mol Morphol* (2015) 23(2):109–12. doi: 10.1097/PAI.0000000000000097

15. Lee JJ, Granter SR, Laga AC, Saavedra AP, Zhan Q, Guo W, et al. 5-hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. *Mod Pathol* (2015) 28(2):218–29. doi: 10.1038/modpathol.2014.99

16. Weinstein D, Leininger J, Hamby C, Safai B. Diagnostic and prognostic biomarkers in melanoma. *J Clin Aesthet Dermatol* (2014) 7(6):13–24.

17. Andres R, Mayordomo JI, Visus C, Isla D, Godino J, Escudero P, et al. Prognostic significance and diagnostic value of protein s-100 and tyrosinase in patients with malignant melanoma. *Am J Clin Oncol* (2008) 31(4):335–9. doi: 10.1097/COC.0b013e318162f11e

18. Beleaua MA, Jung I, Braicu C, Milutin D, Gurzu S. SOX11, SOX10 and MITF gene interaction: a possible diagnostic tool in malignant melanoma. *Life (Basel)* (2021) 11(4):281. doi: 10.3390/life11040281

19. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. *J Cutan Pathol* (2008) 35(5):433–44. doi: 10.1111/j.1600-0560.2007.00891.x

20. Ladstein RG, Bachmann IM, Straume O, Akslen LA. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. *BMC Cancer* (2010) 10:140. doi: 10.1186/1471-2407-10-140

21. Abbas O, Miller DD, Bhawan J. Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. *Am J Dermatopathol* (2014) 36(5):363–79. doi: 10.1097/DAD.0b013e31828a2ec5

22. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature* (2018) 560(7718):382–6. doi: 10.1038/s41586-018-0392-8

23. Zhai W, Zhou X, Zhai M, Li W, Ran Y, Sun Y, et al. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. *Sci China Life Sci* (2021) 64(4):548–62. doi: 10.1007/s11427-020-1740-8

24. Xia L, Wang H, Sun M, Yang Y, Yao C, He S, et al. Peripheral CD4(+) T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. *Sci China Life Sci* (2021) 64(10):1590–601. doi: 10.1007/s11427-020-1861-5

25. Hicks D, Wouters P, Waltman L, de Rijcke S, Rafols I. Bibliometrics: the Leiden manifesto for research metrics. *Nature* (2015) 520(7548):429–31. doi: 10.1038/520429a

26. Ninkov A, Frank JR, Maggio LA. Bibliometrics: methods for studying academic publishing. *Perspect Med Educ* (2022) 11(3):173–6. doi: 10.1007/s40037-021-00695-4

27. Deng P, Shi H, Pan X, Liang H, Wang S, Wu J, et al. Worldwide research trends on diabetic foot ulcers (2004-2020): suggestions for researchers. *J Diabetes Res* (2022) 2022:7991031. doi: 10.1155/2022/7991031

28. Xu Y, Jiang Z, Kuang X, Chen X, Liu H. Research trends in immune checkpoint blockade for melanoma: visualization and bibliometric analysis. *J Med Internet Res* (2022) 24(6):e32728. doi: 10.2196/32728

29. Li S, Guo Y, Hou X, Liu J, Fan W, Ju S, et al. Mapping research trends of uveal melanoma: a bibliomtric analysis. *Int Ophthalmol* (2022) 42(4):1121–31. doi: 10.1007/s10792-021-02098-0

30. Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H, et al. Research trends and most influential clinical studies on anti-PD1/PDL1 immunotherapy for cancers: a bibliometric analysis. *Front Immunol* (2022) 13:862084. doi: 10.3389/fimmu.2022.862084

31. Zhou Q, Pei J, Poon J, Lau AY, Zhang L, Wang Y, et al. Worldwide research trends on aristolochic acids (1957-2017): suggestions for researchers. *PloS One* (2019) 14(5):e0216135. doi: 10.1371/journal.pone.0216135

32. Chen CM. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. *J Am Soc Inf Sci Technol* (2006) 57(3):359–77. doi: 10.1002/asi.20317

33. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. *Scientometrics* (2010) 84(2):523–38. doi: 10.1007/s11192-009-0146-3

34. Aria M, Cuccurullo C. Bibliometrix: an r-tool for comprehensive science mapping analysis. *J Informetrics* (2017) 11(4):959–75. doi: 10.1016/j.joi.2017.08.007

35. Cheng P, Tang H, Dong Y, Liu K, Jiang P, Liu Y. Knowledge mapping of research on land use change and food security: a visual analysis using CiteSpace and VOSviewer. *Int J Environ Res Public Health* (2021) 18(24):13065. doi: 10.3390/ijerph182413065

36. Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. *J Assoc Inf Sci Technol* (2014) 65(2):334–51. doi: 10.1002/asi.22968

37. Zhang J, Song L, Xu L, Fan Y, Wang T, Tian W, et al. Knowledge domain and emerging trends in ferroptosis research: a bibliometric and knowledge-map analysis. *Front Oncol* (2021) 11:686726. doi: 10.3389/fonc.2021.686726

38. Wang Q, Li X, Qiu J, He Y, Wu J, Li J, et al. A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma. *Comput Struct Biotechnol J* (2023) 21:2536–46. doi: 10.1016/j.csbj.2023.04.004

39. Gutierrez-Castaneda LD, Nova JA, Tovar-Parra JD. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review. *Melanoma Res* (2020) 30(1):62–70. doi: 10.1097/CMR.0000000000000628

40. Wang Z, Yin C, Lum LG, Simons A, Weiner GJ. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. *J Hematol Oncol* (2021) 14(1):204. doi: 10.1186/s13045-021-01216-w

41. Chanda M, Cohen MS. Advances in the discovery and development of melanoma drug therapies. *Expert Opin Drug Discovery* (2021) 16(11):1319–47. doi: 10.1080/17460441.2021.1942834

42. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* (2013) 369(2):122–33. doi: 10.1056/NEJMoa1302369

43. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* (2012) 366(26):2443–54. doi: 10.1056/NEJMoa1200690

44. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* (2014) 515(7528):563–7. doi: 10.1038/nature14011

45. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* (2014) 6(224):224ra24. doi: 10.1126/scitranslmed.3007094

46. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* (2016) 387(10031):1909–20. doi: 10.1016/S0140-6736(16)00561-4

47. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* (2009) 27(36):6199–206. doi: 10.1200/JCO.2009.23.4799

48. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* (2010) 363(8):711–23. doi: 10.1056/NEJMoa1003466

49. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med* (2019) 381(16):1535–46. doi: 10.1056/NEJMoa1910836

50. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet* (2019) 51(2):202–6. doi: 10.1038/s41588-018-0312-8

51. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat Rev Cancer* (2016) 16(5):275–87. doi: 10.1038/nrc.2016.36

52. Naik PP. Role of biomarkers in the integrated management of melanoma. *Dis Markers* (2021) 2021:6238317. doi: 10.1155/2021/6238317

53. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. *Nat Rev Clin Oncol* (2017) 14(8):463–82. doi: 10.1038/nrclinonc.2017.43

54. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism,

combinations, and clinical outcome. *Front Pharmacol* (2017) 8:561. doi: 10.3389/fphar.2017.00561

55. Vereecken P, Cornelis F, Van Baren N, Vandersleyen V, Baurain JF. A synopsis of serum biomarkers in cutaneous melanoma patients. *Dermatol Res Pract* (2012) 2012:260643. doi: 10.1155/2012/260643

56. Hessler M, Jalilian E, Xu Q, Reddy S, Horton L, Elkin K, et al. Melanoma biomarkers and their potential application for in vivo diagnostic imaging modalities. *Int J Mol Sci* (2020) 21(24):9583. doi: 10.3390/ijms21249583

57. Duarte AF, Sousa-Pinto B, Azevedo LF, Barros AM, Puig S, Malvehy J, et al. Clinical ABCDE rule for early melanoma detection. *Eur J Dermatol* (2021) 31(6):771–8. doi: 10.1684/ejd.2021.4171

58. Filosa A, Filosa G. Melanoma diagnosis: the importance of histopathological report. *Dermatopathol (Basel)* (2018) 5(1):41–3. doi: 10.1159/000486670

59. Rajabi-Estarabadi A, Bittar JM, Zheng C, Nascimento V, Camacho I, Feun LG, et al. Optical coherence tomography imaging of melanoma skin cancer. *Lasers Med Sci* (2019) 34(2):411–20. doi: 10.1007/s10103-018-2696-1

60. Waddell A, Star P, Guitera P. Advances in the use of reflectance confocal microscopy in melanoma. *Melanoma Manag* (2018) 5(1):MMT04. doi: 10.2217/mmt-2018-0001

61. Giovagnorio F, Andreoli C, De Cicco ML. Color Doppler sonography of focal lesions of the skin and subcutaneous tissue. *J Ultrasound Med* (1999) 18(2):89–93. doi: 10.7863/jum.1999.18.2.89

62. Kim RH, Meehan SA. Immunostain use in the diagnosis of melanomas referred to a tertiary medical center: a 15-year retrospective review (2001-2015). *J Cutan Pathol* (2017) 44(3):221–7. doi: 10.1111/cup.12867

63. Jing X, Michael CW, Theoharis CG. The use of immunocytochemical study in the cytologic diagnosis of melanoma: evaluation of three antibodies. *Diagn Cytopathol* (2013) 41(2):126–30. doi: 10.1002/dc.21791

64. Gleason BC, Nascimento AF. HMB-45 and melan-a are useful in the differential diagnosis between granular cell tumor and malignant melanoma. *Am J Dermatopathol* (2007) 29(1):22–7. doi: 10.1097/01.dad.0000249888.41884.6c

65. Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. *Adv Cancer Res* (2010) 109:73–121. doi: 10.1016/B978-0-12-380890-5.00003-X

66. Xiong TF, Pan FQ, Li D. Expression and clinical significance of S100 family genes in patients with melanoma. *Melanoma Res* (2019) 29(1):23–9. doi: 10.1097/CMR.0000000000000512

67. Chang KL, Folpe AL. Diagnostic utility of microphthalmia transcription factor in malignant melanoma and other tumors. *Adv Anat Pathol* (2001) 8(5):273–5. doi: 10.1097/00125480-200109000-00004

68. Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. *Adv Exp Med Biol* (2015) 867:115–24. doi: 10.1007/978-94-017-7215-0_8

69. Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. *Clin Epigenet* (2017) 9:34. doi: 10.1186/s13148-017-0332-8

70. Mohammadpour A, Derakhshan M, Darabi H, Hedayat P, Momeni M. Melanoma: where we are and where we go. *J Cell Physiol* (2019) 234(4):3307–20. doi: 10.1002/jcp.27286

71. Wang Z, Cao YJ. Adoptive cell therapy targeting neoantigens: a frontier for cancer research. *Front Immunol* (2020) 11:176. doi: 10.3389/fimmu.2020.00176

72. Ti D, Bai M, Li X, Wei J, Chen D, Wu Z, et al. Adaptive T cell immunotherapy in cancer. *Sci China Life Sci* (2021) 64(3):363–71. doi: 10.1007/s11427-020-1713-9

73. Li T, Qian C, Gu Y, Zhang J, Li S, Xia N. Current progress in the development of prophylactic and therapeutic vaccines. *Sci China Life Sci* (2022) 66(4):1–32. doi: 10.1007/s11427-022-2230-4

74. Jin K, Li T, Miao Z, Ran J, Chen L, Mou D, et al. Stat5(-/-) CD4(+) T cells elicit anti-melanoma effect by CD4(+) T cell remolding and Notch1 activation. *Sci China Life Sci* (2022) 65(9):1824–39. doi: 10.1007/s11427-021-2078-6

75. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. *Curr Oncol* (2022) 29(5):3044–60. doi: 10.3390/curroncol29050247

76. Tarhini AA, Joshi I, Garner F. Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. *Immunotherapy* (2021) 13 (12):1011–29. doi: 10.2217/imt-2021-0119

77. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. *Clin Cancer Res* (2011) 17(22):6958–62. doi: 10.1158/1078-0432.CCR-11-1595

78. Scott LJ. Nivolumab: a review in advanced melanoma. *Drugs* (2015) 75 (12):1413–24. doi: 10.1007/s40265-015-0442-6

79. Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. *J Immunother Cancer* (2015) 3:36. doi: 10.1186/s40425-015-0078-9

80. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med* (2014) 371 (20):1867–76. doi: 10.1056/NEJMoa1408868

81. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. *J Clin Oncol* (2008) 26 (12):2046–51. doi: 10.1200/JCO.2007.14.0707

82. Ribero S, Stucci LS, Marra E, Marconcini R, Spagnolo F, Orgiano L, et al. Effect of age on melanoma risk, prognosis and treatment response. *Acta Derm Venereol* (2018) 98(7):624–9. doi: 10.2340/00015555-2944

83. Nosrati M, Kashani-Sabet M. Immunohistochemical diagnostic and prognostic markers for melanoma. *Methods Mol Biol* (2014) 1102:259–73. doi: 10.1007/978-1-62703-727-3_14

84. Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, et al. Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. *Histopathology* (2002) 41(6):519–25. doi: 10.1046/j.1365-2559.2002.01444.x

85. Liu Q, Peng Z, Shen L, Shen L. Prognostic and clinicopathological value of ki-67 in melanoma: a meta-analysis. *Front Oncol* (2021) 11:737760. doi: 10.3389/fonc.2021.737760

86. Mintz-Weber CS, Johnson JP. Identification of the elements regulating the expression of the cell adhesion molecule MCAM/MUC18. loss of AP-2 is not required for MCAM expression in melanoma cell lines. *J Biol Chem* (2000) 275(44):34672–80. doi: 10.1074/jbc.M003812200

87. Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. *J Plast Reconstr Aesthet Surg* (2008) 61 (3):265–71. doi: 10.1016/j.bjps.2007.04.010

88. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. *Plast Reconstr Surg* (2005) 115(2):367–75. doi: 10.1097/01.PRS.0000148417.86768.C9

89. Thirumoorthy N, Shyam Sunder A, Manisenthil Kumar K, Senthil Kumar M, Ganesh G, Chatterjee M. A review of metallothionein isoforms and their role in pathophysiology. *World J Surg Oncol* (2011) 9:54. doi: 10.1186/1477-7819-9-54

90. Larson AR, Konat E, Alani RM. Melanoma biomarkers: current status and vision for the future. *Nat Clin Pract Oncol* (2009) 6(2):105–17. doi: 10.1038/ncponc1296

91. Fan S, Liu X, Wu Y, Li K, Zhao X, Lin W, et al. Prognostic value of lactate dehydrogenase, melanoma inhibitory protein, and s-100B protein in patients with malignant melanoma. *Evid Based Complement Alternat Med* (2022) 2022:9086540. doi: 10.1155/2022/9086540

92. Kaskel P, Berking C, Sander S, Volkenandt M, Peter RU, Krahn G. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. *J Am Acad Dermatol* (1999) 41(6):962–9. doi: 10.1016/S0190-9622(99)70254-9

93. Deichmann M, Kahle B, Moser K, Wacker J, Wust K. Diagnosing melanoma patients entering American joint committee on cancer stage IV, c-reactive protein in serum is superior to lactate dehydrogenase. *Br J Cancer* (2004) 91(4):699–702. doi: 10.1038/sj.bjc.6602043

frontiers | Frontiers in Oncology

TYPE Original Research
PUBLISHED 17 August 2023
DOI 10.3389/fonc.2023.1154107

OPEN ACCESS

EDITED BY
Rosario Caltabiano,
University of Catania, Italy

REVIEWED BY
Lukasz Laczmanski,
Polish Academy of Sciences, Poland
Giovanni Paolino,
San Raffaele Hospital (IRCCS), Italy
Stefano Calvieri,
Sapienza University of Rome, Italy

*CORRESPONDENCE
Xinjian Lin
xlin@fjmu.edu.cn
Biao Wang
biaowang@fjmu.edu.cn

†These authors have contributed equally to this work

RECEIVED 30 January 2023
ACCEPTED 03 August 2023
PUBLISHED 17 August 2023

CITATION
Cai B, Lin Q, Ke R, Shan X, Yu J, Ni X, Lin X and Wang B (2023) Causal association between serum 25-Hydroxyvitamin D levels and cutaneous melanoma: a two-sample Mendelian randomization study. *Front. Oncol.* 13:1154107. doi: 10.3389/fonc.2023.1154107

Causal association between serum 25-Hydroxyvitamin D levels and cutaneous melanoma: a two-sample Mendelian randomization study

Beichen Cai[1,2,3,4†], Qian Lin[1,3,4†], Ruonan Ke[1,3], Xiuying Shan[1,3], Jiaqi Yu[1,3,4], Xuejun Ni[1,3], Xinjian Lin[1,3,5*] and Biao Wang[1,2,3,4*]

[1]Department of Plastic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China, [2]Fujian Key Laboratory of Oral Diseases, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, Fujian, China, [3]Department of Plastic Surgery, National Regional Medical Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China, [4]Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China, [5]Key Laboratory of Gastrointestinal Cancer, Fujian Medical University, Ministry of Education, Fuzhou, Fujian, China

Background: Despite numerous observational studies on the association between serum 25-Hydroxyvitamin D levels and cutaneous melanoma, causal inferences remain ambiguous due to confounding and reverse causality. This study aimed to elucidate the causal relationship between serum 25-Hydroxyvitamin D levels and melanoma incidence using Mendelian randomization (MR).

Methods: A two-sample MR was conducted using genetic variants associated with serum 25-Hydroxyvitamin D levels as instrumental variables. Summary statistics for these variants were derived from genome-wide association studies, and those for melanoma risk were obtained from a comprehensive melanoma case-control study. Robustness of the results was assessed through sensitivity analyses, including the "leave-one-out" approach and tests for potential pleiotropy.

Results: The MR analysis provided substantial evidence of a positive causal relationship between serum 25-Hydroxyvitamin D levels and the incidence of cutaneous melanoma, suggesting that each unit increase in serum 25-Hydroxyvitamin D levels corresponds with an increased risk of melanoma. Tests for pleiotropy showed minimal effects, and the sensitivity analysis confirmed no disproportionate influence by any individual single nucleotide polymorphism (SNP).

Conclusion: The findings indicated a potentially causal positive association between serum 25-Hydroxyvitamin D levels and melanoma risk, challenging traditional beliefs about vitamin D's role in melanoma. This emphasizes the need for a balanced and personalized approach to vitamin D supplementation and sun

exposure, particularly in high-risk populations. These results should be interpreted with caution due to potential unrecognized pleiotropy and confounding factors. Future research should focus on validating these findings in diverse populations and exploring underlying biological mechanisms.

KEYWORDS

serum 25-hydroxyvitamin D, cutaneous melanoma, Mendelian randomization, genetic variants, causal inference, sun exposure

1 Introduction

Cutaneous melanoma, a malignant neoplasm stemming from skin melanocytes (1), is a major worldwide health concern due to escalating incidence and high mortality rates (2). Over the past few decades, this aggressive skin cancer with a pronounced metastatic propensity has seen a marked increase in prevalence, underscoring the urgency of a thorough understanding of its etiology (3). The etiology of melanoma is multifactorial, involving a complex combination of environmental and genetic determinants (4). Exposure to ultraviolet (UV) radiation is a well-established risk factor, playing a pivotal role in the disease's onset and progression (5). However, our understanding of other potential modifiable risk factors, such as Vitamin D—which is predominantly generated through UV exposure—is less clear and warrants further investigation (6).

Despite significant advancements in early detection, prevention measures, and therapeutic strategies, melanoma presents considerable challenges (7). These challenges are largely due to its resistance to conventional treatments, advanced stages at diagnosis, and high metastatic potential (8, 9). Comprehensive insight into the disease's etiology, risk factors, and the specific determinants of pathogenesis is crucial for devising more effective prevention strategies, targeted therapies, and improving overall prognosis for patients. This further emphasizes the importance of examining genetic and environmental interactions, especially concerning potential modifiable factors such as Vitamin D (10).

Vitamin D, synthesized primarily through sunlight exposure and dietary intake, is crucial for multiple physiological functions including bone health, immune regulation, and cell differentiation and proliferation (11, 12). The regulation of vitamin D metabolism involves the significant action of several enzymes, particularly CYP27A1, CYP27B1, and CYP24A1, which are genes critical for the synthesis and degradation of this vitamin (13, 14). Primarily expressed in the liver, CYP27A1 initiates the conversion of vitamin D into its active form, calcitriol, through a process known as hydroxylation (15). This conversion is further catalyzed by CYP27B1, which is predominantly expressed in the kidneys (16, 17). Meanwhile, CYP24A1, largely found in the kidneys and various other tissues, oversees the breakdown of active vitamin D metabolites into inactive forms (18). This degradation process is integral for maintaining vitamin D homeostasis, emphasizing the crucial role of CYP24A1 in this biological regulatory system (19). The primary circulating form, 25-Hydroxyvitamin D (25(OH)D), serves as a reliable biomarker of Vitamin D status (20). The potential protective role of Vitamin D, specifically serum 25(OH)D, against various cancers, including cutaneous melanoma - a highly aggressive skin cancer - has been a subject of significant research interest (10, 21). This interest is further amplified by the dual role of sunlight as a source of Vitamin D synthesis and a known risk factor for melanoma (22, 23).

However, the epidemiological evidence linking serum 25(OH)D levels and melanoma incidence has been inconsistent (24). Some studies indicate a protective role of higher serum 25(OH)D levels against melanoma (25–28), while others suggest no significant association or produce contradictory results (29–34). These discrepancies are thought to arise from confounding variables such as lifestyle, genetics, sunlight exposure, skin type, and the potential for reverse causation, thus complicating the inference of a causal relationship (35). Given these limitations inherent in observational studies, there is a pressing need for more robust research methodologies that can provide more valid causal inferences.

This research utilizes a two-sample Mendelian Randomization (MR) approach to investigate the potential causal link between serum 25-Hydroxyvitamin D levels and the incidence of cutaneous melanoma (36, 37). The MR methodology, which employs Single Nucleotide Polymorphisms (SNPs) as instrumental variables (IVs), offers an effective strategy to estimate causal relationships, mitigating bias from confounding factors and reverse causation that often confound traditional observational studies (38, 39). The study relies on three fundamental MR assumptions: relevance, independence, and exclusion restriction, to ensure that selected SNPs have a robust association with serum 25-Hydroxyvitamin D levels, are not associated with confounding variables, and affect melanoma risk exclusively through their impact on serum 25-Hydroxyvitamin D levels (40). The selection of SNPs and the outcome data were sourced from large-scale, publicly available genome-wide association study (GWAS) datasets (41).

Three key MR analysis methods were applied: Inverse Variance Weighted (IVW), weighted median, and MR-Egger regression (42). These techniques provide a comprehensive examination of the potential causal relationship while addressing varying conditions of instrument validity and pleiotropy. To verify the robustness and validity of the findings, a series of sensitivity analyses were conducted, including Cochran's Q Test, a Pleiotropy Test, and a "leave-one-out" analysis (43). The Radial MR method, an

innovative technique for outlier identification and exclusion, was also employed, thereby enhancing the reliability of the findings (44). The analysis of this study indicate a statistically significant causal association between serum 25-Hydroxyvitamin D levels and melanoma incidence.

Our findings not only shed light on the potential role of Vitamin D in melanoma pathogenesis but also underscore the possible implications for prevention and therapeutic strategies, particularly in regard to vitamin D optimization strategies. This study bridges a gap in the existing literature and sets the foundation for future research, although clinical decision-making should carefully consider the inherent limitations of MR studies, individual health considerations, and the multifaceted nature of melanoma etiology. Our findings point to new avenues for melanoma prevention, but further investigation is warranted to fully elucidate the precise biological implications and clinical applicability of serum 25-Hydroxyvitamin D levels in melanoma risk.

2 Materials and methods

2.1 Mendelian randomization study design

Our study was undertaken following the framework of a two-sample MR model utilizing preselected instrumental variables (37, 45). The schematic framework of the MR design is delineated in Figure 1. The validity of our research hinged on three pivotal assumptions (40): (1) Relevance Assumption: the Single Nucleotide Polymorphisms demonstrated a robust association with serum 25-Hydroxyvitamin D concentrations which were measured using a validated assay method; (2) Independence Assumption: SNPs were not linked to confounding variables which were identified based on established biological and epidemiological knowledge about potential confounders of the association between 25-Hydroxyvitamin D and melanoma; (3) Exclusion Restriction Assumption: SNPs influence melanoma outcomes solely through their potential impact on serum 25-Hydroxyvitamin D levels which required a comprehensive review of the existing literature to exclude other potential causal pathways (39). In adherence to MR analysis standards, we carefully selected SNPs that were previously reported to be strongly associated with serum 25-Hydroxyvitamin D concentrations. These were chosen as they were not linked to known confounding variables and their influence on melanoma was only due to their potential impact on serum 25-Hydroxyvitamin D levels, thereby satisfying the three key MR assumptions.

In order to ensure the robustness of our study, a comprehensive verification of these assumptions was performed through a thorough statistical analysis of SNP–exposure and SNP–outcome associations (46). This was crucial in order to meet the rigorous statistical requirements for a valid MR study and strengthen the credibility of our conclusions. To further substantiate our findings and strengthen the validity of our study, our analyses also accounted for potential bidirectional relationships, secondary pleiotropic effects, and population stratification, which may pose plausible threats to the validity of these assumptions.

The MR analyses were executed using R software (version 4.0.3), supplemented with the "TwoSampleMR" (version 0.5.6) and "RadialMR" (version 1.0) packages. The R environment was preferred due to its extensive statistical functionalities and capacity to handle large-scale genomic datasets, crucial for executing an MR study of this magnitude (47). The TwoSampleMR package enables the implementation of two-sample MR analysis by providing functions for data extraction, harmonization, and performing several statistical methods, while the RadialMR package, based on modified second-order weights, allows for the detection and subsequent exclusion of outliers (37).

2.2 Data acquisition for exposure and outcome

Genetic associations for the serum 25-Hydroxyvitamin D levels (ebi-a-GCST90000618) were sought in publicly available genome-wide association study datasets, which contained data for 496,946 samples and 6,896,093 SNPs (48). These large, heterogeneous datasets provide a valuable and diverse genetic background for assessing the association of SNPs with vitamin D levels (49). These large datasets were chosen to ensure adequate power to detect even small effect sizes and to allow for the inclusion of a large number of IVs (50). These datasets fulfilled the minimum criteria requisite for importation from the European Bioinformatics Institute (EBI) database of complete GWAS summary data (51). We pinpointed SNPs exhibiting robust associations with serum 25-Hydroxyvitamin D, establishing a stringent threshold for statistical significance ($P < 5*10^{-9}$), linkage disequilibrium (LD) $r^2 < 0.001$, and LD distance > 10,000 kb. The F statistic was employed to rule out weak instrument bias that might contravene the first MR assumption, thereby evaluating the strength of the association between SNPs and serum 25-Hydroxyvitamin D levels (52, 53). This rigorous selection process ensures the minimization of false-positive results, enhancing the reliability of our IVs. The use of such large and comprehensive GWAS datasets ensures the robustness and external validity of our findings (54). The stringent criteria set for SNP selection help ensure the quality of IVs and the accuracy of subsequent analyses.

Regarding the outcome data, we obtained melanoma skin cancer GWAS data ieu-b-4969 from the ieu-b datasets, a summary data compilation generated by several consortia that were manually curated, initially created for MR-Base (55). This dataset was selected for its extensive coverage and high-quality data, ensuring that the subsequent analyses would be adequately powered and encompass a comprehensive range of genetic variations associated with melanoma (56). This melanoma data consisted of 375,767 samples, and included 11,396,019 SNPs which were all carefully checked for quality control measures including genotyping accuracy and Hardy-Weinberg equilibrium. We emphasized harmonization to minimize inconsistencies and discrepancies between the different datasets, which is a critical aspect when working with such large-scale genetic data. The data was harmonized for subsequent MR analysis including the alignment of the effect allele and standardization of the units of measurement for both the exposure and outcome variables. Moreover, in order to



FIGURE 1
Flow diagram delineating the design process of a two-sample Mendelian randomization study. This figure includes a description of the selection of instrumental variables, identification of exposure and outcome datasets, and the methods used for the MR analysis and sensitivity analysis.

mitigate any potential bias, we strictly observed a minor allele frequency (MAF) cut-off of 0.01, thus ensuring that all included SNPs had sufficient population frequency to warrant their inclusion (57).

2.3 MR analysis

A two-sample MR analysis was performed employing three primary methods: inverse variance weighted median, weighted median, and MR-Egger, aiming to assess the potential causal relationship between serum 25-Hydroxyvitamin D levels and melanoma (37). These three methods each address different potential sources of bias in MR analyses, and thus together provide a robust and comprehensive evaluation of the causal relationship. IVW approach combines the strengths of different SNPs and their individual effects in an efficient manner to yield an overall estimate. Weighted median allows for more heterogeneity, enabling up to 50% of the genetic variants to be invalid instruments. Meanwhile, MR-Egger provides a measure of directional pleiotropy and is less prone to bias when the assumptions of the other two methods are violated. Each analysis was conducted using the corresponding two-sample MR packages in R, per developers' guidelines. The use of multiple methods provides a comprehensive and robust assessment of potential causal relationships, while also providing an opportunity for comparison and cross-validation of the results.

The IVW approach combined meta-analysis with Wald estimates for each SNP to yield an aggregate effect estimate for melanoma. IVW results remain unbiased provided no horizontal pleiotropy is observed (58). The Wald ratio for each SNP was calculated as the ratio of the SNP-outcome association to the SNP-exposure association (59). Horizontal pleiotropy, where genetic variants affect the outcome through pathways other than the exposure, can introduce bias into the MR estimates. The assumption of no horizontal pleiotropy is critical as it ensures that the SNP's effect on melanoma is channeled solely through its influence on serum 25-Hydroxyvitamin D levels, thereby ensuring valid estimates (60).

While estimates from the random and fixed effects IVW models are identical, the variance in the random effects model is inflated to account for SNP heterogeneity. Consequently, the fixed-effect model was implemented in scenarios devoid of observed heterogeneity ($p > 0.05$) which assumes that the true effect size is the same for all SNPs and any variation is due to sampling error, thus providing a more conservative estimate. Adoption of the appropriate model as per the observed heterogeneity helps prevent inaccuracies that could arise due to the misapplication of a fixed or random effects model.

MR-Egger regression, grounded on the assumption of instrument strength independence from direct effect, enables the evaluation of pleiotropy presence via the intercept term (61). This intercept can be interpreted as an estimate of the average direct effect of the genetic variants on the outcome, not through the exposure. In other words, it provides a measure of the overall directional pleiotropy. An intercept value equal to zero suggests nonexistence of horizontal pleiotropy and MR-Egger regression

outcome consistency with IVW. This method also allows for the assessment of any potential directional pleiotropy - a significant deviation from zero indicates that the IVs may be affecting the outcome through pathways other than 25-Hydroxyvitamin D levels. Pleiotropy, if undetected, can introduce bias and misdirect our interpretations of the results.

The correlation LD between selected SNPs and potential confounding factors required careful assessment to ensure methodological robustness and conformity with the second MR assumption, as any correlation is unacceptable. In the context of an MR analysis, SNPs in LD could violate the Independence Assumption and confound the results. Therefore, a clumping procedure was undertaken to ensure the SNPs were in minimal LD with each other, thereby enhancing the validity of our study. This step is crucial as it reduces the possibility of SNP-SNP interaction, which can confound the results.

2.4 Sensitivity analysis

We utilized Cochran's Q Test and a Pleiotropy Test to assess the robustness of our findings (62). Cochran's Q statistics were employed to quantify the heterogeneity among the IVs (63). Heterogeneity among the IVs could reflect an invalid assumption of no horizontal pleiotropy or a violation of the Exclusion Restriction Assumption. This allowed us to understand if the individual SNP effects were more varied than what would be expected by chance alone. In addition, to pinpoint potentially heterogeneous SNPs, a "leave-one-out" analysis was carried out (64). This analysis evaluated the reliability of the relationship between SNPs and exposure, and assessed whether any particular SNP was contributing disproportionately to significant results. Evidence of heterogeneity suggests that certain genetic instruments may be invalid ($p < 0.05$). The leave-one-out analysis is a robust way to identify any single genetic instrument that may unduly influence the study results, ensuring the stability of our MR estimates. Such an analysis is invaluable in identifying and excluding potential outlier SNPs that may unduly influence the MR estimates.

Pleiotropy tests were carried out to investigate the influence of serum 25-Hydroxyvitamin D levels on melanoma risk within the context of MR analysis (65). A p-value less than 0.05 indicates an absence of horizontal pleiotropy among selected genetic instruments and suggests the need for a more comprehensive modelling framework to identify outliers. Detecting pleiotropy early is vital for maintaining the integrity of the study, as unidentified pleiotropy can potentially bias the MR results. Any indication of pleiotropy prompted an in-depth exploration of the data and warranted a comprehensive examination of the outliers in our modelling framework. Figure 2 is the schematic representation of the comprehensive design of the analysis process for the Mendelian randomization study (66).

2.5 Radial MR analysis

Our study utilized an innovative methodology, employing modified second-order weights, to investigate potential outliers within MR analysis. This was facilitated through the use of the "RadialMR" package (version 1.0) in the R programming environment, permitting the identification of outliers that could distort the causal estimates and enabling subsequent reanalysis after their exclusion (44). The modified second-order weights calculated using RadialMR account for both the first and second moments of the error term. This is in contrast to the traditional MR-Egger regression that only considers the first moment. By considering both moments, RadialMR can detect influential outliers that might bias the MR estimates and remove them, thus providing a more robust and reliable estimate of the causal effect. The entire process was automated within the package, ensuring the standardization of the method across all the data.

Radial MR has been increasingly recognized for its capability to detect and adjust for potential outlier SNPs. By reweighting the SNP estimates and corresponding standard errors based on their deviance from the overall MR estimate, the Radial MR methodology can help limit undue influence from outlier SNPs. It offers another layer of robustness to our study and can contribute significantly to the precision of the estimates. In the course of the Radial MR analysis, SNPs identified as outliers were removed in a stepwise manner and the MR estimates were recalculated at each step. The iterative nature of the Radial MR analysis allowed us to examine the impact of each SNP and assess the stability of our results. If a particular SNP caused a significant deviation in the MR estimate, this might indicate a violation of the assumptions underlying MR analysis, such as pleiotropy or linkage with confounding factors.



FIGURE 2
Schematic representation of the comprehensive design of the Mendelian randomization study. This figure provides a visual summary of our study design, illustrating the key steps in the data acquisition, analysis, and interpretation process.

3 Results

3.1 Causality between serum 25-Hydroxyvitamin D levels and melanoma incidence

A statistically significant causal association was inferred between serum 25-Hydroxyvitamin D levels and the incidence of melanoma, as determined by the Inverse Variance Weighted (IVW) Mendelian Randomization (MR) method (β = 0.0022159, p = 0.0494391) (Figure 3). This approach uses genetic variants as instrumental variables (IVs) to dissect causal associations in observational studies. With the avoidance of environmental confounding and bias due to reverse causation, which commonly plague conventional observational studies, the MR approach gives robust evidence of causality.

In the realm of MR, the β coefficient indicates the magnitude of the effect size or the estimated change in the outcome (melanoma incidence in this case) associated with a one unit increase in the exposure (serum 25-Hydroxyvitamin D levels). The p-value is indicative of the statistical significance of this association, with our p = 0.0494391 suggesting that this association is significant at the 5% level. The result indicates that for each unit increase in serum 25-Hydroxyvitamin D levels, the incidence of melanoma increases by 0.0022159 units. It's worth noting that this β coefficient, despite being relatively small, points towards a positive relationship, suggesting an increase in melanoma incidence with elevated serum 25-Hydroxyvitamin D levels. It's important to acknowledge the fact that even a seemingly minuscule rise in melanoma risk can be of significant public health relevance, given the severity and escalating incidence of this form of skin cancer worldwide (67).

The scatter plot shown in Figure 3 visually portrays the individual genetic variants that contribute to the aggregate data point, representing the causal estimate. Each data point on the scatter plot signifies a genetic variant, with its position being determined by its association with both melanoma risk and vitamin D levels. The slope of the regression line captures the average causal effect of these genetic variants, providing a visual representation of the aggregate causal estimate determined by the IVW method.

In the context of MR studies, heterogeneity refers to the variability in the estimates of the causal effect derived from each individual genetic variant. The Cochran Q-test of heterogeneity, applied to the IVW method, indicated the absence of significant heterogeneity in the study (Q = 95.46249, P = 0.1299563) (Table 1). This Cochran Q-test result further bolsters the study's validity by demonstrating the homogeneity of the genetic instruments used (68). A non-significant Q statistic indicates that the variation across the different causal estimates is within what might be expected due to sampling variability, suggesting the lack of bias in the causal estimation. This Q statistic and associated p-value highlight that the individual effects sizes derived from the different SNPs included in the MR analysis do not significantly differ from each other, thereby confirming homogeneity among the studies and supporting the overall validity of the pooled causal estimate. However, the p-value



FIGURE 3
Scatter plot illustrating the associations between melanoma skin cancer (y-axis) and Serum 25-Hydroxyvitamin D levels (x-axis). The slope of the regression line serves as an estimate of the causal effect between these variables.

TABLE 1 Detailed MR findings of the causal association between serum 25-Hydroxyvitamin D levels and melanoma incidence.

Method	nSNP	β	Se	pval	Q_pval	Pleiotropy
Inverse variance weighted	82	0.0021413	0.0017640	0.2283738	0.1299563	0.9560984
MR Egger	82	0.0002823	0.0017567	0.8723171	0.1144536	
Weighted median	82	0.0022159	0.0011278	0.0494391		
Simple mode	82	0.0021478	0.0032797	0.5143997		
Weighted mode	82	0.0007570	0.0015899	0.6352514		

above 0.05 does not entirely exclude the possibility of minor heterogeneity among the included SNPs.

Table 1 presents the results from various Mendelian randomization analyses, employing different methodologies such as Inverse Variance Weighted, MR Egger, Weighted Median, Simple Mode, and Weighted Mode. Each row provides key metrics including the number of SNPs (nSNP), effect size (β), standard error (Se), p-value, Q p-value (a measure of heterogeneity), and a Pleiotropy test result, thus offering a comprehensive view of the genetic association and potential bias in each analysis method.

3.2 Robustness of the causal relationship between serum 25-Hydroxyvitamin D levels and melanoma

In the robustness assessment through a "leave-one-out" sensitivity analysis, the IVW estimates obtained after successively excluding each SNP approximated the IVW estimates from the complete set of SNPs. This consistency suggested that no individual SNP exerted a substantial influence on the estimated causal relationship (Figure 4). This analysis is pivotal in mitigating the potential of a single SNP disproportionately skewing the estimated



FIGURE 4
Leave-one-out sensitivity analysis of the impact of serum 25-Hydroxyvitamin D levels on melanoma skin cancer incidence. Each circle represents an estimate of the causal effect susceptibility between Serum 25-Hydroxyvitamin D levels and melanoma skin cancer, with the bars indicating the confidence interval (CI).

effect size. The consistent estimates from this analysis highlight the robustness of the IVW method, reducing the likelihood of overestimated or spurious causal inferences. If the revised estimates do not deviate significantly from the original, it implies that no single SNP disproportionally affects the results. It indicates that the identified correlation does not rely on any particular SNP, lending credibility to the inference that the effect is a genuine result of the overall genetic variation.

This figure visualizes the dispersion of the causal effect estimates upon successive omission of each SNP. The position of the circles along the y-axis represents the effect estimate, while the horizontal bars reflect the degree of uncertainty around these estimates. The tight clustering of these points along the y-axis reflects the consistency of the estimates, reinforcing the stability of the causal inference.

A detailed annotation of the SNPs illustrated on the ordinate of Figure 4 is provided in Supplementary Table 1 by searching in the PhenoScanner V2 database (69, 70). This table not only lists the gene symbols corresponding to each SNP, but it also highlights the traits associated with these genetic variations, thereby emphasizing potential phenotypic implications of these genomic discrepancies. This feature underscores the potential phenotypic ramifications inherent in these genetic variations, highlighting the complex interplay between genotype and phenotype. In interpreting these genetic associations, it is imperative to consider the broader genomic context in which these SNPs exist. Notably, while the SNPs' impact on 25-Hydroxyvitamin D levels might influence melanoma risk, they could also confer pleiotropic effects that potentially influence other phenotypes. This data provides an exhaustive map of the genomic landscape surrounding the examined association, enabling a deeper understanding of the genetic underpinnings potentially influencing both Vitamin D levels and melanoma risk

3.3 Assessing pleiotropic impact on the causal link between serum 25-Hydroxyvitamin D levels and melanoma incidence

To further evaluate the robustness of the MR study, a pleiotropic test was conducted. Pleiotropy is a phenomenon where a single gene or genetic variant influences multiple traits. It can be a potential source of bias in MR studies, making its assessment vital for ensuring the accuracy of the results. In order for MR to maintain validity, it is essential that there is no violation of the exclusion restriction assumption - that is, genetic variants should not be directly associated with the outcome beyond their influence on the exposure. Pleiotropy, particularly horizontal pleiotropy, where the effect of a genetic variant on the outcome surpasses its impact on the exposure, can potentially bias the MR results. Our pleiotropic test indicated no substantial pleiotropic effect, reinforcing the validity of our findings (Figure 5). The genetic variants used as IVs in our MR analysis did not show signs of significantly influencing melanoma incidence through pathways other than their impact on serum 25-Hydroxyvitamin D levels.



FIGURE 5
Funnel plot of the estimated causal effect of serum 25-Hydroxyvitamin D levels on melanoma skin cancer incidence. Each point symbolizes the estimated causal effect of each instrumental variable (IV). The dark blue vertical line represents the MR-Egger method-derived causal effect estimate, while the light blue line signifies the equivalent estimate derived via the IVW method.

This is a critical consideration, as ignoring potential pleiotropy could lead to erroneous interpretations of the causal relationship. The absence of horizontal pleiotropy is crucial in our MR framework as it upholds the direction and magnitude of the estimated causal relationship between the variables (60).

This funnel plot serves as a visual assessment of potential pleiotropic effects. The spread of the points provides an indication of the degree of heterogeneity across the causal estimates obtained from individual IVs. The symmetry of the plot around the causal effect line further reinforces the absence of substantial horizontal pleiotropy. The clustering of IVs around the vertical line, indicating the MR-Egger method-derived causal effect estimate, supports the notion of symmetric distribution, a key assumption in MR-Egger regression, thereby demonstrating the absence of substantial horizontal pleiotropy (71). The close alignment of the MR-Egger and IVW estimates further supports the argument that pleiotropy is unlikely to have significantly distorted our results.

3.4 Persistent correlation between serum 25-Hydroxyvitamin D levels and melanoma by the radial MR analysis

In the final stages of our study, the Radial MR method was harnessed to assess the outliers identified earlier. The outcome of this rigorous analysis revealed a positive correlation in MR results, even upon outlier exclusion. This persistent correlation underscores the robustness of our findings against statistical anomalies (Figure 6). The Radial MR method, an advanced outlier-detection technique, provides another level of reliability by ensuring the robustness of the study's conclusions despite the presence of potential outliers. The persistent positive correlation indicates that the key findings of the study are not overly reliant on a small number of influential data points. Outliers in genetic association studies can often be a consequence of various factors such as genetic heterogeneity, population stratification, or genotyping errors (72). By conducting a Radial MR analysis, which excludes potential outliers, we have ensured that the observed correlation is not an artifact of a few extreme observations, further strengthening the robustness of our conclusions. Despite the presence of outliers, as indicated by the yellow portions of the plot, the overall shape and pattern of the plot underscores the consistent association between Vitamin D levels and melanoma risk.

In summation, our Mendelian randomization study provides evidence for a causal relationship between serum 25-Hydroxyvitamin D levels and the risk of melanoma. This relationship has been reinforced through a series of rigorous validations including sensitivity, pleiotropic, and outlier analyses. Our results propose a positive causal effect of serum 25-Hydroxyvitamin D levels on melanoma incidence.

However, it is pertinent to emphasize that MR results should not be interpreted in isolation, but need to be considered within the context of the broader body of evidence. While MR analyses provide



FIGURE 6
A Radial MR plot detailing the IVW radial of SNPs. The blue portions of the plot denote variant SNPs, while the yellow portions signify the identified outliers. This plot gives a visual representation of the impact of each SNP on the overall result, distinguishing between regular genetic variants and the outliers. The IVW radial plot indicates that the influence of the outliers on the overall outcome is minimal, supporting the conclusion that our results are robust.

evidence for causal relationships in an observational setting, validation through experimental or interventional studies is necessary to gain insight into the actual biological mechanisms that underpin this relationship. The ideal way to pursue this would be through prospective cohort studies or randomized controlled trials. Moreover, any conclusions should be interpreted keeping in view the overall health benefits of vitamin D, and the complex interplay between vitamin D physiology, skin cancer biology, and genetics.

4 Discussion

Our two-sample MR study, using the IVW method and leveraging genetic variants as IVs, provided substantial evidence for a causal association between serum 25-Hydroxyvitamin D levels and the incidence of cutaneous melanoma. This approach circumvented the environmental confounding and reverse causation bias, commonly encountered in traditional observational studies. Our study yielded a β coefficient of 0.0022159, indicating a significant positive correlation between increased serum 25-Hydroxyvitamin D levels and melanoma incidence. This relationship was consistently shown to be statistically significant, albeit with a small β coefficient, indicating that each unit increase in serum 25-Hydroxyvitamin D levels corresponds with an increased risk of melanoma. This is notable considering the increasing global incidence of this skin cancer.

We assessed the robustness of our results through multiple measures. The lack of significant heterogeneity among the genetic variants used reinforced the validity of our pooled causal estimate. Further, the "leave-one-out" sensitivity analysis affirmed that no individual SNP exerted a disproportionate influence on the estimated causal relationship. Tests for potential pleiotropy found minimal effects, which further validated the causality inferred. The Radial MR analysis, even after outlier exclusion, consistently demonstrated a persistent positive correlation between serum 25-Hydroxyvitamin D levels and melanoma incidence.

The study's results have profound public health implications, suggesting that, contrary to traditional beliefs, elevated serum 25-Hydroxyvitamin D levels may play a contributory role in the development of melanoma. This provides a nuanced perspective on melanoma etiology, which can guide future investigations and potentially inform prevention strategies. Despite the generally beneficial health effects attributed to serum 25-Hydroxyvitamin D (73), its potential influence on melanoma development should not be overlooked.

This study presents a unique perspective, in contrast to some existing literature, by revealing a positive causal relationship between increased serum 25-Hydroxyvitamin D levels and melanoma risk (27, 34). This finding diverges from previous observational studies that have often suggested an inverse or null association, potentially due to limitations inherent in such studies such as confounding and reverse causality (27, 74–76). The divergence from observational studies reflects the intricate nature of Vitamin D metabolism, immune modulation, skin carcinogenesis, and the multifaceted role of UV radiation (77, 78). It further emphasizes the importance of nuanced, context-specific investigations and robust methodologies to decipher this complex relationship (28, 34, 79).

These divergent findings underscore the complex interplay between Vitamin D physiology, sun exposure necessary for Vitamin D synthesis, and the risk of skin cancer (80, 81). On one hand, Vitamin D is acknowledged for its beneficial roles in health (82), while on the other hand, sun exposure, being a significant source of Vitamin D, is also a primary risk factor for melanoma due to potential DNA damage from ultraviolet radiation (83). This dynamic highlights the intricate balance between the potential benefits and hazards of sun exposure. UV radiation is a shared risk factor for melanoma and a primary source of Vitamin D synthesis, creating a complex interplay between the potential benefits and hazards of sun exposure and Vitamin D's generally protective effects (32).

The research findings necessitate a reassessment of current recommendations concerning sun exposure and vitamin D supplementation, especially for high-risk populations (84). The study questions the perception of vitamin D as an exclusively beneficial agent, highlighting the potential risks associated with its excessive intake. This calls for a nuanced understanding of vitamin D's role in melanoma pathogenesis and advocates a careful risk-benefit assessment regarding vitamin D supplementation and sun exposure. A key insight from the study is the critical need for personalized medicine strategies that take into account individuals' genetic susceptibility when deciding about Vitamin D supplementation.

The study underscores the utility of Mendelian randomization as a robust tool in biomedical research, capable of identifying causal relationships that might be overlooked in traditional observational studies. This strengthens the opportunity to delve deeper into the complex interplay between vitamin D metabolism, genetics, and skin cancer biology (85). However, despite the potential association between elevated vitamin D levels and melanoma, the study reaffirms the established health benefits of maintaining adequate vitamin D levels. It emphasizes the importance of a balanced approach to vitamin D supplementation and sun exposure, alongside careful monitoring of serum vitamin D levels, especially in populations at high risk of melanoma.

From a policy perspective, these findings prompt a thorough reevaluation of vitamin D supplementation guidelines, particularly for high-risk populations (86). Regarding biomedical research, the discovery of this relationship presents opportunities to probe the underlying biological mechanisms that may explain how elevated serum 25-Hydroxyvitamin D levels contribute to increased melanoma risk (87). Nonetheless, given the intricate nature of vitamin D metabolism and its various health benefits, the study's findings should be interpreted with caution.

While the study provides valuable insights, it does possess a few inherent limitations. Firstly, the study assumes that the instrumental variables, in this case, genetic variants, impact the outcome solely via their effect on the exposure, a requirement known as the exclusion restriction criterion. However, despite our rigorous tests, we cannot definitively exclude the possibility of unrecognized pleiotropy, where a gene could affect multiple traits, or unknown confounding factors influencing our findings. Secondly, our analysis does not provide detailed insights into the biological mechanisms connecting serum

25-Hydroxyvitamin D levels and melanoma risk. The identified causal relationship does not fully unravel the complex biology of Vitamin D and its role in melanoma incidence. Further experimental validation or prospective cohort studies are necessary to comprehend these mechanisms.

Our study also acknowledges limitations related to the generalizability of the findings. The genetic instruments used were primarily identified in populations of European ancestry, potentially limiting the application of our results to other ethnic groups. Additionally, our study did not account for individual-level confounders, nor did it explore potential non-linear relationships between serum 25-Hydroxyvitamin D levels and melanoma risk. The study also overlooked the modulatory roles of factors like age, sex, and environmental UV exposure, given its reliance on summarized population-level data. Moreover, our analysis assumes a linear relationship between exposure and outcome, which may oversimplify the biological reality.

Future research should adopt an integrative approach that validates initial findings, investigates underlying biological mechanisms, expands the scope of genetic studies, replicates results in diverse populations, and explores potential confounding factors. Studies should focus on establishing the optimal range of vitamin D levels that balance the potential risks and benefits, the health implications of vitamin D in skin cancer prevention, and the association of vitamin D with other forms of skin cancer.

5 Conclusion

The comprehensive MR study evidenced a positive causal relationship between serum 25-Hydroxyvitamin D levels and melanoma incidence, holding significant implications for public health policies, clinical guidelines, and cancer prevention strategies. However, given the intricacy of vitamin D metabolism, skin cancer biology, and the broader health benefits of vitamin D, these findings necessitate cautious interpretation and further exploration. Continued research is needed to consolidate these findings, unravel the complex interplay between genetics, environment, and biology, and fully understand the biological mechanisms underlying this association. Despite the inherent limitations, Mendelian randomization proves a valuable tool in biomedical research, resolving causal ambiguities and enhancing context-specific, evidence-based health interventions. Future research should focus on corroborating these findings, dissecting all contributing factors to melanoma risk, and illuminating novel therapeutic targets. Ultimately, any health policy or strategy modulating vitamin D levels must balance these findings with the broader health benefits of vitamin D.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author contributions

BC, QL and BW made substantial contributions to the conception and design of the study. BC, QL, RK and XS performed data acquisition and analysis. BC, JY and XN made substantial contributions to drafting the article and graphs. XL and BW reviewed and marked the complete manuscript. All the authors read and approved the final manuscript.

Funding

This work was supported by grants from Special Scientific Research Project of Fujian Provincial Finance Project (No. 2019B031); Young and Middle-aged Key Personnel Training Project of Fujian Provincial Health Commission(No. 2020GGB029); Youth Scientific Research Project of Fujian Provincial Health Commission (No. 2020QNA048); Startup Fund for Scientific Research of Fujian Medical University (No. 2019QH2030).

Acknowledgments

Genetic association estimates for the study were obtained from the UK Biobank study and FinnGen consortium. The authors thank all investigators for sharing these data.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1154107/full#supplementary-material

SUPPLEMENTARY TABLE 1
Gene symbols and traits corresponding to the SNPs listed in the ordinate of .

References

1. Centeno PP, Pavet V, Marais R. The journey from melanocytes to melanoma. *Nat Rev Cancer* (2023) 23(6):372–90. doi: 10.1038/s41568-023-00565-7

2. Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. *Signal Transduct Target Ther* (2021) 6(1):424. doi: 10.1038/s41392-021-00827-6

3. Yang K, Oak ASW, Slominski RM, Brożyna AA, Slominski AT. Current molecular markers of melanoma and treatment targets. *Int J Mol Sci* (2020) 21 (10):3535. doi: 10.3390/ijms21103535

4. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. *Eur J Cancer (Oxford England: 1990)* (2005) 41(1):45–60. doi: 10.1016/j.ejca.2004.10.016

5. Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, et al. Sun exposure and mortality from melanoma. *J Natl Cancer Institute* (2005) 97(3):195–9. doi: 10.1093/jnci/dji019

6. Brożyna AA, Hoffman RM, Slominski AT. Relevance of vitamin D in melanoma development, progression and therapy. *Anticancer Res* (2020) 40(1):473–89. doi: 10.21873/anticanres.13976

7. Curti BD, Faries MB. Recent advances in the treatment of melanoma. *New Engl J Med* (2021) 384(23):2229–40. doi: 10.1056/NEJMra2034861

8. Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. *Nat Immunol* (2022) 23(5):660–70. doi: 10.1038/s41590-022-01141-1

9. Aroldi F, Middleton MR. Long-term outcomes of immune checkpoint inhibition in metastatic melanoma. *Am J Clin Dermatol* (2022) 23(3):331–8. doi: 10.1007/s40257-022-00681-4

10. Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. *J Tech Methods Pathol* (2017) 97(6):706–24. doi: 10.1038/labinvest.2017.3

11. Gallagher JC, Rosen CJ. Vitamin D: 100 years of discoveries, yet controversy continues. *Lancet Diabetes Endocrinol* (2023) 11(5):362–74. doi: 10.1016/S2213-8587(23)00060-8

12. Rebelos E, Tentolouris N, Jude E. The role of vitamin D in health and disease: A narrative review on the mechanisms linking vitamin D with disease and the effects of supplementation. *Drugs* (2023) 83(8):665–85. doi: 10.1007/s40265-023-01875-8

13. Jolliffe DA, Walton RT, Griffiths CJ, Martineau AR. Single nucleotide polymorphisms in the vitamin D pathway associating with circulating concentrations of vitamin D metabolites and non-skeletal health outcomes: Review of genetic association studies. *J Steroid Biochem Mol Biol* (2016) 164:18–29. doi: 10.1016/j.jsbmb.2015.12.007

14. Tuckey RC, Cheng CYS, Slominski AT. The serum vitamin D metabolome: What we know and what is still to discover. *J Steroid Biochem Mol Biol* (2019) 186:4–21. doi: 10.1016/j.jsbmb.2018.09.003

15. Norlin M, Wikvall K. Enzymatic activation in vitamin D signaling - Past, present and future. *Arch Biochem Biophysics* (2023) 742:109639. doi: 10.1016/j.abb.2023.109639

16. Latacz M, Snarska J, Kostyra E, Fiedorowicz E, Savelkoul HF, Grzybowski R, et al. Single nucleotide polymorphisms in 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene: the risk of Malignant tumors and other chronic diseases. *Nutrients* (2020) 12(3):801. doi: 10.3390/nu12030801

17. Meyer MB, Pike JW. Mechanistic homeostasis of vitamin D metabolism in the kidney through reciprocal modulation of Cyp27b1 and Cyp24a1 expression. *J Steroid Biochem Mol Biol* (2020) 196:105500. doi: 10.1016/j.jsbmb.2019.105500

18. Zhou Y, Zhao LJ, Xu X, Ye A, Travers-Gustafson D, Zhou B, et al. DNA methylation levels of CYP2R1 and CYP24A1 predict vitamin D response variation. *J Steroid Biochem Mol Biol* (2014) 144 Pt A:207–14. doi: 10.1016/j.jsbmb.2013.10.004

19. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. *Arch Biochem Biophysics* (2012) 523(1):9–18. doi: 10.1016/j.abb.2011.11.003

20. Slominski AT, Kim TK, Shehabi HZ, Semak I, Tang EK, Nguyen MN, et al. *In vivo* evidence for a novel pathway of vitamin D_3 metabolism initiated by P450scc and modified by CYP27B1. *Off Publ Fed Am Societies Exp Biol* (2012) 26(9):3901–15. doi: 10.1096/fj.12-208975

21. Martin-Gorgojo A, Gilaberte Y, Nagore E. Vitamin D and skin cancer: an epidemiological, patient-centered update and review. *Nutrients* (2021) 13(12):4292. doi: 10.3390/nu13124292

22. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to Malignant melanoma? *Br J Dermatol* (2002) 147(2):197–213. doi: 10.1046/j.1365-2133.2002.04960.x

23. Berwick M, Garcia A. Solar UV exposure and mortality from skin tumors: an update. *Adv Exp Med Biol* (2020) 1268:143–54. doi: 10.1007/978-3-030-46227-7_7

24. Slominski AT, Brożyna AA, Skobowiat C, Zmijewski MA, Kim TK, Janjetovic Z, et al. On the role of classical and novel forms of vitamin D in melanoma progression and management. *J Steroid Biochem Mol Biol* (2018) 177:159–70. doi: 10.1016/j.jsbmb.2017.06.013

25. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. *J Clin Oncol* (2009) 27(32):5439–44. doi: 10.1200/JCO.2009.22.1135

26. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. *Eur J Cancer (Oxford England: 1990)* (2009) 45(18):3271–81. doi: 10.1016/j.ejca.2009.06.011

27. Tsai TY, Kuo CY, Huang YC. The association between serum vitamin D level and risk and prognosis of melanoma: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* (2020) 34(8):1722–9. doi: 10.1111/jdv.16189

28. Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. *Eur J Cancer Prev* (2019) 28(3):203–11. doi: 10.1097/CEJ.0000000000000437

29. Asgari MM, Maruti SS, Kushi LH, White E. A cohort study of vitamin D intake and melanoma risk. *J Invest Dermatol* (2009) 129(7):1675–80. doi: 10.1038/jid.2008.451

30. Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E, et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: *post hoc* analyses of the women's health initiative randomized controlled trial. *J Clin Oncol* (2011) 29(22):3078–84. doi: 10.1200/JCO.2011.34.5967

31. Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, et al. Serum total 25-hydroxyvitamin D levels in patients with cutaneous Malignant melanoma: A case-control study in a low-risk Southern European population. *Dermatol Pract Conceptual* (2020) 10(1):e2020010. doi: 10.5826/dpc.1001a10

32. Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies. *Sci Rep* (2020) 10(1):13151. doi: 10.1038/s41598-020-70078-y

33. Stenehjem JS, Støer NC, Ghiasvand R, Grimsrud TK, Babigumira R, Rees JR, et al. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk. *Sci Rep* (2020) 10 (1):20129. doi: 10.1038/s41598-020-77155-2

34. Liyanage UE, Law MH, Barrett JH, Iles MM, MacGregor S. Is there a causal relationship between vitamin D and melanoma risk? A Mendelian randomization study. *Br J Dermatol* (2020) 182(1):97–103. doi: 10.1111/bjd.18238

35. Hutchinson PE, Pringle JH. Consideration of possible effects of vitamin D on established cancer, with reference to Malignant melanoma. *Pigment Cell Melanoma Res* (2022) 35(4):408–24. doi: 10.1111/pcmr.13040

36. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med* (2008) 27(8):1133–63. doi: 10.1002/sim.3034

37. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med* (2017) 36(11):1783–802. doi: 10.1002/sim.7221

38. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* (2013) 37 (7):658–65. doi: 10.1002/gepi.21758

39. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res* (2017) 26(5):2333–55. doi: 10.1177/0962280215597579

40. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ (Clin Res ed)* (2018) 362: k601. doi: 10.1136/bmj.k601

41. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PloS Genet* (2017) 13(11): e1007081. doi: 10.1371/journal.pgen.1007081

42. jBowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* (2016) 40(4):304–14. doi: 10.1002/gepi.21965

43. Poldrack RA, Huckins G, Varoquaux G. Establishment of best practices for evidence for prediction: A review. *JAMA Psychiatry* (2020) 77(5):534–40. doi: 10.1001/jamapsychiatry.2019.3671

44. Bowden J, Spiller W, Del Greco MF, Sheehan N, Thompson J, Minelli C, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *Int J Epidemiol* (2018) 47(4):1264–78. doi: 10.1093/ije/dyy101

45. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* (2014) 23(R1):R89–98. doi: 10.1093/hmg/ddu328

46. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. *Eur J Epidemiol* (2015) 30(7):543–52. doi: 10.1007/s10654-015-0011-z

47. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol* (2017) 46(6):1734–9. doi: 10.1093/ije/dyx034

48. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* (2009) 41(10):1088–93. doi: 10.1038/ng.440

49. Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for biobank-scale datasets. *Nat Genet* (2018) 50(7):906–8. doi: 10.1038/s41588-018-0144-6

50. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. *Int J Epidemiol* (2011) 40(3):740–52. doi: 10.1093/ije/dyq151

51. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. *eLife* (2018) 7:e34408. doi: 10.7554/eLife.34408

52. Burgess S, Thompson SG. Bias in causal estimates from Mendelian randomization studies with weak instruments. *Stat Med* (2011) 30(11):1312–23. doi: 10.1002/sim.4197

53. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* (2011) 40(3):755–64. doi: 10.1093/ije/dyr036

54. Xin J, Gu D, Chen S, Ben S, Li H, Zhang Z, et al. SUMMER: a Mendelian randomization interactive server to systematically evaluate the causal effects of risk factors and circulating biomarkers on pan-cancer survival. *Nucleic Acids Res* (2023) 51 (D1):D1160–d7. doi: 10.1093/nar/gkac677

55. Bell KJL. Causal inference in melanoma epidemiology using Mendelian randomization. *Br J Dermatol* (2020) 182(1):13–4. doi: 10.1111/bjd.18646

56. Dusingize JC, Olsen CM, An J, Pandeya N, Law MH, Thompson BS, et al. Body mass index and height and risk of cutaneous melanoma: Mendelian randomization analyses. *Int J Epidemiol* (2020) 49(4):1236–45. doi: 10.1093/ije/dyaa009

57. Rüeger S, McDaid A, Kutalik Z. Evaluation and application of summary statistic imputation to discover new height-associated loci. *PloS Genet* (2018) 14(5):e1007371. doi: 10.1371/journal.pgen.1007371

58. Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* (2018) 50(8):1196. doi: 10.1038/s41588-018-0164-2

59. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol* (2013) 42(5):1497–501. doi: 10.1093/ije/dyt179

60. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* (2018) 50(5):693–8. doi: 10.1038/s41588-018-0099-7

61. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* (2015) 44(2):512–25. doi: 10.1093/ije/dyv080

62. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants. *Epidemiol (Cambridge Mass)* (2017) 28(1):30–42. doi: 10.1097/EDE.0000000000000559

63. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* (2019) 48(3):713–27. doi: 10.1093/ije/dyy262

64. Cheng H, Garrick DJ, Fernando RL. Efficient strategies for leave-one-out cross validation for genomic best linear unbiased prediction. *J Anim Sci Biotechnol* (2017) 8:38. doi: 10.1186/s40104-017-0164-6

65. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet* (2018) 27(R2):R195–r208. doi: 10.1093/hmg/ddy163

66. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. *Am J Epidemiol* (2013) 178 (7):1177–84. doi: 10.1093/aje/kwt084

67. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res* (2019) 4:186. doi: 10.12688/wellcomeopenres.15555.1

68. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. *Stat Med* (2015) 34(21):2926–40. doi: 10.1002/sim.6522

69. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinf (Oxford England)* (2019) 35(22):4851–3. doi: 10.1093/bioinformatics/btz469

70. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of human genotype-phenotype associations. *Bioinf (Oxford England)* (2016) 32(20):3207–9. doi: 10.1093/bioinformatics/btw373

71. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol* (2017) 32(5):377–89. doi: 10.1007/s10654-017-0255-x

72. Birke M, Schöpe J, Wagenpfeil S, Vogt T, Reichrath J. Association of vitamin D receptor gene polymorphisms with melanoma risk: A meta-analysis and systematic review. *Anticancer Res* (2020) 40(2):583–95. doi: 10.21873/anticanres.13988

73. Piotrowska A, Wierzbicka J, Żmijewski MA. Vitamin D in the skin physiology and pathology. *Acta Biochim Polonica* (2016) 63(1):17–29. doi: 10.18388/abp.2015_1104

74. Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human Malignant melanoma cell lines. *J Surg Res* (1996) 61(1):127–33. doi: 10.1006/jsre.1996.0092

75. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. *Am J Public Health* (2006) 96(2):252–61. doi: 10.2105/AJPH.2004.045260

76. Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. *Eur J Cancer (Oxford England: 1990)* (2014) 50(15):2649–58. doi: 10.1016/j.ejca.2014.06.024

77. Becker AL, Carpenter EL, Slominski AT, Indra AK. The role of the vitamin D receptor in the pathogenesis, prognosis, and treatment of cutaneous melanoma. *Front Oncol* (2021) 11:743667. doi: 10.3389/fonc.2021.743667

78. Bolerazska B, Rabajdova M, Spakova I, Marekova M. Current knowledge on the active form of Vitamin D synthesized in the skin and its effects on Malignant melanoma. *Neoplasma* (2017) 64(1):1–12. doi: 10.4149/neo_2017_101

79. Shellenberger RA, Gowda S, Kurn H, Albright J, Mayo MH. Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis. *Melanoma Res* (2023) 33(4):265–74. doi: 10.1097/CMR.0000000000000897

80. Orlow I, Shi Y, Kanetsky PA, Thomas NE, Luo L, Corrales-Guerrero S, et al. The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival. *Pigment Cell Melanoma Res* (2018) 31 (2):287–96. doi: 10.1111/pcmr.12653

81. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. *Gene* (2004) 338(2):143–56. doi: 10.1016/j.gene.2004.05.014

82. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. *Nat Rev Cancer* (2007) 7(9):684–700. doi: 10.1038/nrc2196

83. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. *J Photochem Photobiol B Biol* (2001) 63(1-3):8–18. doi: 10.1016/S1011-1344(01)00198-1

84. Paolino G, Moliterni E, Corsetti P, Didona D, Bottoni U, Calvieri S, et al. Vitamin D and melanoma: state of the art and possible therapeutic uses. *Giornale Italiano di Dermatol e Venereol: Organo Ufficiale Societa Italiana di Dermatol e Sifilografia* (2019) 154(1):64–71. doi: 10.23736/S0392-0488.17.05801-1

85. Moliterni E, Paolino G, Veronese N, Bottoni U, Corsetti P, Cardone M, et al. Prognostic correlation between vitamin D serological levels, Body Mass Index and clinical-pathological features in melanoma patients. *Giornale Italiano di Dermatol e Venereol: Organo Ufficiale Societa Italiana di Dermatol e Sifilografia* (2018) 153(5):732–3. doi: 10.23736/S0392-0488.17.05652-8

86. Pellegrini M, D'Eusebio C, Ponzo V, Tonella L, Finocchiaro C, Fierro MT, et al. Nutritional interventions for patients with melanoma: from prevention to therapy-an update. *Nutrients* (2021) 13(11):4018. doi: 10.3390/nu13114018

87. Podgorska E, Kim TK, Janjetovic Z, Urbanska K, Tuckey RC, Bae S, et al. Knocking out the vitamin D receptor enhances Malignancy and decreases responsiveness to vitamin D3 Hydroxyderivatives in human melanoma cells. *Cancers* (2021) 13(13):3111. doi: 10.3390/cancers13133111

frontiers | Frontiers in Cell and Developmental Biology

TYPE Original Research
PUBLISHED 06 September 2023
DOI 10.3389/fcell.2023.1171047

OPEN ACCESS

EDITED BY
Zhizhou Shi,
Kunming University of Science and Technology, China

REVIEWED BY
Camelia Quek,
The University of Sydney, Australia
Yiman Liu,
University of Pennsylvania, United States

*CORRESPONDENCE
Ling Zhang,
2459437556@qq.com
Run Ma,
467161115@qq.com
Yunyao Liu,
yunyaoliu@cpu.edu.cn

†These authors have contributed equally to this work

RECEIVED 21 February 2023
ACCEPTED 28 August 2023
PUBLISHED 06 September 2023

CITATION
Tao L, Cui Y, Sun J, Cao Y, Dai Z, Ge X, Zhang L, Ma R and Liu Y (2023), Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma. *Front. Cell Dev. Biol.* 11:1171047. doi: 10.3389/fcell.2023.1171047

Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma

Lei Tao[1†], Yingyue Cui[2†], Jiarui Sun[2], Yu Cao[1], Zhen Dai[1], Xiaoming Ge[1], Ling Zhang[1*], Run Ma[3*] and Yunyao Liu[2*]

[1]Nanjing Institute for Food and Drug Control, Nanjing, China, [2]State Key Laboratory of Natural Medicines, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China, [3]The Second Affiliated Hospital of Kunming Medical University, Kunming, China

Introduction: Despite many recent emerging therapeutic modalities that have prolonged the survival of melanoma patients, the prognosis of melanoma remains discouraging, and further understanding of the mechanisms underlying melanoma progression is needed. Melanoma patients often have multiple genetic mutations, with BRAF mutations being the most common. In this study, public databases were exploited to explore a potential therapeutic target for BRAF-mutated melanoma.

Methods: In this study, we analyzed differentially expressed genes (DEGs) in normal tissues and melanomas, Braf wild-type and Braf mutant melanomas using information from TCGA databases and the GEO database. Subsequently, we analyzed the differential expression of CYTL1 in various tumor tissues and its effect on melanoma prognosis, and resolved the mutation status of CYTL1 and its related signalling pathways. By knocking down CYTL1 in melanoma cells, the effects of CYTL1 on melanoma cell proliferation, migration and invasion were further examined by CCK8 assay, Transwell assay and cell migration assay.

Results: 24 overlapping genes were identified by analyzing DEGs common to melanoma and normal tissue, BRAF-mutated and BRAF wild-type melanoma. Among them, CYTL1 was highly expressed in melanoma, especially in BRAF-mutated melanoma, and the high expression of CYTL1 was associated with epithelial-mesenchymal transition (EMT), cell cycle, and cellular response to UV. In melanoma patients, especially BRAF-mutated melanoma patients, clinical studies showed a positive correlation between increased CYTL1 expression and shorter overall survival (OS) and disease-free survival (DFS). *In vitro* experiments further confirmed that the knockdown of CYTL1 significantly inhibited the migration and invasive ability of melanoma cells.

Conclusion: CYTL1 is a valuable prognostic biomarker and a potentially effective therapeutic target in melanoma, especially BRAF-mutated melanoma.

KEYWORDS

melanoma, BRAF mutations, CYTL1, molecular biomarker, cell migration and invasion

1 Introduction

Cutaneous melanoma, which originates from melanin-producing skin melanocytes, is one of the most aggressive and difficult-to-treat human cancers. Over the past 50 years, its incidence has risen globally (Sung et al., 2021). The 5-year survival rate for patients diagnosed with metastatic melanoma is approximately 20%. It is characterized by the presence of mutations in multiple genes (Guo et al., 2021). BRAF mutations are the most predominant in melanoma development (Schadendorf et al., 2018). BRAF mutations are present in more than 50% of melanomas, with BRAFV600E being the most prevalent mutation type. This results in constitutive activation of RAF mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling, which encourages melanoma proliferation and anti-apoptosis (Shen et al., 2020). Significant advancements in the treatment of melanoma have recently been made. However, because of its propensity for distant metastasis, poor prognosis, and frequent recurrence, melanoma remains a refractory illness. Thus, it is vital to research the molecular mechanisms behind melanoma formation and to look for efficient treatment targets.

A secreted protein containing 136 amino acids called cytokine-like 1 (CYTL1) was initially discovered in human $CD34^+$ hematopoietic cells (Zhu et al., 2019). Since CYTL1 is highly expressed in cartilage tissues, such as the mouse inner ear and human articular cartilage, it helps maintain the homeostasis of these tissues and inhibits cartilage destruction in osteoarthritis (Shin et al., 2019; Zhu et al., 2020). CYTL1 has so far been demonstrated to have a variety of biological capabilities, including chemotaxis and pro-angiogenesis (Schneller et al., 2019; Xue et al., 2020). High levels of CYTL1 expression were found in tumor tissues and cell lines of human neuroblastoma, and silencing CYTL1 prevented the growth, migration, and invasion of neuroblastoma cells (Wen et al., 2012). In addition, CYTL1 is overexpressed and heavily methylated in human lung squamous cell carcinoma. Early in carcinogenesis, DNA methylation is linked to gene expression, and methylation of the promoter region silences genes. The hypermethylation of CYTL1 is consistent with its downregulation in SCC (Kwon et al., 2012). It has recently been shown that in breast cancer cells, CYTL1 is a tumor suppressor that keeps NDUFV1 stable and prevents metabolic reprogramming (Xue et al., 2022). According to the research mentioned above, different tumor types demonstrate varied expression patterns and roles for the cytokine CYTL1.

Bioinformatics analysis and gene expression profiling are helpful techniques to study the mechanisms of cancer development and reveal markers that predict patient prognosis (Chen et al., 2017; Peng et al., 2017). Reanalysis and integration of the vast quantity of data kept in public databases may yield fresh insights into the pathogenic processes underlying cancer. In this study, we analyzed the genes associated with BRAF mutations in the TCGA database. Comparing the distinct protein DEGs between melanoma and healthy tissues, overlapping DEGs were discovered. By building a protein-protein interaction (PPI) network and doing a functional enrichment analysis, we were able to pinpoint the gene CYTL1, which may be crucial to the emergence and development of melanoma with BRAF mutations.

By knocking down CYTL1 in BRAF-mutated melanoma cells, we found that CYTL1 has a negligible effect on melanoma cell proliferation but affects melanoma invasion and metastasis. In conclusion, CYTL1 may be a pro-oncogenic factor in melanoma. It could be a potential biomarker for diagnosis and prognosis, as well as a promising molecular target in BRAF-mutated melanoma.

2 Methods and materials

2.1 Microarray data

From the GEO database, we chose the profiles GSE46517 and GSE114445. 31 melanoma, nine nevus, and eight normal skin samples were included in GSE46517, which was built on the Agilent GPL96 platform (HG-U133A, Affymetrix Human Genome, U133A Array). The Agilent GPL570 platform-based GSE114445 (HG-U133 Plus 2, Affymetrix Human Genome U133 Plus 2.0 Array) contained 16 melanoma, seven dysplastic nevus samples, and six healthy skin samples. We studied the prognostic impact of CYTL1 in different tumors using the TIMER2.0 database (Li et al., 2020) and CYTL1 mutations and CNA in melanoma samples from 12 databases using the cBioPortal database (Cerami et al., 2012).

2.2 PPI network, GO, and KEGG pathway analysis of DEGs

We identified CYTL1 gene by protein-protein interaction (PPI) network construction and functional enrichment analysis. The STRING database (http://string-db.org) provides an objective analysis and vertical combination of protein-protein interactions (Szklarczyk et al., 2015). The PPI networks of DEGs were constructed with a combined score >0.4, and the network was visualized with Cytoscape (version 3.8.0).

The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the DEGs were performed with DAVID (https://david.ncifcrf.gov/), which consists of integrated biological knowledgebase and analytic tools (Huang da et al., 2009). GO terms, and KEGG pathways with corrected p-value <0.05 were considered significantly enriched.

2.3 Expression level of DEGs and survival analysis

GEPIA (http://gepia.cancer-pku.cn/index.html) was used to analyze the RNA sequencing expression data for 471 cutaneous melanoma samples from the TCGA database and 1809 normal skin tissue samples from the GTEx database in accordance with a standard processing pipeline (Huang da et al., 2009). The fragments per kilobase per million reads (FPKM) values were calculated for gene quantification. Differential expression analysis of the control and PI groups was performed using DESeq2 (version 1.16.1), and genes with padj< 0.05 and $|\log_2$ (fold change)| > 1 were identified as DEGs. A volcano plot and a heatmap were generated with the 'Ggpolt2' and 'ComplexHeatmap' R packages.

2.4 Immune infiltration analysis

Tumor immune infiltration levels were determined using the single-sample gene set enrichment analysis (ssGSEA) method and the "GSVA" R package based on the TCGA-SKCM dataset (Bindea et al., 2013). Correlation analysis between CYTL1 and immune cell type infiltration was performed by Spearman rank correlation coefficient analysis. Charts and graphs were generated using the "ggplot2" R package (Tang et al., 2022). The correlation between CYTL1 expression and the relative number of tumor-infiltrating lymphocytes was calculated using the Tumor-Immune System Interaction Database website (TISIDB; http://cis.Hku.hk/TISIDB/) (Ru et al., 2019). *p*-values were determined by Spearman and Wilcoxon rank-sum tests.

2.5 Cell culture

The melanoma cell lines A2058 (RRID:CVCL_1059), A375 (RRID:CVCL_0132), M14 (RRID:CVCL_1395), and SK-MEL-28 (RRID:CVCL_0526) were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China) and cultivated in DMEM media with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All experiments were performed with mycoplasma cells, and all cell lines were validated using STR (or SNP) profiling over the past 3 years.

2.6 Cell transfection

For small interference (siRNA) transfection, A2058 cells were seeded in 6-well plates in medium without antibiotics. After 24 h, 50 nmol/L of CYTL1 siRNA (siCYTL1) were used for gene silencing. Control cell transfection was performed with a Negative Control siRNA (siNC). Cell transfections were carried out with Lipofectamine RNAiMax (Invitrogen), following the manufacturer's instructions. siCYTL1 and siNC were purchased from Sangon Biotech (Shanghai, China).

2.7 Western blot assay

RIPA buffer was used to obtain cell lysates, and Western blotting was performed as previously described (Liu et al., 2020), with primary antibodies raised against CYTL1 (Abcam) and GAPDH (Santa Cruz).

2.8 RT-qPCR assay

In the RT-qPCR assay, cells were lysed by RNA isolator (Vazyme, Nanjing, China, Cat. R401-01-AA). Following the manufacturer's instructions, total RNAs were extracted, and the RT reagent kit (Vazyme, Nanjing) was used to reverse-transcribe them. The following primers were used in this study:

GAPDH-F:AATCCCATCACCATCTTCCA.
GAPDH-R:TGGACTCCACGACGTACTCA.
CYTL1-F: GAGCCCTCGGAGCCATGT.
CYTL1-R: AGGACCGTAGTCACTGGGAT.

2.9 CCK8 assay

The CCK-8 assay was performed to detect cell viability. 1000 cells per well in 96-well plates were used for inoculation. 10 μL of the CCK-8 solution was added to each well after 24 h, 48 h, and 72 h. The absorbance of each well was measured at 450 nm after the plates had been incubated for 1–4 h.

2.10 Wound healing assay

A2058 cells and A2058 cells that were knocked down of CYTL1 in the logarithmic phase were inoculated in a 6-well plate, and the experiment was carried out after the cells were completely attached. The surface of the monolayer cells was drawn in a straight line as the data before cell migration (0h). After 12 h and 24 h, observe the scratch repair and take photos. Randomly select the pictures of each group to calculate the cell migration efficiency.

2.11 Transwell assay

A2058 cells and A2058 cells that were knocked down of CYTL1 cells were diluted into 5×10^5 cells/mL cell suspension in a serum-free medium. The transwell chambers were set up in a 24-well plate, and 400 μL of cell suspension and 600 μL of complete medium were added to the top and bottom chambers, respectively. Take the transwell chambers out of the culture after 24 h and use a cotton swab to remove any cells that have not made it through the microporous filter. The unmigrated cells were fixed with 100% methanol for 5 min, 0.5% crystal violet staining for 30 s, washed with water to remove the floating color and observed under the microscope. The fields (top, bottom, left, right, middle) randomly selected were taken pictures to calculate the average number of migratory cells.

2.12 Statistical analysis

Three duplicates of each experiment were carried out. GraphPad Prism was used to calculate the statistical analysis. Student's t-test was used to assess the significance of the results between the two experimental groups, and one-way ANOVA was used to examine multiple group comparisons. Significant values included $p < 0.05$ (*), $p < 0.01$ (**), and $p < 0.001$ (***).

3 Results

3.1 Screening of potential targets in melanoma cells with BRAF mutation

A total of 471 cutaneous melanoma samples were included in the TCGA database, and 1809 normal skin tissue samples were included in the GTEx database. Analysis of the samples in both databases revealed that 495 up-regulated genes and 2802 down-regulated genes were identified (Figure 1A). Subsequently, we divided the cutaneous melanoma samples into BRAF wild and BRAF mutant types. Among them, 231 samples were BRAF wild type and 235 samples



FIGURE 1
Screening of potential targets in melanoma cells with BRAF mutation. **(A,B)** Volcano plot of the differentially expressed genes in melanoma according to the TCGA dataset. **(C)** Venn of all overlapping DEGs. **(D)** Protein−protein interaction network of the overlapping DEGs. **(E)** Gene Ontology enrichment analyses of the overlapping DEGs.

were BRAF mutant. We performed differential gene analysis and found 148 up-regulated genes and 29 down-regulated genes (Figure 1B). Among these differentially expressed genes (DEGs), 24 genes overlapped (Figure 1C). Among these overlapping DEGs, recognized tumor-associated genes such as TP53, JUN, MMPs, and STAT3 were located at the center of the STING protein interactions network (Figure 1D). We performed GO functional enrichment analysis to gain more insight into the screened DEGs. According to the GO analysis, the DEGs were primarily enriched in the following functions: regulation of peptidase activity, endopeptidase activity, gliogenesis, glial cell differentiation, and collagen-containing extracellular matrix (Figure 1E).



FIGURE 2
High expression of CYTL1 is associated with a poor prognosis of melanoma. **(A)** Forest plot of the *p*-value, risk coefficient (HR) and univariate analysis of the overlapping DEGs in melanoma. **(B)** Kaplan-Meier survival curves of SKCM patients with high expression or low expression of the overlapping DEGs.

3.2 High expression of CYTL1 is associated with a poor prognosis of melanoma

To further validate the role of DEGs in melanoma, we examined the relationship between 24 DEGs and patient prognosis. SNX10, S100B, CSPG4, AIM2, FDCSP, KCNJ10, COL22A1, ITIH6, IL27RA, SERPINE2, OLIG1, CD200, METTL7B, and TIMP1 were found to be highly expressed in melanoma, yet negatively correlated with prognosis, i.e., the prognosis is better when the expression is higher. Increased expression of CYTL1 was associated with a poorer prognosis. Low expression of BOK in melanoma was positively correlated with prognosis, i.e., the prognosis is poorer when the expression is higher (Figure 2). These analyses showed that CYTL1 could be crucial to melanoma development.

3.3 High expression of CYTL1 is associated with poor prognosis in BRAF mutant melanoma

We further analyzed the differential expression of CYTL1 in different tumors and normal tissues. The results showed that CYTL1 was differentially expressed in a variety of tumors. CYTL1 was low expressed in ACC, BLCA, BRCA, CESC, COAD, ESCA, LUAD, LUSC, PRAD, READ, STAD, THCA, and UCEC, and highly expressed in CHOL, DLBC, GBM, KIRC, LAML, LGG, LIHC, PAAD, SKCM, TGCT, THYM, and UCS (Figure 3A). It is hypothesized that the primary factor influencing CYTL1 transcript levels is the kind of tumor. We next analyzed the expression of CYTL1 in two datasets (GSE46517 and GSE114445) in the GEO database. The results showed that CYTL1 showed a gradually increasing trend in normal skin, nevus, and melanoma (Figures 3B, C). Since the original data of these databases were from different sources, we used data from various sources to validate each other, which increased the authenticity and credibility of the conclusions.

Next, we analyzed the prognostic impact of CYTL1 in different tumors using the TIMER2.0 database. The results showed that CYTL1 significantly inhibited the survival of patients with BLCA, LGG, LIHC, SKCM, and STAD. In contrast, in ACC, CYTL1 acted as a tumor suppressor and prolonged the survival of patients (Figure 3D). Subsequently, we analyzed the OS and DFS of CYTL1 in cutaneous melanoma and BRAF-mutated melanoma. The results showed that CYTL1 was a pro-oncogenic factor in both melanoma and BRAF-mutated melanoma, and its high



FIGURE 3
High expression of CYTL1 is associated with poor prognosis in BRAF mutant melanoma. **(A)**. CYTL1 expression levels in different tumor tissues and adjacent normal tissues from TCGA and GTEx databases. The expression level of CYTL1 in GSE46517 **(B)** and GSE114445 **(C,D)**. Heat map of the normalized coefficient of CYTL1 in Cox mode. Kaplan-Meier survival curves of OS **(E)** and DSS **(F)** in SKCM patients with high CYTL1 expression or low CYTL1 expression. Kaplan-Meier survival curves of OS **(G)** and DSS **(H)** in BRAF-mutant SKCM patients with high CYTL1 expression or low CYTL1 expression.

expression significantly suppressed patients' OS and DFS (Figures 3E–H).

3.4 Genomic mutations in CYTL1 in melanoma

We analyzed CYTL1 mutations and CNA in melanoma samples from 12 databases using the cBioPortal database. CYTL1 had different mutation frequencies in different datasets, 7.89% (UCLC, Cell 2016), 3.47% (DLCI, Nature medicine 2019), 3.13% (MSKCC, NEJM 2014), 2.46% (TCGA, Firehose Legacy), 2.25% (TCGA, PanCancer Atlas), 1.82% (DFCI, Science 2015), 1.28% (Broad, Cancer Discov 2014), and 0.87% (TCGA, Cell 2015), and 0.83% (Broad, Cell 2012) (Figure 4A). There were 11 mutated loci in the CYTL1 gene, with R134C being the most common (Figure 4B). About 1.9% of all patients had CYTL1 gene mutations (Figure 4C).



FIGURE 4
Genomic mutations in CYTL1 in melanoma. **(A)** Alteration frequency of CYTL1 in different data sets. **(B)** Mutation sites for CYTL1 gene mutations. **(C)** Type and frequency of CYTL1 gene mutations in SKCM.

3.5 Analysis of genes and pathways associated with CYTL1 in melanoma

To determine the biological function of CYTL1 in melanoma, we analyzed the differential genes in melanoma patients with high or low CYTL1 expression according to the median expression values of CYTL1 (Figures 5A, B). The KEGG pathway analysis revealed that CYTL1-associated up-regulated genes were mainly enriched in PI3K-Akt signaling pathway, Rap1 signaling pathway, ECM-receptor interaction, and Axon guidance (Figure 5C). CYTL1-associated down-regulated genes were enriched primarily on cytokine-cytokine receptor interaction, Epstein-Barr virus infection, cell adhesion molecules, immune cell differentiation, and chemokine signaling pathway (Figure 5E). GO functional enrichment analysis revealed that CYTL1-associated up-regulated genes were mainly enriched in extracellular structure organization, extracellular matrix organization, pattern specification process, cell-substrate adhesion, urogenital system development, and regionalization (Figure 5D). CYTL1-associated down-regulated genes were mainly enriched in T cell activation, leukocyte cell-cell adhesion, lymphocyte differentiation, and regulation of cell-cell adhesion (Figure 5F).

According to the results of a pathway study using gene set enrichment analysis (GSEA), CYTL1 plays a major role in the epithelial-mesenchymal transition (EMT), angiogenesis, G2M checkpoint, NOTCH signaling pathway, glycolysis, UV-related response, apical junction, and mitochondrial spindle assembly (Figure 6).

3.6 Correlation of CYTL1 expression with immune infiltration

The prognosis of melanoma patients is impacted by tumor-infiltrating lymphocytes, which are critical to the development of cancer. The findings above imply that CYTL1 may be connected to immune-related pathways like T cell activation, cytokine production, cytokine receptor activation, and differentiation of Th17 cells (Figures 5C–F). Therefore, we next examined whether there is a relationship between CYTL1 and immune infiltration in melanoma. Our findings showed that mast cell numbers and CYTL1 mRNA levels showed a substantial and positive correlation. In contrast, CYTL1 expression was negatively correlated with T cells, aDC, B cells, DC, cytotoxic cells, NK CD56bright cells, NK CD56dim cells, pDC, TFH, Th1 cells, and Treg cells (Figures 7A–C). Meanwhile, we analyzed the relationship between CYTL1 and immune infiltration and stromal scores. The results showed that CYTL1 was not significantly correlated with the stromal component in the tumor microenvironment, while high CYTL1 expression significantly inhibited immune infiltration in the tumor microenvironment (Figure 7D).



FIGURE 5
Analysis of genes and pathways associated with CYTL1 in melanoma. **(A)** Volcano plot of the differentially expressed genes in melanoma according to the TCGA dataset. **(B)** The heatmap of the differential gene expression. **(C–F)** GO and KEGG signaling pathways enrichment analyses of the DEGs.

Considering that CYTL1 may be a potential oncogene in melanoma, it was assessed how CYTL1 interacted with PDCD1, CD274, HAVCR2, TIGIT, SIGLEC15, CTLA4, LAG3, and PDCD1LG2. 8378574 (Figure 7E). These findings imply that CYTL1-mediated melanoma oncogenesis may entail tumor immune escape and anti-tumor immunity. In addition, the different copy statuses of CYTL1 affected immune immersion compared to normal tissues (Figure 7F).

3.7 Knockdown of CYTL1 inhibits migration and invasion of BRAF mutant melanoma cells

Finally, we examined the expression of CYTL1 in human melanocytes HEM cells and melanoma cells A2058, A375, M14, and SK-MEL-28. Western blot assay and RT-qPCR experiments showed that the expression levels of CYTL1 in melanoma cells



FIGURE 6
CYTL1-related signaling pathways in SKCM by GSEA software.

were all significantly higher than in HEM cells, among which A2058 cells had the highest CYTL1 levels (Figures 8A, B). Therefore, we selected A2058 cells for the follow-up experiment. Subsequently, we knocked down CYTL1 in A2058 cells to detect the effect of CYTL1 on the proliferation, migration, and invasion of melanoma cells (Figures 8C, D). CCK8 assay showed that CYTL1 had less impact on the proliferation of A2058 cells (Figure 8E). Wound healing assay and transwell migration assay showed that the knockdown of CYTL1 significantly inhibited the migratory ability of melanoma (Figures 8F, G). The transwell invasion assay with the addition of stromal gel showed that inhibition of CYTL1 expression significantly inhibited the invasive ability of A2058 cells (Figure 8H). This result is consistent with the positive correlation between CYTL1 and EMT in Figure 6. Taken together, CYTL1 can affect the invasive metastasis of A2058 cells.

4 Discussion

A significant development in the current management of metastatic melanoma is the identification of BRAF V600E as a



FIGURE 7
Correlation of CYTL1 expression with immune infiltration. **(A–D)** The correlation between CYTL1 expression and infiltration levels of immune cells. **(E)** Correlation analysis of CYTL1 expression and immune checkpoint-related genes in SKCM in the TCGA database. **(F)** Relationship between CYTL1 expression and SKCM tumor immune cell infiltration according to the TIMER database.

therapeutic target. Between 35 and 50 percent of melanomas have active BRAF mutations, which encourage tumor growth *via* the MAPK/ERK signaling pathway (Czarnecka et al., 2020). BRAF inhibitors alone or in combination with MEK inhibitors, for example, significantly boosted OS and PFS in melanoma patients (Perreault et al., 2019). However, with the development of acquired drug resistance, patients' sensitivity to the drugs began to decline, and chronic treatment with these inhibitors encountered challenges. Therefore, analyzing the presence of genes that can act synergistically after BRAF mutations and developing their



FIGURE 8
Knockdown of CYTL1 inhibits migration and invasion of BRAF mutant melanoma cells. **(A)** CYTL1 mRNA levels in different melanoma cells and HEM. $^{**}p \leq 0.01$, compared with HEM. **(B)** The protein levels of CYTL1 in different melanoma cells and HEM. **(C)** CYTL1 mRNA levels in A2058 cells transfected with si-CYTL1. $^{**}p \leq 0.01$, compared with siCon group. **(D)** The protein levels of CYTL1 in A2058 cells transfected with si-CYTL1. Cell viability **(E)**, wound healing **(F)**, cell migration **(G)** and cell invasion **(H)** of A2058 cells transfected with si-CYTL1.

targeting agents are essential research directions to address drug resistance. The results of this study support that CYTL1 may be considered a newly discovered biomarker for the diagnosis, prognosis, and treatment of melanoma. Secretory CYTL1 enhances MAPK/ERK pathway activation through C-C chemokine receptor type 2 in chronic granulocytic leukemia (CMML) (CCR2). By causing leukemic monocytes to undergo apoptosis, inhibition of CYTL1 in conjunction with MEK inhibitors can halt the course of CMML (Sevin et al., 2021). The results of this study and our study suggest that the same treatment modality may be tried for melanoma.

In this study, we analyzed the TCGA database of melanoma versus normal tissue, BRAF mutated melanoma versus BRAF wild-type melanoma and obtained a total of 24 differential genes, i.e., 22 up-regulated differential genes and two down-regulated differential genes, including TP53, MMPs, and other recognised melanoma oncogenes (Weiss et al., 2022). Interestingly, only CYTL1 expression was shown to be adversely connected with patient OS when we looked at the association between these 24 genes and the OS of melanoma patients. By analyzing the GSE46517 and GSE114445 datasets, we found that CYTL1 expression was progressively upregulated in normal skin, nevi or malignant nevi, and melanoma. We also validated CYTL1 expression in melanoma cells and normal melanocytes by RT-qPCR assay and found that in melanomatous cells, compared to normal cells, CYTL1 mRNA expression was considerably higher, indicating that CYTL1 may be a potential diagnostic target with excellent sensitivity and specificity.

The human $CD34^{+}$ cells seen in bone marrow and umbilical cord blood were where CYTL1 was first discovered. CYTL1 possesses a signal peptide at its N-terminal end, from amino acid (aa) residues one to aa22, which is indicative of a secreted protein with a fold like that of the chemokine interleukin (IL)-8, according to bioinformatic analysis (Ai et al., 2016). High levels of CYTL1 expression have been seen in tumor tissues and cell lines from human neuroblastoma, and inhibiting CYTL1 prevents SH-SY5Y neuroblastoma cells from proliferating, migrating, and invading (Wen et al., 2012). In gastric cancer, CYTL1 has also been shown to be a necroptosis-promoting oncogene (Khan et al., 2022). By reducing STAT3 phosphorylation, CYTL1 prevents lung cancer tumor spread (Wang et al., 2019). A recent study reported that intracellular CYTL1 is a potential tumor suppressor that stabilizes NDUFV1 to prevent metabolic reprogramming in breast cancer (Xue et al., 2022). However, in our study, CYTL1 was a pro-oncogenic factor in melanoma, and in melanoma patients, its elevated

expression was linked to a shorter OS and DFS., especially those with BRAF mutations. Knockdown of CYTL1 inhibited the migration and metastasis of melanoma. The different roles of CYTL1 in various tumors deserve to be explored in depth.

In conclusion, CYTL1 expression is significantly upregulated in melanoma, and its upregulation can promote EMT in melanoma cells and promote melanoma progression. High levels of CYTL1 are a poor prognostic factor for melanoma patients and can also be a potential therapeutic target for BRAF-mutated melanoma.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

YL, RM, and LT provided the experimental design. LT, YC, and JS performed the experiments. YC analyzed the data. ZD and XG prepared all figures. YL, RM, and LZ wrote the draft of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by Science and Technology Program of Jiangsu Market Supervision and Administration Bureau (No. KJ2022024); Science and Technology Program of State Administration for Market Regulation (No. 2021MK136); the China Postdoctoral Science Foundation Grant (2021M693513); the Natural Science Foundation of Jiangsu Province (BK20210419).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Ai, Z., Jing, W., and Fang, L. (2016). Cytokine-like protein 1(cytl1): A potential molecular mediator in embryo implantation. *PLoS One* 11 (1), e0147424. doi:10.1371/journal.pone.0147424

Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., et al. (2013). Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* 39 (4), 782–795. doi:10.1016/j.immuni.2013.10.003

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2 (5), 401–404. doi:10.1158/2159-8290.CD-12-0095

Chen, Y., Qi, C., Xia, L., and Li, G. (2017). Identification of novel genetic etiology and key molecular pathways for seminoma via network-based studies. *Int. J. Oncol.* 51 (4), 1280–1290. doi:10.3892/ijo.2017.4092

Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., and Rutkowski, P. (2020). Targeted therapy in melanoma and mechanisms of resistance. *Int. J. Mol. Sci.* 21 (13), 4576. doi:10.3390/ijms21134576

Guo, W., Wang, H., and Li, C. (2021). Signal pathways of melanoma and targeted therapy. *Signal Transduct. Target Ther.* 6 (1), 424. doi:10.1038/s41392-021-00827-6

Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* 4 (1), 44–57. doi:10.1038/nprot.2008.211

Khan, M., Lin, J., Wang, B., Chen, C., Huang, Z., Tian, Y., et al. (2022). A novel necroptosis-related gene index for predicting prognosis and a cold tumor immune microenvironment in stomach adenocarcinoma. *Front. Immunol.* 13, 968165. doi:10.3389/fimmu.2022.968165

Kwon, Y. J., Lee, S. J., Koh, J. S., Kim, S. H., Lee, H. W., Kang, M. C., et al. (2012). Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. *J. Thorac. Oncol.* 7 (1), 20–33. doi:10.1097/JTO.0b013e3182307f62

Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., et al. (2020). TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Res.* 48 (W1), W509–W514. doi:10.1093/nar/gkaa407

Liu, Y., Wang, X., Li, W., Xu, Y., Zhuo, Y., Li, M., et al. (2020). Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription. *Oncogene* 39 (45), 6893–6905. doi:10.1038/s41388-020-01474-x

Peng, J., Wu, Y., Tian, X., Pang, J., Kuai, L., Cao, F., et al. (2017). High-throughput sequencing and Co-expression network analysis of lncRNAs and mRNAs in early brain injury following experimental subarachnoid haemorrhage. *Sci. Rep.* 7, 46577. doi:10.1038/srep46577

Perreault, S., Larouche, V., Tabori, U., Hawkin, C., Lippe, S., Ellezam, B., et al. (2019). A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. *BMC Cancer* 19 (1), 1250. doi:10.1186/s12885-019-6442-2

Ru, B., Wong, C. N., Tong, Y., Zhong, J. Y., Zhong, S. S. W., Wu, W. C., et al. (2019). Tisidb: an integrated repository portal for tumor-immune system interactions. *Bioinformatics* 35 (20), 4200–4202. doi:10.1093/bioinformatics/btz210

Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., et al. (2018). *Melanoma.* Lancet 392 (10151), 971–984. doi:10.1016/S0140-6736(18)31559-9

Schneller, D., Hofer-Warbinek, R., Sturtzel, C., Lipnik, K., Gencelli, B., Seltenhammer, M., et al. (2019). Cytokine-like 1 is a novel proangiogenic factor secreted by and mediating functions of endothelial progenitor cells. *Circ. Res.* 124 (2), 243–255. doi:10.1161/CIRCRESAHA.118.313645

Sevin, M., Debeurme, F., Laplane, L., Badel, S., Morabito, M., Newman, H. L., et al. (2021). Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. *Blood* 137 (24), 3390–3402. doi:10.1182/blood.2020008729

Shen, S., Faouzi, S., Souquere, S., Roy, S., Routier, E., Libenciuc, C., et al. (2020). Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation. *Cell Rep.* 33 (8), 108421. doi:10.1016/j.celrep.2020.108421

Shin, Y., Won, Y., Yang, J. I., and Chun, J. S. (2019). CYTL1 regulates bone homeostasis in mice by modulating osteogenesis of mesenchymal stem cells and osteoclastogenesis of bone marrow-derived macrophages. *Cell Death Dis.* 10 (2), 47. doi:10.1038/s41419-018-1284-4

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 71 (3), 209–249. doi:10.3322/caac.21660

Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., et al. (2015). STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res.* 43, D447–D452. doi:10.1093/nar/gku1003

Tang, S., Zhang, Y., Lin, X., Wang, H., Yong, L., Zhang, H., et al. (2022). CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer. *Oncol. Lett.* 24 (2), 285. doi:10.3892/ol.2022.13405

Wang, X., Li, T., Cheng, Y., Wang, P., Yuan, W., Liu, Q., et al. (2019). CYTL1 inhibits tumor metastasis with decreasing STAT3 phosphorylation. *Oncoimmunology* 8 (5), e1577126. doi:10.1080/2162402X.2019.1577126

Weiss, J. M., Hunter, M. V., Cruz, N. M., Baggiolini, A., Tagore, M., Ma, Y., et al. (2022). Anatomic position determines oncogenic specificity in melanoma. *Nature* 604 (7905), 354–361. doi:10.1038/s41586-022-04584-6

Wen, M., Wang, H., Zhang, X., Long, J., Lv, Z., Kong, Q., et al. (2012). Cytokine-like 1 is involved in the growth and metastasis of neuroblastoma cells. *Int. J. Oncol.* 41 (4), 1419–1424. doi:10.3892/ijo.2012.1552

Xue, H., Li, S., Zhao, X., Guo, F., Jiang, L., Wang, Y., et al. (2020). CYTL1 promotes the activation of neutrophils in a sepsis model. *Inflammation* 43 (1), 274–285. doi:10.1007/s10753-019-01116-9

Xue, W., Li, X., Li, W., Wang, Y., Jiang, C., Zhou, L., et al. (2022). Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer. *Signal Transduct. Target Ther.* 7 (1), 35. doi:10.1038/s41392-021-00856-1

Zhu, S., Kuek, V., Bennett, S., Xu, H., Rosen, V., and Xu, J. (2019). Protein Cytl1: its role in chondrogenesis, cartilage homeostasis, and disease. *Cell Mol. Life Sci.* 76 (18), 3515–3523. doi:10.1007/s00018-019-03137-x

Zhu, W., Yang, X., Liu, S., Wang, M., Ye, S., Luo, H., et al. (2020). The involvement of cytokine-like 1 (Cytl1) in chondrogenesis and cartilage metabolism. *Biochem. Biophys. Res. Commun.* 529 (3), 608–614. doi:10.1016/j.bbrc.2020.06.069

frontiers | Frontiers in Oncology

TYPE Brief Research Report
PUBLISHED 18 September 2023
DOI 10.3389/fonc.2023.1182853

OPEN ACCESS

EDITED BY
Gabriella Liszkay,
National Institute of Oncology (NIO), Hungary

REVIEWED BY
Margit Balazs,
University of Debrecen, Hungary
József Tímár,
Semmelweis University, Hungary

*CORRESPONDENCE
Paola Perego
paola.perego@istitutotumori.mi.it

†These authors have contributed equally to this work

RECEIVED 09 March 2023
ACCEPTED 04 September 2023
PUBLISHED 18 September 2023

CITATION
Guzzetti C, Corno C, Vergani E, Mirra L, Ciusani E, Rodolfo M, Perego P and Beretta GL (2023) Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells.
Front. Oncol. 13:1182853.
doi: 10.3389/fonc.2023.1182853

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells

Carlotta Guzzetti[1†], Cristina Corno[1†], Elisabetta Vergani[2], Luca Mirra[1], Emilio Ciusani[3], Monica Rodolfo[2], Paola Perego[1*] and Giovanni L. Beretta[1]

[1]Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy, [2]Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy, [3]Laboratory of Clinical Pathology and Medical Genetics, Istituto Neurologico Fondazione C. Besta, Milan, Italy

Metastatic dissemination is still one of the major causes of death of melanoma's patients. KiSS1 is a metastasis suppressor originally identified in melanoma cells, known to play an important physiological role in mammals' development and puberty. It has been previously shown that expression of KiSS1 could be increased in lung cancer cells using epigenetic agents, and that KiSS1 could have a pro-apoptotic action in combination with cisplatin. Thus, the aim of the present study was to examine in human melanoma vemurafenib sensitive- and -resistant BRAF mutant cells characterized by different mutational profiles and KiSS1, KiSS1 receptor and KiSS1 drug-induced release, if peptides derived from KiSS1 cleavage, i.e., kisspeptin 54, could increase the sensitivity to vemurafenib of human melanoma, using cellular, molecular and biochemical approaches. We found that kisspeptin 54 increases vemurafenib pro-apoptotic activity in a statistically significant manner, also in drug resistant cellular models. The efficacy of the combination appears to reflect the intrinsic susceptibility of each cell line to PLX4032-induced apoptosis, together with the different mutational profile as well as perturbation of proteins regulating the apoptotic pathway, The results presented here highlight the possibility to exploit KiSS1 to modulate the apoptotic response to therapeutically relevant agents, suggesting a multitasking function of this metastasis suppressor.

KEYWORDS

drug resistance, melanoma, metastasis, kisspeptins, BRAF, vemurafenib

Introduction

The metastasis suppressor KiSS1, originally identified in melanoma, plays a role in tumor cells (1–3), besides contributing to the neuroendocrine control of reproduction (4). The products of the metastasis suppressor gene KiSS1, namely KiSS1-derived peptides (i.e., kisspeptins), are secreted and interact with the KiSS1R/GPR54 receptor (5, 6). The proteolytic cleavage of the 145-aa polypeptide KiSS1 produces the 54-aa peptide, kisspeptin-54 (KP54)/metastin, which is further cleaved into shorter peptides, including kisspeptin-10, KP10; kisspeptin-13, KP13; kisspeptin-14, KP14 (6, 7). These cleaved peptides are secreted and retain their biological activity. KiSS1 has been reported to down-regulate the matrix metalloproteinases (2) and in such a way to inhibit metastasis of cancer cells (2). Although the role of KiSS1 in cancer is not completely clarified, an involvement in controlling metastasis dissemination and response to cisplatin (cDDP) has been proposed (8–10). In melanoma, the metastasis suppression properties of KiSS1 have been reported to counteract metastatic colonization and to control the dormancy of disseminated cells following secretion (5, 11). The loss of KiSS1 in tumor progression/metastases has been associated with other cancer types in addition to melanoma (12). A link between KiSS1 expression and epigenetic mechanisms (e.g., histone acetylation, DNA methylation, microRNAs expression) has been suggested (13, 14). For instance, we have reported that the up-regulation of KiSS1 mRNA levels stimulated by the treatment with histone deacetylase (HDAC) inhibitors resulted in a reduction of the invasive ability of the cDDP-resistant cells (13). More recently, another study from our research team showed a peculiar modulation of KiSS1 levels in liquid biopsies of non-small cell lung cancer (NSCLC) patients, supporting the potential use of KiSS1 as a biomarker for this tumor. The study also highlights the role played by KiSS1-cleaved peptide KP54 in increasing the apoptosis induced by the treatment with cDDP, envisioning possible implications for the use of KP54 in antitumor therapy of this disease (10).

Melanoma is an aggressive disease, responsible for the majority of deaths for skin cancers (15). Though the amelioration of the medical intervention has declined patients mortality, metastatic disease still remains incurable (16). Due to the frequent activating mutation of the BRAF gene, the constitutive activation of the RAS-RAF-MEK-ERK signalling is very common in melanoma. The mutation BRAFV600E, which is found in 40% of melanoma patients, is mainly responsible for melanoma aggressiveness. Patients suffering from metastatic disease have benefited from the introduction in clinical practice of the BRAFV600E kinase inhibitor PLX4032 (vemurafenib) (16, 17). However, these patients develop resistance to vemurafenib within 6–9 months (18) because of the reactivation of the MAPK pathway. In BRAF inhibitor-resistant patients, positive results have been reported by the co-treatment with BRAF and MEK inhibitors. Though the amelioration of the medical intervention by kinase inhibitors and by immunotherapy has declined patients mortality, the advanced metastatic disease still remains incurable (16). Unfortunately, the development of resistance toward the drug combination has limited the achievement of persistent cures (19). In this context, the development of new drugs, as well as innovative therapeutic strategies, is urgent. To face this issue, intensive efforts have been made to better understand the molecular bases of drug resistance in melanoma. Several studies assessing the genomic correlates of resistance to BRAF/MEK inhibitors in patients showed that the development of resistance is a complex process that may display a wide intra-patient and intra-tumoral heterogeneity of underlying mechanisms (20). Pre-clinical studies carried out in cell lines with primary or acquired resistance as model systems have enabled the dissection of molecular mechanisms that act by sustaining MAPK signaling or parallel signaling networks despite BRAF inhibition. *In vitro* studies identified different epigenetic, metabolic, and phenotypic reprogramming events associated to resistance, contributing to the definition of the heterogeneous alterations associated with the reactivation of MAPK signaling (21). In addition, these model systems represent a tool to develop novel drug combinations to improve precision medicine strategies.

Here, we gain further inside to the role played by KiSS1 in modulating the apoptotic response of melanoma cells to antitumor drug exposure and envision a possible combination of vemurafenib with kisspeptins for improving the response to chemotherapy treatment.

Methods

Cell lines and cell sensitivity to antitumor agents

The melanoma cell lines LM16 and LM36, were obtained at the Fondazione IRCCS, Istituto Nazionale dei Tumori of Milan from fresh surgical specimens of a nodal and a cutaneous metastases (22). The corresponding PLX4032-resistant sublines, LM16R and LM36R, were generated by treating the parental counterparts with PLX4032 (3.2 μM) for 96 hours, allowing the few surviving cells to re-grow, and repeating treatment for up to 11 times, until the setting of drug resistance. Their genetic molecular and phenotypic characterization has been reported in previous studies (23–27). In particular, all cell lines exhibited the V600E BRAF mutation. The complete mutational profile has been reported by Vergani et al. (25). Specifically, several genes found mutated in LM36/LM36R, including IGFR2, ARID1A, DDR2, MSH2, PRKDC and FGFR3, are wild-type in LM16/LM16R cells. Additionally, the mutational profile of CDKN2A and NRAS appears to be of interest. The former is found mutated only in LM16 and LM16R cells, whereas NRAS is mutated only in LM36R All the cell lines were cultured in RPMI-1640 medium (Lonza, Basel, Switzerland) supplemented with 10% FBS (Euroclone, Milan, Italy). The cells were cultured within 20 passages starting from thawing of frozen stock and routinely checked for mycoplasma contamination (Mycoalert, Lonza). Melanoma cells were verified for PLX4032 resistance and all the cells were authenticated by the Stem Elite ID System (Promega, Wisconsin, United States). PLX4032 (Selleckchem, Houston, TX, United States) was dissolved and diluted in dimethylsulfoxide (DMSO). Final DMSO concentration in medium never exceeded 0.25%. cDDP (Accord Healthcare Italia, Milan, Italy) was diluted in saline. Temozolomide (TMZ, Selleck

Chemicals, Aurogene Srl, Rome, Italy) was primarily dissolved in DMSO and diluted in water. The KiSS1-derived peptide KP54 was obtained from Anaspec (DBA Italia, Milan, Italy). Exponentially growing cells were seeded in 12-well plate (5000 cells/mL) and, 24 h later, exposed for 72 h to different concentrations of drugs. At the end of the treatment, cells were detached and counted using coulter counter (ZB1, Coulter Electronics). The cellular sensitivity to the drugs is determined as a percentage of cell growth with respect to the untreated control. The IC_{50} is the drug concentration causing 50% reduction of cell growth. RI is the ratio between IC_{50} of resistant cell line and IC_{50} of the sensitive cell line.

Quantitative real time polymerase chain reaction

Gene expression levels of KiSS1 and KiSS1R were analyzed by qRT-PCR according to standard methods in untreated cells. Twenty-four hours after seeding, cells were harvested and total RNA isolated using RNeasy Plus Mini kit (Qiagen, Hilden, Germany). The RNA was reverse transcribed by High Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Monza, Italy). The following TaqMan assays were used: Hs.PT.58.2731441 for KiSS1, Hs.PT.58.27127688 for KiSS1R, and Hs02758991_g1 for GAPDH (Thermo Fisher Scientific). Technical triplicate reactions were carried out with a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific) and data were acquired through the Sequence Detection Systems (SDS) 2.4 software. Reactions were in a 10 µL volume comprising cDNA (2.5 µL), master mix (5 µL, TaqMan Universal Fast PCR Master Mix, Thermo Fisher Scientific) and the specific assay (0.5 µL). The relative quantification (RQ) manager software (Thermo Fisher Scientific) was used to determine relative expression levels in resistant variants using parental cells as calibrator (23).

Quantitative analysis of KiSS1 in melanoma cells and culture medium

KiSS1 levels expressed by the cells or released into the culture medium were measured by ELISA (Human Metastasis Suppressor KiSS-1 kit, Cusabio, Houston, TX, USA), according to the manufacturer's instructions for quantitative analysis. Cells (26700 cells/cm^2) were cultured for 24 h before the 24 h-treatment with PLX4032. At the end of treatment, cells and the corresponding culture media were recovered. Adherent cells were counted to allow normalization of the KiSS1 peptide levels. Cells were lysated and culture media clarified by centrifugation at 13,000 rpm for 5 min. Aliquots of cell extracts and culture media were used for the ELISA. A calibration curve was fitted by plotting the mean plate standard's absorbance (dependent variable) as a function of the known KiSS1 concentrations of the standard (independent variable). This curve was then used to estimate the unknown starting concentration in the test samples. Three independent experiments were performed and the mean value ± standard deviation (SD) was calculated.

KiSS1 silencing in melanoma cell lines

Seventy two hours after seeding in 75 cm^2 flasks (6600 cells/cm^2), LM16 and LM16R cells were transfected using Opti-MEM transfection medium (Gibco by Thermo Fisher Scientific, Waltham, MA, USA) and RNAiMax (Thermo Fisher Scientific), with 30 nM of small interfering RNA (siRNA) to KiSS1 (Silencer Select siRNA s194584, Thermo Fisher Scientific), and control siRNA (Silencer Select Negative Control #2 siRNA, Thermo Fisher Scientific). After 5h, the transfection was stopped by adding complete medium and 48 h later cells were harvested and seeded in 12-well plates (12000 cells/cm^2). Cells were then treated with PLX4032 for 48 h. Knockdown efficiency was evaluated by qRT-PCR at the beginning and at the end of the drug treatment.

Apoptosis analyses

The Annexin V-binding assay (Immunostep, Salamanca, Spain) was used to measure the apoptosis induction following drug exposure. Cells were treated for 48 h with PLX4032, cDDP, TMZ, KP54 alone or with their simultaneous combinations. After washing with cold phosphate-buffered saline (PBS), cells were processed according to manufacturer's protocol. Annexin V-binding was examined by flow cytometry (BD Accuri, Becton Dickinson, Milan, Italy) by acquiring ten thousand events for each sample. Instrument software (Becton Dickinson) was used to analyze the results.

Apoptosis was also evaluated by measuring the activation of caspase 3/7 as well as caspase 8 by luminescent Caspase Glo 3/7 assay System or Caspase-Glo 8 Assay System (Promega, Fitchburg). Cells were seeded in 96-well plates (7,000 cells/well in 100 µL of medium) and 24 h later treated with PLX4032, cDDP, TMZ or KP54 alone or with their simultaneous combinations. After 48 h, the activation of caspases was determined according to the manufacturer's instructions. Relative luminescence units (RLU) were normalized with respect to the total protein content of each well to correct for the growth inhibitory effect of the treatment. Protein content was assayed by the BCA method.

Cell-cycle analysis

Twenty four hours after seeding in 75 cm^2 flasks (10000 cells/cm^2), LM16, LM36, LM16R and LM36R cells were exposed for 48 h to KP54, PLX4032 or to the simultaneous combination of KP54 and PLX4032. After treatment, cells were washed, fixed in ice-cold 70% ethanol, and stored at −20°C. After rehydration in PBS, cells were stained with 10 µg/mL propidium iodide (Sigma-Aldrich, St. Louis, MO, USA) in PBS containing RNase A (66 units/mL; Sigma-Aldrich) for 18 h. The samples were processed by flow cytometry (BD Accuri, Becton Dickinson) by acquiring 30 thousand events for each sample. Kaluza analysis software (2.1 version, Beckman Coulter) was used to analyze the results.

Western blot analysis

Western blot analysis was carried out as previously described (23). Protein lysates fractionated by SDS-PAGE were blotted on nitrocellulose membranes. Blots were pre-blocked in PBS containing 5% (w/v) dried no fat milk and incubated overnight at 4° C with antibodies to anti $p27^{kip1}$ (BD Biosciences, Franklin Lakes, NJ, USA) and anti-actin (Sigma-Aldrich). Blots were developed by chemo-luminescence (GE Healthcare, Chicago, IL, USA). Secondary antibodies were from GE Healthcare.

Results

Sensitivity of melanoma cell lines to PLX4032

In the present study, we used two pairs of vemurafenib (PLX4032)-sensitive and -resistant cells (LM16 and LM16R; LM36 and LM36R) to explore the possible interest of kisspeptins as modulator of response to vemurafenib in cells displaying sensitivity or resistance. Compared to LM16 and LM36, the resistant variants were 145.25 and 59.53 times more resistant to PLX4032, respectively (Table 1). Upon exposure to PLX4032, we observed changes in cell morphology suggesting the activation of cell death (Supplementary Figure 1).

Analysis of the expression of KiSS1 and KiSS1 receptor and evaluation of kisspeptin levels in melanoma cell lines

To characterize the cell models, the expression of KiSS1 and KiSS1R of melanoma cell lines was evaluated using qRT-PCR (Figure 1A). Specifically, compared to LM36R, LM16R show about 30-fold and 3-fold increased levels of KiSS1 and KiSS1R, respectively.

KiSS1 espression of melanoma cells and the levels of KiSS1 released into the culture medium were measured using ELISA (Figure 1B). Compared to LM16, LM16R cells show 3-fold increased KiSS1 levels released into the medium. Though no important differences in the released KiSS1 was observed for LM36R with respect to LM36, an appreciable and statistically significant secretion of KiSS1 was evidenced in both LM36 and LM36R cells, but not in LM16 and LM16R cells, upon treatment with PLX4032. KiSS1 expression was unaffected by the treatment with PLX4032 and was very similar among the cell lines considered. Of note, upon siRNA-mediated silencing of KiSS1, the sensitivity to PLX4032 of LM16 and LM16R cells resulted unaffected (Supplementay Figure 2).

TABLE 1 Sensitivity of melanoma cell lines to PLX4032[a].

Cell lines	PLX4032 (IC_{50}, μM)	RI
LM36	0.043 ± 0.01	/
LM36R	2.56 ± 0.55	59.53
LM16	0.08 ± 0.04	/
LM16R	11.62 ± 4.5	145.25

[a]Cell sensitivity was assessed by cell growth inhibition assay. Cells were seeded and 24 h later exposed to the drugs for 72 h. Cells were then counted using a cell counter. IC_{50} is defined as the drug concentration causing 50% reduction of cell growth. RI, Resistance Index; is the ratio between IC_{50} of resistant cell line and IC_{50} of the sensitive cell line. Experiments were performed in triplicate and data represent mean values ± SD.

Analysis of apoptosis induction

Because we planned to use apoptosis as readout of the treatment efficacy, apoptosis induction was examined in response to treatment of melanoma cells with the BRAF inhibitor PLX4032 as well as to conventional antitumor agents such as cDDP and TMZ. Although cDDP is not used in melanoma therapy, the literature provides evidence of modulation of apoptosis by cDDP in head and neck and lung cancers (9, 10). Thus, cDDP treatment was included in our study. At first, apoptosis induction following PLX4032 exposure was examined in LM36 and LM36R melanoma cells. Moreover, LM36 and LM36R were exposed for 48 h to two different concentrations of PLX4032 alone or in combination with 500 ng/mL KP54 (10). A dose-dependent apoptosis induction was observed following the treatment of LM36 and LM36R with PLX4032 (Figure 2). No apoptosis was revealed upon KP54 exposure alone in both the cell lines. Compared to PLX4032 treatment, an increased number of apoptotic-positive cells was evidenced following the exposure to the combination PLX4032/KP54. This finding was statistically significant only in LM36, although a similar trend/behavior was evidenced in LM36R as well.

In addition, since KP54 combined with cDDP has been reported to result in a synergic interaction that potentiates the antitumor activity of cDDP in head and neck squamous cell carcinoma and lung cancer cells (9, 10), also the combination PLX4032/cDDP was considered. As expected, cDDP exposure resulted in a dose-dependent induction of apoptotis in LM36 and LM36R. Differently from what was observed following the treatment with the combination PLX4032/KP54, the exposure to cDDP/KP54 did not result in amelioration of the apoptosis induction with respect to cDDP as single agent. When using another DNA damaging agent of clinical interest in melanoma, i.e., TMZ, an appreciable induction of apoptosis was revealed in LM36 and LM36R cells. This behavior was independent of the drug concentration used and no implementation of apoptotic-positive cells was shown following the exposure to the combination TMZ/KP54 in sensitive and resistant cells. Of note, LM36 and LM36R showed similar sensitivity to cDDP (RI=1.43), while a collateral sensitivity to TMZ (RI=0.3) was observed for LM36R with respect to LM36 (Supplementary Table 1).

Besides, the analysis of apoptosis in LM16 and LM16R cells upon exposure to PLX4032 showed a modest apoptosis induction only in LM16R cells. Compared to untreated control, no induction of apoptosis was recognized in LM16 cells exposed to PLX4032, suggesting that the cells respond to treatment only inhibiting proliferation The combination PLX4032/KP54 did not improve the apoptotic-positive LM16 cells with respect to the exposure to



FIGURE 1
(A) Analysis of the expression of KiSS1 and KiSS1 receptor in melanoma cells. Twenty-four hours after seeding, exponentially growing cells were harvested and total RNA isolated. Gene expression levels of KiSS1 and KiSS1R were analyzed by qRT-PCR. Histograms represents the mean ± SD of 3 independent experiments. **(B)** Analysis of the levels of kisspeptins expressed or released by melanoma cells upon PLX4032 treatment. Twenty-four hours after seeding, cells were treated with PLX4032 for 24 h. Cells were then harvested and the levels of KiSS1 inside the cells or released into the medium measured by ELISA. ** $p < 0.005$; *** $p < 0.0005$ by one-way ANOVA followed by Bonferroni correction compared to single agents.

PLX4032 alone. Conversely, KP54 significantly increased the PLX4032-induced apoptosis in LM16R cells.

To better define the players of apoptosis induction, the activation of caspase 3/7 and 8 following drug exposure was evaluated (Figure 3). An increased activation of caspase 3/7 and 8 was evidenced in LM36 cells exposed to PLX4032. The combination of PLX4032 with KP54 implemented the activation of caspase 3/7 at both concentrations of PLX4032 considered and that of caspase 8 only at low concentration of PLX4032. The activation of caspase 3/7 and 8 was observed in LM36R exposed only to a high concentration of PLX4032. The exposure of LM36R cells to the combination of PLX4032 with KP54 resulted in reduced activation of both caspase 3/7 and 8. LM36 cells treated with cDDP slightly increased caspase 3/7 and this activation was significantly potentiated by the combination with KP54 only for the higher cDDP concentration. LM36R cells exposed to the higher cDDP concentration



FIGURE 2
Apoptosis induced by the combination of PLX4032, cisplatin or temozolomide with KP54 in melanoma cells as assessed by Annexin V-binding assay. **(A)** Twenty four hours after seeding, LM36 and LM36R cells were exposed to PLX4032, cDDP or TMZ alone or to the combination with 500 ng/ml KP54 and harvested 48 h after treatment for analysis of apoptotic response. **(B)** Twenty four hours afrter seeding, LM16 and LM16R cells were exposed to PLX4032 alone or to the combination PLX4032 and 500 ng/ml KP54 and harvested 48 h after treatment for analysis of apoptotic response. Apoptosis quantitation was carreid out with the BD Accuri software. Histograms represent the mean ± SD of 3 independent experiments. ** $p < 0.005$; *** $p < 0.0005$ by one-way ANOVA followed by Bonferroni correction.

importantly increased the levels of activated caspase 3/7, which was not implemented upon the combination with KP54. No activation of caspase 3/7 was observed after the exposure to the lower concentration of cDDP alone or in combination with KP54. The treatment of LM16 cells with PLX4032 increased the activation of caspase 3/7. Following the exposure of LM16 cells to the combination of PLX4032 with KP54, the activation of caspase 3/7 was significantly implemented only for low concentration of PLX4032. The activation of caspase 3/7 was observed in LM16R cells only upon exposure to high concentration of PLX4032, and



FIGURE 3
Caspase 3/7 and caspase 8 activation induced by the combination of PLX4032 or cisplatin with KP54 in melanoma cells. **(A)** Twenty four hours after seeding, LM36 and LM36R cells were exposed to PLX4032 or cDDP alone or to the combination with 500 ng/ml KP54 and harvested 48 h after treatment for the evaluation of caspase 3/7 or caspase 8 activation. **(B)** Twenty four hours after seeding, LM16 and LM16R cells were exposed to PLX4032 alone or to the combination PLX4032 and 500 ng/ml KP54 and harvested 48 h after treatment for the evaluation of caspase 3/7 activation. Histograms represent the mean ± SD of 3 independent experiments. * $p < 0.05$, ** $p < 0.005$; *** $p < 0.0005$ by one-way ANOVA followed by Bonferroni correction compared to single agents.

this activation was not implemented by the treatment with the combination PLX4032/KP54.

We also explored whether the advantage of the combination of KP54 and PLX4032 could be evident by examining cell viability by cell counting, thereby analyzing the combination efficacy in terms of proliferation inhibition. Compared to single drug exposure, the combination of KP54 with PLX4032, cDDP and TMZ did not impact on cell viability (Supplementary Figure 3). Additionally, since in our previous study we observed the induction of $p27^{kip1}$ in melanoma cells treated with PLX4032 (24) and based on the

observation that LM16 cells exposed to the combination of KP54/PLX4032 improve the PLX4032-mediated induction of $p27^{kip1}$ (Supplementary Figure 4), we sought to investigate whether KP54 exposure perturbes the cell-cycle. With this approach, we found that a common feature of exposure to PLX4032 in LM16 cells was an accumulation in G1 (Supplementary Table 2), that was maintained with the combination KP54/PLX4032, a result supporting the occurrence of an antiproliferative response in these cells.

Conclusions

The clinical management of metastatic melanoma has been revolutionized by the introduction of BRAF and MEK inhibitors. Despite the success achieved, persistent cures are still lacking and the development of drug resistance urgently requires the discovery of new drugs as well as innovative medical strategies. In this context, studies aimed at clarifying the molecular mechanisms subtending melanoma aggressiveness as well as response to treatment are expected to improve the medical management of this disease. In this study, we focused on the metastasis suppressor gene KiSS1, whose function as a modulator of apoptosis in head and neck and lung cancers has already been demonstrated (9, 10). Here, a role for KiSS1 as regulator of the cellular response to vemurafenib in melanoma cell lines all characterized by the BRAF V600E mutation has emerged. Pairs of melanoma cell lines sensitive and resistant to PLX4032, displaying different levels of KiSS1 and KiSS1R as well as a different pattern of KiSS1 release upon PL4032 exposure were considered to study whether the response to antitumor agents can be improved by the combination with KP54. Our results demonstrate that in melanoma models, the apoptotic response to the treatment with PLX4032 is improved following the combination with KP54. A contribution of KiSS1 released upon PLX4032 exposure to such an improvement is also likely, dependent on the fact that increased release is found in the cell lines in which apoptosis is increased by KP54 combination (LM36, LM36R, LM16R), but not in the LM16 cell line. The amelioration of the apoptotic process is evident both in LM16R and LM36 cell lines, with a statistically significant improvement of the percent of apoptotic cells upon treatment with the combination versus PLX4032 alone. Of note, the activation of caspase is observed in the parental cell lines (LM16 and LM36). In LM16 cells, a trend toward an increase of apoptotic cells is evident, thereby the discrepancy between quantitative analysis of apoptosis and caspase activation is only apparent. In LM16 cells, the lack of induction of apoptosis by PLX4032 *per se* suggests that this cell line responds to treatment with an antiproliferative effect and not with apoptosis induction. In LM36 cells, the activation of both caspase 3-7 and caspase 8 is observed and this implies that the process of apoptosis induction appears to involve both the intrinsic and the extrinsic apoptotic pathways. Since this behavior is observed also upon the combination of KP54 with cDDP, the study envisions a general mechanism of action of kisspeptins, supporting that the drug combination can potentiate the activity of antitumor drugs whose mechanism of action involves the induction of apoptosis. Importantly, the siRNA-mediated silencing of KiSS1 has negligible effects on cell growth. However, a reduced cell growth was observed in KiSS1-silenced cells exposed to 10 μM PLX4032. Although there might be a trend, according to the statistical analysis this reduction was not significant. Besides, no increase of apoptosis was observed. Thus, overall, it seems that the most promising approach to modulate response to vemurafenib is a gain of function approach based on the use of kisspeptins. The loss of function approach seems not to allow to easily dissect the contribution of KiSS1 to drug response likely becasue the phenomenon is multifactorial and compensatory signals could occur, thereby masking the phenotype of interest to us. Differently, the gain of function approach based on the use of KP54 triggers stronger cellular changes in terms of cellular response to treatment. Such a response may be variable in different cell lines, also depending on the specific molecular background. Indeed, the mutational profiles of the cell lines indicate a wide heterogeneity between parental cell lines and upon resistance acquisition. Of note, cell response seems to be the result of a balance among multiple factors, given that survival proteins (e.g., Bcl-2) may also be lost in resistant cells (data not shown). The research requires further studies to elucidate the molecular determinants implicated in the drug combination. In particular, deeper investigations aimed at clarifying the role played by the expression of KiSS1 and KiSS1R as well as the contribution of secreted KiSS1 by the tumor are needed.

In conclusion, our results indicate that, beyond its role as a metastasis suppressor, KiSS1 is critical in modulating the apoptotic response of melanoma to antitumor drug treatment and allows to the speculation that the combination with kisspeptins may improve response to chemotherapy treatment with vemurafenib.

Data availability statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

Ethics statement

Ethical approval was not required because the cell lines were developed in our institution in the context of previous projects approved by the ethical committee. The studies were conducted in accordance with the local legislation and institutional requirements.

Author contributions

CG, CC, EC, LM and EV performed the experiments and data collection. GB, CG and PP wrote the first draft of the manuscript. GB, MR and PP contributed to the conception and design of the study and manuscript drafting. PP contributed to funding acquisition. All authors have provided contribution to data analysis, editing, and final approval of the manuscript.

Funding

The authors would like to acknowledge AIRC for funding a fellowship ("Le Falchette di AIRC") to CC.

Acknowledgments

We thank Elisabetta Corna and Nives Carenini for technical support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1182853/full#supplementary-material

References

1. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, et al. KiSS-1, a novel human Malignant melanoma metastasis-suppressor gene. *J Natl Cancer Inst* (1996) 88(23):1731–7. doi: 10.1093/jnci/88.23.1731

2. Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. *Cancer Res* (1997) 57(12):2384–7.

3. Korch C, Hall EM, Dirks WG, Ewing M, Faries M, Varella-Garcia M, et al. Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. *Int J Cancer* (2018) 142(3):561–72. doi: 10.1002/ijc.31067

4. Clarke H, Dhillo WS, Jayasena CN. Comprehensive review on kisspeptin and its role in reproductive disorders. *Endocrinol Metab (Seoul)* (2015) 30(2):124–41. doi: 10.3803/EnM.2015.30.2.124

5. Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E, et al. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. *J Natl Cancer Inst* (2007) 99(4):309–21. doi: 10.1093/jnci/djk053

6. Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. *J Biol Chem* (2001) 276 (37):34631–6. doi: 10.1074/jbc.M104847200

7. Harihar S, Pounds KM, Iwakuma T, Seidah NG, Welch DR. Furin is the major proprotein convertase required for KISS1-to-Kisspeptin processing. *PloS One* (2014) 9 (1):e84958. doi: 10.1371/journal.pone.0084958

8. Guzman S, Brackstone M, Radovick S, Babwah AV, Bhattacharya MM. KISS1/KISS1R in cancer: Friend or foe? *Front Endocrinol (Lausanne)* (2018) 9:437. doi: 10.3389/fendo.2018.00437

9. Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D, et al. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. *Oncogene* (2011) 30(28):3163–73. doi: 10.1038/onc.2011.39

10. Gatti L, Rolli L, Corno C, Carenini N, Corna E, Ciusani E, et al. Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance. *Transl Lung Cancer Res* (2022) 11(7):1315–26. doi: 10.21037/tlcr-22-52

11. Kim JN, Kim TH, Yoon JH, Cho SG. Kisspeptin inhibits colorectal cancer cell invasiveness by activating PKR and PP2A. *Anticancer Res* (2018) 38(10):5791–8. doi: 10.21873/anticanres.12918

12. Harihar S, Welch DR. KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers? *Cancer Metastasis Rev* (2023) 42 (1):183–96. doi: 10.1007/s10555-023-10090-6

13. Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, et al. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor. *Biochem Pharmacol* (2015) 94(2):79–90. doi: 10.1016/j.bcp.2015.01.002

14. Corno C, Perego P. KiSS1 in regulation of metastasis and response to antitumor drugs. *Drug Resist Updat* (2019) 42:12–21. doi: 10.1016/j.drup.2019.02.001

15. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA A Cancer J Clin* (2021) 71(1):7–33. doi: 10.3322/caac.21654

16. Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, et al. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. *Eur J Cancer* (2018) 104:201–9. doi: 10.1016/j.ejca.2018.09.013

17. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol* (2014) 15(3):323–32. doi: 10.1016/S1470-2045(14)70012-9

18. Gershenwald JE, Scolyer RA. Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond. *Ann Surg Oncol* (2018) 25(8):2105–10. doi: 10.1245/s10434-018-6513-7

19. Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US food and drug administration-approved targeted therapy in advanced melanoma. *Onco Targets Ther* (2018) 11:7095–107. doi: 10.2147/OTT.S182721

20. Luebker SA, Koepsell SA. Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies. *Front Oncol* (2019) 9:268. doi: 10.3389/fonc.2019.00268

21. Radić M, Vlašić I, Jazvinšćak Jembrek M, Horvat A, Tadijan A, Sabol M, et al. Characterization of vemurafenib-resistant melanoma cell lines reveals novel hallmarks of targeted therapy resistance. *Int J Mol Sci* (2022) 23(17):9910. doi: 10.3390/ijms23179910

22. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, et al. BRAF alterations are associated with complex mutational profiles in Malignant melanoma. *Oncogene* (2004) 23(35):5968–77. doi: 10.1038/sj.onc.1207780

23. Vergani E, Beretta GL, Aloisi M, Costantino M, Corno C, Frigerio S, et al. Targeting of the lipid metabolism impairs resistance to BRAF kinase inhibitor in melanoma. *Front Cell Dev Biol* (2022) 10:927118. doi: 10.3389/fcell.2022.927118

24. Stamatakos S, Beretta GL, Vergani E, Dugo M, Corno C, Corna E, et al. Deregulated FASN expression in BRAF inhibitor-resistant melanoma cells unveils new targets for drug combinations. *Cancers (Basel)* (2021) 13(9):2284. doi: 10.3390/cancers13092284

25. Vergani E, Busico A, Dugo M, Devecchi A, Valeri B, Cossa M, et al. Genetic layout of melanoma lesions associates to BRAF/MEK-targeted therapy resistance and to transcriptional profiles. *J Invest Dermatol* (2022) 142(11):3030–3040.e5. doi: 10.1016/j.jid.2022.04.027

26. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, et al. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to *PLX4032*. *Neoplasia* (2011) 13(12):1132–42. doi: 10.1593/neo.111102

27. Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. *Oncotarget.* (2016) 7(4):4428–41. doi: 10.18632/oncotarget.6599

frontiers | Frontiers in Pharmacology

TYPE Review
PUBLISHED 19 September 2023
DOI 10.3389/fphar.2023.1252567

OPEN ACCESS

EDITED BY
Marcel Henrique Marcondes Sari,
State University of Midwest Paraná, Brazil

REVIEWED BY
Charareh Pourzand,
University of Bath, United Kingdom
Vinicius Prado,
Federal University of Santa Maria, Brazil

*CORRESPONDENCE
Yongchun Zhang,
1056926754@qq.com

†These authors have contributed equally to this work

RECEIVED 04 July 2023
ACCEPTED 11 September 2023
PUBLISHED 19 September 2023

CITATION
Ta N, Jiang X, Zhang Y and Wang H (2023), Ferroptosis as a promising therapeutic strategy for melanoma. *Front. Pharmacol.* 14:1252567. doi: 10.3389/fphar.2023.1252567

Ferroptosis as a promising therapeutic strategy for melanoma

Na Ta[1†], Xiaodong Jiang[2†], Yongchun Zhang[3*] and Hongquan Wang[4]

[1]Department of Neurosurgery, The Affiliated Hospital of Chifeng University, Chifeng, China, [2]Department of Anatomy, College of Basic Medicine, Chifeng University Health Science Center, Chifeng, China, [3]Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Chifeng University, Chifeng, China, [4]Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Malignant melanoma (MM) is the most common and deadliest type of skin cancer and is associated with high mortality rates across all races and ethnicities. Although present treatment options combined with surgery provide short-term clinical benefit in patients and early diagnosis of non-metastatic MM significantly increases the probability of survival, no efficacious treatments are available for MM. The etiology and pathogenesis of MM are complex. Acquired drug resistance is associated with a pool prognosis in patients with advanced-stage MM. Thus, these patients require new therapeutic strategies to improve their treatment response and prognosis. Multiple studies have revealed that ferroptosis, a non-apoptotic form of regulated cell death (RCD) characterized by iron dependant lipid peroxidation, can prevent the development of MM. Recent studies have indicated that targeting ferroptosis is a promising treatment strategy for MM. This review article summarizes the core mechanisms underlying the development of ferroptosis in MM cells and its potential role as a therapeutic target in MM. We emphasize the emerging types of small molecules inducing ferroptosis pathways by boosting the antitumor activity of BRAFi and immunotherapy and uncover their beneficial effects to treat MM. We also summarize the application of nanosensitizer-mediated unique dynamic therapeutic strategies and ferroptosis-based nanodrug targeting strategies as therapeutic options for MM. This review suggests that pharmacological induction of ferroptosis may be a potential therapeutic target for MM.

KEYWORDS

malignant melanoma, ferroptosis, ferroptosis inducer, small molecules compounds, dynamic therapy, nanomaterial

1 Introduction

Malignant melanoma (MM) is one of the most lethal and aggressive types of skin cancer and is associated with the highest rates of mutation and treatment resistance. It is responsible for the majority of skin-related cancer mortality worldwide, especially in its metastatic form (Anestopoulos et al., 2022; Wagstaff et al., 2022). The incidence of melanoma has been increasing worldwide (Tucker, 2009; Carr et al., 2020; Forsea, 2020; Bolick and Geller, 2021; Memon et al., 2021; Saginala et al., 2021). Both genetic and environmental risk factors have been reported to be associated with the onset of melanoma, with ultraviolet (UV) radiation

exposure being the most prominent factor, especially in fair-skinned populations. Studies have revealed that *BRAF* (B-Raf proto-oncogene, serine/threonine kinase), *KRAS* (Kirsten rat sarcoma), *NRAS* (neuroblastoma RAS viral oncogene homolog), *HRAS* (Harvey Rat sarcoma viral oncogene), *CDKN2B* (Cyclin dependent kinase inhibitor 2B), *PTEN* (phosphatase and the tensin homolog deleted on chromosome 10), *TERT* (telomerase reverse transcriptase), and *p53* are the most commonly mutated genes in MM progression, which can potentially cause resistance to targeted therapy. Moreover, *BRAF* mutations occur in approximately 60.0% of MM cases (Anestopoulos et al., 2022).

MM arises solely from melanocytes that is primarily localized in the skin, or may also occur in mucous membranes (the digestive, respiratory, and genitourinary tracts), the eye, and even in the leptomeninges (Thornton et al., 1988; Abdullah and Keczkes, 1989; Nicolaides et al., 1995; DeMatos et al., 1998). Due to its ability to spread and metastasize rapidly, MM is more dangerous than other skin cancers if not removed at an early stage (Pastwińska et al., 2022). Immune checkpoint inhibitors (ICI) and targeted therapy are the mainstay for the treatment of metastatic MM (Reuben et al., 2017), while surgical resection is the major treatment option for the localized melanoma (Tyrell et al., 2017). Treatment for metastatic melanoma is very challenging, and chemotherapy regimens have been identified as an important therapeutic option in managing patients with metastatic and/or advanced-stage MM. The most important challenge with anti-MM therapies face is that melanoma cells intrinsically evades cell death-induced by anticancer drugs (Abildgaard and Guldberg, 2015; Kalal et al., 2017). Identification of the molecular mechanisms of chemoresistance is vital for the development of effective therapeutic strategies to overcome drug resistance.

Ferroptosis, which is defined as an iron-dependent form of regulated cell death (RCD) driven by lipid peroxidation (LPO) in cellular membranes, has been considered to be a potential therapeutic strategy against tumors, including MM, since its discovery in 2012 (Lei et al., 2021; Wang L. et al., 2023). Increasing evidence over the last decade has shown that activation of ferroptosis suppresses the development of many chemotherapy-resistant cancers (Lu et al., 2017; Guo et al., 2018), and that targeting ferroptosis is a promising treatment strategy for MM. However, a greater and better understanding of the molecular mechanisms underlying the initiation and propagation of ferroptosis as well as the resistance to this form of RCD in MM is needed.

In this review, we have summarized the core mechanisms of ferroptosis in MM and its potential effects in MM treatment. We emphasize the roles of emerging types of small molecules inducing ferroptosis pathways by boosting the antitumor activity of BRAFi and immunotherapy and delineate their beneficial effects in treating MM. In addition, we have summarized the application of nanosensitizer-mediated unique dynamic therapeutic strategies and ferroptosis-based nanodrug targeting strategies as therapeutic options for MM. We also highlight future research perspectives for ferroptosis in MM, which could help enhance the understanding of this topic. This review suggests that pharmacological induction of ferroptosis as a potential therapeutic regimen for MM.

2 Materials and methods

Searches were conducted in the PubMed database for the period between January 2012 and August 2023. The keyword used was "Melanoma" AND "Ferroptosis" Only English reports were considered. Reference lists of original research studies were manually searched. The manuscripts of all potentially relevant research studies that investigate the association between ferroptosis and Melanoma identified during the search of abstracts were then retrieved and reviewed. The MEDLINE search resulted in 145 articles. Of them, 13 were excluded because they were Review Article. The remaining 132 articles were evaluated, from which we exam 1) The role of ferroptosis in melanoma; 2) Induction of ferroptosis as a novel approach to treat melanoma.

3 A concise overview of ferroptosis

Ferroptosis, a term coined in 2012, refers to an new form of RCD driven by an iron-dependent LPO on cellular membranes or organelles (Dixon et al., 2012). The core step in ferroptosis is iron-catalyzed peroxidation of PL-PUFAs. When ferroptosis-promoting factors exceed the buffering capability of ferroptosis-defense systems, lethal lipid peroxides accumulates on cellular membranes, leading to membrane rupture and ferroptosis-mediated cell death (Qiu et al., 2020; Wang Y. et al., 2023) (Figure 1).

Membrane LPO, the core mechanism underlying ferroptosis, is a radical-mediated chain reaction involving a series of chemical reactions among iron, oxidizable lipids, and molecular oxygen (O_2), leading to the incorporation of O_2 into lipids (Conrad and Pratt, 2019; Dixon and Pratt, 2023). The polyunsaturated fatty acid-containing phospholipids (PL-PUFAs) are LPO substrates during ferroptosis (Conrad and Pratt, 2019; Hadian and Stockwell, 2020).

The critical mediators of PL-PUFAs synthesis include acyl-coenzyme A (CoA) synthetase long chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) (Doll et al., 2017; Kagan et al., 2017). ACSL4 induces the ligation of PUFAs with CoA to produce acyl-CoA (ACA), which can be re-esterified by LPCATs to produce PL-PUFAs. Under the help of acetyl-CoA carboxylase, ACA functions as the building block for PUFA synthesis (Hadian and Stockwell, 2020). LPO of PL-PUFAs is primarily catalyzed by iron-mediated Fenton reaction-driven non-enzymatic autoxidation (Gaschler and Stockwell, 2017; Shah et al., 2018; Conrad and Pratt, 2019). The enzymatic reactions mediated by arachidonate lipoxygenase (ALOX) or cytochrome P450 oxidoreductase (POR) under the influence of labile iron have also been shown to promote LPO (Yang et al., 2016; Wenzel et al., 2017; Zou et al., 2020; Koppula et al., 2021; Yan et al., 2021). Membrane-associated PL-PUFAs, labile iron, and POR or ALOXs undergo peroxidation reaction using O_2 to generate lipid peroxides, PL-PUFA-OOH (Hadian and Stockwell, 2020; Zou et al., 2020). In the last step of ferroptosis, LPO or its secondary products, including 4-hydroxy-2-nonenal (4-HNE) or malondialdehyde (MDA), lead to pore formation in plasma and organelle membranes to mediate ferroptosis-related cell death.



FIGURE 1
Core mechanisms of ferroptosis. The core of ferroptosis initiation is iron-dependent lipid peroxidation of polyunsaturated fatty acid (PUFA)-containing phospholipids (PUFA-PLs). When the ferroptosis-promoting factors (or Ferroptosis prerequisites) exceeding the buffering capability of cellular antioxidant systems (or ferroptosis defence systems), lethal accumulation of lipid peroxides on cellular membranes lead to membrane rupture, resulting in ferroptosis-related cell death. The ferroptosis-promoting factors consist of PUFA-PL synthesis and peroxidation, iron metabolism among others. Cells have evolved at least four ferroptosis defence systems, which includes GPX4/xCT system, the FSP1/$CoQH_2$ system, the DHODH/$CoQH_2$ system, and the GCH1/BH_4 system, with different subcellular localizations to detoxify lipid peroxides and thus protect cells against ferroptosis. The cytosolic GPX4 ($GPX4^{cyto}$) cooperates with FSP1 on the plasma membrane (and other non-mitochondrial membranes) and mitochondrial GPX4 ($GPX4^{mito}$) cooperates with DHODH in the mitochondria to neutralize lipid peroxides. ACSL4 and LPCAT3 mediate the synthesis of PUFA-PLs, which are susceptible to LPO through both non-enzymatic and enzymatic mechanisms. Iron initiates the non-enzymatic Fenton reaction and acts as an essential cofactor for ALOXs and POR, which promote LPO. When ferroptosis-promoting factors significantly exceed the detoxification capabilities of ferroptosis defence systems, an excessive and lethal accumulation of lipid peroxides on cellular membranes result in membrane rupture and trigger ferroptosis-mediated cell death.

4 The role of ferroptosis in melanoma

4.1 The metabolic switch dictates the vulnerablity of melanoma to ferroptosis

Mutated oncogenes in cancer cells rewire cellular metabolism networks to meet their increased demand for energy and nutrients (Martinez-Outschoorn et al., 2017; Wolpaw and Dang, 2018); however, this metabolic reprogramming in cancer cells often creates new metabolic liabilities, thereby making cancer cells, including MM, uniquely vulnerable to ferroptosis. The mutated proto-oncogene B-Raf (BRAF) negatively modulates oxidative metabolism in the cancer cells of MM (Haq et al., 2013), while BRAF inhibitors (BRAFi) increase the dependence of melanoma cells on oxidative phosphorylation (OXPHOS) (Haq et al., 2013; Schöckel et al., 2015). The sensitivity of cancer cells with $OXPHOS^{high}$ to chemotherapy has been shown to depend on the accumulation of ROS and may be potentially initiated by the induction of ferroptosis (Gentric et al., 2019). This result suggests that the BRAFi-mediated metabolic switch can make melanoma cells sensitive to ferroptosis inducers, and that SCL7A11 may be a biomarker of the vulnerability of metastatic MM cells to ferroptosis (Gagliardi et al., 2019). Accordingly, trametinib or vemurafenib decrease the expression of SLC7A11 in melanoma cells bearing $BRAF^{V600E}$ mutation (Osrodek et al., 2019).

Studies have also shown lipid metabolism reprogramming occurred in vemurafenib-treated melanoma cells, such as accumulation of PUFAs (Talebi et al., 2018). As an inhibitor targeting the mitochondrial complex I that impairs OXPHOS, BAY 87-2243 combined with vemurafenib inhibits tumor growth of melanoma *in vivo* (Schöckel et al., 2015), partially by inducing ferroptosis (Basit et al., 2017). The metabolic switch toward OXPHOS in melanoma cells can be further complicated by phenotypic alterations, i.e., bearing an acquired resistance to BRAFi and MEK inhibitors (MEKi), such as trametinib, cobimetinib, or binimetinib. Increased dependence on the glutamine metabolism has been shown to be related to acquisition of resistance since the resistance of melanoma cells to BRAFi promotes the synthesis of glucose-derived glutamate and an increase in GSH content (Khamari et al., 2018).

4.2 Ferroptosis evasion fuels tumors in MM

Inhibition of the synthesis of PL-PUFAs and LPO is one of mechanisms by which MM evades ferroptosis and enhances tumor development and metastasis. Recent studies have shown that evasion of ferroptosis (resistance to ferroptosis) through modulation of fatty acid metabolism accounts for cancer metastasis in MM. Before systemic metastasis through the blood, melanomas generally regionally metastasize through the lymphatic system. Melanoma cells in the lymphatic environment can evade ferroptosis, which enhances metastasis through the blood pathway (Ubellacker et al., 2020). The lymphatic environment, which has low levels of free iron as well as GSH and abundant levels of oleic acid (OA, a MUFA) in the lymphatic fluid, enhances evading ferroptosis *in vivo* (Ubellacker et al., 2020). OA suppresses ferroptosis in melanoma cells through MUFA-PL synthesis mediated by ACSL3, which displaces PUFAs from PLs (Ubellacker et al., 2020). Meanwhile, this lymphatic environment-mediated ferroptosis resistance increases subsequent survival of cancer cells during metastasis through the blood (Ubellacker et al., 2020).

Upregulation of ferroptosis defenses is another mechanism of MM tumors to evade ferroptosis, leading to promote tumorigenesis and metastasis. The Nrf2 functions as a master regulator of antioxidant defense and regulates the genes involved in GPX4-GSH-mediated ferroptosis defense, thereby promoting resistance to ferroptosis (Kerins and Ooi, 2018; Dodson et al., 2019; Kajarabille and Latunde-Dada, 2019; Qu et al., 2020; Lei et al., 2022). Strong activation of Nrf2 leads to an increased activity of pentose phosphate pathway that is implicated in the regeneration of GSH, and upregulation of SLC7A11 expression, which confers ferroptosis evasion and promotes tumor growth in drug-resistant MM cells (Khamari et al., 2018).

4.3 GPX4-dependent persister state confers therapy resistance

Increasing evidence has underscored the role of non-mutational mechanisms that confer resistance to cancer cells (Boumahdi and de Sauvage, 2020). Epithelial carcinoma cells can dedifferentiate to adopt a mesenchymal or mixed epithelial-mesenchymal (EM) phenotype, which is named as epithelial-mesenchymal plasticity (EMP) (Williams et al., 2019; Yang J. et al., 2020; Lambert and Weinberg, 2021). EMP is one of type of cancer cell plasticity that defines the ability of cancer cells to undergo dynamical and reversible changes between distinct phenotypical states, leading to the acquisition of cancer stemness properties, eventually resulting in resistance to therapy (Boumahdi and de Sauvage, 2020). Cancer cells with a mesenchymal state that usually become resistance to conventional therapies (i.e., apoptosis inducers) are strongly dependent on GPX4, which is related to upregulated expression of zinc finger E-box binding homeobox 1 (ZEB1) (Krebs et al., 2017). ZEB1 is a lipogenic factor and driver of epithelial-to-mesenchymal transition (EMT). Cancer cells in the mesenchymal state show enhanced PUFA-PL synthesis, possibly resulting from ZEB1-mediated upregulation of PPARγ, which ia a major regulator of lipid metabolism in liver (Viswanathan et al., 2017). High levels of ZEB1 increases cellular sensitivity to ferroptosis (Viswanathan et al., 2017). The enhanced PUFA-PL levels in MM cells can detoxify lipid peroxides dependent on GPX4 for survival, leading to the high vulnerability of these cancer cells to ferroptosis (Viswanathan et al., 2017). Persistent drug-resistant melanoma cells in a mesenchymal-like state have been shown to be highly vulnerable to GPX4 inhibition (Xu et al., 2019). GPX4 dependency makes melanoma cells derived from drug-resistant patients reliant on transforming growth factor beta (TGF-β) (Viswanathan et al., 2017). In addition, ablation of GPX4 induces chemoresistant A375 melanoma cell death, which can be reversed by ferrostatin-1, a ferroptosis inhibitor (Hangauer et al., 2017). In combination with dabrafenib and trametinib, ferrostatin-1 enhances tumor growth of xenografted mice bearing $A375^{GPX4-/-}$ cells, while ferrostatin-1 withdrawal results in inhibiting the growth of $GPX4^{-/-}$ tumors (Hangauer et al., 2017).

4.4 Cellular dedifferentiation status correlates with melanoma ferroptosis sensitivity

Cancer cellular dedifferentiation can drive cancer cell resistance to targeted therapy (Gupta et al., 2019). Particularly, MM cells highly maintain a plastic phenotype, possibly as a result of their origin from the neural crest, which contains a transient stem-cell-like embryonic cell population that can differentiate into various tissue types, including glia, neurons, or cartilage and endocrine cells (Sauka-Spengler and Bronner-Fraser, 2008). Dedifferentiation confers MM resistance to both inhibitors of BRAF and MAPK that are associated with loss of melanoma-specific transcription factor (MITF) (Khamari et al., 2018; Tsoi et al., 2018), which is the master regulator of melanocyte differentiation (Müller et al., 2014; Hugo et al., 2015). Furthermore, MITF downregulation has been shown to promote tumor growth and enhance immune evasion by facilitating the recruitment of immunosuppressive myeloid immune cells into the tumor microenvironment (Riesenberg et al., 2015). The sensitivity of cancer cells to ferroptosis can be dictated by dedifferentiation status, with a negative correlation between differentiation status and the vulnerability to ferroptosis in MM. BRAFi resistance-induced dedifferentiation confers the sensitivity of MM to RSL3 and erastin-induced ferroptosis. Meanwhile, GSH levels have been shown to be significantly related to the cell dedifferentiation stage (Tsoi et al., 2018), implying that GSH functions as a metabolic link between sensitivity to ferroptosis inducers and drug-associated dedifferentiation; this was confirmed by evidence showing that GSH supplementation can inhibit ferroptosis in MM (Tsoi et al., 2018). The cerebellar degeneration-related 1 antisense (CDR1as) functions as a new marker for differentiation status of MM cell, and ablation of CDR1as leads to the metastatic potential of MM (Hanniford et al., 2020). MM cells with high expression of CDR1as, which are marked by low level of microphthalmia-associated transcription factor and high level of the receptor tyrosine kinase AXL, have more sensitivity to inhibition of GPX4, thus inducing ferroptosis (Hanniford et al., 2020).

4.5 Other regulators of ferroptosis in MM

Several regulators working as non-canonical oncogenes are involved in the resistance of MM cells to ferroptosis. Erastin, a ferroptosis inducer, can upregulate the expression of oncogene NEDD4, a ubiquitin ligase(Wang et al., 2007; Yang Y. et al., 2020). Erastin induces ferroptosis through decreasing VDAC2/3 expression in a NEDD4-dependent manner, thereby inhibiting erastin-induced ferroptosis (Yang J. et al., 2020). The calcium/calmodulin dependent protein kinase 2 (CAMKK2), which plays a vital role in regulating intracellular calcium levels and signaling pathways, dictates the sensitivity of MM cells to ferroptosis (Wang H. et al., 2022). CAMKK2 negatively regulates ferroptosis through AMPK-dependently activating Nrf2 and suppressing LPO. CAMKK2 inhibition boosts the efficacy of anti-PD-1 immunotherapy and ferroptosis inducers by promoting ferroptosis through inhibition of the AMPK-Nrf2 pathway (Wang M. et al., 2022). These results suggest that targeting CAMKK2 can serve as a potential regimen for MM treatment by increasing the efficacy of ferroptosis inducers and immunotherapy. GPX4 has also been reported to support the activation of regulatory T (Treg) cells and prevent them from undergoing ferroptosis to suppress antitumor immunity in MM (Xu et al., 2021). T cell receptor/CD28 co-stimulation disturbs immune homeostasis devoid of affecting the survival of Treg cells in the steady state in GPX4-deficiency regulatory T cells (Treg), resulting in abberant accumulation of lipid peroxides, thereby leading to ferroptosis in Treg cells (Xu et al., 2021). Blocking iron availability and neutralizing lipid peroxides inhibits ferroptosis in GPX4-deficient Treg cells. GPX4 deficiency in Treg cells increases the production of mitochondrion-derived superoxide and interleukin-1β that promotes T helper 17 responses, thereby repressing tumor growth and concomitantly potentiating antitumor immunity (Xu et al., 2021). These results establish the vital role of GPX4 in inhibiting the ferroptosis of activated Treg cells, providing a potential therapeutic regimen to improve MM treatment (Xu et al., 2021). High expression of AXL in the majority of melanoma lymph node metastases limits treatment efficacy by promoting MM cell ability to a more aggressive mesenchymal phenotype switch from epithelial(Nyakas et al., 2022). The phospholipase A2 group VI (PLA2G6) was markedly upregulated in MM, and PLA2G6 silencing dramatically inhibited cell proliferation, migration and invasion associated with the ferroptosis (Wang S. et al., 2022). RSL3 and Erastin, the two ferroptosis inducers, can upregulate iron metabolism proteins, including transferrin receptor (TfR), ferritin heavy chain 1 (FTH1), and ferroportin (FPN) by inducing iron regulatory protein1 (IRP1) in MM cells. Ablation of IRP1 inhibits the erastin- and RSL3-induced ferroptosis. Overexpression of TfR and silencing FPN and FTH1 in IRP1 knockdown MM cells significantly enhances the ferroptosis induced by erastin and RSL3. These results suggest that IRP1 promotes erastin- and RSL3-mediated ferroptosis by regulating iron homeostasis (Yao et al., 2021). Sterol regulatory element-binding protein 2 (SREBP2), the master lipogenic regulator, directly upregulates the expression of the intracellular iron carrier transferrin (TF), which reduces the iron and LPO content to suppress ferroptosis and enhance the survival of circulating tumor cells (CTCs) and drug resistance (Hong et al., 2021). Increased lipogenesis mediated by SREBP2 directly upregulates the TF, reducing intracellular LIP, ROS, and LPO and thereby rendering MM resistance to ferroptosis inducers. This crosstalk between the lipogenic pathway and iron homeostasis accounts for therapeutic resistance and CTC-mediated tumorigenesis (Hong et al., 2021). Arginase 2 (Arg2) negatively regulates sorafenib-mediated ferroptosis in MM (Yu et al., 2022). Sorafenib induces melanoma cell death through decreasing expression of Arg2. Silencing Arg2 increases LPO and decreases the Akt phosphorylation. Conversely, overexpressing Arg2 reverses sorafenib-induced ferroptosis, which is inhibited by Akt inhibitor. Thus, inhibition of Arg2 can impair the anticancer efficiency of sorafenib in MM cells. These results suggests that Arg2 functions as a suppressor of ferroptosis through activating the Akt/GPX4 signaling pathway in melanoma cells (Yu et al., 2022).

4.6 The role of microRNAs in regulating ferroptosis in MM

MicroRNAs (miRNA) have been reported to regulate ferroptosis in MM (Luo et al., 2018). miR-137 inhibits ferroptosis by directly targeting SLC1A5, a glutamine transporter, in MM cells. Overexpression of miR-137 suppresses SLC1A5, resulting in decreased uptake of glutamine and accumulation of MDA (Luo et al., 2018). Silencing miR-137 increases the sensitivity of MM cells to RSL3-and erastin-induced ferroptosis, while knockdown of miR-137 boosts the antitumor efficiency of erastin by promoting ferroptosis (Luo et al., 2018). These results indicate that miR-137 negatively regulates ferroptosis through inhibition of glutaminolysis, highlighting a potential therapeutic target for MM (Luo et al., 2018). miR-9 has been shown to function as an inhibitor of ferroptosis through directly binding glutamicoxaloacetic transaminase 1 (GOT1), which catalyzes the conversion of glutamate to α-ketoglutarate. Overexpressed miR-9 directly binds to and suppresses GOT1, leading to inhibition of erastin- and RSL3-induced ferroptosis (Zhang et al., 2018). Silencing miR-9 promotes iron accumulation and LPO and increases the sensitivity of MM cells to erastin and RSL3, while inhibition of glutaminolysis abrogates anti-miR-9 mediated ferroptosis (Zhang et al., 2018). These findings reveal the important role of miRNA in regulating ferroptosis in MM. Increased expression of the lncRNA AGAP2-AS1 promotes tumorigenesis by promoting ferroptosis evasion through increased SLC7A11 mRNA stability by the m^{6}A modification in an IGF2BP2-dependent manner in MM (An et al., 2022). AGAP2-AS1 functions as an oncogene in MM, and its increased expression is known to be significantly associated with a poor prognosis (An et al., 2022). Silencing AGAP2-AS1 inhibits melanocytes growth through increasing erastin-mediated ferroptosis, which was reversed by the ferroptosis inhibitor Ferrostatin-1 (An et al., 2022).

5 Induction of ferroptosis as a novel approach to treat melanoma

Therapy-resistant cancer cells exhibit metabolic states, including but not limited to increased PL-PUFAs associated with EMT, that

influence the vulnerability of cancer cells to the induction of ferroptosis. Melanoma cells exhibit a vulnerability to ferroptosis, which may possibly result from increased accumulation of PUFAs and low levels of GSH (Tsoi et al., 2018). Intriguingly, drug-tolerant persister cancer cells or mesenchymal cancer cells resistance to therapyare vulnerable to ferroptosis, which is likely to be associated with their dependence on GPX4 function (Hangauer et al., 2017; Viswanathan et al., 2017). BRAFi treatment promotes dedifferentiation of MM cells, leading to increased susceptibility of these MM cells to ferroptosis (Tsoi et al., 2018). In this part, we emphasize the emerging types of small molecules that are capable of inducing ferroptosis pathways by boosting the antitumor activity of BRAFi, immunotherapy, and ferroptosis inducers and delineating their beneficial effects in treating MM. Finally, we summarize the application of nanosensitizer-mediated unique dynamic therapeutic strategies and ferroptosis-based nanodrug targeting strategies as therapeutic options for MM.

5.1 Small molecules targeting ferroptosis pathways

5.1.1 Boosting the antitumor activity of BRAFi

Targeted agents for BRAF-mutant MM have significantly improved the overall survival of patients with MM (Proietti et al., 2020; Poulikakos et al., 2022; Zhong et al., 2022). BRAFi as well as five combinations of BRAFi plus an additional agent(s) have been used to manage cancers such as melanoma (Poulikakos et al., 2022). However, since acquired resistance to targeted therapy is common and most patients show resistance to BRAF inhibitors (BRAFi), overcoming resistance to BRAFi is an unmet need and strategies to manage drug resistance are urgently required. Ferroptosis-inducing regimens have been shown to be one approach to overcome resistance to targeted therapy (Zhang et al., 2022). The AXL inhibitor (AXLi) BGB324 increases the sensitivity of A375 cells to the BRAF inhibitor (BRAFi) vemurafenib by stimulating ferroptosis and inhibiting autophagy, suggesting that a combination of AXLi with standard therapy is a promising approach to boost therapeutic outcomes in metastatic MM (Nyakas et al., 2022). Lipid metabolic reprogramming, one of the hallmarks of MM cells, has been shown to contribute to tumor resistance to targeted therapy (Vergani et al., 2022). MM cells show enhanced levels of stearoyl-CoA desaturase 1 (SCD1) and acetyl-CoA acetyltransferase 2 (ACAT2), resulting in resistance to BRAFi (Vergani et al., 2022). Thus, silencing ACAT2 can impair resistance to PLX4032. The acyl-CoA cholesterol acyl transferase (ACAT/SOAT) inhibitor avasimibe shows antiproliferative effects by boosting the antitumor activity of PLX4032/vemurafenib through induction of ferroptosis in MM (Vergani et al., 2022). High expression of AXL promotes the switch from an epithelial to a more aggressive mesenchymal phenotype in melanoma, limiting treatment efficacy. In this regard, the AXL inhibitor (AXLi) BGB324 can increase the sensitivity of A375 cells to the BRAF inhibitor (BRAFi) vemurafenib by inducing ferroptosis and apoptosis and inhibiting autophagy (Nyakas et al., 2022). *C. zeylanicum* essential oil (CINN-EO) has been shown to induce inhibition of cell growth by inducing ferroptosis. CINN-EO promotes the anti-melanoma effect of the mitochondria-targeting antineoplastic drugs tamoxifen and the BRAFi dabrafenib (Cappelli et al., 2023). Recent researches have revealed that sorafenib, the first multi-tyrosine kinase inhibitor to treat differentiated thyroid carcinoma, unresectable HCC, and advanced-stage renal cell carcinoma, induces ferroptosis (Hadian and Stockwell, 2020; Chen et al., 2021). Sorafenib also increases the sensitivity of MM cells to vemurafenib through inducing ferroptosis (Tang et al., 2020).

5.1.2 Boosting cancer immunotherapy

Over the last decade, anti-programmed cell death 1 (PD1) antibodies (Abs) and ICIs, in combination with or without another drugs such as anti-CTLA-4 Abs, have been widely used for the treatment of advanced and metastatic melanoma (Larkin et al., 2015; Larkin et al., 2019). Since anti-PD1 Abs can be used for treating advanced MM even without BRAF mutations, anti-PD1 Ab-based regimens to treat advanced MM have recently been developed (Fujimura et al., 2020). Through abrogation of CTLA-4 and PD-1, ICIs are currently the standard reference therapy in patients with advanced MM. Recent studies have shown that targeting Wnt/β-catenin signaling can boost the efficacy of anti-PD-1 immunotherapy in MM by exacerbating ferroptosis via regulation of MITF (Wang Y. et al., 2022). Induction of ferroptosis significantly inhibits Wnt/β-catenin signaling in MM, and the activation of Wnt/β-catenin signaling enhances the transcription of MITF, resulting in upregulation of the downstream peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and stearoyl-CoA desaturase (SCD1), which suppresses LPO to inhibit ferroptosis (Wang H. et al., 2022). Pharmacological inhibition of β-catenin by ICG001 promotes MM cell ferroptosis by increasing LPO both *in vitro* and *in vivo*. Pharmacologically inhibiting of β-catenin or MITF boosts antitumor activity of anti-PD-1 immunotherapy by promoting ferroptosis in a preclinical xenograft tumor model (Wang M. et al., 2022). These results suggest that targeting the Wnt/β-catenin-MITF pathway is a promising strategy to boost the efficacy of anti-PD-1 immunotherapy through potentiation of ferroptosis in MM.

5.1.3 Boosting the antitumor activity of ferroptosis inducers

Nrf2 is efficiently activated in resistant MM cells, leading to upregulation of the early ferroptosis marker ChaC glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1) and the aldo-keto reductase AKR1C1 ÷ 3 that degrades 12/15-LOX-mediated production of lipid peroxides to induce ferroptosis resistance. However, medroxyprogesterone (MPA), a pan-inhibitor of AKR1C1 ÷ 3, inhibits AKR activity/expression to completely enhance the susceptibility of resistant melanoma cells to ferroptosis induction (Gagliardi et al., 2019). These results indicate that the use of ferroptosis inducers coupled to AKR inhibitors can serve as a new regimen to efficiently kill MM cells.

5.1.4 Small molecules inducing ferroptosis

DET and DETD-35 trigger ferroptosis in PLX4032-sensitive (A375) and PLX4032-resistant (A375-R) BRAFV600E melanoma cells through inhibiting GPX4 via non-covalent binding (Chang et al., 2022). While lnc NEAT1 is known to be upregulated in

melanoma, downregulation of lnc NEAT1 induces ferroptosis through weakening of the direct binding to SLC7A11, indirectly resulting in inhibiting GPX4 and inducing ferroptosis. Gambogenic acid induces ferroptosis through downregulation of lnc NEAT1 (Wang S. et al., 2022). Gambogenic acid significantly inhibits migration, invasion, and EMT in MM cells through inducing ferroptosis via the p53/SLC7A11/GPX4 signaling pathway (Wang et al., 2020). Hyperforin inhibits cell growth by inducing apoptosis, autophagy, and ferroptosis through a reduction in GPX4 expression (Cardile et al., 2023). RSL3-induced cell death is fully reversed by ferrostatin-1 in A375 melanoma cells, indicating their high susceptibility to ferroptosis (Tyurina et al., 2023). RSL3 induces ferroptosis through inhibition of Wnt/β-catenin signaling (Wang Y. et al., 2022). Gallic acid increases the sensitivity of A375 cells to low-level laser through induction of apoptosis and ferroptosis (Khorsandi et al., 2020). Nobiletin exerts antitumor activity through inducing ferroptosis via downregulating GSK3β-mediated Keap1/Nrf2/HO-1 signaling pathway in human MM cells (Feng et al., 2022). Aridanin exhibits antitumor activity by inducing ferroptosis (Mbaveng et al., 2020). TX1-85-1, a small-molecule inhibitor targeting the ErbB3 signaling pathways, sensitizes melanomas to ferroptosis activators (Leu et al., 2022). Mycalols trigger ferroptosis through downregulation of GPX4 and upregulation of NCOA4 (Riccio et al., 2021). BAY 87-2243 stimulates autophagosome formation, mitophagy, and ROS generation, leading to the combined activation of necroptosis and ferroptosis (Basit et al., 2017).

5.2 Nano-based medicines targeting the ferroptosis pathway

5.2.1 Nanomaterial-based dynamic therapy to induce ferroptosis for melanoma treatment

Unique dynamic therapies mediated by nanosensitizers represent an effective tactic for the treatment of deep solid tumors (Sun et al., 2023). Multiple innovative dynamic-therapy strategies using nanosensitizers with unique physicochemical properties that respond to highly penetrating excitations to kill various deep-seated malignant tumors have been recently developed, including sonodynamic therapy (SDT) (Guo J. et al., 2022; Nowak et al., 2022; Yang et al., 2023), X-ray-induced photodynamic therapy (PDT) (Wang et al., 2016; Jiang et al., 2023; Kolarikova et al., 2023), and chemodynamic therapy (CDT) (Yu et al., 2021; Cao et al., 2022). EDN3-CPNPs carrying iron (EDN3-CPNPs) can boost the cancer cell-killing efficacy of ferroptosis-assisted CDT to over 80% at higher doses (Jasim and Gesquiere, 2019). Ir-PBT-BPA, which is formed by light irradiation of cyclometalated Ir(III) complexes, can produce superoxide anion radicals and singlet oxygen, which induce cell death by a combination of ferroptosis and ICD. Ir-PBT-BPA induces the depletion of regulatory T cells and immune response of CD_8^+ T cells while increasing the number of effector memory T cells, thereby achieving long-term antitumor immunity (Wang L. et al., 2023). PPIX-PSilQ NPs induce cell death through the induction of ferroptosis, as evidenced by increased production of ROS and LPO (Vadarevu et al., 2021). Mild photothermal therapy (mPTT, 42°C–45°C) has shown promising potential in tumor therapy with better biological effects and less side effects (He et al., 2023). Fe@OVA-IR820 induces Fe^{3+}-dependent ferroptosis-triggered ICD, which releases endogenous neoantigens and DAMPs that work synergistically with the exogenous antigen ovalbumin (OVA) to provoke an immune response. The photothermal effect of near-infrared irradiation further amplifies these immune responses (Ma G. et al., 2023). The increased recruitment and infiltration of T cells suppresses the primary tumor. The combination of Fe@OVA-IR820 nanovaccine with CTLA-4 checkpoint blockade significantly boosts anticancer immunity and halts the growth of distal simulated metastases (Ma S. et al., 2023). PDT promotes the sensitivity of MM cells to PTT by hampering the tumor microenvironment, whereas PTT-induced heat increases blood flow, improves the supply of oxygen, and boosts the therapeutic effects of PDT (Kong and Chen, 2022). The combination of PDT with PTT has been selected as a tumor-ablation regimen in various cancer indications. Au NRs/Cur/UCNPs@PBE activate both ferroptosis and apoptosis to achieve synergistic PDT/PTT. Au NR/Cur/UCNP@PBE-mediated combined PTT with PDT shows greater antitumor efficacy than other single treatments *in vivo* (Zhong et al., 2021).

5.2.2 Nanomaterials that induce ferroptosis for melanoma treatment

Nanotechnology provides new opportunities for tumor therapy through the induction of ferroptosis (Fei et al., 2020; Sepand et al., 2020; Wang G. et al., 2021; Li et al., 2021; Luo et al., 2021; Wu and Zhang, 2021; Zheng et al., 2021; Fernández-Acosta et al., 2022; Shi et al., 2022; Zeng et al., 2022; Liu K. et al., 2023; Liu Q. et al., 2023; Ma S. et al., 2023). This part presents approaches for harnessing nanomaterials to induce ferroptosis and kill cancer cells. MM.GW486, an exosome inhibitor with a ferroptosis inducer (iron ion), has been used in a hyaluronic acid (HA)-based nanoplatform (HGF-NPs). HGF-NPs inhibit exosomal PD-L1 and immunostimulation. HGF-enhanced tumor cellular ferroptosis. The combination of HGF with anti-PD-L1 immunotherapy has been shown to effectively inhibit MM metastasis (Wang Y. et al., 2021). The alpha melanocyte-stimulating hormone (αMSH) targets melanocortin-1 receptor (MC1-R), a surface receptor that is expressed on malignant MM cells (Miao et al., 2007). Kim et al., (2016) developed silica-based ultrasmall αMSH-PEG-C′ dots with a 6-nm diameter, in which silica-based particles with a Cy5-encapsulated fluorescent core and polyethylene glycol (PEG) coating and αMSH-modified exterior. These αMSH-PEG-C′ dots inhibited tumor growth by inducing ferroptosis. The inhibitor of ferroptosis, liproxstatin-1reverse αMSH-PEG-C′-mediated tumor growth inhibition, in tumor xenografts in mice (Kim et al., 2016). Jiang and others constructed a photosynthetic microcapsules (PMCs), which encapsulate cyanobacteria and upconversion nanoparticles in alginate microcapsules and are driven by external near-infrared photons. The combination of PMCs with X-rays induced ferroptosis in MM cells and xenografts, providing evidence for the development of lipid peroxidation, GPX4 suppression, Fe^{2+} release, and GSH reduction (Jiang et al., 2022). Consequently, the combined treatment overcame the intrinsic and acquired resistance to MM, thereby inhibiting metastases and improving the survival rate of melanoma-bearing mice (Jiang et al., 2022). Li et al., (2023)

constructed a nanoscale metal-organic framework (MOF) Cu-BTC as a carrier and loaded diethyldithiocarbamate (DDTC) through coordination interactions, i.e., Cu-BTC @DDTC. Cu-BTC@DDTC shows anticancer potential by inducing ferroptosis, especially in combination with low-dose cisplatin (Li et al., 2023). Upregulated miR-21-3p promotes IFN-γ-mediated ferroptosis by potentiating LPO in MM. miR-21-3p increases the sensitivity to ferroptosis by directly targeting thioredoxin reductase 1 (TXNRD1) to increase lipid ROS generation. Overexpressed miR-21-3p acts synergistically with anti-PD-1 antibody to promote ferroptosis in MM. miR-21-3p-loaded gold nanoparticles have been shown to boost the efficacy of anti-PD-1 antibodies without causing prominent side effects in a mouse model (Guo W. et al., 2022).

6 Conclusion and perspectives

This review presents the recent progress in our understanding of the role of ferroptosis in melanoma. Metabolic switch, GPX4-dependent persister state, cellular dedifferentiation status, and ferroptosis evasion dictate the sensitivity or resistance of melanoma to ferroptosis. Emerging evidence has confirmed the role of microRNAs in the regulation of ferroptosis in MM. Due to accumulation of PUFAs and low levels of GSH, MM cells show vulnerability to ferroptosis. Induction of ferroptosis is generally considered to be an effective approach to induce cell death in therapy-resistant MM cells. Small molecules targeting ferroptosis pathways can boost the antitumor activity of BRAFi and cancer immunotherapy. Meanwhile, nano-based medicines can induce the ferroptosis pathway in MM through dynamic therapy and nanomaterials that induce ferroptosis. However, these findings also highlight the need to understand the factors dictating the sensitivity of MM cells to ferroptosis, considering the substantial patient-to-patient variability in drug resistance mechanisms. In this scenario, identification of new molecular markers that correlate the phenotype of MM cells with vulnerability to induction of ferroptosis and identifying other regulators that control the acquisition of this phenotype should be the research directions in future studies. Relatively little is known about the process through which ferroptosis orchestrates diverse cellular events, and future research in MM should undoubtedly focus more on delineating the roles of additional potential regulators of ferroptosis, including hippo signaling, transsulfuration, mevalonate synthesis pathways, and iron metabolism. How current findings replicate across multiple MM models. Although some ferroptosis inducers have shown a safe profile in mice, a critical requirement is to translate these findings to human patients with MM to understand whether the same conclusions can be drawn for human patients as well. In addition, several small molecules have been identified as ferroptosis inducers in other cancers. Thus, these drugs may be repurposed for the treatment of MM. Therefore, continued exploration of the roles of ferroptosis in MM, and the relationship between ferroptosis and MM will facilitate the discovery of novel therapeutic strategies for MM.

Author contributions

NT: Writing—original draft, Visualization. XJ: Data curation. YZ: Writing—review and editing. HW: Conceptualization, Supervision, Funding acquisition. All authors contributed to the article and approved the submitted version.

Funding

This work was supported in part by the Natural Science Foundation of Inner Mongolia Autonomous Region (IMAR) (2022MS08046), Science Foundation of Universities of IMAR (NJZY23038), and Science Foundation of Inner Mongolia Key Laboratory of human genetic diseases (YC202305 and YC202304).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Abdullah, A. N., and Keczkes, K. (1989). Cutaneous and ocular side-effects of PUVA photochemotherapy-a 10-year follow-up study. *Clin. Exp. Dermatol.* 14, 421–424. doi:10.1111/j.1365-2230.1989.tb02602.x

Abildgaard, C., and Guldberg, P. (2015). Molecular drivers of cellular metabolic reprogramming in melanoma. *Trends Mol. Med.* 21, 164–171. doi:10.1016/j.molmed.2014.12.007

An, L., Huang, J., Ge, S., Zhang, X., and Wang, J. (2022). lncRNA AGAP2-AS1 facilitates tumorigenesis and ferroptosis resistance through SLC7A11 by IGF2BP2 pathway in melanoma. *Comput. Math. Methods Med.* 2022, 1972516. doi:10.1155/2022/1972516

Anestopoulos, I., Kyriakou, S., Tragkola, V., Paraskevaidis, I., Tzika, E., Mitsiogianni, M., et al. (2022). Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. *Pharmacol. Ther.* 240, 108301. doi:10.1016/j.pharmthera.2022.108301

Basit, F., van Oppen, L. M., Schöckel, L., Bossenbroek, H. M., van Emst-de Vries, S. E., Hermeling, J. C., et al. (2017). Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. *Cell Death Dis.* 8, e2716. doi:10.1038/cddis.2017.133

Bolick, N. L., and Geller, A. C. (2021). Epidemiology of melanoma. *Hematol. Oncol. Clin. North Am.* 35, 57–72. doi:10.1016/j.hoc.2020.08.011

Boumahdi, S., and de Sauvage, F. J. (2020). The great escape: Tumour cell plasticity in resistance to targeted therapy. *Nat. Rev. Drug Discov.* 19, 39–56. doi:10.1038/s41573-019-0044-1

Cao, C., Wang, X., Yang, N., Song, X., and Dong, X. (2022). Recent advances of cancer chemodynamic therapy based on Fenton/Fenton-like chemistry. *Chem. Sci.* 13, 863–889. doi:10.1039/d1sc05482a

Cappelli, G., Giovannini, D., Vilardo, L., Basso, A., Iannetti, I., Massa, M., et al. (2023). Cinnamomum zeylanicum blume essential oil inhibits metastatic melanoma cell proliferation by triggering an incomplete tumour cell stress response. *Int. J. Mol. Sci.* 24, 5698. doi:10.3390/ijms24065698

Cardile, A., Zanrè, V., Campagnari, R., Asson, F., Addo, S. S., Orlandi, E., et al. (2023). Hyperforin elicits cytostatic/cytotoxic activity in human melanoma cell lines, inhibiting pro-survival NF-κB, STAT3, AP1 transcription factors and the expression of functional proteins involved in mitochondrial and cytosolic metabolism. *Int. J. Mol. Sci.* 24, 1263. doi:10.3390/ijms24021263

Carr, S., Smith, C., and Wernberg, J. (2020). Epidemiology and risk factors of melanoma. *Surg. Clin. North Am.* 100, 1–12. doi:10.1016/j.suc.2019.09.005

Chang, M. T., Tsai, L. C., Nakagawa-Goto, K., Lee, K. H., and Shyur, L. F. (2022). Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming. *Pharmacol. Res.* 178, 106148. doi:10.1016/j.phrs.2022.106148

Chen, X., Kang, R., Kroemer, G., and Tang, D. (2021). Broadening horizons: The role of ferroptosis in cancer. *Nat. Rev. Clin. Oncol.* 18, 280–296. doi:10.1038/s41571-020-00462-0

Conrad, M., and Pratt, D. A. (2019). The chemical basis of ferroptosis. *Nat. Chem. Biol.* 15, 1137–1147. doi:10.1038/s41589-019-0408-1

DeMatos, P., Tyler, D. S., and Seigler, H. F. (1998). Malignant melanoma of the mucous membranes: A review of 119 cases. *Ann. Surg. Oncol.* 5, 733–742. doi:10.1007/BF02303485

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., et al. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. *Cell* 149, 1060–1072. doi:10.1016/j.cell.2012.03.042

Dixon, S. J., and Pratt, D. A. (2023). Ferroptosis: A flexible constellation of related biochemical mechanisms. *Mol. Cell* 83, 1030–1042. doi:10.1016/j.molcel.2023.03.005

Dodson, M., Castro-Portuguez, R., and Zhang, D. D. (2019). NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. *Redox Biol.* 23, 101107. doi:10.1016/j.redox.2019.101107

Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. *Nat. Chem. Biol.* 13, 91–98. doi:10.1038/nchembio.2239

Fei, W., Zhang, Y., Ye, Y., Li, C., Yao, Y., Zhang, M., et al. (2020). Bioactive metal-containing nanomaterials for ferroptotic cancer therapy. *J. Mater Chem. B* 8, 10461–10473. doi:10.1039/d0tb02138e

Feng, S., Zhou, Y., Huang, H., Lin, Y., Zeng, Y., Han, S., et al. (2022). Nobiletin induces ferroptosis in human skin melanoma cells through the gsk3β-mediated keap1/nrf2/HO-1 signalling pathway. *Front. Genet.* 13, 865073. doi:10.3389/fgene.2022.865073

Fernández-Acosta, R., Iriarte-Mesa, C., Alvarez-Alminaque, D., Hassannia, B., Wiernicki, B., Díaz-García, A. M., et al. (2022). Novel iron oxide nanoparticles induce ferroptosis in a panel of cancer cell lines. *Molecules* 27, 3970. doi:10.3390/molecules27133970

Forsea, A. M. (2020). Melanoma epidemiology and early detection in europe: Diversity and disparities. *Dermatol Pract. Concept* 10, e2020033. doi:10.5826/dpc.1003a33

Fujimura, T., Kambayashi, Y., Ohuchi, K., Muto, Y., and Aiba, S. (2020). Treatment of advanced melanoma: Past, present and future. *Life (Basel)* 10, 208. doi:10.3390/life10090208

Gagliardi, M., Cotella, D., Santoro, C., Corà, D., Barlev, N. A., Piacentini, M., et al. (2019). Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. *Cell Death Dis.* 10, 902. doi:10.1038/s41419-019-2143-7

Gaschler, M. M., and Stockwell, B. R. (2017). Lipid peroxidation in cell death. *Biochem. Biophys. Res. Commun.* 482, 419–425. doi:10.1016/j.bbrc.2016.10.086

Gentric, G., Kieffer, Y., Mieulet, V., Goundiam, O., Bonneau, C., Nemati, F., et al. (2019). PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers. *Cell Metab.* 29, 156–173. doi:10.1016/j.cmet.2018.09.002

Guo, J., Pan, X., Wang, C., and Liu, H. (2022a). Molecular imaging-guided sonodynamic therapy. *Bioconjug. Chem.* 33, 993–1010. doi:10.1021/acs.bioconjchem.1c00288

Guo, J., Xu, B., Han, Q., Zhou, H., Xia, Y., Gong, C., et al. (2018). Ferroptosis: A novel anti-tumor action for cisplatin. *Cancer Res. Treat.* 50, 445–460. doi:10.4143/crt.2016.572

Guo, W., Wu, Z., Chen, J., Guo, S., You, W., Wang, S., et al. (2022b). Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis. *J. Immunother. Cancer* 10, e004381. doi:10.1136/jitc-2021-004381

Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., and Kuperwasser, C. (2019). Phenotypic plasticity: Driver of cancer initiation, progression, and therapy resistance. *Cell Stem Cell* 24, 65–78. doi:10.1016/j.stem.2018.11.011

Hadian, K., and Stockwell, B. R. (2020). SnapShot: Ferroptosis. *Cell* 181, 1188–1188.e1. doi:10.1016/j.cell.2020.04.039

Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., et al. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. *Nature* 551, 247–250. doi:10.1038/nature24297

Hanniford, D., Ulloa-Morales, A., Karz, A., Berzoti-Coelho, M. G., Moubarak, R. S., Sánchez-Sendra, B., et al. (2020). Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis. *Cancer Cell* 37, 55–70. doi:10.1016/j.ccell.2019.12.007

Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., et al. (2013). Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. *Cancer Cell* 23, 302–315. doi:10.1016/j.ccr.2013.02.003

He, X., Zhang, S., Tian, Y., Cheng, W., and Jing, H. (2023). Research progress of nanomedicine-based mild photothermal therapy in tumor. *Int. J. Nanomedicine* 18, 1433–1468. doi:10.2147/IJN.S405020

Hong, X., Roh, W., Sullivan, R. J., Wong, K., Wittner, B. S., Guo, H., et al. (2021). The lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis. *Cancer Discov.* 11, 678–695. doi:10.1158/2159-8290.CD-19-1500

Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., et al. (2015). Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. *Cell* 162, 1271–1285. doi:10.1016/j.cell.2015.07.061

Jasim, K. A., and Gesquiere, A. J. (2019). Ultrastable and biofunctionalizable conjugated polymer nanoparticles with encapsulated iron for ferroptosis assisted chemodynamic therapy. *Mol. Pharm.* 16, 4852–4866. doi:10.1021/acs.molpharmaceut.9b00737

Jiang, J., Wang, W., Zheng, H., Chen, X., Liu, X., Xie, Q., et al. (2022). Nano-enabled photosynthesis in tumours to activate lipid peroxidation for overcoming cancer resistances. *Biomaterials* 285, 121561. doi:10.1016/j.biomaterials.2022.121561

Jiang, W., Liang, M., Lei, Q., Li, G., and Wu, S. (2023). The current status of photodynamic therapy in cancer treatment. *Cancers (Basel)* 15, 585. doi:10.3390/cancers15030585

Kagan, V. E., Mao, G., Qu, F., Angeli, J. P., Doll, S., Croix, C. S., et al. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. *Nat. Chem. Biol.* 13, 81–90. doi:10.1038/nchembio.2238

Kajarabille, N., and Latunde-Dada, G. O. (2019). Programmed cell-death by ferroptosis: Antioxidants as mitigators. *Int. J. Mol. Sci.* 20, 4968. doi:10.3390/ijms20194968

Kalal, B. S., Upadhya, D., and Pai, V. R. (2017). Chemotherapy resistance mechanisms in advanced skin cancer. *Oncol. Rev.* 11, 326. doi:10.4081/oncol.2017.326

Kerins, M. J., and Ooi, A. (2018). The roles of NRF2 in modulating cellular iron homeostasis. *Antioxid. Redox Signal.* 29, 1756–1773. doi:10.1089/ars.2017.7176

Khamari, R., Trinh, A., Gabert, P. E., Corazao-Rozas, P., Riveros-Cruz, S., Balayssac, S., et al. (2018). Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. *Cell Death Dis.* 9, 325. doi:10.1038/s41419-018-0340-4

Khorsandi, K., Kianmehr, Z., Hosseinmardi, Z., and Hosseinzadeh, R. (2020). Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis. *Cancer Cell Int.* 20, 18. doi:10.1186/s12935-020-1100-y

Kim, S. E., Zhang, L., Ma, K., Riegman, M., Chen, F., Ingold, I., et al. (2016). Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. *Nat. Nanotechnol.* 11, 977–985. doi:10.1038/nnano.2016.164

Kolarikova, M., Hosikova, B., Dilenko, H., Barton-Tomankova, K., Valkova, L., Bajgar, R., et al. (2023). Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments. *Med. Res. Rev.* 43, 717–774. doi:10.1002/med.21935

Kong, C., and Chen, X. (2022). Combined photodynamic and photothermal therapy and immunotherapy for cancer treatment: A review. *Int. J. Nanomedicine* 17, 6427–6446. doi:10.2147/IJN.S388996

Koppula, P., Zhuang, L., and Gan, B. (2021). Cytochrome P450 reductase (POR) as a ferroptosis fuel. *Protein Cell* 12, 675–679. doi:10.1007/s13238-021-00823-0

Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., et al. (2017). The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. *Nat. Cell Biol.* 19, 518–529. doi:10.1038/ncb3513

Lambert, A. W., and Weinberg, R. A. (2021). Linking EMT programmes to normal and neoplastic epithelial stem cells. *Nat. Rev. Cancer* 21, 325–338. doi:10.1038/s41568-021-00332-6

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., et al. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N. Engl. J. Med.* 373, 23–34. doi:10.1056/NEJMoa1504030

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., et al. (2019). Five-Year survival with combined nivolumab and ipilimumab in advanced melanoma. *N. Engl. J. Med.* 381, 1535–1546. doi:10.1056/NEJMoa1910836

Lei, G., Mao, C., Yan, Y., Zhuang, L., and Gan, B. (2021). Ferroptosis, radiotherapy, and combination therapeutic strategies. *Protein Cell* 12, 836–857. doi:10.1007/s13238-021-00841-y

Lei, G., Zhuang, L., and Gan, B. (2022). Targeting ferroptosis as a vulnerability in cancer. *Nat. Rev. Cancer* 22, 381–396. doi:10.1038/s41568-022-00459-0

Leu, J. I., Murphy, M. E., and George, D. L. (2022). Targeting ErbB3 and cellular NADPH/NADP(+) abundance sensitizes cutaneous melanomas to ferroptosis inducers. *ACS Chem. Biol.* 17, 1038–1044. doi:10.1021/acschembio.2c00113

Li, C., Zhou, S., Chen, C., Zhu, L., Li, S., Song, Z., et al. (2023). DDTC-Cu(I) based metal-organic framework (MOF) for targeted melanoma therapy by inducing SLC7A11/GPX4-mediated ferroptosis. *Colloids Surf. B Biointerfaces* 225, 113253. doi:10.1016/j.colsurfb.2023.113253

Li, Y., Wei, X., Tao, F., Deng, C., Lv, C., Chen, C., et al. (2021). The potential application of nanomaterials for ferroptosis-based cancer therapy. *Biomed. Mater* 16, 042013. doi:10.1088/1748-605X/ac058a

Liu, K., Huang, L., Qi, S., Liu, S., Xie, W., Du, L., et al. (2023a). Ferroptosis: The entanglement between traditional drugs and nanodrugs in tumor therapy. *Adv. Healthc. Mater* 12, e2203085. doi:10.1002/adhm.202203085

Liu, Q., Zhao, Y., Zhou, H., and Chen, C. (2023b). Ferroptosis: Challenges and opportunities for nanomaterials in cancer therapy. *Regen. Biomater.* 10, rbad004. doi:10.1093/rb/rbad004

Lu, B., Chen, X. B., Ying, M. D., He, Q. J., Cao, J., and Yang, B. (2017). The role of ferroptosis in cancer development and treatment response. *Front. Pharmacol.* 8, 992. doi:10.3389/fphar.2017.00992

Luo, L., Wang, H., Tian, W., Li, X., Zhu, Z., Huang, R., et al. (2021). Targeting ferroptosis-based cancer therapy using nanomaterials: Strategies and applications. *Theranostics* 11, 9937–9952. doi:10.7150/thno.65480

Luo, M., Wu, L., Zhang, K., Wang, H., Zhang, T., Gutierrez, L., et al. (2018). miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. *Cell Death Differ.* 25, 1457–1472. doi:10.1038/s41418-017-0053-8

Ma, G., Wang, K., Pang, X., Xu, S., Gao, Y., Liang, Y., et al. (2023a). Self-assembled nanomaterials for ferroptosis-based cancer theranostics. *Biomater. Sci.* 11, 1962–1980. doi:10.1039/d2bm02000a

Ma, S., Liang, X., Yang, N., Yang, J., Zhang, J., Pan, X., et al. (2023b). Boosting cancer immunotherapy by biomineralized nanovaccine with ferroptosis-inducing and photothermal properties. *Biomater. Sci.* 11, 518–532. doi:10.1039/d2bm01126c

Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., and Lisanti, M. P. (2017). Cancer metabolism: A therapeutic perspective. *Nat. Rev. Clin. Oncol.* 14, 11–31. doi:10.1038/nrclinonc.2016.60

Mbaveng, A. T., Chi, G. F., Bonsou, I. N., Abdelfatah, S., Tamfu, A. N., Yeboah, E., et al. (2020). N-acetylglycoside of oleanolic acid (aridanin) displays promising cytotoxicity towards human and animal cancer cells, inducing apoptotic, ferroptotic and necroptotic cell death. *Phytomedicine* 76, 153261. doi:10.1016/j.phymed.2020.153261

Memon, A., Bannister, P., Rogers, I., Sundin, J., Al-Ayadhy, B., James, P. W., et al. (2021). Changing epidemiology and age-specific incidence of cutaneous malignant melanoma in England: An analysis of the national cancer registration data by age, gender and anatomical site, 1981-2018. *Lancet Reg. Health Eur.* 2, 100024. doi:10.1016/j.lanepe.2021.100024

Miao, Y., Benwell, K., and Quinn, T. P. (2007). 99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. *J. Nucl. Med.* 48, 73–80.

Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., et al. (2014). Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. *Nat. Commun.* 5, 5712. doi:10.1038/ncomms6712

Nicolaides, P., Newton, R. W., and Kelsey, A. (1995). Primary malignant melanoma of meninges: Atypical presentation of subacute meningitis. *Pediatr. Neurol.* 12, 172–174. doi:10.1016/0887-8994(94)00155-u

Nowak, K. M., Schwartz, M. R., Breza, V. R., and Price, R. J. (2022). Sonodynamic therapy: Rapid progress and new opportunities for non-invasive tumor cell killing with sound. *Cancer Lett.* 532, 215592. doi:10.1016/j.canlet.2022.215592

Nyakas, M., Fleten, K. G., Haugen, M. H., Engedal, N., Sveen, C., Farstad, I. N., et al. (2022). AXL inhibition improves BRAF-targeted treatment in melanoma. *Sci. Rep.* 12, 5076. doi:10.1038/s41598-022-09078-z

Osrodek, M., Hartman, M. L., and Czyz, M. (2019). Physiologically relevant oxygen concentration (6% O(2)) as an important component of the microenvironment impacting melanoma phenotype and melanoma response to targeted therapeutics *in vitro*. *Int. J. Mol. Sci.* 20, 4203. doi:10.3390/ijms20174203

Pastwińska, J., Karaś, K., Karwaciak, I., and Ratajewski, M. (2022). Targeting EGFR in melanoma - the sea of possibilities to overcome drug resistance. *Biochim. Biophys. Acta Rev. Cancer* 1877, 188754. doi:10.1016/j.bbcan.2022.188754

Poulikakos, P. I., Sullivan, R. J., and Yaeger, R. (2022). Molecular pathways and mechanisms of BRAF in cancer therapy. *Clin. Cancer Res.* 28, 4618–4628. doi:10.1158/1078-0432.CCR-21-2138

Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., et al. (2020). Mechanisms of acquired BRAF inhibitor resistance in melanoma: A systematic review. *Cancers (Basel)* 12, 2801. doi:10.3390/cancers12102801

Qiu, Y., Cao, Y., Cao, W., Jia, Y., and Lu, N. (2020). The application of ferroptosis in diseases. *Pharmacol. Res.* 159, 104919. doi:10.1016/j.phrs.2020.104919

Qu, Z., Sun, J., Zhang, W., Yu, J., and Zhuang, C. (2020). Transcription factor NRF2 as a promising therapeutic target for Alzheimer's disease. *Free Radic. Biol. Med.* 159, 87–102. doi:10.1016/j.freeradbiomed.2020.06.028

Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., et al. (2017). Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. *NPJ Genom Med.* 2, 10. doi:10.1038/s41525-017-0013-8

Riccio, G., Nuzzo, G., Zazo, G., Coppola, D., Senese, G., Romano, L., et al. (2021). Bioactivity screening of antarctic sponges reveals anticancer activity and potential cell death via ferroptosis by mycalols. *Mar. Drugs* 19, 459. doi:10.3390/md19080459

Riesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., et al. (2015). MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. *Nat. Commun.* 6, 8755. doi:10.1038/ncomms9755

Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., and Barsouk, A. (2021). Epidemiology of melanoma. *Med. Sci. (Basel, Switz.* 9, 63. doi:10.3390/medsci9040063

Sauka-Spengler, T., and Bronner-Fraser, M. (2008). A gene regulatory network orchestrates neural crest formation. *Nat. Rev. Mol. Cell Biol.* 9, 557–568. doi:10.1038/nrm2428

Schöckel, L., Glasauer, A., Basit, F., Bitschar, K., Truong, H., Erdmann, G., et al. (2015). Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. *Cancer Metab.* 3, 11. doi:10.1186/s40170-015-0138-0

Sepand, M. R., Ranjbar, S., Kempson, I. M., Akbariani, M., Muganda, W., Müller, M., et al. (2020). Targeting non-apoptotic cell death in cancer treatment by nanomaterials: Recent advances and future outlook. *Nanomedicine* 29, 102243. doi:10.1016/j.nano.2020.102243

Shah, R., Shchepinov, M. S., and Pratt, D. A. (2018). Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. *ACS Cent. Sci.* 4, 387–396. doi:10.1021/acscentsci.7b00589

Shi, Z., Zheng, J., Tang, W., Bai, Y., Zhang, L., Xuan, Z., et al. (2022). Multifunctional nanomaterials for ferroptotic cancer therapy. *Front. Chem.* 10, 868630. doi:10.3389/fchem.2022.868630

Sun, W., Chu, C., Li, S., Ma, X., Liu, P., Chen, S., et al. (2023). Nanosensitizer-mediated unique dynamic therapy tactics for effective inhibition of deep tumors. *Adv. Drug Deliv. Rev.* 192, 114643. doi:10.1016/j.addr.2022.114643

Talebi, A., Dehairs, J., Rambow, F., Rogiers, A., Nittner, D., Derua, R., et al. (2018). Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. *Nat. Commun.* 9, 2500. doi:10.1038/s41467-018-04664-0

Tang, F., Li, S., Liu, D., Chen, J., and Han, C. (2020). Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis. *Transl. Cancer Res.* 9, 1584–1593. doi:10.21037/tcr.2020.01.62

Thornton, C., Brennan, F., Hawkins, S. A., and Allen, I. V. (1988). Primary malignant melanoma of the meninges. *Clin. Neuropathol.* 7, 244–248.

Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., et al. (2018). Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. *Cancer Cell* 33, 890–904. doi:10.1016/j.ccell.2018.03.017

Tucker, M. A. (2009). Melanoma epidemiology. *Hematol. Oncol. Clin. North Am.* 23, 383–395. doi:10.1016/j.hoc.2009.03.010

Tyrell, R., Antia, C., Stanley, S., and Deutsch, G. B. (2017). Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. *Melanoma Manag.* 4, 61–68. doi:10.2217/mmt-2016-0018

Tyurina, Y. Y., Kapralov, A. A., Tyurin, V. A., Shurin, G., Amoscato, A. A., Rajasundaram, D., et al. (2023). Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells *in vitro* and *in vivo*. *Redox Biol.* 61, 102650. doi:10.1016/j.redox.2023.102650

Ubellacker, J. M., Tasdogan, A., Ramesh, V., Shen, B., Mitchell, E. C., Martin-Sandoval, M. S., et al. (2020). Lymph protects metastasizing melanoma cells from ferroptosis. *Nature* 585, 113–118. doi:10.1038/s41586-020-2623-z

Vadarevu, H., Juneja, R., Lyles, Z., and Vivero-Escoto, J. L. (2021). Light-activated protoporphyrin IX-based polysilsesquioxane nanoparticles induce ferroptosis in melanoma cells. *Nanomater. (Basel)* 11, 2324. doi:10.3390/nano11092324

Vergani, E., Beretta, G. L., Aloisi, M., Costantino, M., Corno, C., Frigerio, S., et al. (2022). Targeting of the lipid metabolism impairs resistance to BRAF kinase inhibitor in melanoma. *Front. Cell Dev. Biol.* 10, 927118. doi:10.3389/fcell.2022.927118

Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., et al. (2017). Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. *Nature* 547, 453–457. doi:10.1038/nature23007

Wagstaff, W., Mwamba, R. N., Grullon, K., Armstrong, M., Zhao, P., Hendren-Santiago, B., et al. (2022). Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance. *Genes Dis.* 9, 1608–1623. doi:10.1016/j.gendis.2022.04.004

Wang, G. D., Nguyen, H. T., Chen, H., Cox, P. B., Wang, L., Nagata, K., et al. (2016). X-ray induced photodynamic therapy: A combination of radiotherapy and photodynamic therapy. *Theranostics* 6, 2295–2305. doi:10.7150/thno.16141

Wang, G., Xie, L., Li, B., Sang, W., Yan, J., Li, J., et al. (2021a). A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis. *Nat. Commun.* 12, 5733. doi:10.1038/s41467-021-25990-w

Wang, H., Zhang, H., Chen, Y., Wang, H., Tian, Y., Yi, X., et al. (2022a). Targeting wnt/β-catenin signaling exacerbates ferroptosis and increases the efficacy of melanoma immunotherapy via the regulation of MITF. *Cells* 11, 3580. doi:10.3390/cells11223580

Wang, L., Karges, J., Wei, F., Xie, L., Chen, Z., Gasser, G., et al. (2023a). A mitochondria-localized iridium(iii) photosensitizer for two-photon photodynamic immunotherapy against melanoma. *Chem. Sci.* 14, 1461–1471. doi:10.1039/d2sc06675k

Wang, M., Cheng, H., Wu, H., Liu, C., Li, S., Li, B., et al. (2022b). Gambogenic acid antagonizes the expression and effects of long non-coding RNA NEAT1 and triggers autophagy and ferroptosis in melanoma. *Biomed. Pharmacother.* 154, 113636. doi:10.1016/j.biopha.2022.113636

Wang, M., Li, S., Wang, Y., Cheng, H., Su, J., and Li, Q. (2020). Gambogenic acid induces ferroptosis in melanoma cells undergoing epithelial-to-mesenchymal transition. *Toxicol. Appl. Pharmacol.* 401, 115110. doi:10.1016/j.taap.2020.115110

Wang, S., Yi, X., Wu, Z., Guo, S., Dai, W., Wang, H., et al. (2022c). CAMKK2 defines ferroptosis sensitivity of melanoma cells by regulating AMPK–NRF2 pathway. *J. Invest. Dermatol.* 142, 189–200.e8. doi:10.1016/j.jid.2021.05.025

Wang, X., Trotman, L. C., Koppie, T., Alimonti, A., Chen, Z., Gao, Z., et al. (2007). NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. *Cell* 128, 129–139. doi:10.1016/j.cell.2006.11.039

Wang, Y., Liu, T., Li, X., Sheng, H., Ma, X., and Hao, L. (2021b). Ferroptosis-inducing nanomedicine for cancer therapy. *Front. Pharmacol.* 12, 735965. doi:10.3389/fphar.2021.735965

Wang, Y., Song, H., Miao, Q., Wang, Y., Qi, J., Xu, X., et al. (2022d). PLA2G6 silencing suppresses melanoma progression and affects ferroptosis revealed by quantitative proteomics. *Front. Oncol.* 12, 819235. doi:10.3389/fonc.2022.819235

Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., et al. (2023b). Overcoming cancer chemotherapy resistance by the induction of ferroptosis. *Drug resist. updat.* 66, 100916. doi:10.1016/j.drup.2022.100916

Wenzel, S. E., Tyurina, Y. Y., Zhao, J., St Croix, C. M., Dar, H. H., Mao, G., et al. (2017). PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. *Cell* 171, 628–641. doi:10.1016/j.cell.2017.09.044

Williams, E. D., Gao, D., Redfern, A., and Thompson, E. W. (2019). Controversies around epithelial-mesenchymal plasticity in cancer metastasis. *Nat. Rev. Cancer* 19, 716–732. doi:10.1038/s41568-019-0213-x

Wolpaw, A. J., and Dang, C. V. (2018). Exploiting metabolic vulnerabilities of cancer with precision and accuracy. *Trends Cell Biol.* 28, 201–212. doi:10.1016/j.tcb.2017.11.006

Wu, X., and Zhang, H. (2021). Therapeutic strategies of iron-based nanomaterials for cancer therapy. *Biomed. Mater* 16, 032003. doi:10.1088/1748-605X/abd0c4

Xu, C., Sun, S., Johnson, T., Qi, R., Zhang, S., Zhang, J., et al. (2021). The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. *Cell Rep.* 35, 109235. doi:10.1016/j.celrep.2021.109235

Xu, T., Ding, W., Ji, X., Ao, X., Liu, Y., Yu, W., et al. (2019). Molecular mechanisms of ferroptosis and its role in cancer therapy. *J. Cell. Mol. Med.* 23, 4900–4912. doi:10.1111/jcmm.14511

Yan, B., Ai, Y., Sun, Q., Ma, Y., Cao, Y., Wang, J., et al. (2021). Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. *Mol. Cell* 81, 355–369.e10. doi:10.1016/j.molcel.2020.11.024

Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., et al. (2020a). Guidelines and definitions for research on epithelial-mesenchymal transition. *Nat. Rev. Mol. Cell Biol.* 21, 341–352. doi:10.1038/s41580-020-0237-9

Yang, W. S., Kim, K. J., Gaschler, M. M., Patel, M., Shchepinov, M. S., and Stockwell, B. R. (2016). Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. *Proc. Natl. Acad. Sci. U.S.A.* 113, E4966–E4975. doi:10.1073/pnas.1603244113

Yang, Y., Huang, J., Liu, M., Qiu, Y., Chen, Q., Zhao, T., et al. (2023). Emerging sonodynamic therapy-based nanomedicines for cancer immunotherapy. *Adv. Sci. (Weinh)* 10, e2204365. doi:10.1002/advs.202204365

Yang, Y., Luo, M., Zhang, K., Zhang, J., Gao, T., Connell, D. O., et al. (2020b). Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. *Nat. Commun.* 11, 433. doi:10.1038/s41467-020-14324-x

Yao, F., Cui, X., Zhang, Y., Bei, Z., Wang, H., Zhao, D., et al. (2021). Iron regulatory protein 1 promotes ferroptosis by sustaining cellular iron homeostasis in melanoma. *Oncol. Lett.* 22, 657. doi:10.3892/ol.2021.12918

Yu, Y., Ren, Y., Wang, C., Li, Z., Niu, F., Li, Z., et al. (2022). Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma. *Acta Biochim. Biophys. Sin. (Shanghai)* 54, 1658–1670. doi:10.3724/abbs.2022166

Yu, Z., Hu, Y., Sun, Y., and Sun, T. (2021). Chemodynamic therapy combined with multifunctional nanomaterials and their applications in tumor treatment. *Chemistry* 27, 13953–13960. doi:10.1002/chem.202101514

Zeng, Q., Ma, X., Song, Y., Chen, Q., Jiao, Q., and Zhou, L. (2022). Targeting regulated cell death in tumor nanomedicines. *Theranostics* 12, 817–841. doi:10.7150/thno.67932

Zhang, C., Liu, X., Jin, S., Chen, Y., and Guo, R. (2022). Ferroptosis in cancer therapy: A novel approach to reversing drug resistance. *Mol. Cancer* 21, 47. doi:10.1186/s12943-022-01530-y

Zhang, K., Wu, L., Zhang, P., Luo, M., Du, J., Gao, T., et al. (2018). miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma. *Mol. Carcinog.* 57, 1566–1576. doi:10.1002/mc.22878

Zheng, H., Jiang, J., Xu, S., Liu, W., Xie, Q., Cai, X., et al. (2021). Nanoparticle-induced ferroptosis: Detection methods, mechanisms and applications. *Nanoscale* 13, 2266–2285. doi:10.1039/d0nr08478f

Zhong, J., Yan, W., Wang, C., Liu, W., Lin, X., Zou, Z., et al. (2022). BRAF inhibitor resistance in melanoma: Mechanisms and alternative therapeutic strategies. *Curr. Treat. Options Oncol.* 23, 1503–1521. doi:10.1007/s11864-022-01006-7

Zhong, Y., Zhang, X., Yang, L., Liang, F., Zhang, J., Jiang, Y., et al. (2021). Hierarchical dual-responsive cleavable nanosystem for synergetic photodynamic/photothermal therapy against melanoma. *Mater Sci. Eng. C Mater Biol. Appl.* 131, 112524. doi:10.1016/j.msec.2021.112524

Zou, Y., Li, H., Graham, E. T., Deik, A. A., Eaton, J. K., Wang, W., et al. (2020). Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. *Nat. Chem. Biol.* 16, 302–309. doi:10.1038/s41589-020-0472-6

frontiers | Frontiers in Oncology

TYPE Case Report
PUBLISHED 20 September 2023
DOI 10.3389/fonc.2023.1276729

OPEN ACCESS

EDITED BY
Mohammed Kashani-Sabet,
California Pacific Medical Center,
United States

REVIEWED BY
Pierre-Yves Desprez,
California Pacific Medical Center Research Institute, United States
Sekwon Jang,
Inova Schar Cancer Institute, United States

*CORRESPONDENCE
George Ansstas
gasnsstas@wustl.edu

RECEIVED 12 August 2023
ACCEPTED 06 September 2023
PUBLISHED 20 September 2023

CITATION
Khaddour K, Zhou A, Butt O, Huang J and Ansstas G (2023) Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma.
Front. Oncol. 13:1276729.
doi: 10.3389/fonc.2023.1276729

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma

Karam Khaddour[1], Alice Zhou[2], Omar Butt[2], Jiayi Huang[3] and George Ansstas[2*]

[1]Division of Hematology and Oncology, University of Illinois Chicago, Chicago, IL, United States, [2]Department of Medicine, Division of Medical Oncology, Washington University in Saint Louis-Division of Medical Oncology, Saint Louis, MO, United States, [3]Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, United States

Oligometastatic progression represents a unique manifestation of tumor immune-escape that can lead to disease progression during treatment with immune checkpoint inhibitor (ICI). The diagnosis and further optimal management of oligometastatic progression through ICI remains unclear. Diagnostic challenges include practical limitations due to the anatomical sites of oligometastatic progression, such as the para-aortic region, where traditional tissue biopsy carries high risk, and circulating-tumor DNA (ctDNA) could aid in diagnosis and disease monitoring as a supplement to surveillance imaging. In this report, we describe two cases of one patient with metastatic melanoma and the other with metastatic Merkel cell carcinoma (MCC) who were treated with ICI and later developed localized resistance due to oligometastatic progression. We further highlight our experience using stereotactic body radiation therapy (SBRT) as a salvage approach to treat the oligometastatic progression. In addition, we describe the temporal and dynamic relationship of circulating-tumor DNA (ctDNA) prior to, during and after SBRT, which highly suggested the diagnosis without obtaining a histological specimen. Our cases highlight a potential role for SBRT in the management of oligometastatic progression. However, large prospective trials are essential to confirm the utility of this approach.

KEYWORDS

melanoma, merkel cell carcinoma, oligometastatic progression, stereotactic body radiation therapy, immunotherapy, CtDNA

Abbreviations: ICI, Immune checkpoint inhibitors; MCC, Merkel cell carcinoma; RT, Radiation therapy; ctDNA, circulating-tumor DNA; SBRT, Stereotactic body radiation therapy; PET-CT, Positron Emission Tomography- Computed Tomography; SLN, Sentinel lymph node; SUV, standardized uptake value; SRS, stereotactic radiosurgery; ORR, Overall response rate.

Background

Acquired resistance to immune checkpoint inhibitors (ICI) can develop during the treatment of skin cancers including metastatic melanoma and Merkel cell carcinoma (MCC), leading to treatment failure (1, 2). Oligometastatic progression represents a unique manifestation of immune escape during treatment with ICI with the potential for leveraging salvage therapies. There is a lack of knowledge on best treatment approach in these circumstances given lack of available strong evidence (1, 2). Patient-centered discussion in a multidisciplinary setting and participation in clinical trials when available are considered best practice. Of note, one approach of management includes continuation of systemic therapy if there is durable response outside of the oligometastatic progressive site, combined with a localized salvage treatment to the immune-escaped metastatic lesion. Surgical or local radiation therapy are considered on individual basis, although there remains lack of consensus opinion and data to support this concept (3). This is further complicated by the difficulty in the interpretation of clear progression on imaging in the era of ICI where pseudoprogression is common, representing a challenge to appropriate medical decision making. To this end, circulating-tumor DNA (ctDNA) may serve as a supplemental non-invasive tool to provide information on oligometastatic tumor progression and the dynamic changes during local treatment.

In this report, we describe two cases of metastatic melanoma and MCC that were associated with oligometastatic progression during treatment with ICI despite achieving a complete response systemically elsewhere. These oligometastatic lesions were not accessible for tissue biopsy. Our management approach included salvage local stereotactic body radiation therapy (SBRT) with continuation of systemic ICI. We report the outcomes of these two cases, and the dynamic interplay between ctDNA alterations prior to, and after SBRT, which confirmed metastatic involvement without the need for a histological specimen. These results are intriguing and provide the basis for further investigation in larger cohorts to assess the efficacy and safety of salvage SBRT in the management of immune-escaped oligometastatic progression.

Case presentation

Case 1

A 79-year-old female presented with a new nodular erythematous lesion on the right chest wall. Excisional biopsy demonstrated MCC. Positron Emission Tomography- Computed Tomography (PET-CT) was negative for metastatic disease. The patient underwent wide local excision and sentinel lymph node biopsy (SLNB) with pathology demonstrating negative margins and negative SLNB. After 7 months of surveillance, PET-CT demonstrated new liver lesions, which were biopsy proven to be MCC. The patient started pembrolizumab and had complete response within 6 months of initiating treatment. Subsequent PET-CT after 9 months demonstrated an interval enlargement of a portocaval lymph node measuring 3.0 x 2.2 cm with a standardized uptake value (SUV) of 18.7 (Figure 1A). A personalized patient-specific tumor-informed assay (Signatera™) was used to quantify the tumor mutation molecule per milliliter to detect circulating tumor DNA (ctDNA). Measurement of ctDNA demonstrated 42.33 mean tumor molecules per milliliter (MTM/mL) (Supplementary File-1). The patient underwent stereotactic



FIGURE 1
(A) 18 Fludeoxyglucose PET-CT with cross sectional imaging on the left demonstrating an FDG avid portocaval lesion with a standardized uptake value of 18.7 (white arrow). Right figure demonstrates resolution of the FDG-avid lesion after SBRT. **(B)** Timeline of ctDNA changes during and after SBRT. Levels of ctDNA are quantified by mean tumor mutation per milliliter (MTM/mL).

body radiation therapy (SBRT) of 35 Gray in 5 fractions directed to the portocaval nodal basin. Monitoring of ctDNA during radiation treatment demonstrated increased levels followed by undetectable levels (Figure 1B). Repeat PET-CT after 2 months of SBRT demonstrated complete resolution of excessive FDG avid uptake in the portocaval lymph node (Figure 1A). The patient continued pembrolizumab without observed side effects. Surveillance imaging alternating with ctDNA monitoring after 10 months of SBRT continued to show no evidence of disease.

Case 2

A 65-year-old male was diagnosed with *BRAF*^{V600E} metastatic intracranial melanoma. A craniotomy was performed with gross total resection followed by hypofractionated stereotactic radiosurgery (SRS) of the resected tumor bed. The patient then commenced ipilimumab and nivolumab for four cycles followed by maintenance nivolumab. Surveillance imaging demonstrated recurrence of the intracranial mass after 4 months of ICI therapy. He underwent repeat craniotomy and whole brain radiation. BRAF-MEK inhibitors were attempted but the patient had intolerable side effects necessitating discontinuation. He resumed maintenance nivolumab, which was continued for 3 years at which time PET-CT demonstrated a FDG avid aortocaval lymph node measuring 1.7 x 1.6 cm with SUV of 21.8 (Figure 2A). Tissue biopsy was not possible given the location of the lymph node. However, tumor-informed ctDNA was positive and quantified at 20.92 MTM/mL (Figure 2B). After a consensus quorum at multi-disciplinary tumor boards, the patient was treated with SBRT of 50 Gray in 5 fractions. Measurement of ctDNA after one day of initiating SBRT increased to 124.55 MTM/mL. The patient continued nivolumab without observed side effects. Further longitudinal monitoring of ctDNA was undetectable for 10 months (Figure 2B), and there was no evidence of disease recurrence on imaging surveillance.

Discussion

Immune checkpoint inhibitors (ICI) represent the standard of care for the management of metastatic melanoma and advanced non-melanoma cutaneous malignancies. This is highlighted by the durable response ranging from 5.9 to 34.5+ months, and the high overall response rate (56%) associated with pembrolizumab treatment in recurrent locally advanced and metastatic MCC (4, 5). Similarly, the treatment backbone of metastatic melanoma consists of ICI as a first line treatment due to the high response rates and prolonged overall survival (1). However, a substantial proportion of skin cancer patients treated with ICI develop progressive disease during the course of their treatment. Oligometastatic progression represents a unique biological and clinical entity in which cancer progression is limited to ≤ 5 lesions, and confined to a small region or one organ (3). The occurrence of oligometastatic progression during treatment of metastatic skin cancer is common. For example, in the CheckMate-067, approximately one-third of patients with metastatic melanoma treated with ipilimumab and nivolumab developed progressive disease of which 42% had metastatic progression at least in one site with the lymph nodes being the most involved site at progression (6).

There is a lack of data to support best treatment approach for patients with unique patterns of progression such as oligometastatic



FIGURE 2
(A) 18 Fludeoxyglucose PET-CT with cross sectional imaging on the left demonstrating an FDG avid aortocaval lesion with a standardized uptake value of 21.8 (white arrow). Right figure demonstrates resolution of the FDG-avid lesion after SBRT. **(B)** Timeline of ctDNA changes during and after SBRT. Levels of ctDNA are quantified by mean tumor mutation per milliliter (MTM/mL).

disease progression (3). Several studies highlighted a potential role for curative local control with surgery or radiation therapy of the oligometastatic site in different cancers (3). For example, in colorectal cancer and non-small cell lung cancer, surgical resection or the use of SBRT was considered an acceptable option in both synchronous and metachronous progressive oligometastatic disease (3, 7–9). However, most of the evidence is weak-to moderate given that it was derived from non-randomized prospective or retrospective studies (3). In regards to immunotherapy, some patients could develop metachronous oligometastatic disease despite persistent durable complete or partial response elsewhere. These unique cases are challenging to physicians and patients and raise several questions regarding the efficacy of ICI continuation with a salvage local treatment approach aimed at the oligometastatic progressive site, or the option of ICI discontinuation and switching systemic therapy. This decision depends on institution experience, multidisciplinary panel recommendations, and patient preference. National guidelines provide salvage local treatment as an option for consideration (1). Most of this evidence is derived from retrospective studies conducted in the pre-immunotherapy era, which did not focus on oligometastatic progression (10). One recent study provided some insight on the use of local RT with immunotherapy in melanoma. This study included a cohort of 1675 patients with extracranial metastatic melanoma who were receiving ICI and were treated with local RT. The investigators found no overall survival benefit in patients who received RT with immunotherapy versus those who received immunotherapy alone in a multivariate analysis (11). However, this retrospective study did not focus on patients who develop oligo-progression during treatment. Similarly in MCC, the addition of SBRT to ipilimumab and nivolumab did not improve overall survival in a randomized controlled trial (12). Therefore, the role of SBRT in immune-escaped oligometastatic progression remains unexplored. Another challenge in the evaluation of oligometastatic progression arises when the suspicious lesion on imaging is located in an anatomical site where it is difficult to obtain a tissue specimen for histopathological examination. In these situations, clinical manifestations as well as imaging remain the only available tools to suggest a possibility of disease progression, and to warrant further treatment. Despite the reliability of imaging modalities in the diagnosis of tumor progression in melanoma and MCC, false positive results can occur leading to unnecessary invasive diagnostic testing or premature treatment discontinuation as well as patient anxiety (13).

The current available evidence of RT with immunotherapy is focused on the safety and efficacy of using these modalities in combination or a sequential fashion (14). This stems from data supporting the role of RT in reprogramming the tumor microenvironment leading to improved response to ICI and enhancing an abscopal effect (15, 16). A major unanswered question remains on the efficacy of salvage local RT in patients with metastatic skin cancer who respond initially to immunotherapy and later develop oligometastatic progression. The two patients presented here had complete responses to ICI that were maintained but then developed disease progression in one isolated site. We used SBRT as a salvage approach which was aimed at the oligometastatic sites and continued immunotherapy without observed immune related adverse events or disease recurrence.

Moreover, the two patients who had durable response to ICI, developed potential oligometastatic progression on surveillance imaging that were not biopsied. We sought to use ctDNA as a complementary tool to confirm malignant involvement of the locally treated site through longitudinal monitoring using a tumor-specific patient-informed ctDNA platform. We observed a rise in patients' ctDNA from baseline during treatment with SBRT to the involved site. This highly suggested that the treated sites were likely malignant. Elevation of ctDNA levels has been described to occur after surgery and RT due to tumor necrosis and release of fragmented tumor DNA into the peripheral blood (17, 18). Longitudinal surveillance using a combined modality of PET-CT alternating with ctDNA demonstrated no evidence of disease progression after SBRT and ICI in our patients. Of importance, the use of ctDNA for longitudinal monitoring in skin cancer has only been reported in retrospective studies and case-series and lacks strong evidence to support its use in clinical practice (19, 20).

In conclusion, our report is the first to our knowledge to describe the clinical outcomes of two patients with metastatic MCC and melanoma who were treated with immunotherapy and developed oligometastatic progression despite durable response to ICI elsewhere. These patients were treated with SBRT targeting the immune-escaped lesion and continued ICI with no evidence of disease recurrence on imaging and ctDNA monitoring. Our report is important for the following aspects: 1) it highlights a potential role of salvage SBRT in cases where durable response to immunotherapy is maintained outside of a progressive oligometastatic site; 2) it provides an illustration of the dynamic interplay between ctDNA and SBRT which can highly suggest malignant involvement of the suspicious site in cases were biopsies are difficult to obtain; and 3) it suggests a role for ctDNA as a supplemental minimally-invasive tool to imaging for surveillance. This report has its limitations given the small number of patients, retrospective nature of the observation, and the absence of a comparative arm. These results are intriguing and provide a basis for further research in a large prospective cohort.

Data availability statement

Data was acquired through patient chart review using Washington University in Saint Louis medical records.

Ethics statement

Written informed consent was obtained from the participant/patient(s) for the publication of this case report. A copy of the written consent form is available at the editorial office for this journal.

Author contributions

KK: Conceptualization, Data curation, Investigation, Writing – original draft, Writing – review & editing. AZ: Writing – original draft, Writing – review & editing. OB: Writing – review & editing.

JH: Writing – review & editing. GA: Conceptualization, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1276729/full#supplementary-material

References

1. Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, et al. NCCN guidelines® Insights: melanoma: cutaneous, version 2.2021. *J Natl Compr Canc Netw* (2021) 19(4):364–76. doi: 10.6004/jnccn.2021.0018

2. Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. *Cancer Cell* (2020) 37(4):443–55. doi: 10.1016/j.ccell.2020.03.017

3. Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. *Oncotarget* (2015) 6(11):8491–524. doi: 10.18632/oncotarget.3455

4. Nghiem PT, Bhatia S, Lipson EJ, KudChadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. *N Engl J Med* (2016) 374(26):2542–52. doi: 10.1056/NEJMoa1603702

5. Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, KudChadkar RR, Brohl AS, et al. Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy. *J Clin Oncol* (2019) 37 (9):693–702. doi: 10.1200/JCO.18.01896

6. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. *J Clin Oncol* (2022) 40(2):127–37. doi: 10.1200/JCO.21.02229

7. Boudjema K, Locher C, Sabbagh C, Ortega-Deballon P, Heyd B, Bachellier P, et al. Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: A prospective, open-label, randomized, controlled trial. *Ann Surg* (2021) 273(1):49–56. doi: 10.1097/SLA.0000000000003848

8. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. *Ann Surg* (1996) 224(4):509–20. doi: 10.1097/00000658-199610000-00009

9. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial. *JAMA Oncol* (2018) 4(1):e173501. doi: 10.1001/jamaoncol.2017.3501

10. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. *Radiat Oncol* (2011) 6:34. doi: 10.1186/1748-717X-6-34

11. Gabani P, Robinson CG, Ansstas G, Johanns TM, Huang J. Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy. *Radiother Oncol* (2018) 127(2):310–7. doi: 10.1016/j.radonc.2018.02.022

12. Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. *Lancet* (2022) 400(10357):1008–19. doi: 10.1016/S0140-6736(22)01659-2

13. Shim SR, Kim SJ. Diagnostic test accuracy of 18 F-FDG PET or PET/CT in merkel cell carcinoma. *Clin Nucl Med* (2022) 47(10):843–8. doi: 10.1097/RLU.0000000000004321

14. Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. *Signal Transduct Target Ther* (2022) 7(1):258. doi: 10.1038/s41392-022-01102-y

15. Hiniker SM, Reddy SA, Maecker HT, Subrahmanyam PB, Rosenberg-Hasson Y, Swetter SM, et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. *Int J Radiat Oncol Biol Phys* (2016) 96 (3):578–88. doi: 10.1016/j.ijrobp.2016.07.005

16. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. *J Clin Oncol* (2018) 36(16):1611–8. doi: 10.1200/JCO.2017.76.2229

17. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. *J Clin Oncol* (2014) 32(6):579–86. doi: 10.1200/JCO.2012.45.2011

18. Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtröder K, Gögenur M, et al. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. *Mol Oncol* (2020) 14 (8):1670–9. doi: 10.1002/1878-0261.12729

19. Khaddour K, Zhou A, Butt OH, Budde G, Malashevich AK, Ansstas G. Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios. *Front Oncol* (2022) 12:978996. doi: 10.3389/fonc.2022.978996

20. Tivey A, Britton F, Scott JA, Rothwell D, Lorigan P, Lee R. Circulating tumour DNA in melanoma-clinic ready? *Curr Oncol Rep* (2022) 24(3):363–73. doi: 10.1007/s11912-021-01151-6

frontiers | Frontiers in Pharmacology

TYPE Original Research
PUBLISHED 21 September 2023
DOI 10.3389/fphar.2023.1271268

OPEN ACCESS

EDITED BY
Marcel Henrique Marcondes Sari,
State University of Midwest Paraná, Brazil

REVIEWED BY
Vinicius Prado,
Federal University of Santa Maria, Brazil
Yanchang Wang,
Florida State University, United States

*CORRESPONDENCE
Hongqi Tian,
tianhq@kechowpharma.com

†These authors have contributed equally to this work

RECEIVED 02 August 2023
ACCEPTED 05 September 2023
PUBLISHED 21 September 2023

CITATION
Liu Y, Cheng Y, Huang G, Xia X, Wang X and Tian H (2023), Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. *Front. Pharmacol.* 14:1271268. doi: 10.3389/fphar.2023.1271268

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor

Yahong Liu†, Ying Cheng†, Gongchao Huang, Xiangying Xia, Xingkai Wang and Hongqi Tian*

Shanghai Kechow Pharma, Inc., Shanghai, China

Background: Aberrant activation of RAS-RAF-MEK-ERK signaling pathway has been implicated in more than one-third of all malignancies. MEK inhibitors are promising therapeutic approaches to target this signaling pathway. Though four MEK inhibitors have been approved by FDA, these compounds possess either limited efficacy or unfavorable PK profiles with toxicity issues, hindering their broadly application in clinic. Our efforts were focused on the design and development of a novel MEK inhibitor, which subsequently led to the discovery of tunlametinib.

Methods: This study verified the superiority of tunlametinib over the current MEK inhibitors in preclinical studies. The protein kinase selectivity activity of tunlametinib was evaluated against 77 kinases. Anti-proliferation activity was analyzed using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) or (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay. ERK and phospho-ERK levels were evaluated by Western blot analysis. Flow cytometry analysis was employed to investigate cell cycle and arrest. Cell-derived xenograft (CDX) and Patient-derived xenograft (PDX) models were used to evaluate the tumor growth inhibition. The efficacy of tunlametinib as monotherapy treatment was evaluated in *KRAS/BRAF* mutant or wild type xenograft model. Furthermore, the combination studies of tunlametinib with BRAF/KRAS^{G12C}/SHP2 inhibitors or chemotherapeutic agent were conducted by using the cell proliferation assay *in vitro* and xenograft models *in vivo*.

Results: *In vitro*, tunlametinib demonstrated high selectivity with approximately 19-fold greater potency against MEK kinase than MEK162, and nearly 10–100-fold greater potency against *RAS/RAF* mutant cell lines than AZD6244. *In vivo,* tunlametinib resulted in dramatic tumor suppression and profound inhibition of ERK phosphorylation in tumor tissue. Mechanistic study revealed that tunlametinib induced cell cycle arrest at G0/G1 phase and apoptosis of cells in a dose-proportional manner. In addition, tunlametinib demonstrated a favorable pharmacokinetic profile with dose-proportionality and good oral bioavailability,

Abbreviations: CI, combination index; CRC, colorectal cancer; CTLA-4, Cytotoxic T lymphocyte-associated antigen; ERK, extracellular regulated protein kinases; FDA, U.S. Food and Drug Administration; MAPK, Mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium); MTT 3, (4,5-dimethylthiazole-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; NSCLC, non-small cell lung cancer; PDX, patient-derived xenograft; PD-L1, PD-ligand 1; PK, pharmacokinetics; SHP2, Src homology-2 domain-containing protein tyrosine phosphatase-2; TGI, tumor growth inhibition; T_{max}, time to reach peak drug concentration.

with minimal drug exposure accumulation. Furthermore, tunlametinib combined with BRAF/KRAS^{G12C}/SHP2 inhibitors or docetaxel showed synergistically enhanced response and marked tumor inhibition.

Conclusion: Tunlametinib exhibited a promising approach for treating *RAS/RAF* mutant cancers alone or as combination therapies, supporting the evaluation in clinical trials. Currently, the first-in-human phase 1 study and pivotal clinical trial of tunlametinib as monotherapy have been completed and pivotal trials as combination therapy are ongoing.

KEYWORDS

mek inhibitor, RAF/RAS mutant cancer, tunlametinib, drug combination, high potency

1 Introduction

Cancer incidence and mortality are rapidly increasing worldwide, and cancer is expected as the sole most important barrier to increasing life expectancy globally. Estimates of 19.3 million new cases and 10.0 million cancer deaths worldwide in 2020 were reported by World Health Organization (Sung et al., 2021; World Health Organization, 2022). Mitogen-activated protein kinase (MAPK)/extracellular regulated protein kinases (ERK) signaling pathway (also known as RAS/RAF/MEK/ERK signaling pathway) plays a critical role in cancer cell proliferation and apoptosis. Aberrant activation of this signaling pathway has been implicated in more than one-third of all malignancies. In this pathway, activated RAF phosphorylates and activates MEK1 (mitogen-activated protein kinase kinase) and MEK2 kinases, leading to downstream phosphorylation and activation of extracellular signal-regulated kinases, ERK1 and ERK2, which in turn triggers downstream activation of nuclear and cytoplasmic targets associated with transcription, cell proliferation, differentiation and metabolism (Pylayeva-Gupta et al., 2011). Approximately 20% of all human cancers have *RAS* gene activating mutations (Prior et al., 2020), including carcinomas of the lung (30%), colon (50%) and pancreas (90%), thyroid (50%), and melanoma (25%) (Diaz-Flores and Shannon, 2007; Roberts and Der, 2007). Mutation of *BRAF* is present in 7%–10% of all human cancers, while mutated forms of *ARAF* and *CRAF* are extremely rare (Yaeger and Corcoran, 2019).

MEK inhibitors target RAS/RAF/MEK/ERK signaling pathway in both *RAS* and *RAF* mutant genotypes (Solit et al., 2006). To date, four MEK inhibitors, including trametinib (also known as GSK212), cobimetinib, binimetinib (also known as MEK162), and selumetinib (also known as AZD6244), have been approved by U.S. Food and Drug Administration (FDA). Despite progress has been achieved in targeting this signaling pathway, current therapeutic approaches are not efficacious enough in a broad range of cancers. In addition, acquired drug resistance in clinic application is common during targeted therapy. Remarkable progress has been achieved over decades in understanding the profile of MEK inhibitors (Cheng and Tian, 2017). Current MEK inhibitors show either unsatisfactory potency or unfavorable pharmacokinetics (PK) profile with toxicity issue. Of which, selumetinib possesses an unsatisfactory potency *in vitro* and *in vivo*. This probably caused the failure of Randomized Clinical Trial for *KRAS*-mutant non-small cell lung cancer (NSCLC) without significant improvement in progression-free survival (Jänne et al., 2017). Likewise, binimetinib and REDA119 possess moderate potency (Cheng et al., 2019), with IC_{50} range of 30–250 nM (Tran and Cohen, 2020) for *BRAF*- and *NRAS*-mutant cell lines, and 19 nM/47 nM for MEK1/2 kinase (Iverson et al., 2009), respectively. Cobimetinib inhibited hERG channel with IC_{50} of 0.5 μM, suggesting some potential for causing corrected QT (QTc) prolongation *in vivo* (Food and Drug Administration, 2015). Trametinib has a long circulating half-life, resulting in nearly 6-fold drug accumulation (Infante et al., 2012). Hence, novel compounds targeting this pathway without causing unacceptable levels of toxicity are required. To our knowledge, the unfavorable profiles of current MEK inhibitors are closely correlated with their molecular structures. Of these, the interaction force of F-located in benzene ring of cobimetinib as H-acceptor is too weak to closely bind with MEK kinase, resulting in unsatisfactory potency. Trametinib shows poor solubility property and requires DMSO as co-solvate, resulting in drug accumulation in body and toxicity issue (Infante et al., 2012). Selumetinib and binimetinib share a similar structure, possess satisfactory PK profile, but need enhance efficacy (Cheng et al., 2019). Design and development of new MEK inhibitors with improved response and reduced toxicity represents new opportunities to confer effective therapy benefits for *RAS/RAF* mutant cancers.

Driven by the clinical need, our efforts were focused on developing a new MEK inhibitor with enhanced efficacy and favorable PK profile. Retrospective analysis showed that a strong hydrogen-bond interaction between MEK inhibitors and S212 in MEK allosteric pocket results in a superior antitumor efficacy in KRAS-driven tumors as it is critical for blocking MEK feedback phosphorylation by wild-type RAF (Hatzivassiliou et al., 2013). The aromatic nitrogen (N) of binimetinib forms a stronger hydrogen bond interaction with S212 binding site than aromatic fluorine (F) of cobimetinib, which means binimetinib has a higher potency in KRAS-driven cancers than cobimetinib. In addition, unlike trametinib, binimetinib has an exclusive binding mode that does not block binding and phosphorylation by Raf, thereby permitting incredible selectivity of MEK1/2. Hence, the well-known MEK inhibitors binimetinib was chosen as a lead compound under comprehensive analysis. As analyzing the key interactions between MEK inhibitors and the MEK allosteric pocket, a structurally new MEK inhibitor, designated as tunlametinib, was discovered (Figure 1A). Tunlametinib exhibited both enhanced efficacy and favorable PK profile in preclinical study, thereby overcoming the shortcomings of the current MEK inhibitors. In the phase 1 study of tunlametinib monotherapy for NRAS-mutant melanoma, tunlametinib demonstrated acceptable tolerability and



FIGURE 1
Inhibition curve of tunlametinib on MEK1/MAP2K1 (H) kinase. **(A)** Chemical structure of tunlametinib. **(B)** Tunlametinib on MEK1/MAP2K1 (H). Tunlametinib demonstrated a strong inhibition against MEK1/MAP2K (H) kinase with IC_{50} value of 1.9 nM. **(C)** *In vitro* kinase inhibition curves of tunlametinib and MEK162. Compared to MEK 162, tunlametinib showed stronger inhibitory activity, with IC_{50} value of 12.1 ± 1.5 nM versus 223.7 ± 16.9 nM.

substantial clinical activity as well as favorable PK profiles (Zhao et al., 2022; Wang et al., 2023). The encouraging efficacy and well tolerability were further verified in a phase 2 trial (Si et al., 2023). Herein, we describe the preclinical characterization of tunlametinib.

Combination therapies attempt to improve therapeutic responses and reduce the likelihood of acquired resistance in cancer patients (Palmer and Sorger, 2017). Combination therapy with MEK plus BRAF inhibitors could improve therapeutic outcomes in *BRAF*-mutated cancers and delay or prevent drug resistance, also be superior to monotherapy in terms of efficacy without significant increase in toxicity (Richman et al., 2015; Subbiah et al., 2020). Investigator-assessed response rates in *BRAF*-mutated, metastatic melanoma were 64%–75% for trametinib plus dabrafenib, cobimetinib plus vemurafenib and binimetinib plus encorafenib (Heinzerling et al., 2019). Pharmacological MEK inhibition completely abrogated tumor growth in *BRAF* mutant xenografts, whereas *RAS*-mutant tumors were only partially inhibited (Solit et al., 2006). Though drugs targeting *RAS* inhibited the RAS-RAF-MEK deregulation, wild-type *RAS* can also promote *RAS*-driven oncogenesis by downstream effectors (Muzumdar et al., 2017). This makes the treatment for *RAS*-mutant cancer more challenging. Vertical inhibition of the MAPK pathway is a promising therapeutic approach for suppressing pathway signaling and treatment resistance in *RAS*-mutant cancers (Ryan and Corcoran, 2018). Strategies to exploit combination therapies for *RAS*-mutant cancers remain promising and of great interest. SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase and involved in downstream RAS-RAF-MEK-ERK signaling transduction (Ruess et al., 2018). Inhibition of SPH2 delayed tumor progression but not sufficient to achieve tumor regression. Inactivation of SHP2 and MEK inhibitor treatment resulted in a more sustained inhibition of the pathway, reducing resistance to inhibition of MEK (Fedele et al., 2018). Hence, the combination therapies of the new MEK inhibitor with other agents are investigated to explore the potential clinical application.

2 Materials and methods

2.1 Cell-free kinase assay

The protein kinase selectivity activity of tunlametinib was evaluated against 77 kinases. The screen study was performed by Cerep (France). Kinase inhibition activity against MEK1 was conducted in Cerep (France) and Sundia (Shanghai, China). The procedures were described in the Supplementary Materials and Methods.

2.2 Cell culture and proliferation assay

All cell lines were authenticated by short tandem repeat analysis and maintained following the ATCC instructions. For cell proliferation assay of tunlametinib, AZD6244 and GSK212, the study was conducted at Sundia. Anti-proliferation activity was analyzed using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-2H-

tetrazolium bromide (MTT) or (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2 -(4-sulfophenyl)-2H-tetrazolium) (MTS) assay. Specific operation steps were shown in the Supplementary Materials and Methods. The combination index (CI) value between tunlametinib and other compounds was determined using CalcuSyn Version 2.1 software (Biosoft, Cambridge, UK). CI < 1, = 1 or >1 showed synergy, additive or antagonistic effects, respectively.

2.3 Western blot analysis

ERK and phospho-ERK levels were evaluated by Western blot analysis. Cells were seeded into 6-well plates at appropriate density (80%–90% confluence) and treated next day with the indicated inhibitors. Mice bearing A375 xenografts were treated with tunlametinib and tumor tissues were excised at 1 h after oral administration. Cells and tissues were lysed and processed as described in the Supplementary Materials and Methods.

2.4 Tumor cell apoptosis and cell cycle assay

Cell lines were inoculated at the density of 2×10^4 cells per well in a 6-well plate and cultured overnight. Cells were then treated with tunlametinib, AZD6244 and GSK212 at indicated concentrations for 48 h, respectively. The cell cycle or apoptosis analysis was performed by flow cytometry. Specific operation steps were shown in the Supplementary Materials and Methods.

2.5 Study on pharmacokinetics of single or multiple doses administration in SD rats

SD rats were divided into 4 groups, with 3 females and 3 males in each group. Each group was administered successively: single intravenous injection of 0.5 mg/kg tunlametinib, single oral administration of 0.5, 1.5 and 4.5 mg/kg tunlametinib. Blood samples were collected pre-dosing and 0.083, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 h post-dosing on day 1 and day 10. In 1.5 mg/kg oral dose group, rats were continually dosed for another 9 days. The plasma samples were analyzed by LC-MS/MS. The pharmacokinetic parameters were calculated by Phoenix ®WinNonlin ®6.3.

2.6 Efficacy of single drug or combination drug treatment studies *in vivo*

Tumor fragments or cell lines were implanted subcutaneously in the right flank of female BALB/c nude, NU/NU or Nod-Scid mice aged 5–8 weeks and allowed to grow to 100–300 mm^3 on average. The specific tumor model, mice species, implanted tumor derivations are shown in Supplementary Table S1.

The efficacy of tunlametinib as monotherapy treatment was evaluated in *KRAS/BRAF* mutant or wild type xenograft model (conducted at Sundia). To compare the efficacy of MEK inhibitors tunlametinib versus MEK162, two second BRAF mutant xenograft studies were carried out (conducted at TruwayBio Suzhou). Furthermore, the efficacy of tunlametinib was tested in colorectal cancer (CRC) patient-derived model (conducted at Crown Biosciences). Tumor growth inhibition (TGI) was calculated for treatment groups using the formula: $TGI\% = [1-(T_i-T_0)/(V_i-V_0)]\times100$, T_i and V_i are the average tumor volume of the treatment group and vehicle control on the measurement day, respectively; T_0 and V_0 are the mean tumor volume of the treatment group and vehicle control group at the initial treatment day, respectively.

The drug combination efficacy studies were carried out in $KRAS^{G12C}$ mutant or *BRAF* mutant xenograft models when combined tunlametinib with SHP2/$KRAS^{G12C}$/BRAF inhibitors, and in *KRAS* mutant xenograft model when combined with chemotherapeutic drug. Q value was applied to evaluate the synergistic effects between two drugs. Q value was calculated using the formula: $Q = TGI_{AB}/(TGI_A + TGI_B - TGI_A\times TGI_B)$, TGI_A or TGI_B represents tumor growth inhibition due to either of the two drugs respectively, and TGI_{AB} represents the growth inhibition due to the combination of the two drugs. Q > 1, = 1 or <1 indicate synergistic, additive or antagonistic effects, respectively.

The study involving animal participants were reviewed and approved by the Animal Care and Ethics Committee in Sundia MediTech Company, Ltd., Shanghai, China; TruwayBio, Suzhou, China; Crown Biosciences, Beijing, China. The *in vivo* experiment design was shown in Supplementary Figure S1. Specific operation steps were shown in the Supplementary Materials and Methods.

2.7 Statistical analyses

All biochemistry and cell experiments were performed in three replicates per treatment. For *in vivo* efficacy studies, data was shown as mean ± SEM. The student *t*-test was used to analyze the difference between two groups in the efficacy study. *p*-value <0.05 was considered statistically significant.

3 Results

3.1 Tunlametinib is a highly selective and potent MEK inhibitor

To determine the kinase selectivity in a panel of kinases and the inhibitory activity against MEK kinase, the cell-free enzyme assays were conducted. Tunlametinib at 10 μmol/L showed complete inhibition against MEK1 and no inhibition against other 77 kinases tested (Supplementary Information, Supplementary Table S2), suggesting a high selectivity. Further cell-free assay showed that tunlametinib had a significant inhibitory activity against target kinase MEK1, and the IC_{50} was 1.9 nM (Figure 1B). In addition, under the comparison study, tunlametinib exhibited approximately 19-fold greater inhibitory activity against MEK1/MAP2K1(h) kinase than the lead compound MEK162, with IC_{50} value of 12.1 ± 1.5 nM *versus* 223.7 ± 16.9 nM (Figure 1C).

TABLE 1 IC_{50} values of a panel of cancer cell lines exposed to tunlametinib, AZD6244 and GSK212.[a]

Cell lines	Tumor type	Mutation status	Tunlametinib IC_{50} ± SEM (nM)	AZD6244 IC_{50} ± SEM (nM)	GSK212 IC_{50} ± SEM (nM)
A375	Melanoma	$BRAF^{V600E}$	0.86 ± 0.07	67.52 ± 0.07	0.74 ± 0.01
COLO 205	Colon	$BRAF^{V600E}$	0.94 ± 0.26	54.33 ± 2.21	0.74 ± 0.02
Colo-829	Melanoma	$BRAF^{V600E}$	3.46 ± 0.27	301.10 ± 88.79	1.78 ± 0.00
HT-29	Colon	$BRAF^{V600E}$	2.35 ± 0.03	175.28 ± 19.26	1.45 ± 0.20
Calu-6	Lung	$KRAS^{Q61K}$	10.07 ± 1.18	2305.07 ± 203.56	10.56 ± 0.07
A549	Lung	KRAS	59.89 ± 11.06	5732.45 ± 1028.89	45.35 ± 4.76
HL-60	Myeloma	RAS	0.67 ± 0.28	35.26 ± 20.92	0.60 ± 0.28
H1975	Lung	$BRAF^{WT}$, $KRAS^{WT}$	>1000	>50,000	>1000
MRC-5	Lung	Normal cell	>1000	>50,000	>1000

[a]*In vitro* cell viability was determined by MTS, assay.

3.2 Cell proliferation assay

In a panel of cell lines with *RAS* or *RAF* mutation, tunlametinib dramatically inhibited cell proliferation, with IC_{50} values ranging between 0.67 and 59.89 nmol/L. In contrast, tunlametinib, at concentrations up to 10 μmol/L, had minimal inhibitory effect on the proliferation of *RAS/RAF* wild-type tumor cells (H1975) and normal cells (MRC-5). Furthermore, the head-to-head comparison results showed that the inhibitory activity of tunlametinib was similar to GSK212, and more potent than that of AZD6244 (10–100 times). The IC_{50} values and the proliferation inhibition curves are presented in Table 1 and Supplementary Information (Supplementary Figure S2). These results demonstrated that tunlametinib is more effective for *RAS/RAF*-mutant cell lines with improved potency compared to AZD6244.

3.3 Inhibition of ERK phosphorylation in cultured cells

The ability of tunlametinib to inhibit MEK1/2 kinase activity in their cellular environment was evaluated by measuring the phosphorylation state of ERK1/2, the direct substrates of MEK1/2. Furthermore, the inhibitory ability of tunlametinib was compared with another two MEK inhibitors GSK212 and AZD6244. Western blot assays were introduced to detect pERK level after 48-h inhibitors treatment. Results (Figures 2A, B) showed that the ERK phosphorylation level of *BRAF*-mutated melanoma A375 cells decreased in a dose-dependent manner and reached almost completely blocked under treatment of tunlametinib at 100 nM. Besides, the IC_{50} value of tunlametinib on inhibition of ERK phosphorylation in A375 cells was close to the anti-proliferation IC_{50} value *in vitro*, which was about 1.16 nM. Compared with the other two inhibitors, the inhibitory effect of tunlametinib at 1 nM and 10 nM was similar to that of GSK212, but much better than that of AZD6244, consistent with the reduced proliferation of cells.

3.4 Cell cycle and apoptosis

A375 cells were treated with tunlametinib, AZD6244 and GSK212 for 48 h to evaluate the effect on cell cycle. Flow cytometry analysis showed that tunlametinib could dose-dependently increase the proportion of G0/G1 phase in A375 cells at concentration from 1 nM to 9 nM (Figure 2C). Additionally, its effect on cell cycle arrest was more potent than that of AZD6244, and similar to GSK212.

A375 and BRAF-mutated colon cancer COLO 205 cells were treated with tunlametinib, AZD6244, and GSK212 for 48 h to evaluate the effect on cell apoptosis. The proportion of apoptosis cells after compound treatment were within normal limits, suggesting no significant apoptosis-inducing effect on A375 cells (Figure 2D). Meanwhile, the percentage of apoptotic cells in control group was 21.9% on COLO 205 cells. After treated with 1 μM AZD6244 or 20 nM GSK212, the apoptosis rate was 40.6% and 47.0%, respectively; while the proportion of apoptosis was 35.1%, 38.4% and 46.6% after treated with 10, 30 and 90 nM of tunlametinib (Figure 2E). In summary, tunlametinib could dose-dependently induce apoptosis COLO 205 cells, and its effect was stronger than that of AZD6244, but slightly weaker than GSK212.

3.5 Pharmacokinetics profile

After oral administration of 0.5, 1.5 and 4.5 mg/kg tunlametinib to Sprague-Dawley (SD) rats, the time to reach peak drug concentration (T_{max}) was around 0.5–4 h. The area under curve from 0 to 24 h (AUC_{0-24h}) were 3564.8 ± 711.8 ng/mL*h, 6658.2 ± 2126.7 ng/mL*h and 21,581.2 ± 9058.4 ng/mL*h, respectively, demonstrating a good dose-proportionality. The mean absolute bioavailability was 86.6% ± 22.6%, 53.0% ± 15.8% and 57.6% ± 22.5%, respectively, showing a favorable oral bioavailability. There was no significant difference of PK parameters between single dose and 10-day repeated doses, indicating no drug exposure accumulation.



FIGURE 2
The effect of tunlametinib on p-ERK/total ERK inhibition, cell cycle and apoptosis. **(A,B)** The level of p-ERK/total ERK in A375 cells after treated with different concentrations of compounds. A375 cells were treated with tunlametinib at 0.1, 1, 10, 100 nM, with AZD6244 at 10, 100 nM, and with GSK212 at 1, 10 nM. **(C,D)** A375 cells were treated with tunlametinib at 1, 3, 9 nM, with AZD6244 at 100 nM, and GSK212 at 2 nM. **(E)** COLO 205 cells were treated with tunlametinib at 10, 30, 90 nM, with AZD6244 at 1000 nM, and GSK212 at 20 nM.

3.6 Anti-tumor activities of tunlametinib as monotherapy *in vivo*

The anti-tumor activity of tunlametinib as monotherapy was investigated in *BRAF/KRAS* mutant or wild type xenograft model. Consistent with the findings *in vitro*, tunlametinib inhibited tumor growth in a dose-dependent manner in all the xenograft models. Tunlametinib at the low dose exhibited stronger inhibition of the *BRAF* and *KRAS* mutant xenograft model compared to AZD6244 at high dose (Figures 3A–D). Tunlametinib also demonstrated stronger inhibition of *BRAF*-mutant melanoma and colorectal xenograft when compared to MEK162 (Figures 3F, G). Moreover, tunlametinib also showed potent anti-tumor effect in the *BRAF/KRAS* wild type xenograft model mice (Figure 3E). In four patient-derived xenograft (PDX) CRC models harboring *BRAF* mutation (CR0004, CR0029, CR2179, CR6289), tunlametinib at dose of 1 mg/kg QD, responded (>79% TGI) with all the models exhibiting significant tumor growth suppression ($p < 0.05$) (Figures 3H–K). No significant change in body weight of vehicle and



FIGURE 3
Tumor growth of cell line-derived xenografts (CDXs) or patient derived CRC xenograft (PDX) under single agent treatment and p-ERK protein levels in A375 tumor tissue. **(A,C,D)** A375, HT-29, Calu-6 CDX_S were treated with vehicle, tunlametinib (1, 3, 6 mg/kg, QD) or AZD6244 (25 mg/kg, BID). **(B)** COLO 205 CDX was treated with vehicle, tunlametinib (1, 3, 9 mg/kg, QD) or AZD6244 (50 mg/kg, BID). **(E)** NCI-H1975 CDX was treated with vehicle, tunlametinib (3, 9 mg/kg, QD) or docetaxel (10 mg/kg, QW). **(F,G)** A375, COLO 205 CDXs were treated with vehicle, tunlametinib (1, 3 mg/kg) or MEK162 (10 mg/kg, QD). **(H–K)** CR0004, CR0029, CR2179, CR6289 PDXs were treated with vehicle and tunlametinib (1 mg/kg). **(L)** A375 CDX was treated with tunlametinib (0, 1, 3, 6 mg/kg, PO) and tumor tissues were excised at 1 h after single oral dosing of tunlametinib. For A375 CDX model, N = 14 mice in vehicle group, and N = 7 in tunlametinib and AZD6244 treatment groups. For other CDX models, N = 8 mice in each group. For PDX model, N = 2 mice in vehicle group, and N = 3 mice in tunlametinib treatment groups. Data was shown as mean ± SEM, ns $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, ****$p < 0.0001$, student *t*-test.

treatment group in all xenograft models (Supplementary Figure S3).

3.7 Tunlametinib resulted in a profound inhibition of ERK phosphorylation in tumor tissues

Tunlametinib was mechanistically evaluated in mice for antitumor activity against A375 xenografts. ERK phosphorylation was analyzed as the biomarker of MAPK pathway inhibition since ERK is the direct substrate of MEK. Tumor tissues of mice were collected at 1 h after orally administration of tunlametinib with 1 mg/kg, 3 mg/kg or 9 mg/kg. As shown in Figure 3L, the phosphorylation of ERK in tumor tissue was significantly inhibited at 1 mg/kg and achieved completely inhibition at 9 mg/kg. The inhibition percentage of p-ERK were 80.37%, 99.99% and 100.00% respectively, indicating that tunlametinib could inhibit ERK phosphorylation *in vivo* in a dose-dependent manner.

3.8 The synergistic effects of tunlametinib and BRAF/$KRAS^{G12C}$/SHP2 inhibitors or chemotherapeutic agent on cancer cell growth

Increasing evidence showed that multi-targeted combination therapy delayed the onset of acquired resistance, leading to increased progress-free survival and overall survival (Broman et al., 2019). For *BRAF* mutant colon cancer and melanoma, monotherapy showed limited efficacy, however combination



FIGURE 4
Synergistic effects of tunlametinib combined with **(A)**, KRAS^{G12C} inhibitor, **(B–D)**, BRAF inhibitor, **(G)** SHP2 inhibitor or **(E,F)**, chemotherapeutic agent on BRAF- or KRAS-mutant cell lines. Fa-CI curves of KARS- or BRAF- mutant cell lines treated with tunlametinib combined with AMG510, vemurafenib, docetaxel, or SHP099. CI = 1 line represents additive effect; Dots below CI = 1 line represent synergistic effect; Dots above CI = 1 line represent antagonistic effect.

therapy confers a promising therapy approach. Tunlametinib combined with Vemurafenib (a BRAF inhibitor) showed synergistic effect on colorectal COLO 205 and HT-29 under the inhibition extent from 9% to 69% and 21%–81%, respectively. In addition, the minimum of CI value occurred under the IC_{50} treatment of both inhibitors. A similar results were observed on melanoma A375, with only two concentration groups showed antagonism.

It has been proven that the inhibition of phosphorylated ERK1/2 level in tumor cells with *KRAS* mutations may cause wide-type RAF phosphorylation and further result in activation of MEK, thereby restoring pERK level quickly and acquiring rebound. Therefore, it is necessary to introduce MEK inhibitor and KRAS inhibitor combination therapies. The fraction affected-CI curve of tunlametinib and AMG 510 (a KRAS^{G12C} inhibitor) effects on NSCLC H358 indicated that synergistic effect almost existed in all concentrations tested. Notably, CI value decreased to 0.1, which indicated an intense synergistic effect (Figure 4).

Docetaxel, as a chemotherapeutic agent, is a commonly used microtubule-stabilizing cytotoxic drug that has a great potential in clinical application mainly on NSCLC treatment. Combination of tunlametinib with docetaxel in lung cancer H358 and Calu-6 cells showed synergistic effects as the CI value was below 1.

SHP2 is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signaling pathway. SPH2/MEK inhibitor combinations prevent adaptive resistance in *KRAS* mutant cancer model (Fedele et al., 2018). SHP2 inhibitor SHP099 combined with tunlametinib was used to determine whether they have synergistic effect. As expected, synergism was observed on H358 under the inhibition extent from 48% to 97%.

3.9 Combination therapy for cancers with tunlametinib and SHP2/KRAS^{G12C}/BRAF inhibitors or chemotherapeutic agent using animal models

The combination of tunlametinib with SPH2 inhibitor SHP099 enhanced the anti-tumor effect and resulted in synergistic inhibition of *KRAS^{G12C}* mutant tumors (Q = 1.02, $p < 0.01$) (Figure 5A). Likewise, tunlametinib (1 mg/kg, QD, P.O.) combined with KRAS^{G12C} inhibitor AMG 510 resulted in stronger efficacy and exhibited a synergistic effect in *KRAS^{G12C}* mutant xenograft model (Q = 1.02, $p < 0.01$) (Figure 5B), consistent with *in vitro* result. Moreover, combination treatment of tunlametinib with vemurafenib resulted in remarkable tumor inhibition in *BRAF* mutant melanoma cells, which indicates a strong synergistic effect (Q = 1.51, $p < 0.05$) (Figure 5C). Tunlametinib in two oral dosing schedules combined with docetaxel synergistically in all four *RAS* mutant xenograft (Q > 1, $p < 0.05$) (Figures 5D–G). During the treatment period, no significant changes in body weight were observed in all xenograft models (Supplementary Figure S4).

4 Discussion

Here we describe the preclinical characterization of tunlametinib, a novel, highly selective, potent, and orally available



FIGURE 5
Tumor growth curves of combination treatments in cell line-derived xenografts. Tunlametinib combined with SHP2/KRAS^{G12C}/BRAF inhibitors in *KRAS* or *BRAF* mutant xenografts. **(A,B)** Tunlametinib (0.25 mg/kg, then decreased to 0.125 mg/kg from day 10, QD, P.O.) combined with SHP099 (50 mg/kg, then decreased to 25 mg/kg from day 10, Q2D, P.O.) or AMG510 (3 mg/kg, QD, P.O.) in H358 xenograft model (n = 8 mice per group). **(C)** Tunlametinib (1 mg/kg, QD, P.O.) in combination with vemurafenib (25 mg/kg, BID, P.O.) in A375 xenograft model (n = 6 mice per group). **(D)** Tunlametinib (0.5 mg/kg, BID or 3.5 mg/kg, BIW, P.O.) combined with docetaxel (10 mg/kg, then decreased to 7.5 mg/kg from day 8, QW, i. v.) in Calu-6 xenograft models (n = 8 per group). **(E)** Tunlametinib (0.5 mg/kg BID or 3.5 mg/kg BIW, P.O.) combined with docetaxel (10 mg/kg for 2 weeks, decreased to 7.5 mg/kg for 1 week, and 5 mg/kg for 1 week, QW, i. v.) in H358 xenograft models (n = 8 per group). **(F)** Tunlametinib (0.5 mg/kg BID or 3.5 mg/kg BIW, P.O.) combined with docetaxel (10 mg/kg for 2 weeks, then decreased to 7.5 mg/kg for 2 weeks, QW, i. v.) in H441 xenograft models (n = 8 per group). **(G)** Tunlametinib (0.5 mg/kg BID or 3.5 mg/kg BIW, P.O.) combined with docetaxel (10 mg/kg for 1 week, then decreased to 7.5 mg/kg for 4 weeks, QW, i. v.) in A549 xenograft models (n = 8 per group). Data were shown as mean ± SEM, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, student *t*-test.

small molecule MEK inhibitor. Tunlametinib showed remarkable efficacy against *RAS/RAF* mutant cancers *in vitro* and *in vivo*. This indicates that tunlametinib could provide an effective therapy approach for *RAS/RAF* mutant cancers. Tunlametinib emerged as the top candidate from an optimization of molecular structure, as this compound incorporated both improved potency and favorable PK properties. Trametinib, as the first approved MEK inhibitor, has blood drug accumulation with the mean accumulation ratio (day15/day1) with repeat dose of 2 mg approximate 6.0 (Food and Drug Administration, 2013), whereas tunlametinib showed minimal drug accumulation in preclinical and clinical studies (Zhao et al., 2022). Compared with other three FDA-approved MEK inhibitors, tunlametinib showed much more potent both *in vitro* and *in vivo*. The phosphorylation of ERK, biomarker of MEK inhibition, was evidently inhibited after tunlametinib was administered to cells *in vitro* or xenograft model *in vivo*. Moreover, the extent of this

inhibition was in dose-dependent manner and maximally approached to 100%. This suggests that tunlametinib efficiently inhibits the MAPK pathway and results in cell growth suppression. Like GSK212 and AZD6244, tunlametinib induced A375 cell cycle arrest at G0/G1 phase, but did not result in apoptosis, indicating that A375 cells probably respond to tunlametinib by inhibition of cell proliferation through cell cycle or other mechanisms, rather than apoptosis. However, tunlametinib induced apoptosis in COLO 205 cells. This difference could be explained by the possibility MEK inhibitor may induced apoptosis by differentiated mechanism, depending on cell types (Davies et al., 2007). Collectively, tunlametinib demonstrated favorable pharmacokinetic profile and good drug properties.

The challenges in the treatment of some subtype of *RAS* mutant cancers and acquired drug-resistance due to an abundance of escape mechanisms present highlight the need of new strategies to improve clinical outcomes (Heppt et al., 2015). This study further proved that tunlametinib synergistically enhances the potency and efficacy of BRAF inhibitors, SHP2 inhibitors, $KRAS^{G12C}$ inhibitors and chemotherapy agent docetaxel. Tunlametinib may potentially improve therapeutic responses and reduce the likelihood of acquired resistance in cancer patients, especially in *RAS* mutant cancers. $NRAS^{Q61K}$ mutant neuroblastomas were distinctly resistant to SHP2 inhibitors; however, combinations of SHP2 inhibitor with MEK inhibitor were synergistic and reversed resistance to SHP2 inhibition (Valencia-Sama et al., 2020). RTK-driven feedback activation widely exists in *KRAS*-mutant cancer cells, and this pathway feedback activation is mediated through mutant *KRAS*, at least for the G12C, G12D, G12V variants (Lu et al., 2019). Combining SHP2 and MAPK pathway inhibitor for treating *KRAS*-mutant cancers is a rationale strategy in the clinic. Our study demonstrated that the MEK inhibitor tunlametinib combining SPH2 inhibitor SHP099 showed a synergistic effect of tumor inhibition, indicating a promising potential in the clinical utility. Research showed that *KRAS*-amplified cancers are insensitive to MAPK blockade due to adaptive response by rapidly increasing KRAS-GTP levels. However, inhibition of SPH2 could enhance the sensitivity of KRAS-amplified cancer model to MEK inhibition (Wong et al., 2018). Mechanistically, SHP2 inhibitors suppressed activation of *KRAS* mutants, impeded SOS/RAS/MEK/ERK1/2 reactivation in response to MEK inhibitors (Fedele et al., 2018). It is possible that combination of tunlametinib with SPH2 inhibitor could potentially confer a beneficial outcome for wide-type *KRAS*-amplified cancers and could have therapeutic utility in multiple cancers.

In this study, combining tunlametinib with vemurafenib demonstrated a remarkable synergistic effect of tumor inhibition, indicating a sustainable inhibition of MAPK signaling and likely overcoming paradoxical MAPK activation. The novel MEK inhibitor tunlametinib in combination with $KRAS^{G12C}$ inhibitor AMG510 demonstrated high activity in preclinical xenograft models of *KRAS*-mutant cancers, rendering a potentially effective treatment for *RAS*-mutant cancers in clinic. This study could support the combination therapies of tunlametinib in clinical.

A retrospective multicenter analysis of 364 patients concluded that additional MEK inhibition to immune checkpoint inhibition has potential to increase survival of *NRAS*-mutated melanoma patients and improve clinical benefit (Kirchberger et al., 2018). Patients with prior immunotherapy with anti- Cytotoxic T lymphocyte-associated antigen (CTLA-4) or anti-PD-1 antibody may even experience more durable responses to MEK inhibitor. Combining MEK inhibitor and anti-PD-ligand 1 (PD-L1) markedly enhances tumor response in mice with KRAS-mutated colon cancer xenografts. MEK inhibition increased the number of intratumoral antigen-specific $CD8^+$ effector T cell. Tunlametinib as a novel MEK inhibitor with improved efficacy might be an ideal combination partner with immune checkpoint inhibitors.

Overall, our findings constitute a preclinical data of tunlametinib and offer a precision medicine option available that could be tailored to individual mutations and cancers. These data supported the progression of tunlametinib into a first-in-human clinical study (Zhao et al., 2022; Wang et al., 2023). Currently, the first-in-human phase 1 (ClinicalTrials.gov number, NCT03973151, NCT04683354) and pivotal clinical study of tunlametinib (NCT05217303) as monotherapy, and the phase 1 study as combination therapy (NCT05263453) have been completed. More pivotal trials are ongoing (NCT03781219, NCT05233332).

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was approved by Animal Care and Ethics Committee in Sundia MediTech Company, Ltd., Shanghai, China TruwayBio, Suzhou, China; Crown Biosciences, Beijing, China. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

YL: Writing–original draft, Data curation, Formal Analysis, Methodology, Validation. YC: Data curation, Formal Analysis, Methodology, Validation, Writing–original draft, Supervision, Writing–review and editing. GH: Data curation, Formal Analysis, Methodology, Validation, Writing–original draft. XX: Data curation, Formal Analysis, Methodology, Validation, Writing–original draft. XW: Data curation, Formal Analysis, Methodology, Validation, Writing–original draft. HT: Writing–original draft, Conceptualization, Investigation, Supervision, Writing–review and editing.

Funding

The study was funded by Shanghai Kechow Pharma, Inc. This study received funding from Shanghai Kechow Pharma, Inc. The funder had the following involvement with the study: study design, collection, analysis, interpretation of data, the writing of this article and the decision to submit it for publication. All the authors are the employees of Shanghai Kechow Pharma, Inc. HT, YC, and GH are the inventors of patent WO/2013/107283.

Conflict of interest

Authors YL, YC, GH, XX, XW, and HT were employed by Shanghai Kechow Pharma, Inc.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1271268/full#supplementary-material

References

Broman, K. K., Dossett, L. A., Sun, J., Eroglu, Z., and Zager, J. S. (2019). Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. *Expert Opin. Drug Saf.* 18 (5), 381–392. doi:10.1080/14740338.2019.1607289

Cheng, Y., and Tian, H. (2017). Current development status of MEK inhibitors. *Molecules* 22 (10), 1551. doi:10.3390/molecules22101551

Cheng, Y., Wang, X., Xia, X., Zhang, W., and Tian, H. (2019). A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer. *Int. J. Cancer* 145 (2), 586–596. doi:10.1002/ijc.32119

Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., et al. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action *in vivo*, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. *Mol. Cancer Ther.* 6 (8), 2209–2219. doi:10.1158/1535-7163.Mct-07-0231

Diaz-Flores, E., and Shannon, K. (2007). Targeting oncogenic ras. *Genes. Dev.* 21 (16), 1989–1992. doi:10.1101/gad.1587907

Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., et al. (2018). SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. *Cancer Discov.* 8 (10), 1237–1249. doi:10.1158/2159-8290.Cd-18-0444

Food and Drug Administration (2013). Application number: 204114Orig1s000: Clinical pharmacology and biopharmaceutics review(s). Available: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204114Orig1s000ClinPharmR.pdf.

Food and Drug Administration (2015). Approval package for: Application number: 206192Orig1s000. Available: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192Orig1s000Approv.pdf.

Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K., Price, S., Heald, R., et al. (2013). Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. *Nature* 501 (7466), 232–236. doi:10.1038/nature12441

Heinzerling, L., Eigentler, T. K., Fluck, M., Hassel, J. C., Heller-Schenck, D., Leipe, J., et al. (2019). Tolerability of BRAF/MEK inhibitor combinations: Adverse event evaluation and management. *ESMO Open* 4 (3), e000491. doi:10.1136/esmoopen-2019-000491

Heppt, M. V., Tietze, J. K., Graf, S. A., and Berking, C. (2015). Combination therapy of melanoma using kinase inhibitors. *Curr. Opin. Oncol.* 27 (2), 134–140. doi:10.1097/cco.0000000000000160

Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., et al. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. *Lancet Oncol.* 13 (8), 773–781. doi:10.1016/s1470-2045(12)70270-x

Iverson, C., Larson, G., Lai, C., Yeh, L. T., Dadson, C., Weingarten, P., et al. (2009). RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. *Cancer Res.* 69 (17), 6839–6847. doi:10.1158/0008-5472.Can-09-0679

Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., et al. (2017). Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. *Jama* 317 (18), 1844–1853. doi:10.1001/jama.2017.3438

Kirchberger, M. C., Ugurel, S., Mangana, J., Heppt, M. V., Eigentler, T. K., Berking, C., et al. (2018). MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. *Eur. J. Cancer* 98, 10–16. doi:10.1016/j.ejca.2018.04.010

Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., et al. (2019). SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors. *Mol. Cancer Ther.* 18 (7), 1323–1334. doi:10.1158/1535-7163.Mct-18-0852

Muzumdar, M. D., Chen, P. Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., et al. (2017). Survival of pancreatic cancer cells lacking KRAS function. *Nat. Commun.* 8 (1), 1090. doi:10.1038/s41467-017-00942-5

Palmer, A. C., and Sorger, P. K. (2017). Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. *Cell.* 171 (7), 1678–1691. doi:10.1016/j.cell.2017.11.009

Prior, I. A., Hood, F. E., and Hartley, J. L. (2020). The frequency of ras mutations in cancer. *Cancer Res.* 80 (14), 2969–2974. doi:10.1158/0008-5472.Can-19-3682

Pylayeva-Gupta, Y., Grabocka, E., and Bar-Sagi, D. (2011). RAS oncogenes: Weaving a tumorigenic web. *Nat. Rev. Cancer* 11 (11), 761–774. doi:10.1038/nrc3106

Richman, J., Martin-Liberal, J., Diem, S., and Larkin, J. (2015). BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. *Expert Opin. Pharmacother.* 16 (9), 1285–1297. doi:10.1517/14656566.2015.1044971

Roberts, P. J., and Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. *Oncogene* 26 (22), 3291–3310. doi:10.1038/sj.onc.1210422

Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., et al. (2018). Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. *Nat. Med.* 24 (7), 954–960. doi:10.1038/s41591-018-0024-8

Ryan, M. B., and Corcoran, R. B. (2018). Therapeutic strategies to target RAS-mutant cancers. *Nat. Rev. Clin. Oncol.* 15 (11), 709–720. doi:10.1038/s41571-018-0105-0

Si, L., Zou, Z., Zhang, W., Fang, M., Zhang, X., Luo, Z., et al. (2023). Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study. *J. Clin. Oncol.* 41 (16), 9510. doi:10.1200/JCO.2023.41.16_suppl.9510

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 439 (7074), 358–362. doi:10.1038/nature04304

Subbiah, V., Baik, C., and Kirkwood, J. M. (2020). Clinical development of BRAF plus MEK inhibitor combinations. *Trends Cancer* 6 (9), 797–810. doi:10.1016/j.trecan.2020.05.009

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 71 (3), 209–249. doi:10.3322/caac.21660

Tran, B., and Cohen, M. S. (2020). The discovery and development of binimetinib for the treatment of melanoma. *Expert Opin. Drug Discov.* 15 (7), 745–754. doi:10.1080/17460441.2020.1746265

Valencia-Sama, I., Ladumor, Y., Kee, L., Adderley, T., Christopher, G., Robinson, C. M., et al. (2020). NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma. *Cancer Res.* 80 (16), 3413–3423. doi:10.1158/0008-5472.Can-19-3822

Wang, X., Luo, Z., Chen, J., Chen, Y., Ji, D., Fan, L., et al. (2023). First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor tunlametinib in patients with advanced melanoma harboring NRAS mutations. *BMC Med.* 21 (1), 2. doi:10.1186/s12916-022-02669-7

Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., et al. (2018). Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. *Nat. Med.* 24 (7), 968–977. doi:10.1038/s41591-018-0022-x

World Health Organization (2022). Cancer. Available: https://www.who.int/news-room/fact-sheets/detail/cancer (Accessed February 3, 2022).

Yaeger, R., and Corcoran, R. B. (2019). Targeting alterations in the RAF-MEK pathway. *Cancer Discov.* 9 (3), 329–341. doi:10.1158/2159-8290.Cd-18-1321

Zhao, Q., Wang, T., Wang, H., Cui, C., Zhong, W., Fu, D., et al. (2022). Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma. *Front. Pharmacol.* 13, 1039416. doi:10.3389/fphar.2022.1039416

frontiers | Frontiers in Pharmacology

TYPE Original Research
PUBLISHED 29 January 2024
DOI 10.3389/fphar.2023.1315965

OPEN ACCESS

EDITED BY
Marcel Henrique Marcondes Sari,
State University of Midwest Paraná, Brazil

REVIEWED BY
Alexandre De Fátima Cobre,
Federal University of Paraná, Brazil
Jaqueline Carneiro,
Federal University of Paraná, Brazil
Raul Edison Luna Lazo,
Federal University of Paraná, Brazil

*CORRESPONDENCE
Jiansheng Yang,
16622593047@163.com

RECEIVED 10 October 2023
ACCEPTED 31 December 2023
PUBLISHED 29 January 2024

CITATION
Yang J, Cheng C and Wu Z (2024), Mechanisms underlying the therapeutic effects of cinobufagin in treating melanoma based on network pharmacology, single-cell RNA sequencing data, molecular docking, and molecular dynamics simulation.
Front. Pharmacol. 14:1315965.
doi: 10.3389/fphar.2023.1315965

Mechanisms underlying the therapeutic effects of cinobufagin in treating melanoma based on network pharmacology, single-cell RNA sequencing data, molecular docking, and molecular dynamics simulation

Jiansheng Yang[1]*, Chunchao Cheng[2] and Zhuolin Wu[2]

[1]Department of Dermatology, The Peoples Hospital of Yudu County, Ganzhou, China, [2]Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education, and Tianjin City, Tianjin, China

Malignant melanoma is one of the most aggressive of cancers; if not treated early, it can metastasize rapidly. Therefore, drug therapy plays an important role in the treatment of melanoma. Cinobufagin, an active ingredient derived from Venenum bufonis, can inhibit the growth and development of melanoma. However, the mechanism underlying its therapeutic effects is unclear. The purpose of this study was to predict the potential targets of cinobufagin in melanoma. We gathered known and predicted targets for cinobufagin from four online databases. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were then performed. Gene expression data were downloaded from the GSE46517 dataset, and differential gene expression analysis and weighted gene correlation network analysis were performed to identify melanoma-related genes. Using input melanoma-related genes and drug targets in the STRING online database and applying molecular complex detection (MCODE) analysis, we identified key targets that may be the potential targets of cinobufagin in melanoma. Moreover, we assessed the distribution of the pharmacological targets of cinobufagin in melanoma key clusters using single-cell data from the GSE215120 dataset obtained from the Gene Expression Omnibus database. The crucial targets of cinobufagin in melanoma were identified from the intersection of key clusters with melanoma-related genes and drug targets. Receiver operating characteristic curve (ROC) analysis, survival analysis, molecular docking, and molecular dynamics simulation were performed to gain further insights. Our findings suggest that cinobufagin may affect melanoma by arresting the cell cycle by inhibiting three protein tyrosine/serine kinases (EGFR, ERBB2, and CDK2). However, our conclusions are not supported by relevant experimental data and require further study.

KEYWORDS

melanoma, cinobufagin, network pharmacology, EGFR, ERBB2, CDK2

1 Introduction

Malignant melanoma is the most aggressive form of skin tumor, developing from melanin-producing melanocytes (Leonardi et al., 2018). It can develop from multiple nevi and, once formed, invasion and metastasis can occur rapidly (Spagnolo et al., 2019). Genetic mutation is one of the primary drivers in the occurrence and development of melanoma, including oncogene mutations (RAS, BRAF, ALK, and MET) and tumor suppressor mutations (TP53 and CDKN2A) (Tsao et al., 2012). Moreover, several signaling pathways are also implicated in the growth and progression of malignant melanoma, such as PI3K-AKT, RAS-RAF-MEK-ERK, and the canonical Wnt/β-catenin signaling pathway (Lopez-Bergami et al., 2008). Therefore, multiple mechanisms are involved in the development of melanoma. After diagnosis, the main treatment method for early non-metastatic melanoma is surgical resection. However, in the case of advanced malignant melanoma, which often has metastases, a comprehensive and multidisciplinary approach should be applied, such as chemotherapy, radiation, and immunotherapy (Singh et al., 2017). Therefore, it is necessary to find new targets and novel therapeutics for melanoma treatment.

Traditional Chinese medicine (TCM) is a valuable body of knowledge that has made significant contributions to human health worldwide (Dashtdar et al., 2016). Cinobufagin is one of the active components of Venenum Bufonis, a traditional Chinese medicine (Chen et al., 2013). Although cinobufagin was originally used as a painkiller to relieve cancer pain, it can also inhibit the growth of many kinds of tumors. The Chinese State Food and Drug Administration has approved cinobufagin for the treatment of liver and prostate cancer (Meng et al., 2009). Cinobufagin can apparently induce apoptosis and cell cycle arrest in several tumor types, including melanoma (Cui et al., 2010; Qi et al., 2011; Chen et al., 2013; Lu et al., 2016; Zhu et al., 2017; Pan et al., 2019; Zhao et al., 2019). Nonetheless, the underlying mechanism of cinobufagin's effects in malignant melanoma is not well understood.

Network pharmacology is a useful strategy for exploring the underlying mechanisms related to cancer development and the effects of drugs. In our study, we aim to investigate the mechanism of the effect of cinobufagin in melanoma treatment by employing network pharmacology, transcriptional sequencing data analyses, molecular docking, and molecular dynamics simulation.

2 Materials and methods

2.1 Identification of targets of cinobufagin

The SwissTargetPrediction online database (https://www.swisstargetprediction.ch/) and ChEMBL online database (https://www.ebi.ac.uk/chembldb/) were used to inquire about cinobufagin's known and possible targets. The Comparative Toxicogenomics Database (CTD; https://ctdbase.org/) and SuperPred database (http://prediction.charite.de/) were also used to predict possible targets of cinobufagin. The functional enrichment analyses of these drug targets were displayed by the "clusterProfiler" package of the R Programming Language, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (Yu et al., 2012). The three categories of GO analysis for these drug targets were identified, namely, cellular component (CC), biological process (BP), and molecular function (MF), to examine the biological characteristics of these drug targets. KEGG enrichment was used to identify potential signaling pathways.

2.2 Identification of DEGs in melanoma

A total of 83 disease samples and 17 healthy samples in the GSE46517 microarray dataset were acquired from the GEO online database (http://www.ncbi.nlm.nih.gov/geo). First, row data were normalized. Using R software's "limma" package (Ritchie et al., 2015), differentially expressed genes (DEGs) between disease samples and healthy controls were identified with the following criterion: $p < 0.05$ and |fold change|(FC) > 1. Volcano and heatmap plots were generated to show the DEGs and the significant genes were labeled. Gene set enrichment analysis (GSEA) was performed to identify defined genomes (Subramanian et al., 2007). Through GSEA analysis, the differences between the two biological processes of DEGs were identified.

2.3 Weighted gene co-expression network analysis

The WGCNA package of R was used to construct a gene co-expression network in GSE46517 (Langfelder and Horvath, 2008). A hierarchical clustering tree was generated to dispose of the outlier sample. Then, the topological overlap and correlation matrices between genes were calculated. The "pickSoftThreshold" function of the WGCNA package was used to compute the soft threshold power. Through a set screening threshold, we converted the paired correlation matrix into a neighborhood correlation matrix to ensure that the scale-free network individually calculated the paired Pearson correlation coefficients between all genes. The eigenvector values were calculated for each module. We then converted the adjacency matrix to a topological overlap matrix (TOM), computed the corresponding dissimilarity, and conducted a hierarchical clustering analysis. Lastly, we measured the connection between the gene modules and people, normal and abnormal, via gene significance (GS) values and module membership (MM) values and then identified the key modules.

2.4 Generation of protein–protein interaction networks and identification of key clusters

Using the STRING website (https://string-db.org/), the protein–protein interactions (PPIs) of drug targets and melanoma-related genes were investigated. The network nodes and edges of PPIs performed interactions among these proteins. We used Cytoscape software to further optimize the PPI networks, and the molecular complex detection (MCODE) algorithm was performed to screen the key targets that contribute to melanoma growth and proliferation.

2.5 Differential expression of key targets in melanoma and normal tissues

By putting key targets back into the GSE46517 dataset to identify the differential expression of the key cluster between melanoma and control groups, the screening conditions were p-value < 0.05 and |[(log2 fold-change)]| > 1. TCGA melanoma data were downloaded from the UCSC XENA dataset (https://xena.ucsc.edu/). Differential expression of the key targets in TCGA melanoma data was also conducted.

2.6 Single-cell RNA sequencing data analysis and identification of melanoma-associated genes

The row dates of GSE215120 performed in the analysis were downloaded from the GEO online database. We chose six acral melanoma samples for our analysis. Using the Seurat package of R software, we processed data with strict criteria: min.cells = 3, min.features = 200, af$nFeature_RNA ≥ 200 and af$nFeature_RNA ≤ 5,000, af$percent.mt ≤ 20, and af$percent.rb ≤ 20. After cells were filtered based on the above criterion, cells for data analysis were clustered and visually classified using the unified manifold approximation and projection dimensionality reduction techniques. We used R to show the distribution in the "singscore" of pharmacological key targets on the cell subtype.

2.7 Receiver operating characteristic curve analysis and survival analysis

RNA sequencing and survival data on melanoma patients were downloaded from the TCGA public database (http://xena.ucsc.edu/). The crucial targets were identified at the intersection of key clusters, melanoma-related targets, and drug-related genes. Receiver operating characteristic (ROC) curves of these crucial targets were plotted, and these targets were evaluated by computing the area under the ROC curve. We selected the overall survival time of the patients to construct the Kaplan–Meier survival curve and used all three tests (Log–rank, Breslow, and Tarone–Ware) to compare the significant differences between the curves in the graph. Overall survival time is the time from the start of treatment for melanoma patients to the time of death. The censored cases were displayed as "+" on the survival curve.

2.8 Molecular docking and molecular dynamics simulation

The crystal structures of EGFR, ERBB2, and CDK2 were downloaded from the PDB website (EGFR:5FED, ERBB2:3PP0, and CDK2:1B39). For better simulation, protein structures containing active site inhibitors were preferentially selected. The structure of cinobufagin was obtained from ChemDraw. First, the protein was executed using "add hydrogen" and "clean up" in Discovery Studio 2019, and the ligand was also prepared with this tool. We utilized the primitive ligand to provide the binding site. The CDOCKER function was then used to perform molecular docking and calculate -cdocker interaction energy. CDOCKER is a docking method with rigid protein and flexible ligand; -cdocker interaction energy can reflect the energy of the ligand–protein interaction—the higher the score, the stronger the bond. We used Discovery Studio to calculate the binding energy. Molecular dynamics simulation was performed with the Gromacs2020 package. The CHARMm36 force field was employed to execute a molecular dynamics simulation. The system was dissolved in TIP3P water molecules in a dodecahedral box. Energy minimization and NVT and NPT simulations were then performed on the system. Finally, a 50-ns-long molecular dynamics simulation was performed, and root mean square deviation (RMSD) values were calculated.

2.9 Statistical analysis

All statistical analyses in the present research were implemented using R software (version 4.3.1). $p < 0.05$ was used as the threshold for statistical significance.

3 Results

3.1 General targets of cinobufagin

We identified 108 and 241 related targets of cinobufagin from the SwissTargetPrediction and ChEMBL databases, respectively. Through CTD and the SuperPred database, we predicted 39 and 96 additional potential drug targets, respectively (Figure 1A). These 413 drug-related targets were used for GO and KEGG analyses. The biological process category in GO was mainly enriched in positive regulation of the MAPK cascade, response to xenobiotic stimulus, and the adenylate cyclase-modulating G protein-coupled receptor signaling pathway. The GO cellular component category was mainly enriched in the membrane raft, membrane microdomain, and synaptic membrane. The molecular function section was mainly gathered in amide binding, protein serine/threonine kinase activity, and protein serine kinase activity (Figure 1C). KEGG pathway enrichment of these drug targets was mainly gathered in neuroactive ligand–receptor interaction, prostate cancer, hepatitis B, and the cAMP signaling pathway in cancer (Figure 1B). In total, these results suggest that cinobufagin might be regulating protein serine/threonine kinase activity.

3.2 Target genes in melanoma

We downloaded 100 melanoma-related samples from GSE46517 from the GEO database, including 8 normal skin tissues, 9 nevus tissues, 31 primary melanoma tissues, and 52 metastatic melanoma tissues. We normalized raw sequencing data first and then identified DEGs between control groups (including normal skin tissues and nevus tissues) and melanoma groups (including primary melanoma tissues and metastatic melanoma tissues) (Supplementary Figure S1). Among these



FIGURE 1
Screening analysis of cinobufagin targets. **(A)** Venn diagram of cinobufagin in the four databases (CTD: Comparative Toxicogenomics database). **(B)** Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of cinobufagin targets. **(C)** Gene Ontology (GO) enrichment analysis (BP, biological process; CC, cellular component; MF, molecular function) of cinobufagin targets.

genes, 105 were upregulated and 285 were downregulated (Supplementary Table S1). The heatmap plot showed 60 significant DEGs, and the top 12 DEGs were shown in the volcano plot (Figures 2A, B). GSEA analysis was used to evaluate the pathway enrichment of DEGs between the melanoma and normal groups. The results of this analysis showed that DNA replication, mismatch repair, one-carbon pool by folate, other glycan degradation, and primary immunodeficiency were enriched in melanoma groups (Figure 2C). The beta-alanine metabolism, butanoate metabolism, histidine metabolism, steroid hormone biosynthesis, and terpenoid backbone biosynthesis were inhibited (Figure 2D). These results suggest that DNA replication may play an important role in melanoma development.

3.3 WGCNA analysis

We used microarray data on GSE46517 for WGCNA analysis. The outlier detection indicated no significant outliers in the data (Figure 3A). The soft threshold power was evaluated as 6 with a scale-free index of 0.9, indicating that connectivity was reasonable (Figure 3B). The topological overlap matrix and correlation matrix between the data genes were constructed. The co-expression network was then established, and the cluster dendrogram with a dynamic tree cut and merged dynamic plot was constructed (Figure 3C). Finally, the results of data clustering were divided into 14 modules (Figure 3D). The correlation coefficient between each module and melanoma-related phenotype was calculated. The



FIGURE 2
Expression of differentially expressed genes (DEGs) in the GSE46517 dataset. **(A)** Heatmap plot of DEGs in the GSE46517 dataset. **(B)** Volcano plot of DEGs in the GSE4290 dataset. **(C,D)** GSEA analysis based on KEGG analysis.

results suggested that the MEbrown module was the one most significantly related to primary (cor = 0.3, p = 0.003) and metastatic (cor = −0.76, p = 6e-20) melanoma. The correlation heatmap between these modules is shown in Figure 3E. The scatter plot of module membership (MM) and gene significance (GS) showed excellent correlation within the MEbrown module (R = 0.62, p < 1e-200) (Figure 3F). Therefore, the MEbrown module could be an optimized module to explain the anomalous melanoma phenotypes.

3.4 Identification of key targets

We compared the DEGs and MEbrown module genes to identify 329 melanoma-related genes (Figure 4A). 14 genes were identified in intersection between melanoma-related genes and drug targets (Figure 4B). The PPI network of all melanoma-related and drug-related genes was constructed using the STRING online database (Supplementary Figure S2). The molecular complex detection (MCODE) algorithm was used to identify 62 essential subpopulation genes, termed key targets or key clusters (Figure 4C). The GO analysis of key targets showed that the biological process category was mainly enriched in the positive regulation of kinase activity, peptidyl-serine phosphorylation, and peptidyl-serine modification. The Biological Process category shown that the key cluster mainly enriched in miRNA transcription, and chromosomal region, and membrane raft. The results of the molecular function section were gathered in nuclear chromosome, DNA-binding transcription factor binding, and specific DNA-binding transcription factor binding (Figure 4E). Through KEGG-enriched analysis, we found that these key targets were mainly gathered in the cell cycle, PI3K-Akt signaling pathway, and hepatitis B (Figure 4D). Notably, the cell cycle was one of the primary signaling pathways affected by cinobufagin in cancer.



FIGURE 3
Enrichment levels in genomic weighted gene co-expression network analysis (WGCNA). **(A)** Sample dendrogram and trait heatmap. **(B)** Selection of soft thresholds. **(C)** Cluster dendrogram of WGCNA. **(D)** Correlations between gene modules and melanoma status. **(E)** Correlation between modules. **(F)** Correlation between brown module memberships and gene significance.

3.5 The expression and distribution of key targets

Differential expressions between the normal and disease samples of individual key targets were calculated and shown in box plots (Figure 5A). We then downloaded the single-cell data from the GEO database for our analysis. We used the following criteria to filter cells to guarantee their quality for our analysis: cells with > 5,000 and < 200 genes per cell and cells with a > 20% mitochondrial percentage or a > 20% ribosome percentage were filtered out (Supplementary Figure S3A). Then, the harmony package was used to remove the batch effect (Supplementary Figure S3B). The cluster tree was scaled with a resolution of 1.5 (Supplementary Figure S3C), and the principal component value



FIGURE 4
Identification of key targets and functional analysis. **(A)** Intersection of DEGs and WGCNA brown module genes, named melanoma-related genes. **(B)** Intersection of melanoma-related genes and drug targets. **(C)** Cytoscape's plugin code for all melanoma-related genes and drug targets, named key cluster. Deep green: melanoma-related gene; brown: drug targets; deep green and brown: both melanoma-related genes and drug targets. **(D)** KEGG analysis of key genes. **(E)** GO analysis of the key cluster.

was determined as 13. The results of T-distributed stochastic neighbor embedding (t-SNE) gathered 13 cell clusters (Figure 5B). The heatmap showed the gene type of each cluster (Figure 5C). Using the CellMarker database and referring to the work of Yang et al. (Zhang et al., 2022), we annotated these clusters into seven cells, including melanoma, NK cells, T cells, fibroblasts, mono cells, endothelial cells, and B cells (Figure 5D). The AUCell functional score analysis was used to show the distribution of drug targets, with cinobufagin acting mainly on melanoma cell clusters (Figure 5E).



FIGURE 5
Expression and distribution of the key cluster. **(A)** Boxplot of differential expression of key genes in normal tissue and tumor tissue of data in GSE46517. **(B)** Unified manifold approximation and projection clustering into 13 clusters. **(C)** Heatmap of each gene table level. **(D)** Manual annotation of 13 clusters, finally identifying 7 clusters. **(E)** Melanoma drug pathways of action.

3.6 Identification of crucial targets

Through comparison with key targets and intersect genes from the intersection of drug targets and melanoma-related genes, we identified three crucial targets (Figure 6A). The ROC curves showed that all three had excellent robustness for melanoma (area under the ROC curve > 0.8) (Figure 6C). Moreover, melanoma patient survival data downloaded from the TCGA database (http://xena.ucsc.edu/) was used for survival analysis. Results showed that all three target genes had a significant impact on melanoma patient survival (Figure 6D). However, among these crucial targets, EGFR and ERBB2 were downregulated compared with the normal sample, and CDK2 was upregulated (Figure 5A). The expression data from TCGA melanoma show the same results (Figure 6B).

3.7 Molecular docking

To validate the findings from network pharmacology, we selected crucial targets (CDK2, EGFR, and ERBB2) for molecular docking analysis to evaluate the screened targets. The structure of cinobufagin was identified by Chem Draw in 2022. After testing the feasibility of the docking method by redocking, the compound–target interactions, as well as their modes of binding, were visualized using Discovery Studio 2019 (Figures 7A–C). All these had high cdocker interaction



FIGURE 6
Identification of crucial targets, receiver operating characteristic curve (ROC) analysis, and survival analysis. **(A)** Intersection of key clusters and melanoma-related genes and drug targets, named crucial targets. **(B)** Differential expression of crucial targets in normal tissue and tumor tissue of data in TCGA database. **(C)** ROC curve of three crucial targets. **(D)** Survival curve of EGFR, ERBB2, and CDK2.

energy, indicating that all three molecular docking targets combine very well with cinobufagin (Table1).

3.8 Molecular dynamics simulation

To further describe the binding patterns of protein–compound complexes, we performed molecular dynamics simulations of the above three molecular docking models. The RMSD curve can reflect the fluctuations of the system. As shown in Figure 8A, CDK2-cinobufagin was stable after 30 ns, and EGFR-cinobufagin and ERBB2-cinobufagin were stable after 10 ns (Figures 8C, E). The number of hydrogen bonds in the protein–cinobufagin complexes reflected their binding strengths (Figures 8B, D, F). Among them, ERBB2–cinobufagin had the highest hydrogen bond density and strength (Figure 8F). These data suggested that these three crucial targets interacted very well with cinobufagin in accordance with the molecular docking results.

4 Discussion

Malignant melanoma is considered the most aggressive skin cancer—more dangerous than other skin cancers. If not removed at an early stage, it can spread and metastasize rapidly. Thus, anticancer drug therapy is an important anti-melanoma therapy (Helmbach et al., 2001). However, standard chemotherapy does not produce satisfactory results due to chemotherapy resistance (Helmbach et al., 2001; Jilaveanu et al., 2009; Abildgaard and Guldberg, 2015; Kalal et al., 2017). The development of new, effective treatments for melanoma is thus vital.

Venenum bufonis is a traditional Chinese medicine that has been widely used in China (Zhang et al., 2012; Zhu et al., 2017). It has been reported that its extract can inhibit the growth of many tumor cells (Park et al., 2012). Cinobufagin is one of the active components of Venenum bufonis , which piqued our research interest. It is reported that cinobufagin can effectively inhibit the growth and development of lung cancer cells (Adjei et al., 2010),



FIGURE 7
Molecular docking of crucial targets. **(A)** Re-docking of three targets in Discovery Studio 2019 software. **(B,C)** The CDOCKER results of cinobufagin with three crucial targets (CDK2, EGFR, ERBB2).

TABLE 1 Docking information on crucial targets.

Targets of cinobufagin	Re-docking (RMSD)	CDOCKER interaction energy (kcal/mol)	Binding energy (kcal/mol)
EGFR	0.7976	38.045	−43.5327
ERBB2	1.4621	25.9757	−21.7207
CDK2	1.1905	51.525	−62.8743

liver cancer cells (Cui et al., 2010), prostate cancer cells (Yu et al., 2008), and osteosarcoma cells (Dai et al., 2017) *in vitro*. Moreover, cinobufagin can also inhibit the proliferation of melanomas (Pan et al., 2019; Kim et al., 2020; Zhang et al., 2020). However, the underlying mechanism and potential targets of cinobufagin in melanomas are unclear.

In this study, we combined network pharmacology, bulk RNA sequencing data, and single-cell RNA sequencing data to finally identify the potential targets of cinobufagin in melanoma. First, we found and predicted the 413 potential targets of cinobufagin. It is interesting that the molecular function section comprised in GO was gathered in protein serine/threonine kinase activity, protein serine kinase activity, and protein tyrosine kinase activity. Then, we downloaded GEO data for DEGs and WGCNA analysis, finally identifying 329 disease-related genes. By inputting these disease-related and drug-related genes into the STRING online database, we constructed



FIGURE 8
Molecular dynamics analysis. **(A,C,E)** Root mean square deviation (RMSD) of three systems (three crucial targets and cinobufagin). **(B,D,F)** Number of hydrogen bonds in three systems.

a PPI network. To further identify potential targets of cinobufagin in melanoma, we used the molecular complex detection (MCODE) algorithm to define a more important subset. Interestingly, the GO analysis of these key targets showed that the biological process category was enriched in the positive regulation of kinase activity, the regulation of protein serine/threonine kinase activity, and the molecular function category, showing that the key cluster was enriched in protein tyrosine kinase activity and protein serine kinase activity, which was in keeping with previous results. Furthermore, the KEGG analysis showed that these potential targets were mainly enriched in the cell cycle; it is reported that this pathway is one of the main effects of cinobufagin on cancer cells (Pan et al., 2019; Yang et al., 2021). We then downloaded single-cell data from the GEO database to verify the distribution of these key targets. The results show that 62 key targets were mainly gathered in melanoma cells. By intersecting the key cluster and the intersection of drug-related genes and melanoma-related genes, we finally identified three crucial targets, EGFR, ERBB2, and CDK2, which are all protein serine/threonine kinases and are involved in cell cycle regulation (Lo and Hung, 2006; Hirai et al., 2017; Kirova et al., 2022). It has been reported that cinobufagin can inhibit the EGFR-CDK2 signaling pathway in hepatocellular carcinoma, which is consistent with our predicted results (Yang et al., 2021).

The crucial targets we identified all have excellent robustness in melanoma. TCGA data indicate that these three crucial targets have a significant impact on melanoma patient survival by three test methods. It was confusing that EGFR and ERBB2 had low expression in tumor

tissue compared to normal tissue whether in GEO or TCGA data, perhaps due to the disadvantage of bulk sequencing. Finally, we showed the molecular docking results of cinobufagin with these three crucial targets, and the molecular dynamics simulation was performed. These data suggest that docking of cinobufagin with three proteins is reasonable, indicating that these might be potential targets of cinobufagin in melanoma.

Network pharmacology is a practical strategy that uses computer technology to deepen our understanding of the modes of drug action across multiple scales of complexity (Hopkins, 2008). We combined network pharmacology with other sequencing data to identify key targets. Through single-cell sequencing analysis, we found that these key targets were mainly distributed in melanoma cells. We used molecular docking to show that the crucial targets were potential targets of cinobufagin in melanoma. Moreover, the results of our analysis have been partly verified in other tumors (Yang et al., 2021), indicating that this method has great value in drug target prediction.

It should be noted that this study had some limitations. First, sequencing data for our analysis were retrieved from the literature and databases; therefore, the reliability and accuracy of the predictions are dependent on data quality. The second is the absence of evidence to verify our predictions; clinical trials, animal experiments, and X-ray diffractometers are needed to confirm the findings. Third, experimental validation is necessary to further verify cinobufagin's ability to bind and inhibit crucial targets, such as affinity assays (surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC)) or direct mutation studies. Our conclusions remain preliminary as long as computational predictions are not supported by experimental validation.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Author contributions

JY: formal analysis, investigation, methodology, project administration, software, supervision, and writing–original draft. CC: writing–original draft and validation. ZW: writing–review and editing and validation.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1315965/full#supplementary-material

References

Abildgaard, C., and Guldberg, P. (2015). Molecular drivers of cellular metabolic reprogramming in melanoma. *Trends Mol. Med.* 21 (3), 164–171. doi:10.1016/j.molmed.2014.12.007

Adjei, A. A., Mandrekar, S. J., Dy, G. K., Molina, J. R., Adjei, A. A., Gandara, D. R., et al. (2010). Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non–small-cell lung cancer: NCCTG and SWOG study N0426. *J. Clin. Oncol.* 28 (4), 614–619. doi:10.1200/JCO.2009.23.6406

Chen, T., Hu, W., He, H., Gong, Z., Wang, J., Yu, X., et al. (2013). A study on the mechanism of cinobufagin in the treatment of paw cancer pain by modulating local β -endorphin expression *in vivo*. *Evidence-Based Complementary Altern. Med.* 2013, 851256–851259. doi:10.1155/2013/851256

Cui, X., Inagaki, Y., Xu, H., Wang, D., Qi, F., Kokudo, N., et al. (2010). Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 cells. *Biol. Pharm. Bull.* 33 (10), 1728–1732. doi:10.1248/bpb.33.1728

Dai, G., Yu, L., Yang, J., Xia, K., Zhang, Z., Liu, G., et al. (2017). The synergistic antitumor effect of cinobufagin and cisplatin in human osteosarcoma cell line *in vitro* and *in vivo*. *Oncotarget* 8 (49), 85150–85168. doi:10.18632/oncotarget.19554

Dashtdar, M., Dashtdar, M. R., Dashtdar, B., Kardi, K., and Shirazi, MK. (2016). The concept of wind in traditional Chinese medicine. *J. Pharmacopuncture* 19 (4), 293–302. doi:10.3831/KPI.2016.19.030

Helmbach, H., Rossmann, E., Kern, M. A., and Schadendorf, D. (2001). Drug-resistance in human melanoma. *Int. J. Cancer* 93 (5), 617–622. doi:10.1002/ijc.1378

Hirai, M., Arita, Y., McGlade, C. J., Lee, K.-F., Chen, J., and Evans, S. M. (2017). Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. *J. Clin. Investigation* 127 (2), 569–582. doi:10.1172/JCI91081

Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery. *Nat. Chem. Biol.* 4 (11), 682–690. doi:10.1038/nchembio.118

Jilaveanu, L. B., Aziz, S. A., and Kluger, H. M. (2009). Chemotherapy and biologic therapies for melanoma: do they work? *Clin. Dermatology* 27 (6), 614–625. doi:10.1016/j.clindermatol.2008.09.020

Kalal, B. S., Upadhya, D., and Pai, V. R. (2017). Chemotherapy resistance mechanisms in advanced skin cancer. *Oncol. Rev.* 11, 326. doi:10.4081/oncol.2017.326

Kim, G.-H., Fang, X.-Q., Lim, W.-J., Park, J., Kang, T.-B., Kim, J. H., et al. (2020). Cinobufagin suppresses melanoma cell growth by inhibiting LEF1. *Int. J. Mol. Sci.* 21 (18), 6706. doi:10.3390/ijms21186706

Kirova, D. G., Judasova, K., Vorhauser, J., Zerjatke, T., Leung, J. K., Glauche, I., et al. (2022). A ROS-dependent mechanism promotes CDK2 phosphorylation to drive progression through S phase. *Dev. Cell* 57 (14), 1712–1727.e9. doi:10.1016/j.devcel.2022.06.008

Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted correlation network analysis. *BMC Bioinforma.* 9, 559. doi:10.1186/1471-2105-9-559(1)

Leonardi, G., Falzone, L., Salemi, R., Zanghi, A., Spandidos, D., McCubrey, J., et al. (2018). Cutaneous melanoma: from pathogenesis to therapy (Review). *Int. J. Oncol.* 52, 1071–1080. doi:10.3892/ijo.2018.4287

Lo, H. W., and Hung, M. C. (2006). Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. *Br. J. Cancer* 94 (2), 184–188. doi:10.1038/sj.bjc.6602941

Lopez-Bergami, P., Fitchman, B., and Ronai, ZE. (2008). Understanding signaling cascades in melanoma. *Photochem. Photobiol.* 84 (2), 289–306. doi:10.1111/j.1751-1097.2007.00254.x

Lu, X.-s., Qiao, Y.-b., Li, Y., Yang, B., Chen, M.-b., and Xing, C.-g. (2016). Preclinical study of cinobufagin as a promising anti-colorectal cancer agent. *Oncotarget* 8 (1), 988–998. doi:10.18632/oncotarget.13519

Meng, Z., Yang, P., Shen, Y., Bei, W., Zhang, Y., Ge, Y., et al. (2009). Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. *Cancer* 115 (22), 5309–5318. doi:10.1002/cncr.24602

Pan, Z., Zhang, X., Yu, P., Chen, X., Lu, P., Li, M., et al. (2019). Cinobufagin induces cell cycle arrest at the G2/M phase and promotes apoptosis in malignant melanoma cells. *Front. Oncol.* 9, 853. doi:10.3389/fonc.2019.00853

Park, J.-S., Shin, D. Y., Lee, Y.-W., Cho, C.-K., Kim, G. Y., Kim, W.-J., et al. (2012). Apoptotic and anti-metastatic effects of the whole skin of Venenum bufonis in A549 human lung cancer cells. *Int. J. Oncol.* 40 (4), 1210–1219. doi:10.3892/ijo.2011.1310

Qi, F., Inagaki, Y., Gao, B., Cui, X., Xu, H., Kokudo, N., et al. (2011). Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. *Cancer Sci.* 102 (5), 951–958. doi:10.1111/j.1349-7006.2011.01900.x

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., et al. (2015). Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 43 (7), e47–e. doi:10.1093/nar/gkv007

Singh, S., Zafar, A., Khan, S., and Naseem, I. (2017). Towards therapeutic advances in melanoma management: an overview. *Life Sci.* 174, 50–58. doi:10.1016/j.lfs.2017.02.011

Spagnolo, F., Boutros, A., Tanda, E., and Queirolo, P. (2019). The adjuvant treatment revolution for high-risk melanoma patients. *Seminars Cancer Biol.* 59, 283–289. doi:10.1016/j.semcancer.2019.08.024

Subramanian, A., Kuehn, H., Gould, J., Tamayo, P., and Mesirov, J. P. (2007). GSEA-P: a desktop application for gene set enrichment analysis. *Bioinformatics* 23 (23), 3251–3253. doi:10.1093/bioinformatics/btm369

Tsao, H., Chin, L., Garraway, L. A., and Fisher, D. E. (2012). Melanoma: from mutations to medicine. *Genes and Dev.* 26 (11), 1131–1155. doi:10.1101/gad.191999.112

Yang, A.-l., Wu, Q., Hu, Z.-d., Wang, S.-p., Tao, Y.-f., Wang, A.-m., et al. (2021). A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling. *Toxicol. Appl. Pharmacol.*, 431. doi:10.1016/j.taap.2021.115739

Yu, C.-H., Kan, S.-F., Pu, H.-F., Jea Chien, E., and Wang, P. S. (2008). Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. *Cancer Sci.* 99 (12), 2467–2476. doi:10.1111/j.1349-7006.2008.00966.x

Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). clusterProfiler: an R Package for comparing biological themes among gene clusters. *OMICS A J. Integr. Biol.* 16 (5), 284–287. doi:10.1089/omi.2011.0118

Zhang, C., Shen, H., Yang, T., Li, T., Liu, X., Wang, J., et al. (2022). A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. *Nat. Commun.* 13 (1), 7250. doi:10.1038/s41467-022-34877-3

Zhang, D. M., Liu, J. S., Tang, M. K., Yiu, A., Cao, H. H., Jiang, L., et al. (2012). Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. *Eur. J. Pharmacol.* 692 (1-3), 19–28. doi:10.1016/j.ejphar.2012.06.045

Zhang, L., Huang, X., Guo, T., Wang, H., Fan, H., and Fang, L. (2020). Study of cinobufagin as a promising anticancer agent in uveal melanoma through intrinsic apoptosis pathway. *Front. Oncol.* 10, 325. doi:10.3389/fonc.2020.00325

Zhao, L., Fu, L., Xu, Z., Fan, R., Xu, R., Fu, R., et al. (2019). The anticancer effects of cinobufagin on hepatocellular carcinoma Huh-7cells are associated with activation of the p73 signaling pathway. *Mol. Med. Rep.* 19, 4119–4128. doi:10.3892/mmr.2019.10108

Zhu, L., Chen, Y., Wei, C., Yang, X., Cheng, J., Yang, Z., et al. (2017). Anti-proliferative and pro-apoptotic effects of cinobufagin on human breast cancer MCF-7 cells and its molecular mechanism. *Nat. Prod. Res.* 32 (4), 493–497. doi:10.1080/14786419.2017.1315575

Frontiers in Oncology

Advances knowledge of carcinogenesis and tumor progression for better treatment and management

The third most-cited oncology journal, which highlights research in carcinogenesis and tumor progression, bridging the gap between basic research and applications to imrpove diagnosis, therapeutics and management strategies.

Discover the latest Research Topics

See more →

Frontiers

Avenue du Tribunal-Fédéral 34
1005 Lausanne, Switzerland
frontiersin.org

Contact us

+41 (0)21 510 17 00
frontiersin.org/about/contact